Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Application Type
STN
CBER Received Date
PDUFA Goal Date
Division / Office
Priority Review
Reviewer Name
Review Completion Date /
Stamped Date
Supervisory Concurrence

Original Application
125508/0
December 10, 2013
December 10, 2014
DVRPA /OVRR
No
Sixun Yang, MD, PhD
September 17, 2014/December 10,
2014
Nancy Miller, MD, Secondary Reviewer
Doran Fink, MD, PhD, Team Leader
Andrea Hulse, MD, Branch Chief

Applicant
Established Name
Trade Name
Pharmacologic Class
Formulation

Dosage Form and Route of
Administration
Dosing Regimen
Indication(s) and Intended
Population(s)

Orphan Designated (Yes/No)

Merck Sharp & Dohme Corp.
Human Papillomavirus 9-valent
Vaccine, Recombinant
Gardasil 9
Prophylactic Vaccine
Sterile suspension of Recombinant
Virus Like Particles of HPV
6/11/16/18/31/33/45/52/58 absorbed on
500 µg of AAHS
0.5 ml, Intramuscular Injection
3-doses at Day 1, Month 2 and Month
6
Prevention of HPV
6/11/16/18/31/33/45/52/58-Related
Anogenital Lesions in Females 9
through 26 years of age and males 9
through 15 years of age
No

Page i

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

TABLE OF CONTENTS
GLOSSARY .......................................................................................................................1
1. EXECUTIVE SUMMARY ...................................................................................................2
2. CLINICAL AND REGULATORY BACKGROUND..................................................................... 6
2.1 Disease or Health-Related Condition(s) Studied ........................................................... 6
2.2 Currently Available, Pharmacologically Unrelated Treatment(s)/Intervention(s) for
the Proposed Indication(s) .............................................................................................. 7
2.2.1 Prevention ................................................................................................................. 7
2.2.2 Treatment .................................................................................................................. 8
2.3 Safety and Efficacy of Pharmacologically Related Products ....................................... 8
2.4 Previous Human Experience with the Product (Including Foreign Experience) ........ 9
2.4.1 Clinical Trials with qHPV ........................................................................................... 9
2.4.2 Post Licensure Safety of qHPV ............................................................................... 10
2.5 Summary of Pre- and Post-Submission Regulatory Activity Related to the
Submission ..................................................................................................................... 10
2.5.1 Pre-submission Regulatory Activities ...................................................................... 10
2.5.2 Post-BLA Submission Regulatory Activities ............................................................ 11

3. SUBMISSION QUALITY AND GOOD CLINICAL PRACTICES ................................................. 11
3.1 Submission Quality and Completeness ....................................................................... 11
3.2 Compliance with Good Clinical Practices and Submission Integrity ........................ 12
3.3 Financial Disclosures ..................................................................................................... 13

4. SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES ......... 15
4.1 Chemistry, Manufacturing, and Controls ..................................................................... 15
4.2 Assay Validation ............................................................................................................. 15
4.3 Nonclinical Pharmacology/Toxicology ......................................................................... 15
4.4 Clinical Pharmacology ................................................................................................... 15
4.4.1 Mechanism of Action ............................................................................................... 15
4.5 Statistical ......................................................................................................................... 15
4.6 Pharmacovigilance ......................................................................................................... 15

5. SOURCES OF CLINICAL DATA AND OTHER INFORMATION CONSIDERED IN THE REVIEW .... 16
5.1 Review Strategy .............................................................................................................. 16
5.2 BLA/IND Documents That Serve as the Basis for the Clinical Review...................... 16
5.3 Table of Studies/Clinical Trials ...................................................................................... 17
5.4 Consultations .................................................................................................................. 19
5.5 Literature Reviewed ........................................................................................................ 19

6. DISCUSSION OF INDIVIDUAL CLINICAL TRIALS ................................................................ 22
6.1 Trial #1: V503-001 (Designated as Study 1 in the Draft Package Insert) ................... 22
6.1.1 Objectives ................................................................................................................ 22
6.1.2 Design Overview ..................................................................................................... 23
6.1.3 Population ................................................................................................................ 24
6.1.4 Study Treatments or Agents Mandated by the Protocol ......................................... 25
6.1.5 Directions for Use .................................................................................................... 26
6.1.6 Sites and Centers .................................................................................................... 26
6.1.7 Surveillance/Monitoring ........................................................................................... 26
6.1.8 Endpoints and Criteria for Study Success ............................................................... 29
6.1.9 Statistical Considerations and Statistical Analysis Plan .......................................... 31
6.1.10 Study Population and Disposition .......................................................................... 33

Page ii

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
6.1.11 Efficacy Analyses .................................................................................................. 40
6.1.12 Safety Analyses ..................................................................................................... 55
6.1.13 Study Summary and Conclusions ......................................................................... 70
6.2 Trial #2: V503-002 (Designated as Study 2 in the Draft Package Insert) ................... 71
6.2.1 Objectives ................................................................................................................ 72
6.2.2 Design Overview ..................................................................................................... 72
6.2.3 Population ................................................................................................................ 72
6.2.4 Study Treatments or Agents Mandated by the Protocol ......................................... 73
6.2.5 Directions for Use .................................................................................................... 73
6.2.6 Sites and Centers .................................................................................................... 73
6.2.7 Surveillance/Monitoring ........................................................................................... 73
6.2.8 Endpoints and Criteria for Study Success ............................................................... 73
6.2.9 Statistical Considerations and Statistical Analysis Plan .......................................... 74
6.2.10 Study Population and Disposition .......................................................................... 76
6.2.11 Efficacy Analyses .................................................................................................. 78
6.2.12 Safety Analyses ..................................................................................................... 81
6.2.13 Study Summary and Conclusions ......................................................................... 87
6.3 Trial #3: V503-009 (Designated as Study 3 in the Draft Package Insert) ................... 88
6.3.1 Objectives ................................................................................................................ 88
6.3.2 Design Overview ..................................................................................................... 88
6.3.3 Population ................................................................................................................ 88
6.3.4 Study Treatments or Agents Mandated by the Protocol ......................................... 89
6.3.5 Directions for Use .................................................................................................... 89
6.3.6 Sites and Centers .................................................................................................... 89
6.3.7 Surveillance/Monitoring ........................................................................................... 89
6.3.8 Endpoints ................................................................................................................. 89
6.3.9 Statistical Considerations and Statistical Analysis Plan .......................................... 90
6.3.10 Study Population and Disposition .......................................................................... 90
6.3.11 Efficacy Analyses .................................................................................................. 91
6.3.12 Safety Analyses ..................................................................................................... 92
6.3.13 Study Summary and Conclusions ......................................................................... 99

7. INTEGRATED OVERVIEW OF EFFICACY .......................................................................... 99
7.1 Indication #1 .................................................................................................................... 99
7.1.2 Demographics and Baseline Characteristics......................................................... 100
7.1.3 Subject Disposition ................................................................................................ 101
7.1.4 Analysis of Primary Endpoint(s) ............................................................................ 102
7.1.5 Analysis of Secondary Endpoint(s) ....................................................................... 104
7.1.6 Other Endpoints ..................................................................................................... 104
7.1.7 Subpopulations ...................................................................................................... 107
7.1.8 Persistence of Efficacy .......................................................................................... 116
7.1.9 Product-Product Interactions ................................................................................. 119
7.1.11 Efficacy Conclusions ........................................................................................... 122

8. INTEGRATED OVERVIEW OF SAFETY ........................................................................... 124
8.1 Safety Assessment Methods ....................................................................................... 124
8.2 Safety Database ............................................................................................................ 124
8.2.1 Studies/Clinical Trials Used to Evaluate Safety .................................................... 124
8.2.2 Overall Exposure, Demographics of Pooled Safety Populations .......................... 124
8.2.3 Categorization of Adverse Events ......................................................................... 126
8.3 Caveats Introduced by Pooling of Data across Studies/Clinical Trials ................... 126
8.4 Safety Results ............................................................................................................... 127
8.4.1 Deaths ................................................................................................................... 127
8.4.2 Nonfatal Serious Adverse Events .......................................................................... 127
8.4.3 Study Dropouts/Discontinuations .......................................................................... 128

Page iii

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
8.4.4 Common Adverse Events ...................................................................................... 128
8.4.5 Clinical Test Results .............................................................................................. 128
8.4.6 Systemic Adverse Events ...................................................................................... 128
8.4.7 Local Reactogenicity ............................................................................................. 130
8.4.8 Adverse Events of Special Interest ....................................................................... 132
8.5 Additional Safety Evaluations ..................................................................................... 132
8.5.1 Dose Dependency for Adverse Events ................................................................. 132
8.5.2 Product-Demographic Interactions ........................................................................ 133
8.5.5 Product-Product Interactions ................................................................................. 136
8.6 Safety Conclusions ....................................................................................................... 142

9. ADDITIONAL CLINICAL ISSUES .................................................................................... 143
9.1 Special Populations ...................................................................................................... 143
9.1.1 Human Reproduction and Pregnancy Data........................................................... 143
9.1.2 Use during Lactation.............................................................................................. 146
9.1.3 Pediatric Use and PREA Considerations .............................................................. 147
9.1.4 Immunocompromised Patients .............................................................................. 147
9.1.5 Geriatric Use .......................................................................................................... 147
9.2 Safety Update Reports.................................................................................................. 147
9.2.1 Safety Update Report Four Months after the Submission of the BLA ................... 147

10. CONCLUSIONS ........................................................................................................ 148
10.1 Efficacy and Immunogenicity .................................................................................... 148
10.2 Safety conclusion: ...................................................................................................... 149

11. RISK-BENEFIT CONSIDERATIONS AND RECOMMENDATIONS ........................................ 150
11.1 Risk-Benefit Considerations ...................................................................................... 150
11.2 Risk-Benefit Summary and Assessment .................................................................. 152
11.3 Discussion of Regulatory Options ............................................................................ 152
11.4 Recommendations on Regulatory Actions .............................................................. 152
11.5 Labeling Review and Recommendations ................................................................. 152
11.6 Recommendations on Postmarketing Actions ........................................................ 153

Page iv

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

GLOSSARY
9vHPV
AAHS
AEs
AHN or All-HN
AIN
AIS
AN
ASC-H
ASC-US
CFR
CI
CIN
cLIA
CRF
CSR
DNA
DSMB
ECC
eCRF
eDMC
EEC
EGLs
ELISA
FAS
FDA
GCP
GMTs
hCG
HN-TS
HPV
HR
HSIL
IgG
IM
IND
IRB
IVRS
LEEP
LMP
LR
LSIL
LVPP
(b)(4)
MARRS
mMU/mL
MRL
MSD

Nine-valent Human Papillomavirus vaccine
Amorphous Aluminum Hydroxyphosphate Sulfate
Adverse experiences or events
All-HPV Naive
Anal intraepithelial neoplasia
Adenocarcinoma in situ
Allocation number
Atypical squamous cells cannot rule out HSIL
Atypical squamous cells of undetermined significance
Code of Federal Regulations
Confidence interval
Cervical intraepithelial neoplasia
Competitive Luminex Immunoassay
Case report form
Clinical study report
deoxyribonucleic acid
Data and Safety Monitoring Board
Endocervical curettage
Electronic case report form
External Data Monitoring Committee
Endo/ectocervical
External genital lesions
Enzyme-linked immunosorbent assay
Full Analysis Set
Food and Drug Administration
Good Clinical Practice
Geometric Mean Titers
Human chorionic gonadotropin
HPV-Naïve Type-Specific
Human Papillomavirus
High-risk
High-Grade Squamous Intraepithelial Lesion
Immunoglobulin G
Intramuscular
Investigational New Drug
Institutional Review Board
Interactive Voice Response System
Loop Electrosurgical Excision Procedure
Last menstrual period
Low-risk
Low-Grade Squamous Intraepithelial Lesion
Labial/vulvar/perineal and perianal
---(b)(4)--- antibodies
Merck Adverse event Reporting and Review System
milli-Merck Units per milliliter
Merck Research Laboratories
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Page 1

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

MSM
Pap
(b)(4)
PCR
PPE
PPI
qHPV
RR
SAEs
SAP
SCC
SD
SEM
siDMC
ULN
VaIN
VE
VIN
VLP
VRC
WBC

Men-having-sex-with-men
Papanicolaou
----------------(b)(4)-------------------Polymerase Chain Reaction
Per Protocol Efficacy
Per Protocol Immunogenicity
Quadrivalent Human Papillomavirus vaccine
Risk reduction
Serious Adverse Experiences
Statistical analysis plan
Squamous cell carcinoma
Standard deviation
Standard error of the mean
Standing Internal Data Monitoring Committee
Upper limit of normal
Vaginal Intraepithelial Neoplasia
Vaccine efficacy
Vulvar Intraepithelial Neoplasia
Virus-Like Particle
Vaccination Report Card
White blood (cell) count

1. EXECUTIVE SUMMARY
Human Papillomavirus (HPV) infection causes benign and malignant dysplastic disease,
localized primarily in the anogenital area, in both men and women. Chronic HPV infection
significantly increases the risk of cervical and other anogenital cancers. Cervical cancer is the
second most common cancer in women worldwide, with approximately 530,000 new cases
diagnosed each year and 275,000 deaths annually. Overall, HPV is responsible for
approximately 5% of the global cancer burden. Nearly 100% of cervical cancers and 90% anal
cancers are caused by oncogenic HPV types. Approximately 70% cervical cancers and 90% of
anal cancers are caused by HPV types 16 and 18, both of which are targeted by the currently
licensed HPV vaccines, Gardasil (also referred to as qHPV) and Cervarix. However, neither
Gardasil nor Cervarix provides effective cross-protection against other oncogenic HPV types.
Gardasil 9, also referred to as 9vHPV, is an aluminum adjuvanted 9-valent HPV vaccine
manufactured by Merck & Co., Inc. The 9vHPV vaccine targets the five additional oncogenic
HPV types (31, 33, 45, 52 and 58) that cause approximately 20% of cervical cancers and that
are not covered by currently licensed HPV vaccines. Overall, the 9vHPV vaccine has a
potential to prevent 90% anogential cancers. Gardasil 9 is prepared from highly purified virus
like particles (VLP) of the recombinant major capsid (L1) protein of the vaccine containing HPV
types. The VLPs are adsorbed on amorphous aluminum hydroxyphosphate sulfate (AAHS)
adjuvant. Each 0.5-ml dose is formulated to contain 500 µg of AAHS and L1 protein content of
30 μg for HPV 6, 40 μg for HPV 11, 60 μg for HPV 16, 40 μg for HPV 18, and 20 μg each for
HPV 31, 33, 45, 52 and 58. The final container is a sterile suspension for injection in a singledose vial or a prefilled syringe. Hereafter, HPV types 6, 11, 16 and 18 will be referred to as the
“original types” because they are included in qHPV, while HPV types 31, 33, 45, 52 and 58 will
be referred to as the “new types” included in 9vHPV.
The Applicant, Merck & Co., Inc., seeks licensure of Gardasil 9 for prevention of the following
diseases:

Page 2

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

For females aged 9 to 26 years:
• Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16, 18, 31, 33, 45, 52,
and 58.
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31,
33, 45, 52, and 58:
• Cervical intraepithelial neoplasia (CIN) grade 1, 2 and 3 and cervical adenocarcinoma in
situ (AIS).
• Vulvar intraepithelial neoplasia (VIN) grade 2 and 3.
• Vaginal intraepithelial neoplasia (VaIN) grade 2 and 3.
• Anal intraepithelial neoplasia (AIN) grades 1, 2 and 3.
For males aged 9 through 15 years:
• Anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
• AIN grades 1, 2 and 3 caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
To support the above indication, the Applicant submitted six final study reports of clinical trials
with 9vHPV. Study V503-001 was an efficacy study conducted in women 16 through 26 years of
age. Study V503-002 was an immunobridging study to bridge clinical efficacy obtained from
Study V503-001 to children 9 through 15 years of age because of the inadvisability to perform
genital examination in this population and the likely absence of the primary endpoint. Study
V503-009 provided additional immunological bridging from qHPV vaccine to 9vHPV vaccine in
females 9 through 15 years of age, by demonstrating that both vaccines have similar
immunogenicity with respect to HPV types 6, 11, 16, and 18. Study V503-005 evaluated
potential interference of Gardasil 9 with Menactra and Adacel when administered concomitantly
to children 11 through 15 years of age. Study V503-006 evaluated the safety profile of Gardasil
9 in subjects who were previously vaccinated with the qHPV vaccine, as well as immunogenicity
of Gardasil 9 in this population. Study V503-007 was a concomitant administration study with a
non-U.S.-licensed vaccine (Repevax) and provided safety data for 9vHPV in adolescents 11
through 15 years of age. The major findings and of these studies are summarized below.
Study V503-001 was a randomized, double-blinded, qHPV-controlled, adaptively–designed,
phase 2b/3 trial to evaluate the efficacy, immunogenicity, and safety of Gardasil 9 in women 16
through 26 years of age. Part A (phase 2b) was a dose finding study, and Part B (phase 3) was
an efficacy and safety study. Part B also included those subjects enrolled under Part A who
received the dose formulation of 9vHPV vaccine selected for Part B or the qHPV vaccine
control. The study randomized 14,215 females 16 through 26 years of age from 5 continents
and 18 countries into two treatment groups: 7,106 9vHPV recipients and 7,109 qHPV recipients.
Both vaccines were administered intramuscularly (IM) at Day 1, Month 2, and Month 6. The
median duration of follow-up post-Day 1 was approximately 40 months. As agreed to in prelicensure discussions with CBER, effectiveness of 9vHPV with respect to the original HPV types
was inferred by immunobridging from qHPV to 9vHPV via non-inferior immunogenicity
comparison, and the efficacy for the new HPV types was determined by combined proportion of
subjects with CIN2/3-, VIN 2/3- and VaIN 2/3-or worse related to HPV types 31, 33, 45, 52 and
58. Since efficacy evaluation for anal lesions associated with the five new HPV types was not
feasible due to low incidence, CBER agreed that effectiveness with respect to this endpoint
could be inferred from efficacy against genital lesions (due to highly similar pathophysiology),
immunogenicity, and prevention of persistent infection. Safety endpoints included injection site

Page 3

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

and systemic reactions, new onset of medical conditions including potential autoimmune
disorders, and serious adverse events (SAEs).
The immunogenicity results showed that GMT responses for each of the original HPV types
induced by the 9vHPV vaccine in females 16 through 26 years of age were non-inferior as
compared with the qHPV vaccine group at 4 weeks post-dose 3 in the per protocol
immunogenicity (PPI) population. Numerically, the GMT ratios (9vHPV/qHPV) for HPV types 6,
11, 16, and 18 ranged from 0.80 to 1.19 with lower bounds of 95% CIs all above 0.67, the prespecified success criterion. The proportion of subjects who became seropositive to HPV 6, 11,
16, and 18 by Month 7 in the 9vHPV group was also non-inferior to that in the qHPV group.
Therefore, non-inferior immunogenicity of 9vHPV vaccine compared with qHPV vaccine
supports bridging prior efficacy findings for qHPV vaccine with respect to HPV 6/11/16/18related persistent infection and cervical, vulvar, vaginal, external genital, and anal disease to
9vHPV vaccine.
The primary efficacy endpoint for the new HPV types was assessed in the per protocol efficacy
(PPE) population. The overall observed efficacy against HPV 31/33/45/52/58-related highgrade cervical, vulvar and vaginal lesions in females 16 through 26 years of age in the PPE
population was 96.7% (95% CI: 80.9, 99.8; p<0.0001). The results met the success criterion for
this efficacy endpoint, the lower bound of the two-sided 95% CI for the vaccine efficacy being
greater than 25%. The efficacy of the 9vHPV in preventing high grade genital lesions was
consistent (ranging from approximately 87% to 100%) among different subgroups in terms of
age, race, geographic region, ethnicity, hormone contraception use, and lifetime number of
sexual partners. The 9vHPV vaccine also prevented HPV 31/33/45/52/58-related persistent
infection assessed at Month 6 and Month 12. In addition, the 9vHPV vaccine reduced the
proportion of subjects with HPV 31/33/45/52/58-related genital biopsy and definitive therapy by
31.3% and 46.5%, respectively.
Subpopulation analyses across different ages, races, ethnicities, and geographic regions did not
reveal any substantial differences in estimates of vaccine efficacy against HPV 31/33/45/52/58related genital lesions, though this is not surprising given that only one primary endpoint case
was observed in the entire per-protocol efficacy population. Vaccine efficacy against HPV
31/33/45/52/58-related persistent infection was also similar across subpopulations stratified by
age, race, ethnicity, or geographic region. For example, in the per-protocol efficacy population
the point estimates for efficacy against HPV 31/33/45/52/58-related persistent infection were
97.4% for Whites, 97.3% for Blacks, 95.8% for Asians, and 93.7% for Others.
Study V503-002 was an open label multi-centered clinical trial to assess immunogenicity, safety,
and manufacturing consistency of the 9vHPV vaccine. The study enrolled 2534 children 9
through 15 years of age (1890 girls and 644 boys) and 465 young women 16 through 26 years
of age. The results showed that antibody GMTs for each of the 9vHPV vaccine types were noninferior in children compared with young women, with GMT ratios (children/women) at 4 weeks
post-dose 3 ranging from 1.83 to 3.35 for the 9 HPV types. These results support the bridging
of efficacy findings in 16- to 26-year-old women to 9- to 15-year-old children. The GMT
responses for each of the 9 HPV types at 4 weeks post-dose 3 were similar among girls (9
through 15 years of age) randomized to 1 of 3 final manufacturing process vaccine lots and met
the success criteria for clinical demonstration of lot consistency.
The immunogenicity of the 9vHPV vaccine was non-inferior to the qHPV vaccine with respect to
the original HPV types in girls 9 through 15 years of age as shown in Study V503-009, further
supporting the bridging of efficacy of the qHPV vaccine to the 9vHPV vaccine in this age group.

Page 4

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Concomitant administration of the 9vHPV with the pediatric vaccines Menactra and Adacel did
not show any adverse impact on immune responses to any antigen component in the 9vHPV
vaccine, Menactra and Adacel (Study V503-005).
When 9vHPV was administered to subjects who were previously vaccinated with a 3-dose
regimen of the qHPV (Study V503-006), seroconversion rates for all the 9 HPV types were
greater than 98% at 4 weeks after the third dose. Antibody GMTs for the five new HPV types
were lower than those in HPV vaccine naïve subjects in the other studies, though the clinical
significance is unclear.
Safety findings for 9vHPV vaccine were consistent across the six studies and generally similar
to those observed with qHPV. Vaccine-related systemic adverse reactions reported in the
9vHPV treatment group were similar to the qHPV treatment group, while rates of injection-site
reactions were slightly higher in the 9vHPV treatment group (90.2%) compared with the qHPV
treatment group (84.0%). The most common injection-site reactions were injection-site pain,
swelling and erythema. The rates of injection-site reactions in children 9 through 15 years of age
were numerically lower compared with those in females 16 through 26 years of age.
Subpopulation analyses of systemic and injection-site adverse reactions revealed no substantial
differences by race, ethnicity, age, or gender.
Concomitant administration of the 9vHPV with the pediatric vaccines Menactra and Adacel did
not negatively impact the safety profile of the 9vHPV. The safety profile of the 9vHPV vaccine in
subjects who were previously vaccinated with qHPV vaccine was similar to that of the vaccine in
HPV vaccine naive subjects except for numerically higher rates of injection-site swelling and
erythema.
New onset clinical conditions of potential autoimmune etiology were well-balanced between the
9vHPV and qHPV treatment groups except for a small numerical imbalance in reports of
multiple sclerosis (MS): 5 cases in the 9vHPV group and 2 cases in the qHPV group. The cases
appeared to be randomly distributed with regard to geographic region and ethnicity. Because
the number of the cases in each group is small, the clinical relevance is unknown.
Overall pregnancy outcomes among females who became pregnant during the studies,
including rates of spontaneous abortions, were well-balanced between the two treatment
groups. However, post hoc analyses showed that spontaneous abortion rate in subjects who
received the 9vHPV vaccine and became pregnant within 30 days of any vaccination was higher
than those who received the 9vHPV vaccine and became pregnant outside of the 30-day
vaccination window [19.1% (17/89) vs. 9.6% (105/1089)]. In addition, the spontaneous abortion
rate in subjects who received the 9vHPV vaccine and became pregnant within 30 days of any
vaccination was higher than the corresponding rate in subjects in the qHPV treatment group
[19.1% (17/89) vs. 8.0% (7/88)].
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), this application is required to
contain an assessment of the safety and effectiveness of the product for the claimed indication
in all pediatric age groups. The Applicant has fulfilled the pediatric study requirement for
children 9 through 16 years of age in this application. The Applicant requested a partial waiver
from the requirements of PREA for children 0 through 8 years of age. CBER granted the waiver
request for this age group because initiating vaccination prior to age 9 does not represent a

Page 5

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

meaningful therapeutic benefit over initiating vaccination at 9 years of age and older, and
Gardasil 9 is not likely to be used in a substantial number of children in this age group.
Taken together, the submitted data support the effectiveness of 9vHPV in males 9 through 15
years of age and females 9 through 26 years of age in preventing benign and malignant
anogenital lesions caused by the vaccine HPV types as described in the proposed indication.
The safety profile of 9vHPV observed in the clinical trials was favorable and similar to the
licensed qHPV vaccine.
The numerical imbalances described above in cases of MS and spontaneous abortions will be
further assessed through FDA-sponsored post-marketing studies. Rates of selected
autoimmunity-associated diagnoses, including MS, will be assessed through a Mini-Sentinel
study, while FDA and CDC are collaborating to design a post-marketing study utilizing Vaccine
Safety Datalink (VSD) to further evaluate rates of spontaneous abortions. Additionally, Merck
will sponsor a pregnancy registry to further evaluate pregnancy outcomes among females who
are exposed to 9vHPV around the time of conception.
In conclusion, this reviewer recommends approval of the proposed indication and dose regimen
of Gardasil 9 for females 9 through 26 years of age and males 9 through 15 years of age.
2. CLINICAL AND REGULATORY BACKGROUND
2.1 Disease or Health-Related Condition(s) Studied
Human papillomavirus (HPV) infection causes benign and malignant dysplastic anogenital
disease including cervical, vulvar, vaginal, and anal cancers and their precursors, as well as
anogenital warts(1,2).
Cervical cancer is the second most common cancer in women worldwide, and nearly 100% of
cervical cancers are associated with HPV infection(3,4). Of the 470,000 new cases per year
diagnosed worldwide, half will die from this malignancy(5). Eighty percent of these occur in
developing countries. Implementation of cervical cancer screening programs using the Pap test
and/or HPV testing has reduced the incidence of cervical cancer by 75% in developed
countries. These programs have largely shifted the burden of HPV disease from the morbidity
and mortality associated with cervical cancer to the detection, follow-up, and treatment of a
large number of premalignant lesions. For example, every year in the United States, screening
detects approximately 3.5 million cases of Pap test abnormalities, 300,000 cases of high-grade
cervical dysplasia (CIN 2/3), and 10,000 cases of cervical cancer. Approximately 3,000 cervical
cancer deaths occur annually in the United States(5). In 2010 (the most recent year numbers are
available), 1,818 women in the United States were diagnosed with cervical cancer, and 3,939
women in the United States died from cervical cancer(6). The total yearly cost of diagnostic
screening and treatment of cervical cancer in the U.S. is approximately $6 billion(5).
Most anal cancers (90%), and approximately 50% of vulvar and vaginal cancers, are caused by
HPV. Each year, about 5,500 Americans are diagnosed with these cancers. All three cancers
arise from pre-malignant precursor lesions. Anal cancer rates among men-having-sex-with-men
(MSM) have increased greatly in the past 30 years. Rates of HPV-related vulvar and vaginal
cancers have also increased. These cancers share epidemiologic features with cervical cancer,
and they are often found in women with cervical pre-cancer and cancer(3,7).

Page 6

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Anogenital warts are generally benign, exophytic, hyperkeratotic lesions. In women, the lesions
may appear over the vulva, urethra, vagina, perineum, and anus. Most patients with anogenital
warts are asymptomatic(8). Treatment consists of chemical or physical ablation. However,
therapy is often unsuccessful and recurrence rates are high(9).
Though most HPV infections are self-limited, persistent infection may occur and lead to
dysplastic disease. Cervical cancer pathopysiology typifies the process by which HPV infection
causes anogenital diseases in general. In most cases, low-grade cervical intraepithelial
neoplasia (CIN 1) resolves without clinical sequelae, but in some cases CIN persists and
develops further into CIN 2/3 (moderate and high grade cervical dysplasia and cervical
carcinoma in situ) and cancer(10). Rates of progression of CIN 2/3 to cervical cancer are high,
and rates of regression to normal are low. The determinants of progression versus clearance of
HPV disease have not been well defined. However, persistent detection of HR HPV DNA is a
predictor for progression to cervical cancer(10-12).
HPV viruses are small, non-enveloped icosahedral capsid viruses containing double stranded
deoxyribonucleic acid (DNA). The Late (L) genes encode the two capsid proteins (L1, major
capsid protein) and L2 (minor capsid protein). Proteins encoded on the early (E) portion of the
genome are involved in viral DNA synthesis. The E6 and E7 proteins induce epithelial cell
hyperproliferation by inhibiting cell cycle regulatory proteins.
The HPV family of viruses represents nearly 100 related epitheliotropic DNA viruses that have
been classified by types and species(13). Clinically, HPV types are classified into high-risk (HR)
cancer causing types (in descending order of frequency in tumor specimens: HPV 16, 18, 45,
31, 33, 52, 58, 35, 59, 56, 39, 51, 73, 66 and 68) and low-risk (LR) types (causing generally
benign lesions: e.g., HPV 6, 11, 42, 43, 44)(14). Phylogenetically, HPV are classified into several
species. Species A7 and A9 contain most of the HR types. The A7 Species includes HPV types
18, 39, 45, 59, and 68. The A9 Species includes HPV types 16, 31, 33, 35, 52, and 58. HPV
types 16 and 18 are responsible for most (over 70%) cases of cervical cancer(5,15-18). Species
A10 contains LR HPV Types 6 and 11, which are responsible for over 90% of anogenital warts.
HPV types 16, 18 and 45 are associated with the highest propensity to progress to invasive
cervical cancer as evidenced by the relatively lower proportion of women with normal cytology
who are infected with HPV types 16, 18 or 45 compared to the percentage with cervical cancers
related to those same types(19). HPV types 31, 33, 52, and 58 (the additional high-risk HPV
types included in the 9vHPV vaccine) are also associated with higher rates of detection in
invasive cervical cancer as compared to detection in normal cytology specimens.
2.2 Currently Available, Pharmacologically Unrelated Treatment(s)/Intervention(s) for the
Proposed Indication(s)
2.2.1 Prevention
Several studies in men have reported that condom use is associated with fewer genital HPV
infections and a shorter duration of infection in these men who were infected(20). However, HPV
can infect genital areas that are not covered by condoms. For women, a meta-analysis found
no consistent evidence that condom use in their sexual partners reduced the risk of acquisition
of cervical HPV infection, but it was associated with some protection against genital warts, CIN
2/3 and cervical cancer(21). The success of Pap screening in reducing the incidence of cervical
cancer has been attributed to excision of CIN 2/3 lesions prior to the development of cancer(22).

Page 7

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

2.2.2 Treatment
The mainstays of treatment of high-grade CIN (i.e., CIN 2 or worse) are excision or ablation of
the transformation zone of the cervix (an anatomic area that contains the transition from the
squamous epithelium of the ectocervix to the glandular epithelium of the endocervix).
Hysterectomy is an option for women who are incompletely treated with excision or ablation or
who have recurrent CIN. The efficacy rate for both ablation and excision is approximately 90%
to 95%. Overall, the rate of recurrent or persistent CIN is 5-17% despite therapy with any of the
excision or ablative techniques(23). However, both excision and ablation have been associated
with an increased risk of adverse obstetric outcomes (pregnancy loss, cervical incompetence,
premature rupture of membranes, preterm delivery), and morbidity (hemorrhage, pain,
dysmenorrhea, discharge, cervical stenosis)(23).
Both medical and surgical options are available for treatment of genital warts. Treatment
effectiveness studies show highly variable results. There is no definitive evidence that any of the
available treatments are superior to any other, and no single treatment is ideal for all patients or
all warts. All therapies are associated with localized discomfort including itching, burning,
erosions, and pain since the epithelium is disrupted, and complications resulting from treatment
include scarring and chronic genital area pain(24, 25)
Treatment options for invasive cancers are surgery, radiation therapy and chemotherapy.
Prognosis following treatments is largely dependent on disease stage. Cervical cancer
treatment is associated with pelvic pain, sexual dysfunction, bowel dysfunction, urinary
incontinence, and ovarian failure including infertility and premature menopause, which can
persist for years or lifelong following treatment.
2.3 Safety and Efficacy of Pharmacologically Related Products
Two HPV vaccines, Gardasil and Cervarix, are licensed in the United States and numerous
countries worldwide. Both Gardasil and Cervarix contain recombinant VLPs of HPV types 16
and 18 and provide varying degrees of cross-protection against persistent infection and cervical
dysplasias associated with HPV 31, 33 and 45. However, the cross-protection seems to wane
over time. Gardasil also protects against HPV types 6 and 11, which cause 90% genital warts.
Both vaccines are formulated in a sterile suspension for intramuscular injection (IM). Each dose
of Gardasil (in 0.5 ml) contains 20 µg, 40 µg, 40 µg and 20 µg, of L1 proteins of HPV types 6,
11, 16 and 18, respectively, and approximately 225 µg of the proprietary adjuvant AAHS. Each
dose of Cervarix (in 0.5m) contains 20 µg each of HPV types 16 and 18 L1 proteins, and the
adjuvant AS04, which contains 50 µg of monophosphoryl lipid A and 0.5 mg of aluminum
hydroxide.
Gardasil was registered in 127 countries, with an estimated >95 million doses distributed
worldwide, and Cervarix was registered in >115 countries, with an estimated >33 million doses
distributed worldwide(26). Both Gardasil and Cervarix(27) have demonstrated similar efficacy
against the vaccine-targeted types for a range of cervical endpoints from persistent infection to
CIN 3 in women naïve to the corresponding type at the time of vaccination. However, protection
from incident infection or disease from non-vaccine types is restricted, and the vaccines have no
effect on prevalent infection or disease. Gardasil has demonstrated strong protection against
genital warts, VIN and VaIN associated with the vaccine types in women, and also protected
men for incident infection, genital warts and AIN by the vaccine types. For practical reasons,
efficacy studies have not been conducted in preadolescent and adolescent girls and boys.
Efficacy in this population was inferred from clinical trials in adults by immunogenicity bridging.

Page 8

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

The safety profile of both vaccines was assessed extensively in randomized controlled clinical
trials conducted prior to licensure and has been further elucidated following licensure from
surveillance and specific studies in large populations. In summary, both vaccines are associated
with relatively high rates of injection site reactions, particularly pain, but this is usually of short
duration and resolves spontaneously. Systemic reactions (headache, fever, nausea, dizziness,
and vomiting) have generally been mild and self-limited. Post vaccination syncope has
occurred, but can be avoided with appropriate care. Serious vaccine-attributable adverse
events, such as anaphylaxis, are rare. Post marketing case reports have linked vaccination with
a range of new onset chronic conditions, including autoimmune diseases. However, wellconducted population-based studies show no association between the HPV vaccines and such
conditions(26).
One observer-blinded randomized head-to-head study compared Cervarix and Gardasil
directly(28). In the approximately 1,100 women aged 18–45 years, solicited AEs were
significantly more common following Cervarix [95.1% (95 % CI 92.8–96.7)] compared with
Gardasil [85.1% (95% CI 81.8–88.1)]. Severe injection site reactions (pain, redness and
swelling) were more common in Cervarix recipients [17.4% (95% CI 14.2–20.9)] compared with
Gardasil recipients [3.4% (95 % CI 2.0–5.4)]. At 24-month follow-up, the proportions reporting
serious adverse events (SAEs), significant medical conditions, new onset chronic diseases or
autoimmune diseases were similar between the two groups. The safety results of this single
head-to-head study are generally consistent with those from separate studies of both vaccines
reported in their package inserts (PIs). The safety and efficacy of Gardasil are discussed in
further detail in the next section.
2.4 Previous Human Experience with the Product (Including Foreign Experience)
Gardasil 9 (also designated as 9vHPV in this review) is a non-infectious recombinant 9-valent
HPV vaccine prepared from the purified VLPs of L1 protein HPV types 6, 11, 16, 18, 31, 33, 45,
52 and 58. The L1 proteins are produced by separate fermentations using recombinant
Saccharomyces cerevisiae and self-assembled into VLPs. There is no previous human
experience with 9vHPV and it has not been approved for marketing in any country. However,
previous human experience with qHPV is relevant to 9vHPV since the vaccines are similar in
composition and contain four common HPV types (6, 11, 16 and 18).
2.4.1 Clinical Trials with qHPV
Administration of a 3-dose regimen (Month 0, 2 and 6) of qHPV to women naïve to the relevant
vaccine HPV types at Day 1 through completion of the vaccination regimen was over 94%
efficacious in preventing the development of HPV 16- and 18-related CIN 2/3, adenocarcinoma
in situ (AIS), VIN 2/3 and VaIN 2/3; HPV 6- and 11-related external genital lesions (including
condyloma acuminata); HPV 6-, 11-, 16-, and 18-related AIN; and HPV 6-, 11-, 16-, and 18related persistent infection. Efficacy was maintained for ≥5 years post-vaccination(29). The qHPV
vaccine affords some cross-protection against other oncogenic HPV types. However, this crossprotection is incomplete and limited to only a few types(30).
A pooled analysis of clinical trials showed that injection site reactions were significantly more
common in qHPV recipients compared with recipients of aluminum containing placebo(31).
Injection site pain was most common (83% vs. 77%), with severe pain reported in 4% of qHPV
recipients compared with 2% of aluminum-containing placebo recipients. Erythema (24% vs.
18%) and swelling (24 vs. 16%) were also more common in vaccine recipients. Common
systemic adverse experiences did not differ markedly between groups, with headache most
common (26%), followed by fever (13%) and nausea (6%). There was no significant difference

Page 9

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

in the frequency of SAEs overall or by system organ class over a median follow-up period of 3.6
years and >34,000 person-years-at-risk. Six vaccine-related SAEs were experienced by five
qHPV recipients: recurrent vaginal hemorrhage, bronchospasm, gastroenteritis, ulcerative
colitis, and a combination of hypertension and headache. Deaths occurred in 0.1% of both
vaccine and control recipients, respectively, with no death assessed as related to the vaccine.
The overall proportions of subjects reporting new onset autoimmune conditions were not
different between the qHPV and placebo groups (2.4 % in each); specific conditions that were
nominally higher among qHPV recipients included thyroiditis, rheumatoid arthritis and
proteinuria. Analysis of pooled data from many clinical trials has still not provided enough
participants to detect meaningful differences in these low-incidence events.
2.4.2 Post Licensure Safety of qHPV
The qHPV vaccine was initially approved by the FDA in June 2006. As reported by CDC’s
Morbidity and Mortality Weekly Report on July 26, 2013(32), from June 2006 through March
2013, approximately 56 million doses of qHPV were distributed in the United States. During this
period, the Vaccine Adverse Event Reporting System (VAERS) received a total of 21,194
adverse event reports occurring in females after receipt of qHPV; 92.1% were classified as nonserious. Among non-serious adverse events, the most commonly reported generalized
symptoms were syncope, dizziness, nausea, headache, fever, and urticaria; the most commonly
reported local symptoms were injection-site pain, redness, and swelling. Among the 7.9% of
qHPV-related VAERS reports classified as serious, headache, nausea, vomiting, fatigue,
dizziness, syncope, and generalized weakness were the most frequently reported symptoms.
Overall reporting of adverse events to VAERS is consistent with pre-licensure clinical trial data.
2.5 Summary of Pre- and Post-Submission Regulatory Activity Related to the Submission
2.5.1 Pre-submission Regulatory Activities
•

August 3, 2007, Original IND Submission

•

September 22, 2008, End of Phase 2 (EOP2) Meetings
The Applicant proposed a co-primary endpoint assessment of persistent infection related
to the new HPV types (31, 33, 45, 52 and 58) and immune responses to the original
HPV types (6, 11, 16 and 18). The Applicant requested a seamless phase 2/3 adaptive
trial design. The following agreements were reached between CBER and the Applicant:
o The primary efficacy endpoint in the clinical trial to support licensure of 9vHPV for
prevention of HPV 31, 33, 45, 52 and 58 would be limited to the combined
histopathological endpoints of HPV 31, 33, 45, 52 and 58-related CIN 2/3 or worse
and VIN 2/3- and VaIN 2/3- or worse in the PPE population. The success criterion
would be a lower bound (LB) of vaccine efficacy (VE) of the two-sided 95% CI being
greater than 25%. Persistent infection would be a secondary endpoint.
o The clinical benefit of 9vHPV against the original HPV types would be demonstrated
by non-inferiority comparison between qHPV and 9vHPV as assessed by antibody
responses to the original HPV types. The success criterion would be a LB of the
two-sided 95% CI for the geometric mean titer (GMT) ratio (9vHPV/qHPV) being
greater than 0.67 for each HPV type.
o Transfer of label claims for qHPV would be granted for 9vHPV if and only if the
efficacy were demonstrated for the combined histopathological endpoints mentioned
above, non-inferior immunogenicity of 9vHPV were obtained as compared to qHPV
in regards to the original HPV types, and no safety issues were identified.

Page 10

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

o

The proposed seamless adaptive trial design was acceptable.

•

November 21, 2008, the Applicant submitted a revised clinical protocol based on the
EOP2 meeting agreements.

•

December 23, 2009 Fast Track Designation requested

•

February 19, 2010 Fast Track Designation granted

•

June 28, 2011, Type C Meeting to discuss the study(ies) design(s) to support use in
males 9 through 26 years of age.
o

The Applicant proposed to conduct a safety and immunogenicity study in males 9
through 15 years of age (to be submitted as part of the original BLA submission).

o

CBER requested a safety and immunogenicity study in males 16 through 26 years of
age in order to bridge efficacy to this population to be submitted as a supplemental.

Reviewer’s comments: Efficacy of qHPV against anal disease due to vaccine HPV types
was assessed in males 16 through 26 years of age, but not in females. The efficacy of
qHPV against anal disease due to HPV 6, 11, 16 and 18 in females and boys 9 through 15
years of age was inferred by immunological bridging from males 16 through 26 years of
age.
In contrast to HPV associated cervical cancers, HPV associated anal cancer is
predominately caused by HPV types 16 and 18. For example, among HPV-positive anal
cancerous lesions, 87% were HPV 16 positive and 9% were HPV 18 positive(33). It is not
feasible to assess efficacy of 9vHPV against anal disease due to HPV types 31, 33, 45, 52
and 58 using qHPV as a comparator because very few cases of anal lesions are caused by
the new HPV types in 9vHPV. In addition, it is ethically problematic to conduct a placebo
controlled study to evaluate the efficacy of 9vHPV in prevention of HPV related anal
lesions. Inferring efficacy in males from the core efficacy study in females 16 through 26
years of age by immunological bridging is therefore acceptable.
•

December 6, 2011 Pre-BLA Meeting

2.5.2 Post-BLA Submission Regulatory Activities
•

May 20, 2014 CBER requested that the Applicant conduct an internal audit of Study Site
----(b)(4)(b)(6)-- under Study V503-001 for potential issues of non-compliance with Good
Clinical Practices (GCP).

•

July 31, 2014 CBER requested that the Applicant provide additional information
regarding public allegations of non-compliance with GCP at clinical sites (b)(3)(b)(4)(b)(7)
in (b)(3)(b)(4)(b)(7) in Study V503-002.

3. SUBMISSION QUALITY AND GOOD CLINICAL PRACTICES
3.1 Submission Quality and Completeness
The submission in general was adequately organized and integrated to accommodate the
conduct of a complete clinical review without unreasonable difficulty.

Page 11

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

3.2 Compliance with Good Clinical Practices and Submission Integrity
This application contains six studies (Protocol V503-001, -002, -005, -006, -007 and -009). All
studies except for V503-009 were at least partially conducted under IND 13447. The designs of
studies under IND13447 adhered to good clinical practices, including elements of informed
consent as required by 21 CFR 50.25 and pediatric ethical considerations as outlined in 21 CFR
50.51-54. Study V503-009 was requested by the European Medicines Agency to provide
additional supporting data to bridge immunogenicity from qHPV to 9vHPV vaccines in girls 9
through 15 years of age. This study was not conducted under IND. The clinical protocol states
that the investigator and the sponsor agreed to conduct the study in an efficient and diligent
manner in accordance with this protocol, International Conference of Hominization (ICH) GCP
standards, Declaration of Helsinki and applicable regulatory requirements, as well as any
European and/or local applicable laws and regulations relating to the conduct of the study.
Reviewer’s comments: Under Module 5.2, the Applicant indicated that the studies under
Protocols V503-001, -002, -005, -006, and -007 conducted at non-U.S. sites were not conducted
under IND13447. In response to IRs dated February 14, 2014 and April 23, 2014 requesting
clarification on these hybrid IND/non-IND studies, Merck submitted a response under STN
125508/0.13 on May 12, 2014 indicating that non-U.S. sites followed all FDA requirements
except for signing Form 1572.
BIMO inspected four U.S. study sites and two foreign country sites, and no concerns were
identified in the course of these inspections. The four U.S. study sites included Georgia
Regents University Research and Medical college of Georgia Research (enrolled 105 subjects
for V503-001 and 26 subjections for V503-002), H. Lee Moffitt Cancer Center and Research
Institute (enrolled 113 subjects for V503-001), University of Washington (enrolled 139 subjects
for V503-001), and Primary Physicians Research Inc. in Pennsylvania (enrolled 55 for V503002). The two foreign sites included Vaccine Trial Center of Mahido University in Bangkok,
Thailand (enrolled 135 subjects for V503-001, and 130 subjects for V503-002), and
Frederiksberg Hospital in Frederiksberg, Denmark (enrolled 953 subjects for V503-001).
During the review of this application, CBER became aware that another vaccine manufacturer
was closing a site ----(b)(4)(b)(6)----- for multiple violations including:
• Violations of GCP with regard to obtaining informed consent
• Backdating, copy and pasting clinical assessments/visit notes, medical charts completed
days after subject visits
• Lack of evidence that PI was providing adequate oversight or even directly involved in
the conduct of the study
The investigator at site (b)(4)(b)(6) was also involved in Study V503-001, which enrolled 247 subjects
who received 9vHPV vaccine and 248 subjects who received qHPV vaccine. An Information
Request was sent to Merck on May 20, 2014, to inquire if Merck had conducted (or was
planning to conduct) an internal audit of this site. Merck then conducted an internal audit of this
site. Merck submitted the audit to CBER under STN 125508/0.31 on September 2, 2014. The
preliminary audit showed deviations in the informed consent process and deviations from the
clinical protocol.
Further investigation conducted by the Applicant showed that all 580 subjects entering the study
provided primary informed consent upon enrollment. The Applicant also confirmed that all 580
subjects except 3 signed the final, revised informed consent. As mentioned in the submission of
STN 125508/0.31, there were gaps in the process of obtaining certain applicable re-consents

Page 12

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

from some study subjects at this site. The results regarding this investigation were submitted to
STN 125508/0.40 on October 6, 2014.
Reviewer’s comments: Based on the additional information provided by the Applicant, the noncompliance with GCP was limited to the re-consent process. The clinical and statistical
reviewers thoroughly assessed the adverse events, immunogenicity results, and gynecological
results (PCR, cytology and pathology). The rates and intensities of adverse events, antibody
responses to the vaccine HPV types, and gynecological data collected from the site were similar
to those observed in other sites under Study V503-001. Two subjects contributed to the cases
of primary efficacy analysis: one in the 9vHPV group (the only one primary efficacy case in
Study V503-001), and one in the qHPV group. The data collected from this site appears to be
consistent with other sites in this study. Consequently, the review team determined that the
data collected from this study site should be included in the clinical assessment. Please also
refer to the BIMO review by Ms. Erin Mcdowell.
In addition, the review team became aware of allegations of non-compliance of GCP at two
clinical sites ---(b)(3)(b)(4)(b)(7)--- in Study V503-002. CBER requested that the Applicant
provide additional information regarding the allegations and medical monitor reports of these
sites on July 31, 2014. The Applicant submitted the requested information to STN 125508/0.30
on August 8, 2014.
Site -------------------------------------------(b)(3)(b)(4)(b)(7)------------------------------------------------ of all
subjects in Study V503-002. The review team assessed copies of informed consent documents
and Medical Monitor reports for these two sites submitted by the Applicant and determined that
these documents do potentially corroborate some of the allegations. The proportion of subjects
with injection-site reactions reported in Site (b)(3)(b)(4)(b)(7), much lower compared with the
overall rate reported in Study V503-002 (80.6%), (b)(3)(b)(4)(b)(7) reported an oral temperature
≥37.8ºC in Site (b)(3)(b)(4)(b)(7) (compared with 8.8% in Study V503-002), suggesting that adverse events
may have been under-reported at these sites.
Reviewer comments: Based on the above findings, especially the problems with the informed
consent process, the review team determined that data collected from these study sites should
be excluded from the clinical assessment and package insert. Please also refer to the BIMO
review by Ms. Erin Mcdowell. On October 31, 2014 CBER asked the Applicant to re-analyze
data excluding Study Sites (b)(3)(b)(4)(b)(7) and to revise the package insert accordingly. The reanalysis data were submitted to STN 125508/0.43, and were reviewed and incorporated into
this review (please refer to Sections 6.2, 7 and 8) and the PI. The data reviewed in Sections
6.2, 7, and 8 of this document reflect the exclusion of the two (b)(3)(b)(4)(b)(7) sites from the dataset of
study V503-002. Sensitivity analyses showed that exclusion of these data resulted in no
changes greater than 1% for rates of any adverse events, no changes in seroconversion rate for
any vaccine HPV type, and no changes greater than 2% for GMTs for any vaccine HPV type.
3.3 Financial Disclosures
The Applicant has adequately disclosed financial interests/arrangements with clinical
investigators under Studies V503-001, -002, -005, -006 and -007 as recommended in the
Guidance for Industry Financial Disclosure by Clinical Investigators. All investigators in these
five studies except one investigator under Study V503-002 have provided financial disclosure
information. Five investigators from 3 studies (Study V503-001, -002 and -006) received
significant payments from the Applicant.

Page 13

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Financial disclosure information for Study V503-009 was not included in the original submission
but was submitted to STN 125508/0.4_Module 1.11.3 on March 14, 2014, following a CBER
request on February 14, 2014.
Potential issues with financial disclosure for the six clinical studies submitted to this BLA are
summarized below.
Five investigators in the three studies had disclosable financial interests/arrangements.
• One Investigator who participated in Studies V503-001, -002 and -006 received
Significant Payments of Other Sorts of -------(b)(6)------ (internal search by the Applicant).
The payments reported by this investigator to the Applicant were -----(b)(6)-----.
• Two investigators who participated in Study V503-001 received Significant Payments of
Other Sorts (internal search by the Applicant) of -----------------(b)(6)----------------,
respectively. The corresponding payments reported by the investigators to the Applicant
were --------------(b)(6)-------------, respectively.
• Two investigators who participated in Study V503-002 received Significant Payments of
Other Sorts (internal search by the Applicant) of ----------(b)(6)---------- reported by
investigator) and ----------(b)(6)----------- reported by investigator), respectively.
CBER requested the following information from the Applicant on February 14, 2014:
• Please provide a description of the steps taken to minimize potential bias.
• Please provide details as to the nature of the payments to the five investigators and
specify the Merck product involved for each payment.
• Please explain why the payments to the five investigators reported by Merck via internal
search are different from those reported by the investigators to Merck.
• Please provide the number of primary efficacy cases in Study V503-001 (tabulated by
qHPV and 9vHPV treatment arms) reported by the investigators with disclosable
financial interests.
On March 14, 2014, the Applicant submitted its responses to STN 125508/0.4. The Applicant
explained that for Studies V503-001 and V503-009, potential bias would be minimized by the
study design (randomized and double blind). For V503-002, all subjects received 9vHPV,
subjects were randomized in equal numbers to three manufacturing product lots, and laboratory
personnel were blinded. Therefore, the risks of bias in immunogenicity evaluation were
mitigated. However, potential bias for safety evaluation still exists. The payments to the
investigators were for symposia, consultant fees, medical education and research, speaker fees
and participation on an advisory board. The discrepancies in payments reported by the
Applicant and the investigators were caused by different reporting periods used by the
investigators and the Applicant.
Reviewer’s Comments: Only one primary endpoint case (in the qHPV group from study site
0005) was reported from study sites involving the investigators discussed above. The
Applicant’s explanations and clarifications are acceptable. As for the potential bias for safety
evaluation, it is a limitation of the study design and is discussed further in Section 8 of this
review.

Page 14

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

4. SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES
4.1 Chemistry, Manufacturing, and Controls
The manufacturing process for the five new HPV types in 9vHPV vaccine remains unchanged
for the HPV types contained in the licensed qHPV vaccine. The CMC reviewer states that there
are no substantive issues that will impact approval of the application. Please refer to the CMC
review by Dr. Haruhiko Murata for details.
4.2 Assay Validation
The assay reviewers identified issues in the validations for the assays to assess responses to
pertussis and meningococcal antigens used in the concomitant vaccination study (V503-005).
The reviewers determined that the issues may be addressed by assessing the performance of
the assays during the time in which samples were tested. If the assays can be shown to have
been well controlled during sample analysis, and since the data from the study do not indicate
any unusual results, the assays may be deemed appropriate for use. However, these issues
should be addressed before the assays are used for future studies. Please refer to the Assay
Validation Review by Ms. Freyja Lynn for details.
4.3 Nonclinical Pharmacology/Toxicology
Based on the nonclinical toxicity assessments of the V503 vaccine submitted in this BLA, there
are no significant safety issues to preclude the BLA from being approved. Please refer to the
toxicology review by Dr. Nabil Al-Humadi for details.
4.4 Clinical Pharmacology
No clinical pharmacology studies of the 9vHPV vaccine were conducted in support of this
application
4.4.1 Mechanism of Action
Animal studies suggest that the protective effect of L1 VLP vaccines may be mediated by the
development of IgG neutralizing antibodies directed against HPV L1 capsid proteins generated
as a result of vaccination.
4.5 Statistical
The statistical reviewer verified that the primary study endpoint analyses cited by the Applicant
were supported by the submitted data. Please refer to the statistical review by Dr. Lihan Yan for
details.
4.6 Pharmacovigilance
The pharmacovigilance medical reviewer recommends a post-marketing safety study to assess
risk of spontaneous abortion following vaccination, with particular attention to pregnancies that
occur within 30 days of vaccination with 9vHPV. A study of this type may require a
computerized database of linked anonymized longitudinal medical records, in which medical
record data for pregnant women is available for at least one year prior to their last menstrual
period, and can be linked to the administration of vaccines. No REMS is warranted at this time.
Please refer to the pharmacovigilance review by Dr. Adamma Mba-Jonas for the integrated risk
assessment.

Page 15

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

5. SOURCES OF CLINICAL DATA AND OTHER INFORMATION CONSIDERED IN THE REVIEW
5.1 Review Strategy
The results of six clinical studies are included in this BLA submission. Study V503-001 provides
major clinical efficacy, immunogenicity and safety data to support licensure of 9vHPV in females
16 through 26 years of age. Study V503-002 provides immunogenicity data to infer clinical
effectiveness in boys and girls 9 through 15 years of age because clinical efficacy studies were
not feasible in this population. Study V503-002 also includes a lot consistency study. The
review efforts focused on these two studies, which are reviewed and documented separately
under Section 6. Study V503-009 is a non-inferiority immunogenicity study of antibody
responses to HPV types 6, 11, 16 and 18 comparing qHPV and 9vHPV in girls 9 through 15
years of age. Because the immunogenicity and safety data for this study are listed separately in
the draft package insert, this study is also reviewed individually under Section 6.
The remaining three supportive studies are included in the review analyses under Sections 7
[Integrated Summary of Efficacy (ISE)] and 8 [Integrated Summary of Safety (ISS)]. Studies
V503-005 and V503-007 provide immunogenicity and safety data in children 11 through 15
years of age who received 9vHPV concomitantly administered with Menactra/Adacel and
Repevax, respectively. Study V503-006 provides immunogenicity and safety data on 9vHPV
administered to females 12 through 26 years of age who previously received Gardasil
vaccination. Immunogenicity data for Studies V503-005 and V503-006 are reviewed under
Section 7, and the safety data are reviewed under Section 8. Because Repevax is not licensed
in the U.S., immunogenicity data from subjects vaccinated concomitantly with 9vHPV and
Repevax (Study V503-007) are briefly summarized and documented in the ISE. The remaining
pooled safety and immunogenicity data from all the 6 studies (including Study V503-007) are
analyzed in Sections 7 and 8.
5.2 BLA/IND Documents That Serve as the Basis for the Clinical Review
This clinical review considered the following documents submitted to the BLA, as listed by
electronic common technical document (eCTD) module:
• BLA 125508/0.0, Module 1.3.4 (Financial Disclosure)
• BLA 125508/0.0, Module 1.6.2 (Meeting Background Materials)
• BLA 125508/0.0, Module 1.7.1 (Fast Track Designation Request)
• BLA 125508/0.0, Module 1.9.1 (Request for Waive of Pediatric Studies)
• BLA 125508/0.0, Module 1.14.1.1 (Draft Carton and Container Labels)
• BLA 125508/0.0, Module 1.14.1.3 (Draft Labeling Text)
• BLA 125508/0.0, Module 1.16 (Risk Management Plans)
• BLA 125508/0.0, Module 2.5 (Clinical overview)
• BLA 125508/0.0, Module 2.7.3 (Summary of clinical efficacy, i.e., Integrated Summary of
Efficacy)
• BLA 125508/0.0, Module 2.7.4 (Summary of clinical safety, i.e., Integrated Summary of
Safety)
• BLA 125508/0.0, Module 5.2 (Summary Level of Clinical Site Information)
• BLA 125508/0.0, Module 5.3.5.1.p001 [Clinical Study Report for P001 (V503-001)]
• BLA 125508/0.0, Module 5.3.5.1.p009 [Clinical Study Report for P009 (V503-009)]
• BLA 125508/0.0, Module 5.3.5.1.p002 [Clinical Study Report for P002 (V503-002)]
• BLA 125508/0.0, Module 5.3.5.1.p005 [Clinical Study Report for P005 (V503-005)]

Page 16

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

BLA 125508/0.0, Module 5.3.5.1.p007 [Clinical Study Report for P007 (V503-007)]
BLA 125508/0.0, Module 5.3.5.1.p006 [Clinical Study Report for P006 (V503-006)]
BLA 125508/0.0, Module 5.3.5.1.NA [Gardasil Historical Studies]
BLA 125508/0.0, Module 5.3.5.3 (Statistical Analysis Plan)
BLA 125508/0.0, Module 5.3.6 (Post-marketing Studies of Gardasil)
BLA 125508/0.3, Module 1.14.1.2 Annotated Draft Labeling Text (revised)
BLA 125508/0.4, Module 1.11.3 Efficacy Information Amendment (Response to CBER
Information Request #1)
BLA 125508/0.6, Module 1.11.3 Efficacy Information Amendment (Response to CBER
Information Request #2)
BLA 125508/0.8, Module 1.11.3 Safety Update Report (4 months)
BLA 125508/0.13, Module 1.11.3 Efficacy Information Amendment (Response to CBER
Information Request #5: Spontaneous abortions)
BLA 125508/0.22, Module 1.11.3 Response to CBER Information Request #13
Regarding Multiple Sclerosis
BLA 125508/0.25, Module 1.11.3 Efficacy Information Amendment (Response to CBER
Information Request #13: Spontaneous abortions)
BLA 125508/0.30, Module 1.11.3 Efficacy Information Amendment (Response to CBER
Information Request #16: (b)(3)(b)(4)(b)(7) Sites Non-compliance with GCP)
BLA 125508/0.31, Module 1.11.3 Efficacy Information Amendment (Response to CBER
Information Request #10: (b)(3)(b)(4)(b)(7) Site Non-compliance with GCP)
BLA 125508/0.34, Module 1.11.3 Response to Information Request (IR) on Site
(b)(3)(b)(4)(b)(7)

•
•
•
•
•

BLA 125508/0.35, Module 1.11.3 Response to IR for Post-marketing Assessment of
Spontaneous Abortions
BLA 125508/0.38, Module 1.11.3 Sensitivity Analyses (Excluding Study Sites -------(b)(3)(b)(4)(b)(7) and Study Sites (b)(3)(b)(4)(b)(7))
BLA 125508/0.39, Module 1.11.3 Response to IR#18 for Causality Assessment of the
Case of Pulmonary Vasculitis
BLA 125508/0.41, Module 1.11.3 Response to IR#18 for Causality Assessment of the
Case of Pulmonary Vasculitis-Follow-up Response
BLA 125508/0.43, Module 1.11.3 Response to IR#19 for Re-analyses of Excluding
(b)(3)(b)(4)(b)(7) Sites (b)(3)(b)(4)(b)(7)

5.3 Table of Studies/Clinical Trials
The clinical studies reviewed in this BLA are summarized in Table 1 and Table 2 below.
Table 1: Overview of Clinical Studies V503-001, -002 and -009.
Study ID
IND Number
NCT Number
Study Phase
Study Centers
Participants Planned
Participants Enrolled
Age Range

V503-001
13447
00543543
2b/3
105 international
14620
Phase 2b: 1242;
Phase 3: 14215
16 to 26

V503-002
13447
00943722
3
70 international
2800
2999

V503-009
Not Under IND
01304498
3
24 centers in Europe
600
600

9-26

9 to 15

Page 17

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Study ID
Demographics

V503-001
Females only

9vHPV Recipients

8020 (7099 received
Mid-dose)
Low-dose, Mid-dose and
High-dose
3 doses IM at Day 1,
Month 2 & Month 6
qHPV, 3 doses IM at Day
1, Month 2 & Month 6
Phase 2b: 1:1:1:1;
Phase 3: 1:1

9vHPV Dose
9vHPV Regimen
Comparator
Randomization Ratio

Study Duration
Primary Efficacy
Endpoints

Major Findings

Phase 2b: 7 months;
Phase 3: ≥42 months
Combined proportion of
subjects with HPV type
31, 33, 45, 52 and 58related CIN2 or VIN2/3 or
VaIN2/3 or worse;
Antibody GMTs for HPV
types 6, 11, 16 and 18
Efficacy: 96.7% (95%CI:
80.9, 99.8) in prevention
of combined genital
lesions associated with
the five new HPV types.
Immunogenicity: Noninferiority -demonstrated
between 9vHPV and
qHPV for HPV types 6,
11, 16, and 18.

V503-002
63.0% 9-15 year-old
females; 21.5% 9-15
year-old males; 15.5%
16-26 year-old females
2991

V503-009
Females only

Mid-dose

Mid-dose

3 doses IM at Day 1,
Month 2 & Month 6
NA

12 months

3 doses IM at Day 1,
Month 2 & Month 6
qHPV, 3 doses IM at Day
1, Month 2 & Month 6
1:1 with two age strata (9
to 12 and 13 to 15 years
of age)
7 months

Antibody GMTs for all 9
vaccine HPV types

Antibody GMTs for HPV
types 6, 11, 16 and 18

Non-inferiority
demonstrated between 9
through 15 year-olds and
16 through 26 year old
females for all 9 vaccine
HPV types.
Lot consistency criteria
were met for all 9 vaccine
HPV types.

Non-inferiority
demonstrated between
9vHPV and qHPV for
HPV types 6, 11, 16, and
18.

1:1:1 (Lot consistency)

300

Table 2: Overview of Clinical Studies V503-005, -006, and -007
Study ID
IND Number
NCT Number
Study Phase
Study Centers
Participants Enrolled
Age Range
Demographics

V503-005
13447
00988884
3
Multi-centers
1241
11 to 15 years
620 males, 621 females

9vHPV Recipients
9vHPV Dose
9vHPV Regimen

1241
Mid dose
3 doses IM at Day 1,
Month 2 & Month 6, with
concomitant
administration of the first
dose of 9vHPV with
Menactra and Adacel
Administration of 9vHPV

Comparator

V503-006
13447
01047345
3
Multi-centers
924
12 to 26 years
Females previously
vaccinated with qHPV
618
Mid dose
3 doses IM at Day 1,
Month 2 & Month 6

Placebo

V503-007
13447
01073293
3
Multi-centers
1054
11 t0 15 years
526 males, 528 females
1054
Mid dose
3 doses IM at Day 1, Month
2 & Month 6, with
concomitant administration
of the first dose of 9vHPV
with Repevax.
Administration of 9vHPV

Page 18

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Study ID

Randomization Ratio
Study Duration
Primary Efficacy
Endpoints

Major Findings

V503-005
without concomitant
administration of
Menactra and Adacel
1: 1
7 months
Antibody GMTs for all 9
vaccine HPV types and
antigens in Menactra and
Adacel
Concomitant
administration of the first
dose of 9vHPV with
Menactra and Adacel
does not impact the
immune responses to any
of the vaccines.

V503-006

V503-007
without concomitant
administration of Repevax

2: 1
7 months
Antibody GMTs and
seroconversion rates
for all 9 vaccine HPV
types
Seroconversion rates
for all 9 vaccine HPV
types were similar
among prior qHPV
recipients compared to
HPV vaccine-naïve
subjects in other
studies, though
antibody GMTs were
reduced for HPV types
31, 33, 45, 52 and 58.

1: 1
7 months
Antibody GMTs for all 9
vaccine HPV types and
antigens in Repevax
Concomitant administration
of the first dose of 9vHPV
with Repevax does not
impact the immune
responses to 9vHPV and
Repevax.

5.4 Consultations
No Advisory Committee meeting was held and no external consults were sought.
5.5 Literature Reviewed
1. Paavonen J. Human Papillomavirus infection and the development of cervical cancer
and related genital neoplasias. Int J Infect Dis 2007; 11(Suppl 2): S3-S9.
2. Madkan VK, et al. Tyring SK, The oncogenic potential of human papillomaviruses: are
view on the role of host genetics and environmental cofactors.Br J Dermatol 2007; 157:
228-41.
3. Bosch FX and Munoz N. The viral etiology of cervical cancer. Virus Research 2002;
89:183-90.
4. Walboomers JMM, et al. Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol 1999; 189: 12-9.
5. Jansen KU and Shaw AR. Human papillomavirus vaccines and prevention of cervical
cancer. Ann Rev Med 2004; 55: 319-31.
6. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2010
Incidence and Mortality Web-based Report. 2013; http://www.cdc.gov/uscs.
7. Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs
2005; 10: 5-19.
8. Chuang TY, et al. Condyloma acuminatum in Rochester, Minn, 1950-1978:II anaplasias
and unfavorable outcomes. Arch Dermatol 1984;120: 476-83.

Page 19

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

9. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology
and treatment. Clin Infec Dis 1995; 20 (Suppl 1):S91-S97.
10. Nobbenhuis MAE, et al. Relation of human papillomavirus status to cervical lesions and
consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 2025.
11. Wallin KL, et al. Type specific persistence of human papillomavirus DNA before the
development of invasive cervical cancer. N. Engl. J. Med. 1999; 341(22): 1633-8.
12. Melbye M and Frisch M. The role of human papillomaviruses in anogenital cancers.
Semin Cancer Biol 1998; 8: 307-13.
13. DeVilliers EM, et al. Classification of papillomaviruses. Virology 2004; 324:17-27.
14. Muñoz N, et al. Against which human papillomavirus types shall we vaccinate and
screen? The international perspective. Int J Cancer 2004; 111: 278-85.
15. Muñoz N, et al. Epidemiologic classification of human papillomavirus types associated
with cervical cancer. N Engl J Med 2003; 348: 518-27.
16. Guan P et al. Human papillomavirus types in 115,789 HPV-positive women: A metaanalysis from cervical infection to cancer. Int J. Cancer, 2012; 131: 2349-59.
17. Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer:
a retrospective cross-sectional worldwide study. Lancet Oncol, 2010; 11: 1048-56.
18. Smith JS, et al. Human papillomavirus type distribution in invasive cervical cancer and
high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621-32.
19. Bosch FX et al. HPV prevalence in normal Pap smears, high-grade lesions and cervical
cancers: Epidemiology and Natural History of HPV Infections and Type-specific
Implications in Cervical Neoplasia. Vaccine 2008; 26S: K1-K16.
20. Partridge JM and Koutsky LA. Genital human papillomavirus infection in men. Lancet
Infect Dis 2006; 6:21-31
21. Manhart LE and Koutsky LA. Do condoms prevent genital HPV infection, external
genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29: 725735
22. Consensus Development Panel. Consensus statement: National Institutes of Health
Consensus Development Conference statement on cervical cancer. Gynecol Oncol
1997; 66: 351-61.
23. Maritn-Hirsch PPL et al. Surgery for cervical intraepithelial neoplasia (Review).
Cochrane Database Syst Rev 2000; (2): CD001318
24. Workowski KA and Berman S. Sexually Transmitted Diseases Treatment Guidelines,
2010. MMWR Recomm Rep 2010; Vol 59/RR-12.

Page 20

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

25. Lacey CJ, et al. 2012 European guideline for the management of anogenital warts. J
Eur Acad Dermatol Venereol, 2013, 27, e263–e270
26. Macartney KK, et al. Safety of Human Papillomavirus Vaccines: A Review. Drug Saf
2013; 36:393–412
27. Schiller JT, et al. A Review of Clinical Trials of Human Papillomavirus Prophylactic
Vaccines. Vaccine 2012; 30S: F123– F138
28. Einstein MH, et al. Comparison of the immunogenicity and safety of Cervarix (TM) and
Gardasil® human papillomavirus (HPV) cervical cancer vaccines in 18-45 years. Hum
Vaccines. 2009; 5: 705-19.
29. Olsson SE, et al. Induction of immune memory following administration of a prophylactic
quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP)
vaccine. Vaccine 2007; 25: 4931-9.
30. Herrero R. Human Papillomavirus (HPV) Vaccines: Limited Cross-Protection against
Additional HPV Types. Infect Dis. 2009; 199(7): 919-22.
31. Block SL, et al. Clinical trial and post licensure safety profile of a prophylactic human
papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis
J. 2010; 29: 95–101.
32. MMWR, CDC: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6229a4.htm#tab2
33. Giuliano AR, et al. Epidemiology of human papillomavirus infection in men, cancers
other cervical and benign conditions. Vaccine. 2008; 26S: K17-28.
34. Koch-Henriksen N and SØrensen PS. The changing demographic pattern of multiple
sclerosis epidemiology. Lancet Neurol, 2010: 9:520-32.
35. Castle PE et al. Short term persistence of human papillomavirus and risk of cervical
precancer and cancer: population based cohort study. Br Med J 2009; 339: b2569
36. Kjær SK et. Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or
Worse Following Human Papillomavirus Infection: Role of Persistence, J. Natl Cancer
Inst, 2010, 102: 1478-88.
37. WHO 2014, Congenital anomalies: http://www.who.int/mediacentre/factsheets/fs370/en/
38. Garcia-Enguidanos A et al. Risk factors in miscarriage: a review. Eur. J. Obstetr.
Gunnecol. Reprod. Biol., 2002; 102: 111-9.
39. MacDorman MF & Kirmeyer Sl, The challenge of fetal mortality. NCHS Data Brief, 2009;
16: 1-8.

Page 21

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6. DISCUSSION OF INDIVIDUAL CLINICAL TRIALS
6.1 Trial #1: V503-001 (Designated as Study 1 in the Draft Package Insert)
Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled with
Gardasil, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of 9vHPV Vaccine
Administered to 16- to 26-Year-Old Women
Reviewer’s comment: In-house blinding was defined as blinding of the sponsor's research
personnel except the statistician creating the schedule.
6.1.1 Objectives
Protocol V503-001 was a phase 2b/3 pivotal, adaptively designed, qHPV-controlled, dose
ranging, efficacy, immunogenicity and safety study of 9vHPV in females 16 through 26 years of
age.
6.1.1.1 Objectives of Part A (Phase 2b)
1. To evaluate the tolerability of the 9vHPV vaccine when administered to 16- to 26-yearold women.
2. To select a formulation of 9-valent HPV L1 VLP vaccine for use in the efficacy evaluation
in Part B.
6.1.1.2 Objectives of Part B (Phase 3) Efficacy Study
Primary Objectives:
1. To evaluate the tolerability of 9vHPV vaccine when administered to 16- to 26-year-old
women.
2. To demonstrate that administration of 9vHPV vaccine will reduce the combined
proportion of subjects with HPV 31-, 33-, 45-, 52-, and 58-related high grade cervical
abnormalities (CIN 2/3), Adenocarcinoma In Situ (AIS), invasive cervical carcinoma,
high-grade Vulvar Intraepithelial Neoplasia (VIN 2/3), high grade Vaginal Intraepithelial
Neoplasia (VaIN 2/3), vulvar cancer, or vaginal cancer, compared with GARDASIL™ in
16- to 26-year-old adolescent and young adult women who are seronegative at Day 1
and PCR negative Day 1 through Month 7 to the relevant HPV type.
Reviewer’s comment: The composite clinical endpoint of the five new HPV type related
high grade cervical, vulvar and vaginal disease described above constitutes the primary
efficacy cases.
3. To demonstrate that the 9vHPV vaccine induces non-inferior GMTs for anti-HPV 6, 11,
16, and 18 compared to qHPV.
Secondary Objectives
1. To demonstrate that 9vHPV will reduce the combined proportion of subjects with HPV
31-, 33-, 45-, 52-, and 58-related persistent infection (6 months or longer) compared with
qHPV in 16- to 26-year-old females in PPE population.
2. To demonstrate that 9vHPV induces non-inferior immune responses with respect to
seroconversion percentages for HPV 6, 11, 16, and 18 compared to qHPV.
3. To quantify the amount by which the administration of 9vHPV reduced the combined
proportion of subjects with HPV 31-, 33-, 45-, 52-, and 58-related cervical, vulvar and

Page 22

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

vaginal disease compared with qHPV in 16- to 26-year-old females who were
seronegative at Day 1 and PCR negative Day 1 through Month 7 to the relevant HPV
type(s).
4. To evaluate the persistence of anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 immune
responses generated by 9vHPV.
5. To evaluate the impact of administration of 9vHPV on the proportion of subjects with Pap
test abnormalities [ASC-US (Positive for High Risk HPV) or worse].
Exploratory Objectives
1. To demonstrate that 9vHPV reduces the combined proportion of subjects with HPV 31-,
33-, 45-, 52-, and 58-related persistent infection for a duration 12 months or longer
compared with qHPV in 16- to 26-year old females who were seronegative at Day 1 and
PCR negative Day 1 through Month 7 to the relevant HPV type(s).
2. To evaluate the impact of 9vHPV on the combined proportion of subjects with CIN, AIS,
and cervical cancer caused by any HPV type.
3. To evaluate the impact of 9vHPV on the combined proportion of subjects with vulvar and
vaginal disease caused by any HPV type.
4. To evaluate the impact of 9vHPV on the proportion of subjects with Pap test
abnormalities (ASC-US [Positive for High Risk HPV] or worse) related to HPV Types 31,
33, 45, 52, & 58.
5. To evaluate the impact of 9vHPV on the proportion of subjects with cervical biopsy and
cervical definitive therapy treatments.
6.1.2 Design Overview
This was a phase 2b/3 adaptively designed, randomized, double-blind (operating under inhouse blinding procedures), qHPV controlled, multinational, dose-ranging, safety,
immunogenicity and efficacy study with a target enrollment of 14,620 subjects. The study was
enrolled in two parts. Approximately 1240 subjects were enrolled in Part A and were equally
randomized to 3 dose formulations of 9vHPV or qHPV. One dose formulation of 9vHPV was
selected for Part B based on interim immunogenicity results. Approximately 13,380 subjects
were enrolled in Part B and were equally randomized to the selected dose formulation of 9vHPV
or qHPV. Each subject was scheduled to receive 3 doses of the assigned study vaccine
intramuscularly at Day 1, Month 2 and Month 6. Three substudies were conducted:
• A dose-ranging substudy including all subjects enrolled in Part A with an evaluation of
immunogenicity and safety from Day 1 through Month 7.
• An efficacy substudy including all subjects in Part A who received qHPV or the dose
formulation of 9vHPV selected for Part B and all subjects in Part B, with an efficacy and
safety evaluation from Day 1 through at least Month 42.
• An immunogenicity substudy including all subjects enrolled in Part B with an
immunogenicity evaluation from Day 1 through Month 42.
To assess efficacy, Pap testing was performed at Day 1 and Months 7, 12, 18, 24, 30, 36, 42,
48, and 54, and Pap test abnormalities were followed up according to a pre-defined mandatory
triage algorithm. All subjects were followed for efficacy at least up to Month 42. Efficacy
analyses were conducted after 30 primary efficacy endpoint cases had accrued. To evaluate
immunogenicity, sera were obtained at Day 1 and Months 3, 7, 12, 24, 36 and 42. All subjects
were followed for safety for the duration of the study.
Reviewer’s comments: The optimal dose for Part B was selected by a Merck committee based
on immunogenicity data. The selected dose formulation was communicated to the Data Safety
Monitoring Board (DSMB) to ensure there was no safety concern identified for the dose. After

Page 23

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

the dose formulation was selected, the unblinded statistician generated a list of subjects who
received the formulations that were not chosen for further evaluation in Part B. These subjects
completed their regimens and were followed for safety and immunogenicity through Month 7.
6.1.3 Population
6.1.3.1 Main Inclusion Criteria
• Female between the ages of 16 and 26 years inclusive on the day of randomization.
• Never had Pap testing or only had normal Pap test results.
• Subject (or, for minor subjects, parent/legal guardian and subject) fully understood study
procedures, alternative treatments available, the risks involved with the study, and
voluntarily agreed to participate by giving written informed consent.
• Able to read, understand, and complete the vaccination report card.
• Judged to be in good physical health on the basis of medical history, physical
examination, and laboratory results.
• The subject had the following lifetime sexual history at the time of enrollment:
o One to 4 male and/or female sexual partners; or
o No male and/or female sexual partners, was 18 years of age or older, and
planned to become sexually active within the first 3-6 months of the study.
o Male partner was defined as someone with whom the subject had penile
penetrative sexual intercourse. Female partner was defined as someone who
had contacted, either by penetrative (with fingers or other objects) or nonpenetrative means, the subject’s genitalia during sexual activity.
6.1.3.2 Main Exclusion Criteria
• A history of an abnormal cervical biopsy result (CIN or worse).
• A history of a positive test for HPV.
• Current user of recreational or illicit drugs or had a recent history (within the last year) of
drug or alcohol abuse or dependence. Alcohol abusers were defined as those who drank
despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
• History of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty
breathing, hypotension or shock) that required medical intervention.
• Subject had known allergy to any vaccine component, including aluminum, yeast, or
BENZONASE (nuclease, Nycomed [used to remove residual nucleic acids from this and
other vaccines]).
• Currently immunocompromised or was diagnosed as having a congenital or acquired
immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus
(SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel
disease, or other autoimmune condition.
• History of splenectomy.
• Receiving or had received in the year prior to enrollment chemotherapy,
immunosuppressive therapies, or radiation therapy.
• Received any immune globulin product or blood-derived product within the 3 months
prior to the Day 1 vaccination, or planned to receive any such product during Day 1
through Month 7 of the study.
• History of thrombocytopenia or other coagulation disorder that would contraindicate
intramuscular injections.
• Expecting to donate eggs during Day 1 through Month 7 of the study.

Page 24

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•
•
•

•

Concurrently enrolled in clinical studies of investigational agents or studies involving
collection of cervical specimens.
Received a marketed HPV vaccine, or had participated in an HPV vaccine clinical trial
and had received either active agent or placebo.
History or current evidence of any condition, therapy, lab abnormality or other
circumstance that might confound the results of the study, or interfere with the subject’s
participation for the full duration of the study, such that it was not in the best interest of
the subject to participate.
History of or clinical evidence at the Day 1 pelvic examination of HPV related external
genital lesions (e.g., condyloma acuminata or VIN) or external genital cancer, HPVrelated vaginal lesions (e.g., condyloma acuminata or VaIN) or vaginal cancer.

6.1.4 Study Treatments or Agents Mandated by the Protocol
6.1.4.1 Study Product Description
Gardasil 9 is a sterile, white cloudy liquid suspension containing recombinant VLPs of HPV
types 6, 11, 16, 18, 31, 33,45, 52, and 58 absorbed on 500 µg of adjuvant amorphous aluminum
hydroxyphosphate sulfate (AAHS). The vaccine was filled into single-dose vials to ensure a
minimum recoverable volume of 0.5 mL for injection. The product formulations used for this
study were Lots WL00025085, WL00025087, WL00025088, WL00027320, WL00030772,
WL00030851, WL00030920 and WL00034579 (Data source: Table 2, page 5 of Module
3.2.P.5.4, STN 125508/0, and Table 9-4, STN 125508/0, Module 5.3.5.1.p001-CSR of V503001, p131).
Three dose formulations of 9vHPV were assessed in this study:
• Low dose formulation: Each 0.5 ml dose contains 20μg of VLP for each HPV type
(except for 40 µg for types 11 and 16) absorbed on 500 μg AAHS. The total dose of
VLPs is 220 µg.
• Mid dose formulation: Each 0.5 ml dose contains 30 µg of VLP for types 6 and 18, 40
µg for type 11, 60 µg of for type 16, and 20 µg for the other HPV types absorbed on 500
µg of AAHS. The total dose of VLPs is 270 µg.
• High dose formulation: Each 0.5 dose contains 30 µg of VLP for each HPV type (except
40 µg for type 11, 80 µg for type 16, and 55 μg for type 18) adsorbed on 500 μg AAHS.
The total dose of VLPs is 355 µg.
Gardasil is a quadrivalent HPV vaccine manufactured and marketed by Merck. Each 0.5 ml
dose contains 20 µg of VLP for HPV types 6 and 18 and 40 µg for types 11 and 16 absorbed on
225 µg of AAHS. The total dose of VLPs is 120 µg. The product formulations used for this
study were Lots WL00024099, WL00027324, WL00029942, and WL00040674 (Data source:
Table 9-4, STN 125508/0, Module 5.3.5.1.p001-CSR of V503-001, p131).
Reviewer’s comments: The amount of AAHS adjuvant used for all 3 dose formulations of
9vHPV was 500 µg, more than twice that used in qHPV. The higher amount of AAHS is the
same as that used in Recombivax HB™, a recombinant protein-based vaccine licensed in many
countries including the U.S. to prevent infection with hepatitis B virus. Recombivax HB™ has
been administered to millions of infants, adolescents, and adults, and no significant safety issue
has been identified.

Page 25

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.1.4.2 Randomization, Dose Schedule and Route of Administration
Part A (Phase 2b): Study participants were randomized at 1: 1: 1: 1 to receive a dose of either
qHPV or one of 3 formulations of 9vHPV vaccine (V503-low, V503-mid and V503-high)
administered intramuscularly at Day 1 and Months 2 and 6.
Part B (Phase 3): Participants were randomized at 1:1 to receive a dose of either qHPV or
9vHPV (V503-mid selected from Part A) administered intramuscularly at Day 1 and Months 2
and 6.
6.1.4.3 Concomitant medications
Use of medicines and non-study vaccines was documented in the data collection system.
Unless medically necessary, subjects and investigators were advised to avoid use of
immunosuppressive drugs and blood products from 3 days prior to Day 1 through Month 7, nonstudy inactivated vaccines for 14 days prior to each study vaccination through 14 days after
each vaccination, or attenuated vaccines for 21 days prior to each study vaccination through 14
days after each vaccination. Subjects were allowed to receive allergen desensitization therapy
and tuberculin skin testing while participating in the study.
6.1.5 Directions for Use
The vaccines (qHPV or 9vHPV) were withdrawn from vials and administered intramuscularly
using a 1.0-mL syringe. The deltoid muscle of the non-dominant arm was the preferred site of
vaccination. Injections were avoided within 2 cm of a tattoo, scar, or skin deformity.
Reviewer’s comment: A total of 15 subjects who received injectable contraceptives (e.g.,
DEPO-PROVERA) or implanted contraceptives (e.g., NORPLANT) in both arms in the previous
9 months, were given the injection in the thigh rather than in an arm.
6.1.6 Sites and Centers
The study was an international clinical trial conducted at 105 study centers: 28 centers in the
United States (US) and 77 centers internationally. The median number of subjects enrolled at
each center was 100 (ranging 14 – 1105).
6.1.7 Surveillance/Monitoring
Table 3 summarizes the surveillance and monitoring for Study V503-001. All scheduled visits
were conducted at study sites. Collection of medical history and physical examination was
conducted at Day 1 for all subjects. Vital signs were taken prior to each vaccination. In order to
assess HPV status at baseline, study participants underwent the following protocol-mandated
testing on Day 1: (1) gynecological history and examination; (2) testing of serum for anti-HPV
antibodies; (3) PCR testing of cervical and external genital samples for HPV DNA; and (4)
ThinPrep™ Pap test. All Pap tests were performed within the context of the study and were read
by a central laboratory designated by the Applicant.

Page 26

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 3: Surveillance and Monitoring for Study V503-001
Visit (Day or Month)
Visit Window

Day 1

Informed Consent, Allocation
Number
Inclusion/Exclusion Criteria
Medical / Gynecologic History
New conditions or Adverse
Experiences
Medications and Non-Study
Vaccines
Pregnancy Test§
Anti-HPV (including Retention
Serum) †
Vital Signs
Gynecologic Physical
Examination
LVPP and EEC Swabs for HPV
PCR
Pap Test (ThinPrep™)
STI Testing
External Genital Wart Inspection
Vaccination (IM)
Provide Vaccination Report Card
Review and Collect VRC data‡
Adverse Experiences, Clinical
Follow-up for Safety‡

X

D16

M2

M3

M6

M7

M12

M18

M24

M30

M36

M42

M48

M54

±3wk

±1wk

±4wk

-1wk
to
±3wk

±4wk

±4wk

±4wk

±4wk

±4wk

±4wk

±4wk

±4wk

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X
X

X

X
X

X

X
X

X*

X*

X
X

X

X
X

X

X

X

X
X
X
X
X

X

X
X

X
X
X
X

X*

X

X

X

X*

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X
X
X

X
X
X

X
X
X

X
X
X

X
X
X

X
X
X

X
X
X

X
X
X

X
X
X

X
X

X

X

X

X

X

X

X

X

X
X
X
X

X

Source: Adapted from Table 9-2, STN 125508/0, Module 5.3.5.1-Clinical Study Report of Study V503-001 (page 112-114).
† Serum for anti-HPV measurements may be collected after the pelvic examination, but must be collected before vaccination.
‡Observe subjects for 30 minutes after each vaccination for immediate untoward effects. The subject should use the Vaccination Report card (VRC) to document
this safety information: oral temperature in the evening after each study vaccination and daily, at the same time of day, for 4 days after each study vaccination;
injection-site or systemic adverse experience(s) starting after each study vaccination for a total of 15 days. Serious adverse experiences (SAEs), pregnancy
events, and lactation events should be reported to the sponsor as instructed in the protocol.
* These samples were taken from a randomized subset of 20% of subjects in PPI population.

Page 27

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.1.7.1 Immunogenicity Assessment
Serum was collected from all subjects at visits specified in Table 3 for analysis of antiHPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibody responses by HPV-9 competitive
Luminex Immunoassay (cLIA). All subjects in Part A were included in the Part A primary
immunogenicity analysis for dose selection for Part B. All subjects enrolled in Part B
were included in the Part B immunogenicity hypothesis testing at Month 7. For the
purpose of demonstrating vaccine-induced anti-HPV antibody persistence at Months 12,
24, 36, and 42, a random sample of approximately 20% of Part B subjects was tested
and analyzed.
6.1.7.2 Efficacy Assessment
Pelvic samples, including external genital and cervicovaginal swabs and Pap test
samples, were collected as scheduled in Table 3. All subjects were followed for efficacy
through at least Month 42. Labial/vulvar/perineal/perianal (LVPP) and endo/ectocervical
(EEC) swabs were tested for detection of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, and 59 by PCR assay to assess persistent HPV infection endpoints.
Any subject with an abnormal Pap test was referred for colposcopy using a protocol
mandated triage algorithm. The colposcopist obtained cervical biopsies of areas of the
most severe abnormalities and could choose to perform an endocervical curettage
(ECC) if no cervical dysplasia was observed. A subject might need subsequent cervical
definitive therapy per the protocol-mandated cervical definitive therapy guidelines.
Vaginal lesions were biopsied if they were observed during a Pap test, colposcopy, or at
any other time. A thorough external genital wart/lesion inspection was performed at
routine visits. External genital warts/lesions noted after Day 1 were biopsied. In addition,
subjects with histologically confirmed HPV-related external genital lesions (e.g.,
condyloma acuminata, VIN, cancer) or vaginal warts (e.g., condyloma acuminata, VaIN,
cancer) were referred to colposcopy if the biopsies were not obtained during a
colposcopy.
Tissue obtained from biopsy and cervical definitive therapy procedures was analyzed by
MRL HPV Thinsection PCR assay (for detection of HPV types 6, 11, 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, and 59) and by a consensus diagnosis from the HPV Vaccine
Program Pathology Panel to assess clinical disease efficacy endpoints. The panel
consisted of four pathologists who reviewed all biopsy slides and adjudicated all
pathology specimens for the purpose of providing the official pathologic diagnosis-Each
Pathology Panel member independently reviewed the slides, blinded to vaccination
group and the subject's HPV PCR status, to formulate a consensus. Consensus
Diagnosis Process: The two panelists within each pair reviewed the slides from a given
subject independently, blinded to the HPV status of the tissue specimen, the Central
Laboratory’s diagnosis, other panelist’s diagnosis, and other demographic and clinical
data of the study subjects. If the diagnoses made by the initial two panelists agreed, that
diagnosis was considered the final consensus diagnosis. If the two diagnoses were
discrepant, the slide would be sent to a third pathologist for diagnosis. The third panelist
was not aware he/she was a “tie-breaker”. On rare occasions in which all three
diagnoses disagreed, a fourth pathologist reviewed the slides. The final diagnosis was
the one rendered by two pathologists. If each of the pathologists provided a different
diagnosis for a given biopsy, a panel meeting consisting of all four pathologists would

Page 28

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

take place to reach the final consensus. The consensus diagnosis of the panel
represented the final diagnosis for study purposes.
The analysis of LVPP/EEC swabs and tissue specimens included PCR analysis for nonvaccine HPV types (35, 39, 51, 56, 59, and potentially others) to document rates of
disease associated with non-vaccine HPV types and to assess cross-protection.
6.1.7.3 Safety Assessment
All subjects were monitored for safety for the duration of the study as outlined below:
• All subjects received a vaccination report card (VRC) after each vaccination. On
the VRC, the subject or the parent/guardian of the subject was asked to record
the subject’s oral temperature in the evening after each study vaccination and
daily for 4 days after each vaccination to identify febrile events. Also, the subject
was asked to record injection-site and systemic adverse experiences,
concomitant medications, and concomitant vaccinations on the VRC for 15 days
after each vaccination including the day of vaccination.
• SAEs were collected regardless of causality from Day 1 through 6 months
following the last vaccination. Events of fetal loss were reported as SAEs if the
last menstrual period (LMP) was between Day 1 and 6 months following the last
vaccination.
• Deaths, vaccine-related SAEs, and study procedure-related SAEs were collected
throughout the study.
• New medical conditions not present at baseline and not reported as an adverse
experience were collected throughout the study.
• Any overdose of test vaccine (9vHPV or qHPV), defined as a subject receiving
more than 3 doses of vaccine (0.5 mL each dose) or receiving ≥0.75 mL of
vaccine in any one dose, was recorded.
Pregnancy and lactation information was also collected. Any female subject with a
positive pregnancy test at Day 1 was not vaccinated and was not allowed to participate
in the study. Female subjects with a positive pregnancy test after Day 1 who had
received fewer than 3 vaccinations were offered the option to complete the vaccination
series but were not given further vaccinations until after the final pregnancy outcome
was determined. Pregnancy and associated adverse experiences, lactation (if a subject
received study vaccine while breastfeeding during the Day 1 through Month 7 period),
and SAEs in study subjects and infants were followed to final outcome.
6.1.8 Endpoints and Criteria for Study Success
6.1.8.1 Primary Safety and Tolerability Endpoints
• Occurrence of injection site adverse experiences prompted for on the VRC (such
as redness, swelling, and pain/tenderness/soreness occurring Day 1 through Day
5 following any vaccination) and elevated temperature (≥100.0°F or ≥37.8ºC),
from Day 1 to Day 5 following any vaccination.
• Severe injection-site adverse experiences and the rates of any vaccine-related
SAEs.
Hypothesis: 9vHPV would be generally well tolerated in 16 through 26 year-old women.

Page 29

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.1.8.2 Primary Efficacy Endpoint
The primary efficacy endpoint was combined cases of HPV 31-, 33-, 45-, 52-, and 58related CIN 2/3- or VIN 2/3- or VaIN 2/3- or worse. To be classified as an endpoint case
for the primary analysis, a subject must have developed at least one of the following
after the completion of the Month 7 visit:
• CIN 2/3, AIS, or invasive cervical carcinoma related to HPV types 31, 33, 45, 52
or 58. This endpoint was defined to have occurred if on a single cervical biopsy,
endocervical curettage (ECC), Loop Electrosurgical Excision Procedure (LEEP),
or conization (cold knife/laser) specimen, there was: (a) a HPV Vaccine Program
Pathology Panel consensus diagnosis of CIN 2/3, AIS, or cervical cancer; AND
(b) detection of at least one of HPV types 31, 33, 45, 52 or 58 by Thinsection
PCR in an adjacent section from the same tissue block.
• VIN 2/3, VaIN 2/3, vulvar cancer, or vaginal cancer related to HPV types 31, 33,
45, 52 or 58. This endpoint was defined to have occurred if on a single biopsy or
excised tissue, there was: (a) a HPV Vaccine Program Pathology Panel
consensus diagnosis of VIN 2/3, VaIN 2/3, vulvar cancer, or vaginal cancer; AND
(b) detection of at least one of HPV types 31, 33, 45, 52 or 58 by thin section
PCR in an adjacent section from the same tissue block.
An additional efficacy endpoint evaluated in a sensitivity analysis defined a case of
disease as requiring a consensus diagnosis of HPV disease by the pathology panel, the
appropriate HPV type detected in an adjacent section of the same tissue block AND at
least one specimen acquired immediately prior to or subsequent to the biopsy or
definitive therapy sample that was positive for the same HPV type that was found in the
biopsy.
The statistical criterion for success for the primary efficacy endpoint required that the LB
of the two-sided 95% CI for 9vHPV vaccine efficacy (relative to qHPV) be greater than
25%.
6.1.8.3 Primary Immunogenicity Endpoints
The primary immunogenicity endpoints were anti-HPV type 6, 11, 16, and 18 antibody
GMTs 4 weeks post dose 3 assessed among subjects who were seronegative at Day 1
and PCR negative Day 1 through Month 7 to the relevant HPV type(s). The GMTs for
each of HPV types 6, 11, 16, and 18 were tested separately.
The criterion for success for each type-specific non-inferiority comparison of GMTs was
that the LB of the two-sided 95% CI for the geometric mean ratio of 9vHPV versus qHPV
be greater than 0.67.
Reviewer’s comments: The immunoassay used in this study was the HPV-9 cLIA.
During Phase 2b evaluation, a pre-validated assay was used. For the Phase 3
immunogenicity which included all subjects who received mid dose formulation of 9vHPV
or qHPV, the sera were re-assessed using the validated assay.
6.1.8.4 Secondary Efficacy Endpoints
HPV 31-, 33-, 45-, 52-, and 58-related persistent infection detected in samples from two
or more consecutive visits at least 6 or 12 months apart: This endpoint was defined to
have occurred if a subject who, after completion of the Month 7 visit, was positive for the
same HPV type by PCR assay in two or more consecutive cervicovaginal/external

Page 30

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

genital swab, biopsy, or definitive therapy samples obtained at two or more consecutive
visits at least 6 or 12 months apart.
The statistical criterion for success was that the LB of the two-sided 95% CI for 9vHPV
vaccine efficacy (relative to qHPV) be greater than 25%.
Reviewer’s Comments: In the original submission, the documented duration of
persistent infection could be affected by visit windows of up to one month before or after
the scheduled visit. CBER requested in the first requested information letter dated
February 14, 2014, that only subjects with duration of persistent infection equal to or
greater than 6 or 12 months be included in the analyses of persistent infection. The
Applicant agreed to do so and the revised data were submitted to STN 125508/0.4,
Module 1.11.3. The revised data are assessed and incorporated in this review.
HPV 31-, 33-, 45-, 52-, and 58-related cervical, vulvar and vaginal disease: This
endpoint was defined as a subject who, after completion of the Month 7 visit, was found
to have a biopsy or excised tissue specimen with (a) a HPV Vaccine Program Pathology
Panel consensus diagnosis of CIN (any grade), AIS, cervical cancer, genital wart,
VIN(any grade), VaIN (any grade), vulvar cancer, or vaginal cancer, AND (b) detection of
at least one of HPV types 31, 33, 45, 52, or 58 by Thinsection PCR in an adjacent
section from the same tissue block.
Pap test abnormalities: A case was defined as a subject who, after completion of the
Day 1 visit, was found to have a Pap test result of atypical squamous cells of
undetermined significance (ASC-US) with positive HPV probe or worse [ASC-US
positive for High Risk HPV, LSIL, atypical squamous cells suggestive of a high-grade
intraepithelial lesion (ASC-H), HSIL, atypical glandular cells, or AIS].
Seroconversion: A subject with a cLIA titer at or above the serostatus cutoff for a given
HPV type was defined as seropositive for that HPV type (or seroconverted if below the
cutoff pre-vaccination). The seropositivity cutoffs for HPV types 6, 11, 16, 18, 31, 33, 45,
52, and 58 were 30, 16, 20, 24, 10, 8, 8, 8, and 8 mMU/mL, respectively.
6.1.8.5 Criterion for Study Success
The evaluation of primary safety and efficacy objectives for the 9vHPV vaccine included
combined data from subjects enrolled in Part A who received qHPV or the 9vHPV dose
selected for Part B (mid dose formulation) and subjects enrolled in Part B. The
evaluation of the primary immunogenicity objective included the subjects enrolled in Part
B only. The study was considered successful if success was achieved on all primary
endpoints or hypotheses (safety, efficacy and immunogenicity). Success on the
secondary efficacy endpoints was not necessary to declare the study successful.
6.1.9 Statistical Considerations and Statistical Analysis Plan
6.1.9.1 Study Hypotheses, and Sample Size and Power Calculations
Primary Efficacy Endpoint

Page 31

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Efficacy evaluations were conducted on subjects who received either the 9vHPV (middose formulation) or qHPV. The null hypothesis of the study was that the vaccine
efficacy (VE) was ≤ 25%, and the alternative hypothesis was that VE was >25%.
The study was powered to demonstrate statistically significant efficacy against the
primary efficacy endpoint using a fixed event design. Assuming that the efficacy of
9vHPV relative to qHPV against the primary efficacy endpoint would be approximately
83%, then a total of 30 primary efficacy endpoint cases would be needed to provide at
least 90% power to achieve a LB of the 95% CI of VE >25% at a one-sided α=0.025
level of significance. To ensure that at least 30 cases of primary efficacy endpoint were
accrued, approximately 14,000 subjects (9vHPV and qHPV groups combined) were
enrolled. The assumptions below were used for the sample size calculation:
• Seropositivity at Day 1 and/or PCR positivity at Day 1 through Month 7 to HPV
types 31, 33, 45, 52 and 58 would not be greater than 23%.
• Attrition rate between Day 1 and Month 7 would not be greater than 10%
• Annual attrition rate post-Month 7 would not be greater than 5%.
• Annual incidence rates for the primary efficacy endpoint would be 0.35 per 100
person-years.
• Median follow-up time would be 30 month post randomization.
No interim analyses were planned relating to the testing of the primary efficacy
hypotheses. Therefore, no multiplicity adjustment was done in the testing of the primary
efficacy hypotheses. No type 1 error inflation was expected from this study design.
Primary Immunogenicity Endpoint
The overall sample size in the study was determined by the efficacy analysis. With
approximately 13,380 subjects in Part B, this study had over 99% power for the primary
immunogenicity hypothesis of non-inferiority with respect to antibody GMTs for HPV
types 6, 11, 16 and 18. The calculations were based on the following assumptions:
• 15%, 15%, 18% and 10% of the subjects would be initially seropositive or PCR
positive to HPV types 6, 11, 16 and 18, respectively.
• The expected attrition rate through Month 7 time point would be 10%
• The percentage of subjects excluded due to vaccinations or serology samples
out of range would be no more than 8%.
• The standard deviations of the natural logarithms of the Month 7 titers would be
no more than 1.2 mMU/ml for each HPV type.
6.1.9.2 Handling of Missing Data
In the analysis of vaccine efficacy with respect to HPV 31/33/45/522/58-related
persistent infection and disease endpoints, subjects with missing data were handled as
described in Table 4.

Page 32

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 4: Disposition of Handling of Missing Data in Efficacy Populations (Study V503001)
Type of Missing Data

Subject Included
or Excluded in
Analysis
Included

Subject Eligible to Be
Case Based on Missing
Data
No

Subject lost-to-follow-up before becoming an
endpoint case and before the end of the study
Incomplete data with respect to persistent
Included
No
infection endpoint. Subject not previously
classified as an endpoint case, and detected with
vaccine HPV type-related infection at the
subject’s last study visit
Missing Day 1 serology result for relevant HPV
Excluded
N/A
type
Missing one or both Day 1 PCR swab results for
Excluded
N/A
relevant HPV type
Missing Month 7 EEC or LVPP swab PCR results Excluded
N/A
for relevant HPV type
Missing post-Month 7 EEC or LVPP swab PCR
Included
Only if the other swab is
result for relevant HPV type
positive
Missing post-Month 7 Thinsection PCR result for
Included
No
relevant HPV type for a biopsy specimen.
Missing post-Month 7 Pathology Panel diagnosis Included
Yes-Infection endpoints
for a biopsy specimen
No- Disease endpoints
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001, CSR, Section 16.1.9.4, Table 10
(p302).

6.1.10 Study Population and Disposition
6.1.10.1 Populations Enrolled/Analyzed
Efficacy Analyses Populations
Per-Protocol Efficacy (PPE) Population: This population was used for the primary
efficacy analysis and included all subjects who:
• Received all 3 vaccinations with the correct clinical material within one year
• Had one or more follow-up visits following Month 7.
• Had Month 7 PCR swab samples collected within 14 to 72 days post-dose 3
• Were seronegative for the relevant HPV type(s) at Day 1 and PCR negative for
the relevant HPV type(s) on all cervicovaginal swabs and biopsies from Day 1
through Month 7. HPV types 6 and 11 L1 proteins are highly homologous,
resulting in strong cross-reactivity between the two types. Therefore, evaluations
of efficacy with respect to either HPV type 6 or HPV type 11 required that
subjects be negative at the aforementioned time points for both HPV 6 and 11.
For evaluations of efficacy with respect to any other vaccine HPV type, subjects
needed only to be negative at the aforementioned time points for the HPV type
under evaluation.
• Did not violate the protocol in ways that could interfere with the evaluation of
immune response to injections of the 9vHPV or qHPV vaccines.
Modified Intent-to-Treat (MITT) Analyses

Page 33

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Three MITT populations were analyzed to support the analyses in the PPE population, to
explore the robustness of the vaccine efficacy, and to evaluate the secondary and
exploratory efficacy objectives. The definitions of the MITT populations used in the
9vHPV clinical development program were similar to those used in the qHPV clinical
development program. Subjects who received at least one vaccination and had any
follow-up visit following the first vaccination could be included in all three populations. In
all three populations, events occurring any time after Day 1 were eligible to be counted
as endpoint cases if they met the appropriate case definitions. The populations were
defined as follows:
1. HPV-Naïve, Type-Specific Population (HN-TS): This population included only
subjects who were seronegative and PCR-negative at enrollment for the relevant
HPV types, as defined in the Primary Per-Protocol Analysis. The numbers of
subjects in this population ranged from 5953 to 6704 depending on clinical
endpoints.
2. Full Analysis Set (FAS): This population included all randomized subject who
received at least one dose of the 9vHPV or qHPV vaccines and had at least one
follow-up visit after Day 1. The number of subjects in this population for 9vHPV
and qHPV groups was 7099 and 7105, respectively.
3. All-HPV Naïve Population (All-HN): This population included only subjects who
(a) were seronegative and PCR-negative at enrollment for all 9 vaccine HPV
types; (b) were PCR-negative at enrollment for all other non-vaccine HPV types
for which PCR assays were available; and (c) had a normal Pap test result at
enrollment. The numbers of subjects in this population ranged from 2865 to 3032
depending on clinical endpoints, Pap tests and relevant HPV types.
Immunogenicity Analyses Population
Per-Protocol Immunogenicity (PPI) Population: The PPI population was used for the
primary immunogenicity analysis and included all subjects who:
1. Had received all three vaccinations with the correct dose of the correct clinical
material, with each vaccination visit within acceptable windows as specified in the
protocol.
2. Had provided a Month 7 serology sample with a valid result within 21 to 49 days
post-dose 3.
3. Were seronegative for the relevant HPV type at Day 1 and PCR negative for the
relevant HPV type on all swabs and biopsies from Day 1 through Month 7.
4. Had no other protocol violations that could interfere with the evaluation of the
subject's immune response to the study vaccine.
Safety Analysis Population
All safety analyses were performed on the All-Subjects-as-Treated (ASaT) population.
The ASaT population included all randomized subjects who received at least one
injection of 9vHPV or qHPV and had follow-up data. For subjects who received injection
series that did not correspond to any of the protocol-defined vaccination groups (i.e.,
cross-treated subjects), a safety profile listing was created separately from the safety
reports that were provided for the protocol-defined vaccination groups.
6.1.10.1.1 Demographics
Table 5 displays the demographic characteristics of subjects randomized into this
efficacy study, by vaccination group. The two vaccination groups were balanced with

Page 34

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

respect to these demographic characteristics. The mean age of randomized subjects
was 21.9 years. All subjects were between 16 and 26 years of age as specified in the
protocol. The distribution of age at enrollment into the study was generally similar
between the vaccination groups. Approximately 12.8%, 33.9%, 33.4%, and 20.0% of the
subjects were from the Asia-Pacific region, Europe, Latin America, and North America,
respectively. The largest race category was White (55.2%) followed by Multi-racial
(26.8%), Asian (14.3%), and Black or African American (3.3%). The remaining subjects
were American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or did
not report their race (Unknown).
Table 5: Subject Characteristics (Study V503-001, All Randomized Subjects, Efficacy
Substudy)
Characteristics
Gender
Female
Age (Years)
16 to 18
19 to 21
22 to 24
25 to 26

9vHPV
N (%)

qHPV
N (%)

7,106 (100.0)

7,109 (100.0)

674 (9.5 )
2,489 (35.0)
2,666 (37.5)
1,277 (18.0)

747 (10.5)
2,437 (34.3)
2,701 (38.0)
1,224 (17.2)

Mean
21.9
21.8
SD
2.5
2.5
Median
22.0
22.0
Race
American Indian Or Alaska Native
6 (0.1)
10 (0.1)
Asian
1,022 (14.4)
1,006 (14.2)
Black
243 (3.4)
233 (3.3)
Multi-Racial
1,897 (26.7)
1,909 (26.9)
Native Hawaiian or other Pacific Islander
5 (0.1)
10 (0.1)
White
3,923 (55.2)
3,928 (55.3)
Unknown
10 (0.1)
13 (0.2)
Ethnicity
Hispanic Or Latino
2,525 (35.5)
2,510 (35.3)
Not Hispanic Or Latino
4,580 (64.5)
4,599 (64.7)
Null
1 (0.0)
0 (0.0)
Region
Asia-Pacific
905 (12.7)
909 (12.8)
Europe
2,406 (33.9)
2,409 (33.9)
Latin America
2,372 (33.4)
2,372 (33.4)
North America
1,423 (20.0)
1,419 (20.0)
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001, CSR, Table 10-13 (p223)

6.1.10.1.2 Medical/Behavioral Characterization of the Enrolled Population
Summary of Sexual History, Gynecological and Pregnancy History, and
Contraceptive Use
Table 6 presents the sexual history, gynecological and pregnancy history, and
contraceptive use at enrollment for all randomized subjects by vaccination group.
Overall, the two vaccine groups were well balanced in terms of number of sexual

Page 35

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

partners, gynecological procedures, genital tract infections, number of pregnancies,
number of live births and abortions, and contraceptive use.
Table 6: Sexual History, Gynecological and Pregnancy History and Contraceptive Use at
Enrollment by Vaccine Group (All Randomized Subjects, Study V503-001, Efficacy
Substudy)
Sexual and Pregnancy History

9vHPV (N=7,106)
n (%)
7,102 (99.9)

qHPV (N=7,109)
n (%)
7,108 (100.0)

Subjects With Sexual History Data
Virgins
Non-Virgins
169 (2.4)
199 (2.8)
Lifetime Number of Sexual
6,933 (97.6)2,063 (29.0) 6,909 (97.2)
Partners Among Non-Virgins
1,691 (23.8)
2,023 (28.5)
1
3,179 (44.8)
1,698 (23.9)
2
2
3,188 (44.9)
≥3
2
Median
Gynecological History
Cervical, Vaginal, and Vulvar Surgical
14 (0.2)
19 (0.3)
Procedures
Genital Tract Infections or Sexually
1,007 (14.2)
1,002 (14.)
Transmitted Diseases
Pregnancy History
Number of Past Pregnancy
0
5,797 (81.6)
5,896 (82.9)
1
924 (13.0)
838 (11.8)
≥2
380 (5.3)
372 (5.2)
1
Number of Full Term Live Births
1
589 (45.2)
581 (48.0)
≥2
189 (14.5)
182 (15.0)
1
Number of Premature Live Births
1
58 (4.4)
59(4.9)
≥2
11 (0.8)
8 (0.7)
1
Number of Spontaneous Abortions
1
254 (19.5)
254 (21.0)
≥2
32 (2.5)
30 (2.5)
1
Number of Electric Abortions
1
20 (1.5)
12 (1.0)
≥2
0 (0.0)
2 (0.2)
1
Number of Fetal Deaths
1
10 (0.8)
11 (0.9)
2
3 (0.2)
0 (0.0)
1
Subjects with Congenital Abomalies
Unknown
5 (0.4)
2 (0.2)
Yes
16 (1.2)
16 (1.3)
No
1,109 (85.0)
1,033 (85.4)
NA
174 (13.3)
159 (13.1)
Contraceptive Use
Barrier
2,318 (32.6)
2,303 (32.4)
Behavior
1,014 (14.3)
1,035 (14.6)
Hormonal
4,273 (60.2)
4,292 (60.4)
Others
216 (3.0)
182 (2.6)
Source: Generated by CBER reviewer from STN 125508/0_Module 5.3.5.1.p001_CSR, Table 1015 (p226), Table 10-16 (228), Table 10-18 (p237-8), and Table 10-19 (p240)
N=Number of subjects randomized.

Page 36

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
n=Number of subjects in the respective category.
1
Percentages calculated as 100*(n/number of subjects with ≥ 1 past pregnancy).

Summary of HPV-Related Laboratory Tests Performed at Day 1
Table 7 displays Pap test results at Day 1 for all randomized subjects by vaccination
group. Among the 14,072 total subjects with a satisfactory Pap test result, 11.9%
(n=1,673) of subjects had either borderline abnormal or abnormal Pap results, with LSIL
being the most common single abnormal Pap test result and occurring in 7.1% (n=999)
of subjects. The proportion of subjects reporting an abnormal Pap test result was
generally comparable across the two vaccination group. Two subjects (both in 9vHPV
group) had high grade lesions (one case of atypical glandular cells and one case of
squamous cell carcinoma) at Day 1.
Table 7: Summary of Pap Test Results at Day 1 by Vaccination Group (All Randomized
Subjects, Study V503-001, Efficacy Substudy)
Pap Tests
Subjects with Satisfactory Day
1 Pap Test Results

9vHPV (N=7,106)
n (%)
7,033

qHPV (N=7,109)
n (%)
7,039

Total (N=14,215)
n (%)
14,072

1

Day 1 Pap Test Diagnosis
Negative for SIL
6,198 (88.1)
6,202 (88.1)
12,400 (88.1)
Borderline Abnormal Pap
124 (1.8)
115 (1.6)
239 (1.7)
Abnormal Pap
712 (10.1)
722 (10.3)
1,434 (10.2)
ASC-US (HR positive)
163 (2.3)
193 (2.7)
356 (2.5)
LSIL
509 (7.2)
490 (7.0)
999 (7.1)
ASC-H
7 (0.1)
18 (0.3)
25 (0.2)
HSIL
31 (0.4)
21 (0.3)
52 (0.4)
Atypical glandular cells
1 (<0.1)
0 (0.0)
1 (<0.1)
Squamous cell carcinoma
1 (<0.1)
0 (0.0)
1 (<0.1)
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001_CSR, Table 10-20 (p243).
1
Percentages for Pap test diagnoses calculated as 100*(n/number of subjects with satisfactory
Pap test result).
N=Number of subjects randomized.
n=Number of subjects who have the indicated diagnosis or Pap test result.
ASC-H=Atypical squamous cells, cannot exclude HSIL; ASC-US=Atypical squamous cells of
undetermined significance; HPV=Human papillomavirus; HR=High risk HPV probe result;
HSIL=High-grade squamous intraepithelial lesion; LSIL=Low-grade squamous intraepithelial
lesion; Pap=Papanicolaou's test; SIL=Squamous intraepithelial lesion.

Table 8 summarizes the composite proportions of subjects with positive PCR or serology
for HPV types 6, 11, 16, 18, 31, 33, 45, 52, or 58 at Day 1 by vaccination group in the
efficacy substudy. A total of 38.3% and 27.5% of subjects were positive for at least one
vaccine HPV type by serology or by PCR, respectively. The proportions of subjects
positive for at least one HPV type were similar between the two treatment groups and
were similar to those of subjects in the immunogenicity substudy.
The propositions of subjects with positive PCR or serology for any of the individual 14
HPV types assessed at Day 1 (i.e., HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
or 59) were also similar between the two treatment groups (data not shown). [Data
Source: STN 125508/0_Module 5.3.5.1.p001, Table 10-23 (p251) and Table 10-24
(p252)]

Page 37

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 8: Summary of Composite Proportions of Subjects with Positive PCR or Serology
for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, or 58 at Day 1 by Vaccination Group (All
Randomized Subjects, Study V503-001, Efficacy Substudy
Day 1 PCR and Serology
Negative to HPV types 6, 11, 16, 18, 31, 33, 45,
52 and 58
By Serology
By PCR
By Serology or PCR

9vHPV (N=7,106)
m/n (%)

qHPV (N=7,109)
m/n (%)

4,311/7,082 (60.9)
5,032/6,919 (72.7)
3,605/6,970 (51.7)

4,431/7,078 (62.6)
5,023/6,943 (72.3)
3,638/6,983 (52.1)

Positive to HPV types 6, 11, 16, 18, 31, 33, 45,
52 or 58
By Serology
2,771/7,082 (39.1)
2,647/7,078 (37.4)
1,920/6,943 (27.7)
By PCR
1,887/6,919 (27.3)
By Serology or PCR
3,365/6,970 (48.3)
3,345/6,983 (47.9)
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001_CSR, Table 10-21 (p248).
N=Number of subjects randomized.
m=Number of subjects positive for at least one HPV type by the indicated test.
n=Number of subjects with non-missing data (serology, PCR, or both) at Day 1 for HPV-types 6,
11, 16, 18, 31, 33, 45, 52 and 58.

6.1.10.1.3 Subject Disposition
Part A subjects who received either the selected dose formulation of 9vHPV (mid-dose
formulation) or qHPV were enrolled in both the dose-ranging substudy and the efficacy
substudy. Therefore, baseline data for these subjects was included in reports for both
the dose-ranging substudy cohorts and the efficacy substudy cohorts.
The immunogenicity substudy represented a subset of the efficacy substudy that
included approximately 95% of the subjects enrolled in the efficacy substudy. Therefore,
only selected immunogenicity substudy baseline data are reported in this section. These
include basic information about the immunogenicity substudy cohorts (i.e., subject
characteristics and accounting of subjects in the per protocol immunogenicity population)
and information about HPV serostatus at baseline.
Disposition of Subjects in the Study
A total of 15,334 subjects were screened to participate in V503-001. Of these,
approximately 97% (n=14,840) were randomized.
Dose-ranging substudy: A total of 1,242 subjects were enrolled in the dose-ranging
substudy under Part A. Overall, 99.8% of subjects received at least one dose, and
95.7% of subjects received all three dose. In total, 5.2% of subjects discontinued the
study, 0.2% of subjects due to adverse events, 2.9% of subjects due to lost to follow up,
2.0% of subjects due to withdrawal by subjects and 0.1% of subjects due to protocol
violation. Of these, 617 subjects (Mid-dose 9vHPV and qHPV cohorts) were also
included in the efficacy substudy. Subject disposition is provided in Table 9.

Page 38

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 9: Disposition of Subjects (Study V503-001, Dose-Ranging Study, Day 1 to Month
7)
Disposition

Randomized
Vaccinated at
Dose 1
Dose 2
Dose 3
Completed
Discontinued
Adverse Event
Lost to Follow-up
Protocol Violation
Withdrawal by Subject

Low-Dose
9vHPV
N (%)
315

Mid-Dose
9vHPV
N (%)
307

High-Dose
9vHPV
N (%)
310

qHPV
N (%)

Total
N (%)

310

1242

312 (99.0)
305 (96.8)
300 (95.2)
295 (93.7)
20 (6.3)
1 (0.3)
12 (3.8)
0 (0.0)
7 (2.2)

307 (100.0)
300 (97.7)
291 (94.8)
290 (94.5)
17 (5.5)
1 (0.3)
8 (2.6)
0 (0.0)
8 (2.6)

310 (100.0)
306 (98.7)
297 (95.8)
296 (95.5)
14 (4.5)
0 (0.0)
9 (2.9)
0 (0.0)
5 (1.6)

310 (100.0)
305 (98.4)
300 (96.8)
297 (95.8)
13 (4.2)
0 (0.0)
7 (2.3)
1 (0.3)
5 (1.6)

1239 (99.8)
1216 (97.9)
1188 (95.7)
1178 (94.8)
64 (5.2)
2 (0.2)
36 (2.9)
1 (0.1)
25 (2.0)

Source: Adapted from STN 125508/0, Module 5.3.5.1.p001_CSR, Table 10-1 (p196)
Efficacy substudy cohorts – A total of 14,215 subjects were enrolled in the efficacy
substudy. Overall, 99.9% of subjects received at least one dose, and 97.5% of subjects
received all three doses. In total, 14.0% of subjects discontinued the study, 0.1% of
subjects due to adverse events, 7.1% of subjects due to lost to follow up, 6.6% of
subjects due to withdrawal by subjects and 0.2% of subjects due to other reasons.
Summary of subject disposition by vaccination group is provided in Table 10.
Table 10: Subject Disposition (Day 1 through Visit Cut-off Date April 10, 2013, Study
V503-001)
Disposition
9vHPV
qHPV
Total
N (%)
N (%)
N (%)
Subjects Screened
15,334
Subjects Randomized
14,840
Excluded from efficacy substudy (Low625
and High-dose 9vHPV)
Included in efficacy substudy (Mid-dose 7,106 (100) 7,109 (100) 14,215 (100)
9vHPV, qHPV)
Received at least one vaccination
7,099 (99.9) 7,105 (99.9) 14,204 (99.9)
Completed 3-dose vaccination regimen 6,928 (97.5) 6,934 (97.5) 13,862 (97.5)
Completed the study
838 (11.8)
863 (12.1)
1,701 (12.0)
On active study follow-up
5,250 (73.9) 5,273 (74.2) 10,523 (74.0)
1,018 (14.3) 973 (13.7)
1,991 (14.0)
Discontinued from the study
11 (0.2)
6 (0.1)
17 (0.1)
Adverse Event
528 (7.4)
487 (6.9)
1,015 (7.1)
Lost-to-follow-up
4 (0.1)
5 (0.1)
9 (0.1)
Physician decision
0
(0.0)
1
(<0.1)
1 (<0.1)
Pregnancy
6 (0.1)
6 (0.1)
12 (0.1)
Protocol violation
469 (6.6)
468 (6.6)
937 (6.6)
Withdrawal by subject
Source: Adapted from STN 125508/0.13, Module 1.11.3_Table 1 (p2, Requested information).
Percent was calculated relative to the number of subjects randomized in the vaccination groups
included in the efficacy substudy.

Page 39

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.1.11 Efficacy Analyses
6.1.11.1 Analyses of Primary Endpoint(s)
Immunogenicity Bridging - Results Supporting Vaccine Prophylactic Effectiveness
for the Original qHPV Types (6/11/16/18)
The efficacy findings for qHPV with respect to the original types were bridged to 9vHPV
based on the demonstration of non-inferior immunogenicity. As show in Table 11, noninferiority of GMT antibody responses in the 9vHPV group was demonstrated for each of
HPV types 6, 11, 16, and 18 in 9vHPV group relative to GMT antibody responses in the
qHPV group at four weeks post-dose 3 in the PPI population. The GMT ratios ranged
from 0.80 to 1.19 with the LB of 95% CIs all above 0.67, the success criterion for noninferiority.
Table 11: Non-Inferiority Comparison of Month 7 Anti-HPV 6, 11, 16 and 18 Antibody
Geometric Mean Titers (GMTs) between 9vHPV and qHPV Recipients (Study V503-001,
Per Protocol Immunogenicity Population)
Antibody
Assay
Anti-HPV6
Anti-HPV11
Anti-HPV16
Anti-HPV18

9vHPV
(N=6,792)
n
3,993
3,995
4,032
4,539

GMT (mMU/ml)
893.1
666.3
3,131.1
804.6

qHPV
(N=6,795)
N
3,975
3,982
4,062
4,541

9vHPV/qHPV
(95%CI)
GMT (mMU/ml)
875.2
830.0
3,156.6
678.7

1.02 (0.99, 1.06)
0.80 (0.77, 0.83)
0.99 (0.96, 1.03)
1.19 (1.14, 1.23)

Source: Adapted from STN 125508/0_Module 2.7.3, Table 2.7.3 hpvdiesease:13 (p115).
Note: PPI population included all subjects who were not general protocol violators, received all 3
vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR negative Day 1 through
Month 7 for the relevant HPV types, and had a Month 7 serum sample collected within an acceptable day
range.
N=Number of subjects randomized to the respective vaccination group who received at least 1 injection.
n=Number of subjects contributing to the analysis

In the PPI population, the seroconversion rates for each of HPV types 6, 11, 16, and 18
at 4 weeks post dose 3 of 9vHPV were also non-inferior to the seroconversion rates
following qHPV (Table 12). The LB exceeded -5.0 percentage points, the non-inferiority
success criterion, for all HPV types.
Table 12: Statistical Comparison of Month 7 Anti-HPV Antibody Seroconversion Rates
Between 9vHPV and qHPV Recipients for HPV types 6, 11, 16, and 18 (Study V503001, PPI Population)
Antibody
Assay
Anti-HPV6
Anti-HPV11
Anti-HPV16
Anti-HPV18

9vHPV
(N=6,792)
n
3,993
3,995
4,032
4,539

Seroconversion
99.8%
100.0%
100.0%
99.8%

qHPV
(N=6,795)
N
3,975
3,982
4,062
4,541

9vHPV - qHPV
(95%CI)
Seroconversion
99.8%
99.9%
100.0%
99.7%

0.0 (-0.3, 0.2)
0.0 (-0.1, 0.2)
0.0 (-0.1, 0.2)
0.0 (-0.1, 0.4)

Source: Adapted from STN 125508/0_Module 2.7.3, Appendix 2.7.3 hpvdiesease: 8 (p424).
Note: PPI population included all subjects who were not general protocol violators, received all 3
vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR negative Day 1 through
Month 7 for the relevant HPV type(s), and had a Month 7 serum sample collected within an acceptable day
range.

Page 40

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
N=Number of subjects randomized to the respective vaccination group who received at least 1 injection.
n=Number of subjects contributing to the analysis

Efficacy of 9vHPV against HPV 31/33/45/52/58-Related High Grade Cervical, Vulvar,
or Vaginal Lesions
Table 13 presents the results of the primary efficacy analysis of high grade cervical,
vulvar, and vaginal disease related to HPV types 31, 33, 45, 52, and 58 in the PPE
population. No cases of AIS, cervical cancer, vulvar cancer or vaginal cancer occurred in
either group. As shown in the table, the overall observed efficacy of the 9vHPV vaccine
against HPV 31/33/45/52/58-related high-grade cervical, vulvar and vaginal lesions was
96.7% (95% CI: 80.9, 99.8; p<0.0001) among subjects who were naïve to the relevant
HPV type during the vaccination period. The observed LB of the 95% CI was greater
than 25%, the statistical success criterion for the primary efficacy endpoint.
Table 13: Analysis of Efficacy against HPV 31/33/45/52/58-Related CIN 2/3, AIS,
Cervical Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal Cancer (Study V503001, Per-Protocol Efficacy Analysis Population)
Endpoints

9vHPV (N=7,099)
No. of cases/n

qHPV (N=7,105)
No. of cases/n

% Efficacy of
9vHPV
(95% CI)
96.7 (80.9, 99.8)

HPV 31/33/45/52/58-Related
1/6,016
30/6,017
CIN 2/3, AIS, Cervical Cancer,
VIN 2/3, VaIN 2/3, Vulvar
Cancer, and Vaginal Cancer
By HPV Type
HPV 31-Related
0/5,308
7/5,252
100 (40.1, 100)
HPV 33-Related
0/5,624
7/5,628
100 (39.3, 100)
HPV 45-Related
0/5,724
2/5,724
100 (-246.8, 100)
HPV 52-Related
0/5,320
11/5,216
100 (67.3, 100)
HPV 58-Related
1/5,361
6/5,340
83.4 (- 23.9, 99.3)
By Lesion Type
CIN 2 or worse
1/5,948
27/5,943
96.3 (79.5, 99.8)
CIN 2/3 or AIS
1/5,948
27/5,943
96.3 (79.5, 99.8)
CIN 2/3
1/5,948
27/5,943
96.3 (79.5, 99.8)
CIN 2
1/5,948
23/5,943
95.6 (76.3, 99.8)
CIN 3
0/5,948
5/5,943
100 (-0.2, 100)
VIN 2/3 or VaIN 2/3 or worse
0/6,009
3/6,012
100 (-71.5, 100)
VIN 2/3 or worse
0/6,009
0/6,012
NA
VaIN 2/3 or worse
0/6,009
3/6,012
100 (-71.5, 100)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p0011_CSR, Table 11-1 (p282-3).
PPE population consisted of individuals who received all 3 vaccinations within one year of
enrollment, did not have major protocol deviations, and were PCR negative and seronegative to
the relevant HPV type(s) (Types 31, 33, 45, 52, and 58) prior to dose 1 and PCR negative from
Day 1 through one month post-dose 3 (Month 7).
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of subjects who were randomized to the respective group and received at least one
injection.
n=Number of subjects who had at least one follow-up visit after Month 7.
AIS=Adenocarcinoma in situ; CIN=Cervical intraepithelial neoplasia; NA=Not applicable;
VaIN=Vaginal intraepithelial neoplasia; VIN=Vulvar intraepithelial neoplasia

Page 41

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comments: Although efficacy was statistically significant for the combined
efficacy endpoint (HPV 31/33/45/52/58-related CIN2/3-, VIN 2/3-, VaIN 2/3- or worse),
the vast majority of the cases contributing to the combined endpoint were cervical
lesions (i.e., CIN). With a lower bound on the 95%CI of -71.5%, efficacy against VIN2+
or VaIN2+ has not been demonstrated. However, the study was not powered to
demonstrate efficacy by each lesion grade.
The single case of the primary efficacy endpoint in the 9vHPV group was a subject
(SUBJID=18149) who was PCR-negative from Day 1 through the Month 7 study visit for
HPV 58 and was eligible for inclusion in the HPV 58 PPE analysis. This subject had
LSIL at the Day 1 and Month 7 visits and was PCR-positive for HPV 56 at Day 1 through
Month 42. The subject had a definitive therapy procedure at four months after the
scheduled Month 7 visit. One of four quadrants of the tissue sample obtained during the
definitive therapy procedure was diagnosed as a case of CIN 2 by the Pathology Panel
and was also PCR-positive for HPV 56 and 58. Per case definition, the subject was
counted as a case of the primary efficacy endpoint for HPV 58 at approximately 11
months after dose 1. Except for the single-time PCR-positive for HPV 58 at Month 11,
the subject was PCR-negative for HPV 58 at all other time points through Month 42.
For the 30 primary endpoint cases observed in qHPV group, 11 cases showed coinfection in the lesion biopsy tissues with HPV types other than 31, 33, 45, 52 or 58.
These non-vaccine HPV types were present in the specimens obtained at baseline (Day
1 and/or Month 7) and were present together with vaccine HPV types (31, 33, 45, 52 or
58) in the biopsy tissues when the diagnoses were made in 4 (AN 71340, AN 21049,
AN 69544 and AN72985) out of the 11 cases with co-infections. In addition, 18 primary
endpoint cases were associated with co-infection with HPV types other than 31, 33, 45,
52 or 58 as determined by PCR in specimens of cervicoviginal/external-genital swabs
taken prior to biopsies used for to diagnose the primary endpoint cases. These
circumstances complicated the definitive diagnoses of the primary endpoint cases.
According to the per-protocol definition of a primary endpoint case, the diagnosis of a
primary endpoint case in the PPE population required the presence of both a high grade
intraepithelial lesion and at least one of the HPV types 31, 33, 45, 52 or 58, regardless of
the presence of other HPV types in the same lesion. If these lesions were attributed to
HPV types detected in the lesion other than the 5 new vaccine types in 9vHPV, the
efficacy point estimate would be lower (with wider 95% CI). However, only 2 lesions in
the qHPV group were positive for a higher-risk oncogenic HPV type (16) in addition to
one of the 9vHPV new vaccine types, so the remainders of cases were most likely due
to the 9vHPV vaccine types identified in the lesions.
Consistent with the results in the PPE population, 9vHPV reduced the primary efficacy
endpoint cases in the HN-TS population with an LB of 95% CI >68% (Table 14). No
cases of AIS, cervical cancer, vulvar cancer or vaginal cancer occurred in either group in
this population. All endpoint cases in the 9vHPV group occurred on or before 18 months
after vaccination dose 1. Among the six cases of HPV 31/33/45/52/58-related high grade
cervical, vulvar, and vaginal disease in the 9vHPV group in the HN-TS population:
• Five subjects (SUBJID=18149; 18828; 19890; 67888; 70988) were PCR-positive
at Day 1 for at least one oncogenic HPV type other than the HPV type associated
with the endpoint case
• One subject (SUBJID=75402) was PCR-negative at Day 1 for all the oncogenic
HPV types tested, was then PCR-positive for multiple oncogenic HPV types at 8
Page 42

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

months post Day 1, and was diagnosed as a case of HPV 31-related CIN 3 at 10
months post Day 1.
Reviewer’s comment: Subject 75402 was seropositive for HPV types 18 and 58, but
seronegative for other HPV types including HPV 31 and 56 at baseline. She was
reported PCR positive for HPV 56 (E7) before study. On Day 1 (prior to Dose 1), all
genital and cervical swabs were PCR negative for all the HPV types and her Pap smear
was negative. At Month 7, her swabs showed PCR positive for HPV types 18, 31, 51, 52
and 56, and her Pap smear showed LSIL. At Month 10, her cervical specimen showed
CIN3 and PCR positive for HPV 31 (L1, E6 and E7); all other HPV types (6, 11, 16, 18,
33, 35, 39, 45, 52, 56, 58 and 59) were negative. It appears that this subject was
infected with at least HPV 18, 56 and 58 prior to participating in the clinical trial.
Because of the limited information, it was unknown if this patient had pre-existing
cervical lesions although Pap smear at baseline was negative. Since the specimen with
a CIN3 lesion also showed PCR positive for HPV 31 but no other HPV types, the CIN 3
lesion was diagnosed as a case of HPV 31-related CIN 3 per protocol primary case
definition.
Table 14: Analysis of Efficacy against HPV 31/33/45/52/58-Related CIN 2/3, AIS,
Cervical Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal Cancer (Study V503001, HPV-Naive Type-Specific Analysis Population)
Endpoints

9vHPV (N=7,099)
No. of cases/n

qHPV (N=7,105)
No. of cases/n

% Efficacy of
9vHPV
(95% CI)
85.7 (68.4, 94.1)

HPV 31/33/45/52/58-Related
6/6,873
42/6,866
CIN 2/3, AIS, Cervical Cancer,
VIN 2/3, VaIN 2/3, Vulvar
Cancer, and Vaginal Cancer
By HPV Type
HPV 31-Related
2/6,110
12/6,104
83.3 (28.0, 97.3)
HPV 33-Related
1/6,444
8/6,467
87.4 (19.7, 99.4)
HPV 45-Related
0/6,562
3/6,571
100 (-72.3, 100)
HPV 52-Related
2/6,140
17/6,129
88.2 (53.7, 98.1)
HPV 58-Related
1/6,173
9/6,193
88.8 (19.6, 99.5)
By Lesion Type
CIN 2 or worse
5/6,735
39/6,718
87.2 (67.8, 95.2)
CIN 2/3 or AIS
5/6,735
39/6,718
87.2 (67.8, 95.2)
CIN 2/3
5/6,735
39/6,718
87.2 (67.8, 95.2)
CIN 2
4/6,735
33/6,718
87.9 (67.1, 96.1)
CIN 3
3/6,735
9/6,718
66.6 (-22.5, 92.2)
VIN 2/3 or VaIN 2/3 or worse
1/6,870
3/6,865
66.6 (-203.1, 98.7)
VIN 2/3 or worse
1/6,870
0/6,865
NA
VaIN 2/3 or worse
0/6,870
3/6,865
100 (-71.9, 100)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p0011_CSR, Table 11-2 (p285-6).
HPV Naïve Type-Specific (HN-TS) population included only subjects who were seronegative and
PCR negative at Day 1 to the relevant HPV types.
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of subjects who were randomized to the respective group and received at least one
injection.
n=Number of subjects who had at least one follow-up visit after Month 7.
AIS=Adenocarcinoma in situ; CIN=Cervical intraepithelial neoplasia; NA=Not applicable;
VaIN=Vaginal intraepithelial neoplasia; VIN=Vulvar intraepithelial neoplasia.

Page 43

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comments: The efficacy estimates for the HN-TS population were
generally lower compared with PPE population because the HN-TS population included
subjects who were infected with relevant HPV types prior to completion of the
vaccination series.
Sensitivity Analyses Relating to the Primary Efficacy Endpoint
Sensitivity analyses were conducted to evaluate the robustness of primary endpoint
efficacy estimates. These analyses assessed the impacts of losses-to-follow-up, the
rigor of the endpoint case definition, and the rigor of the endpoint case ascertainment.
These sensitivity analyses did not change the overall conclusion that 9vHPV prevented
high-grade cervical disease related HPV 31/33/445/52/58.
Impact of Losses-to-Follow-up on the Estimate of Efficacy
A proportion of subjects lost-to-follow-up were imputed as primary endpoint cases under
the assumption of no vaccine efficacy. Therefore, the cumulative incidence probability of
HPV 31/33/45/52/58-related primary cases in qHPV group (excluding subjects who were
lost-to-follow-up) was estimated for both 9vHPV and qHPV groups. In the qHPV group,
the cumulative incidence probability of becoming a primary efficacy endpoint case was
0.0057. Thus 0.57% of subjects lost to follow-up in each of the 9vHPV and qHPV groups
were imputed as endpoint cases.
A total of 596 and 581 subjects in PPE population were lost-to-follow-up in the 9vHPV
and qHPV groups, respectively, through 60 months of follow-up (The cumulative
incidence was presented in Table 14.3-26, p1714 of the CSR, not shown in this review).
Thus, 3.4 and 3.3 additional cases were imputed in the 9vHPV and qHPV vaccine
groups, respectively. The total numbers of cases in the adjusted PPE analysis were 4.4
(out of 6,016) for 9vHPV and 33.3 (out of 6017) for qHPV, and the adjusted efficacy
estimate was 87.9% (95% CI 67.2, 96.1).
In the HN-TS population, the cumulative incidence probability of becoming a case of the
primary efficacy endpoints in HN-TS population was 0.008. A total of 917 and 895
subjects were lost-to-follow-up in 9vHPV and qHPV groups, respectively, through 60
months of follow-up. Thus, 7.3 and 7.1 additional cases were imputed in the 9vHPV and
qHPV groups, respectively. The total numbers of cases in the adjusted HN-TS analysis
were 13.3 (out of 6,873) for 9vHPV and 49.1 (out of 6,866) for qHPV, and the adjusted
efficacy estimate was 73.5% (95% CI 51.6, 86.0).
Impact of Primary Endpoint Case Definition on the Estimate of Efficacy
The first sensitivity analysis performed to evaluate the impact of the endpoint case
definition was intended to add rigor to the HPV type-attribution on the tissue samples on
which diagnosis of high-grade disease were adjudicated. To this end, in addition to
meeting all the protocol-defined criteria for a primary efficacy endpoint case
(HPV 31/33/45/52/58-related high grade cervical, vulvar, or vaginal disease endpoint
case), subjects were also required to be PCR-positive to the same HPV type on a study
visit immediately before or immediately after the study visit when the subject became a
primary efficacy endpoint case. Results of this sensitivity analysis by analysis
populations and efficacy endpoints are shown in Table 15.

Page 44

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 15: Analysis of Efficacy against HPV 31/33/45/52/58-Related CIN 2/3, AIS,
Cervical Cancer, VIN 2/3, VaIN 2/3, Vulvar Cancer, and Vaginal Cancer with Preceding
or Succeeding Infection with the Same HPV Type (Study V503-001, PPE, HN-TS, and
FAS Analysis Populations)
Analysis Population and
Endpoints

9vHPV (N=7099)
No. of cases/n

qHPV (N=7105)
No. of cases/n

Observed Efficacy
of 9vHPV
% (95% CI)

PPE
High Grade Cervical, Vulvar
0/6016
29/6017
100 (88.5, 100)
and Vaginal Disease
CIN 2/3 or worse
0/5948
26/5942
100 (86.9, 100)
VIN 2/3 or VaIN 2/3 or worse
0/6009
3/6012
100 (-71.5, 100)
HN-TS
High Grade Cervical, Vulvar
3/6876
40/6870
92.5 (77.3, 98.0)
and Vaginal Disease
CIN 2/3 or worse
2/6735
37/6718
94.6 (79.5, 99.1)
VIN 2/3 or VaIN 2/3 or worse
1/6873
3/6869
66.6 ( -203.1, 98.7)
FAS
High Grade Cervical, Vulvar
118/7027
148/7027
20.1 (-1.7, 37.8)
and Vaginal Disease
CIN 2/3 or worse
114/6882
142/6871
19.4 (-3.8, 37.6)
VIN 2/3 or VaIN 2/3 or worse
5/7027
6/7026
16.3 ( -201.9, 75.0)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p0011_CSR, Table11-87 (p642).
N = Number of randomized subjects who received at least 1 injection.
n = Number of subjects in the given population who had at least one follow-up visit after Month 7
in the PPE population; after Day 1 in all other analysis populations.
AIS=Adenocarcinoma in situ; CI=Confidence interval; CIN=Cervical intraepithelial neoplasia;
HPV=Human papillomavirus; VaIN=Vaginal intraepithelial neoplasia; VIN=Vulvar intraepithelial
neoplasia

Reviewer’s comments: This population included subjects who were infected with
relevant HPV types before study initiation or completion of the vaccination series. The
efficacy of the 9vHPV was not demonstrated in the FAS population because the FAS
population included subjects who were infected with relevant HPV types prior to initiation
or completion of the vaccination series, and the sample size was not powered to
demonstrate efficacy in this population.
The second sensitivity analysis performed to evaluate the impact of the endpoint case
definition was intended to evaluate the impact of the adjudication approach (Pathology
Panel diagnosis vs. Central Pathology Laboratory diagnosis). To this end, in addition to
meeting all the protocol-defined criteria for a primary efficacy endpoint case, the
diagnosis attributed to tissue samples was the most histopathologically advanced of the
diagnoses rendered by the Pathology Panel and the Central Pathology Laboratory.
Results of this sensitivity analysis were similar to those obtained in the first sensitivity
analysis in the PPE, HN-TS, and FAS populations regarding primary case definition as
shown in Table 15 above.
Impact of Cervical Disease Endpoint Case Definition on the Estimate of Efficacy
The efficacy analyses presented above excluded cases of HPV-related disease
endpoints that were based on cervical tissue samples not being preceded by an

Page 45

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

abnormal Pap test diagnosis. Without these exclusions,.the efficacy estimates for
prevention of HPV 31, 33, 45, 52 and 58-related CIN 2/3 or worse in the PPE and HNTS populations were 93.7% (95% CI: 81.1, 98.4) and 85.7% (95% CI: 68.3, 94.1),
respectively.
6.1.11.2 Analyses of Secondary Endpoints
Comparison of 9vHPV and qHPV in Prevention of HPV 31/33/45/52/58-Related
Cervical, Vulvar, or Vaginal Lesions
Table 16 presents the efficacy analysis for prevention of cervical, vulvar, and vaginal
disease (including low-grade disease) related to HPV types 31, 33, 45, 52, and 58 in the
PPE population. As shown in the table, the efficacy of the 9vHPV vaccine was 97.1%
with an LB of 95% CI 91.8% in preventing combined cervical, vulvar, and vaginal
disease of all grades related to HPV types 31, 33, 45, 52, and 58 in the PPE population.
Reviewer’s comments: This endpoint corresponds to secondary efficacy objective 4.
There was no pre-specified success criterion for this endpoint.
Table 16: Analysis of Efficacy for Prevention of HPV 31/33/45/52/58-Related Cervical,
Vulvar, and Vaginal Disease (Study V503-001, Per-Protocol Efficacy Analysis
Population)
Endpoints

9vHPV (N=7,099)
No. of cases/n

qHPV (N=7,105)
No. of cases/n

Efficacy of
9vHPV
% (95% CI)
97.1 (91.8, 99.2)

HPV 31/33/45/52/58-Related
3/6,016
103/6,017
Cervical, Vulvar, and Vaginal
Disease
Cervical Disease
2/5,948
88/5,943
97.7 (92.2, 99.6)
CN1
1/5,948
69/5,943
98.6 (92.4, 99.9)
CIN2 or worse
1/5,948
27/5,943
96.3 (79.5, 99.8)
Vulvar and Vaginal Disease
1/6,009
16/6,012
93.8 (61.5, 99.7)
Condyloma
0/6,009
3/6,012
100 (-71.6, 100)
VIN 1 or VaIN 1
1/6,009
12/6,012
91.7 (51.3, 99.6)
VIN 2/3 or VaIN 2/3 or worse
0/6,009
3/6,012
100 (-71.5, 100)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p0011_CSR, Table 11-3 (p289).
The per-protocol efficacy (PPE) population consisted of individuals who received all three
vaccinations within one year of enrollment, did not have major protocol deviations, and were
naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 31, 33, 45, 52, and
58) prior to dose 1 and PCR negative for the relevant HPV types from Day 1 through 1 month
post-dose 3 (Month 7).
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of randomized subjects who received at least one injection.
n=Number of subjects who had at least one follow-up visit after Month 7.
CIN=Cervical intraepithelial neoplasia; VaIN=Vaginal intraepithelial neoplasia; VIN=Vulvar
intraepithelial neoplasia

Consistent with the results in the PPE population, efficacy of the 9vHPV vaccine was
91.7% (LB of 95% CI: 85.4%) in preventing combined cervical, vulvar, and vaginal
disease of all grades related to HPV types 31, 33, 45, 52, and 58 in the HN-TS
population (Table 17).

Page 46

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 17: Analysis of Efficacy against HPV 31/33/45/52/58-Related Cervical, Vulvar, and
Vaginal Disease (Study V503-001, HN-TS Population)
Endpoints

9vHPV (N=7,099)
No. of cases/n
12/6,873

qHPV (N=7,105)
No. of cases/n
144/6,866

Efficacy of 9vHPV
% (95% CI)
91.7 (85.4, 95.4)

HPV 31/33/45/52/58-Related
Cervical, Vulvar, and Vaginal
Disease
Cervical Disease
9/7,735
125/6,718
92.8 (86.5, 96.5)
CN1
5/7,735
99/6,718
95.0 (88.2, 98.1)
CIN2 or worse
5/7,735
39/6,718
87.2 (67.8, 95.2)
Vulvar and Vaginal Disease
3/6,870
22/6,012
86.3 (56.4, 96.5)
Condyloma
1/6,870
6/6,012
83.3 (-24.6, 99.3)
VIN 1 or VaIN 1
1/6,870
16/6,012
93.7 (61.4, 99.7)
VIN 2/3 or VaIN 2/3 or worse
1/6,870
3/6,012
66.6 (-203.1, 98.7)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p0011_CSR, Table 11-4 (p293).
HPV Naïve Type-Specific (HN-TS) population included only subjects who were seronegative and
PCR negative at Day 1 to the relevant HPV types.
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of randomized subjects who received at least one injection.
n=Number of subjects who had at least one follow-up visit after Month 7.
CIN=Cervical intraepithelial neoplasia; VaIN=Vaginal intraepithelial neoplasia; VIN=Vulvar
intraepithelial neoplasia

Comparison of 9vHPV and qHPV in Prevention of HPV 31/33/45/52/58-Related
Persistent Infection
Type specific persistent HPV infection as monitored by genotyping can identify women
at increased risk of cervical neoplasia more accurately than a single or repeated
presence of HPV test. Table 18 presents the efficacy analysis of 9vHPV as compared to
qHPV in preventing persistent infection related to HPV types 31, 33, 45, 52, and 58 in
the PPE population. As shown in the table, the pre-specified success criteria relating to
persistent infection of ≥6 months duration (LB of 95% CI of efficacy >25%) and
persistent infection of ≥12 months duration (LB of the 95% CI of efficacy > 0%) were
met. For each of HPV types 31, 33, 45, 52, and 58, the LBs of 95% CI of efficacy
against persistent infection of ≥6 months and ≥12 months duration were >90% and
>85%, respectively.
Table 18: Analysis of Efficacy against HPV 31/33/45/52/58-Related Persistent Infection
(Study V503-001, PPE Populations)
Endpoints
Persistent Infection ≥6 Months
HPV 31/33/45/52/58-Related
HPV 31-Related
HPV 33-Related
HPV 45-Related
HPV 52-Related
HPV 58-Related
Persistent Infection≥12 Months
HPV 31/33/45/52/58-Related
HPV 31-Related

9vHPV
(N=7,099)
No. of Cases/n

qHPV (N=7,105)
No. of Cases/n

Efficacy of 9vHPV
% (95% CI)

26/5,939
5/ 5,251
1/5,553
3/5,649
8/5,263
9/5,297

642/5,953
113/5,198
83/5,560
89/5,658
297/5,160
175/5,284

96.2 (94.4, 97.5)
95.7 (90.0, 98.3)
98.8 (93.8, 99.9)
96.7 (90.6, 99.1)
97.4 (95.0, 98.9)
95.0 (90.3, 97.5)

15/5,939
3/5,251

375/5,953
68/5,198

96.1 (93.7, 97.9
95.7 (87.6, 98.8)

Page 47

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
HPV 33-Related
0/5,553
48/5,560
100 (92.9, 100)
HPV 45-Related
2/5,649
49/5,658
95.9 (85.4, 99.3)
HPV 52-Related
5/5,263
161/5,160
97.0 (93.3, 98.8)
HPV 58-Related
5/5,297
95/5,284
94.8 (87.8, 98.0)
Source: Adapted from STN 125508/0.4_Module 1.11.3, Table Q17-1.
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of randomized subjects who received at least one injection.
n=Number of subjects in the population who had at least one follow-up visit after Month 7.

Similar results, albeit with slightly lower efficacy point estimates and LB 95% CI, were
seen in the HN-TS population (Table 19).
Table 19: Analysis of Efficacy against HPV 31/33/45/52/58-Related Persistent Infection
(Study V503-001, HN-TS Analysis Populations)
Endpoints

9vHPV
(N=7,099)
No. of Cases/n

qHPV (N=7,105)
No. of Cases/n

Efficacy of 9vHPV
% (95% CI)

Persistent Infection ≥6 Months
HPV 31/33/45/52/58-Related
121/6,704
918/6,699
87.6 (85.1, 89.9)
HPV 31-Related
22/5,971
177/5,953
87.8 (81.1, 92.5)
HPV 33-Related
11/6,281
113/6,314
90.3 (82.6, 95.1)
HPV 45-Related
19/6,395
123/6,412
84.6 (75.6, 90.6)
HPV 52-Related
47/5,991
421/5,983
89.2 (85.5, 92.2)
HPV 58-Related
31/6,020
258/6,040
88.2 (83.1, 92.1)
Persistent Infection≥12 Months
HPV 31/33/45/52/58-Related
83/6,704
585/6,699
86.4 (82.9, 89.3)
HPV 31-Related
16/5,971
117/5,953
86.5 (77.8, 92.5)
HPV 33-Related
9/6,281
72/6,314
87.5 (75.0, 93.9)
HPV 45-Related
13/6,395
70/6,412
81.4 (67.0, 90.2)
HPV 52-Related
32/5,991
247/5,983
87.3 (82.0, 91.3)
HPV 58-Related
22/6,020
155/6,040
85.9 (77.9, 91.4)
Source: Adapted from STN 125508/0.4_Module 1.11.3, Table Q17-1.
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of randomized subjects who received at least 1 injection.
n=Number of subjects in the population at Day 1.

Reviewer’s comments: The analyses of persistent infections originally included a one
month visit window, meaning that the documented duration of persistent infection could
be shorter than the stated endpoints (6 or 12 months). CBER asked the Applicant to reanalyze persistent infection data by including only subjects with documented infection
strictly equal to or greater than 6 or 12 months. The results shown above represent the
modified analyses with strict endpoint definitions.
Seroconversion Rates for Anti-HPV 31, 33, 45, 52, and 58 Antibodies Induced by
9vHPV
Table 20 presents the results of the per-protocol analysis of seroconversion rates at
Month 7, as assessed by type-specific cLIA, for anti-HPV 31, 33, 45, 52 and 58
antibodies elicited in 9vHPV recipients. The seroconversion rates were above 99% for
each of HPV types 31, 33, 45, 52, and 58 at 4 weeks post-dose 3 in the PPI population.
The success criterion (LB 95% CI >90%) was met for each HPV type.

Page 48

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 20: Seroconversion Rates for anti-HPV 31, 33, 45, 52 and 58 Antibodies at Month
7 (Study V503-001, PPI Population, N=6792)
HPV Type
m/n
Seroconversion Rate1
% (95% CI)
31
4457/4466
99.8 (99.6, 99.9)
33
4689/4702
99.7 (99.5, 99.9)
45
4773/4792
99.6 (99.4, 99.8
52
4446/4455
99.8 (99.6, 99.9)
58
4476/4486
99.8 (99.6, 99.9)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p001_CSR, Table 11-97 (690).
1
Percent represents proportion of subjects with serum levels ≥10, 8, 8, 8, and 8mMU/mL for HPV
types 31, 33, 45, 52, and 58, respectively.
N=number of randomized subjects who received at least one injection.
n=number of subjects contributing to the analysis
m=number of subjects seropositive to the relevant HPV type(s)

6.1.11.3 Subpopulation Analyses
Subpopulation analyses were conducted based on the following demographic and
baseline characteristics:
• Age at the start of vaccination: ≤20 vs. ≥21 years old.
• Race: Asian, Black, White, and All others.
• Ethnicity: Hispanic vs. not Hispanic.
• Geographic region: Asia-Pacific, Europe, Latin America, North America.
• Hormonal contraception use at the start of vaccination: Using vs. Not Using
hormonal contraception.
• Lifetime number of male or female sex partners at the start of vaccination: None,
1 to 2, and ≥3.
Assessments were conducted on the PPE and HN-TS analysis populations. For the HNTS population, assessments were also conducted on the following subgroups defined
based on completion of the 3-dose vaccination regimen:
• 3 doses completed vs. ≤2 doses completed
• The ≤2 doses completed was further subdivided into the subgroups: 2 doses
completed and 1 dose completed.
HPV 31/33/45/52/58-Related High Grade Cervical, Vulvar, or Vaginal Lesions
Assessments in PPE Population
As seen from Table 21, estimates of efficacy against HPV 31/33/45/52/58-related highgrade cervical, vulvar, and vaginal disease were consistent across the different
subgroups that were investigated.

Page 49

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 21: Analysis of Efficacy against HPV 31/33/45/52/58-Related CIN2/3. AIS,
Cervical Cancer, VIN2/3, VaIN2/3, Vulvar Cancer and Vaginal Cancer by Subgroups
(Study V503-001, Per Protocol Efficacy Analysis Population)
Characteristics
Subgroup

9vHPV (N=7099)
No. of cases/n

qHPV (N=7105)
No. of cases/n

Observed Efficacy
of 9vHPV
% (95% CI)
96.7 (80.9, 99.8)

All subjects
1/6016
30/6017
Age
≤20 years
0/1790
19/1889
100 (79.8, 100)
≥21 years
1/4226
11/4128
91.1 (47.4, 99.6)
Race
Asian
0/885
1/866
100 (≤-999,100)
Black
0/199
0/187
NA
White
0/3318
21/3306
100 (82.9, 100)
All Others
1/1614
8/1658
87.3 (19.0, 99.4)
Ethnicity
Hispanic
1/2146
11/2154
90.9 (46.6, 99.6)
Non-Hispanic
0/3870
19/3863
100 (80.6, 100)
Geographic Region
Asia-Pacific
0/791
0/788
NA
Europe
0/2051
12/2027
100 (69.7,100)
Latin America
1/2032
11/2052
90.9 (46.2,99.6)
North America
0/1142
7/1150
100 (38.3,100)
Hormonal Contraception
Use at Day 1
Using hormonal contraception
1/3661
20/3671
95.0 (72.0, 99.8)
Not using hormonal
0/2355
10/2346
100 (63.9, 100)
contraception
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001_CSR, Table 11-78 (p612-14).
N=Number of randomized subjects who received at least one injection.
n=Number of subjects who had at least one follow-up visit after Month 7.

Assessments in the HN-TS Population
Similar to the assessments in the PPE population, estimates of efficacy against HPV
31/33/42/52/58-related high-grade cervical, vulvar, and vaginal disease were consistent
across different subgroups except the Asia-Pacific subgroup, where there was one
primary endpoint case for both 9vHPV and qHPV (Table 22). Because there was no
endpoint case among all subjects who received ≤ 2 doses of 9vHPV or qHPV, efficacy of
9vHPV relative to qHPV could not be estimated for this endpoint.
Table 22: Analysis of Efficacy against HPV 31/33/45/52/58-Related CIN2/3, AIS,
Cervical Cancer, VIN2/3, VaIN2/3, Vulvar Cancer and Vaginal Cancer by Subgroups
(Study V503-001, HPV-Naïve Type-Specific Analysis Population)
Characteristics
Subgroup
All subjects
Age
≤20 years
≥21 years
Race
Asian

9vHPV (N=7099)
No. of cases/n

qHPV (N=7105)
No. of cases/n

6/6873

42/6866

Observed Efficacy
of 9vHPV
% (95% CI)
85.7 (68.4, 94.1)

2/2078
4/4795

24/2179
18/4687

91.4 (68.4, 98.5)
78.1 (37.3, 93.2)

1/987

2/969

51.1 (-524.5, 989.3)

Page 50

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Characteristics
Subgroup

9vHPV (N=7099)
No. of cases/n

qHPV (N=7105)
No. of cases/n

Observed Efficacy
of 9vHPV
% (95% CI)
100 (≤-999, 100)
86.1 (60.7, 95.5)
89.9 (35.5, 99.5)

Black
0/237
1/224
White
4/3793
29/3794
All Others
1/1856
10/1879
Ethnicity
Hispanic
1/2450
15/2429
93.4 (57.9, 99.7)
Non-Hispanic
5/4423
27/4437
81.3 (52.8, 93.2)
Geographic region
Asia-Pacific
1/873
1/874
0.3 (≤-999, 97.4)
Europe
2/2336
16/2328
87.5 (52.1, 98.0)
Latin America
1/2303
14/2301
92.9 (57.0, 99.7)
North America
2/1361
11/1363
81.4 (21.4, 97.0)
Hormonal Contraception
Use at Day 1
Using hormonal
2/4127
28/4129
92.8 (74.0, 98.8)
contraception
Not using hormonal
4/2746
14/2737
71.6 (13.6, 91.4)
contraception
Vaccine Dose Completion
3 doses completed
6/6778
42/6777
85.7 (68.4, 94.1)
≤2 doses completed
0/95
0/89
NA
2 doses completed
0/83
0/77
NA
1 dose completed
0/12
0/12
NA
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001_CSR, Table 11-79 (p615-17).
N = Number of randomized subjects who received at least one injection.
n = Number of subjects who had at least one follow-up visit after Day 1

Reviewer’s comment: Although the efficacy point estimates for each subgroup in both
PPE and HN-TS populations are relatively consistent, the 95% CI vary greatly. This is
because the numbers of primary endpoint cases in the analysis populations are small,
and some subgroups have sparse case counts.
HPV 31/33/45/52/58-Related Persistent Infection
Results of assessments in the PPE Population
Table 23 presents the observed efficacy of 9vHPV in prevention of HPV 31/33/45/52/58related persistent infection ≥ 6 months duration in different subgroups in the PPE
population. As seen from the table, efficacy estimates were consistent across
subgroups. For all the evaluated subgroups, the lower bound of the 95% CI was greater
than 80%. Consistent with the results in PPE, efficacy estimates were greater than 85%
in all subgroups in HN-TS population. The LBs 95% CIs were greater than 75% for all
subgroups in this population. In this analysis population, nine subjects in 9vHPV group
and eight subjects in qHPV group received ≤2-doses of the vaccines. Of these, there
were three cases of persistent infection in the qHPV group and no cases in the 9vHPV
group.

Page 51

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 23: Analysis of Efficacy against HPV 31/33/45/52/58-Related Persistent Infection
≥6 Months by Subgroups (Study V503-001, Per protocol Efficacy Analysis Population)
Characteristics
Subgroup

9vHPV (N=7099)
No. of cases/n

qHPV (N=7105)
No. of cases/n

Observed Efficacy
of 9vHPV
% (95% CI)
96.0 (94.4, 97.2)

All subjects
35/5939
810/5953
Age
≤20 years
15/1770
349/1870
95.9 (93.4, 97.8)
≥21 years
20/4169
461/4083
96.0 (93.8, 97.6)
Race
Asian
3/868
67/858
95.8 (88.0. 98.9)
Black
1/197
32/185
97.3 (84.3, 99.9)
White
12/3276
429/3273
97.4 (95.4, 98.5)
All Others
19/1598
282/1637
93.7 (90.0, 96.2)
Ethnicity
Hispanic
20/2122
369/2129
95.0 (92.4, 97.0)
Non-Hispanic
15/3817
441/3824
96.8 (94.8, 98.2)
Geographic Region
Asia-Pacific
4/776
66/781
94.2 (84.9, 98.1)
Europe
8/2031
257/2003
97.1 (94.5, 96.9)
Latin America
20/2009
355/2028
94.8 (92.0, 96.9)
North America
3/1123
132/1141
97.8 (93.7, 99.4)
Hormonal Contraception
Use at Day 1
Using hormonal
17/3610
488/3632
96.7 (94.8, 98.1)
contraception
Not using hormonal
18/2329
322/2321
94.8 (91.9, 96.8)
contraception
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001_ CSR, Table 11-82 (p628-9).
N = Number of randomized subjects who received at least one injection.
n = Number of subjects who had at least one follow-up visit after Month 7.

6.1.11.4 Dropouts and/or Discontinuations
The methods regarding handling missing data are presented in Section 6.1.9.2. The
dropout rates for both 9vHPV and qHPV treatment were less than 10% throughout the
60-month follow-up period. As shown in the sensitivity analyses (Section 6.1.11.1), the
estimate of vaccine efficacy was not substantially different when cases were imputed
among subjects who were lost to follow up.
6.1.11.5 Exploratory and Post Hoc Analyses
Efficacy of 9vHPV against HPV 31/33/45/52/58-Related Cervical and External
Genital Procedures and Cervical Definitive Therapy
Table 24 shows the efficacy of 9vHPV against cervical and external genital procedures
and cervical definitive therapy related to HPV types 31, 33, 45, 52, and 58 in the PPE
and HN-TS populations. As shown in the table, 9vHPV significantly reduced cases of the
composite endpoint of HPV 31/33/45/52/58-related biopsy (external genital and cervical
biopsies combined) and cervical definitive therapy for both PPE and HN-TS populations.
The point estimates of efficacy for the two populations were greater than 80% with a LB
of 95% CI greater than 65%.

Page 52

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 24: Efficacy of 9vHPV against HPV 31/33/45/52/58-Related Cervical and External
Genital Procedures (Study V503-001, PPE and HN-TS Population)
Analysis Population and
Endpoints

9vHPV (N=7,99)
No. of Cases/n

qHPV (N=7,105)
No. of Cases/n

Efficacy of
9vHPV
% (95% CI)

PPE Population
HPV 31/33/45/52/58-Related
7/6,016
222/6,017
96.9 (93.6, 98.6)
Biopsy
HPV 31/33/45/52/58-Related
4/6,012
32/6,014
87.5 (65.7, 96.0)
Definitive Therapy
HN-TS Population
HPV 31/33/45/52/58-Related
28/6,873
317/6,866
91.3 (87.3, 94.3)
Biopsy
HPV 31/33/45/52/58-Related
8/6,835
48/6,718
83.3 (66.1, 93.2)
Definitive Therapy
Source: Adapted from STN 125508/0_Module 5.3.5.1.p001_CSR, Tables 11-8 and 11-9(p312315)
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of randomized subjects who received at least one injection.
n=Number of subjects who had at least one follow-up visit after Day 1.

Comparison of 9vHPV and qHPV in Prevention of HPV 6/11/16/18-Related Cervical,
Vulvar, or Vaginal Lesions, and Persistent Infection
The 9v HPV vaccine demonstrated equivalent protection against HPV 6-, 11-, 16-, and
18-related cervical, vulvar or vaginal lesions in PPE population. Similar results were
also observed in the HN-TS population.
Overall, 6 and 7 cases of HPV 6/11/16/18-related cervical, vulvar, and vaginal disease
were observed in 9vHPV and qHPV groups, respectively. In the 9vHPV group, the 6
cases were: 4 cases of HPV 6-related condyloma (SUBJID=17844, 19776, 22255, and
22418), 1 case of HPV 18-related condyloma (SUBJID=21481) and 1 case of HPV 18related CIN 2 (SUBJID=75718). In the qHPV group, the 7 cases were: 2 cases of HPV
16-related CIN 1 (SUBJID=19087; 67886), 2 cases of HPV 16-related VIN/VaIN 1
(SUBJID=67364 and 69006), 2 cases of HPV 16-related VIN/VaIN 2/3 (SUBJID=68448
and 72000), and 1 case of HPV 6-related CIN 2/3 (SUBJID=18933).
Reviewer’s comment: For evaluation of efficacy with respect to specific HPV types (i.e.,
HPV types under evaluation), the PPE population could include subjects who were
seropositive at Day 1 and/or PCR positive from Day 1 through Month 7 for the HPV
types not under evaluation.
As discussed in Section 6.1.11.1, co-infection is very common, which confounds the
attribution of causality of the observed lesions to any particular co-infecting serotype. It
cannot be determined whether cases of HPV 6/11/16/18-related cervical, vulvar, and
vaginal disease were caused by HPV types other than 6/11/16/18 or were true cases of
vaccine failure.
The 9vHPV vaccine also demonstrated protection against HPV 6/11/16/18-related
persistent infection (≥6 months or ≥12 months) in both the PPE and HN-TS populations.
For persistent infection ≥6 months, the risk reduction for 9vHPV relative to qHPV was

Page 53

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

26.4% (95% CI: 4.3, 47.5) and 18.3% (95% CI: 2.1, 34.8) in the PPE and HN-TS
populations, respectively, For persistent infection ≥12 months, the risk reduction for
9vHPV relative to qHPV was 31.3% (95% CI: 21.9, 606) in PPE population and 9.3%
(95% CI: -21.0, 32.6) in HN-TS population,[Data source: V503-001 CRS, Table 11-12,
p332-4].
Impact of 9vHPV on FAS Population
Impact of 9vHPV against the Rates of Persistent Infection and Cervical, Vulvar, or
Vaginal Disease Related to Vaccine HPV Types
Table 25 summarizes the comparison of 9vHPV with qHPV preventing persistent
infection (≥ 6 month duration) and cervical, vulvar, and vaginal disease related to
vaccine HPV types in the FAS analysis population.
There was a moderate reduction in the proportion of subjects with HPV 31/33/45/52/58related persistent infection and low grade cervical, vulvar and vaginal disease in the
9vHPV group compared with the qHPV group. However, the risk reduction estimate for
the composite endpoint of HPV 31/33/45/52/58-related high-grade cervical, vulvar, and
vaginal disease was not statistically significant. There were no statistically significant
differences in any HPV-6/11/16/18-related efficacy endpoints between the 9vHPV and
qHPV groups.
Reviewer comment: As described above the study was not powered to demonstrate
efficacy in this population.
Table 25: Impact of 9vHPV against Rates of Persistent Infection and Cervical, Vulvar,
and Vaginal Disease Related to Vaccine HPV Types (Study V503-001, FAS1 Population)
Endpoints
HPV 31/33/45/52/58-Related
High-grade Cervical, Vulvar, and
Vaginal Disease
Cervical, Vulvar, and Vaginal
Disease (Any Grade)
CIN 1
CIN 2 or worse
Vulvar and Vaginal Disease (Any
Grade)
Condyloma
VIN 1 or VaIN 1
VIN 2/3 or VaIN 2/3 or worse
Persistent Infection ≥6 Months
HPV 6/11/16/18-Related
Cervical, Vulvar, and Vaginal
Disease (Any Grade)
CIN 2 or worse
VIN 2/3 or VaIN 2/3 or worse
HPV 6/11/16/18/31/33/45/52/58Related
Persistent Infection ≥ 6 Months
Cervical, Vulvar, and Vaginal
Disease

9vHPV (N=7099)
No. of Cases/n

qHPV (N=7105)
No. of Cases/n

Efficacy of 9vHPV
% (95% CI)

129/7024

155/7022

16.5 (-5.8, 34.4)

208/7024

354/7022

41.5 (30.8, 51.0)

116/6882
125/6882
19/7021

228/6871
149/6871
36/7021

49.2 (36.6,59.5)
15.8 (-7.5, 34.1)
47.1 (8.4, 71.3)

9/7021
10/7021
5/7021
795/6818

11/7021
23/7021
6/7021
1759/6822

17.9 (-118.0, 69.9)
56.4 (6.8, 81.5)
16.3 (-201.9, 75.0)
58.4 (54.7, 61.8)

244/7024

230/7022

-6.7 (-28.3, 11.3)

138/6882
11/7021

117/6841
13/7021

-18.5 (-52.9, 8.1)
15.1 (-95.8, 65.5)

1319/6777
384/7024

2154/6785
517/7022

43.4 (39.4, 47.2)
26.0 (15.6, 35.3)

Page 54

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
9vHPV (N=7099) qHPV (N=7105) Efficacy of 9vHPV
Endpoints
No. of Cases/n
No. of Cases/n
% (95% CI)
Cervical Disease
335/6882
443/6871
24.4 (12.9, 34.6)
CIN 1
197/6882
290/6871
32.1 (18.4, 43.7)
CIN 2 or worse
221/6882
229/6871
3.0 (-17.2, 19.8)
CIN 2
165/6882
171/6871
3.1 (-20.7, 22.2)
CIN 3
121/6882
112/6871
-8.5 (-41.6, 16.8)
AIS
10/6882
7/6871
-43.3 (-343.7, 48.9)
Cervical Cancer
0/6882
1/6871
100 (-999, 100)
Vulvar and Vaginal Disease
71/7021
92/7021
22.6 (-6.0, 43.5)
Condyloma
46/7021
51/7021
9.5 (-37.6, 40.6)
Source: Adapted from STN 125508/_Module 5.3.5.1.p001_CSR, Tables 11-45 (p453), 11-46
(p459-476), 11-47 (p479-483), 11-50 (p507-521) and 11-57 (p553-4).
1
FAS population consisted of all individuals who received at least 1 vaccination and had at least
one follow-up after Day 1.
Subjects were counted once in each applicable endpoint category. A subject might appear in
more than one category.
N=Number of randomized subjects who received at least one injection.
n=Number of subjects who had at least one follow-up visit after Day 1.
AIS=Adenocarcinoma in situ; CIN=Cervical intraepithelial neoplasia; VaIN=Vaginal intraepithelial
neoplasia; VIN=Vulvar intraepithelial neoplasia

Therapeutic Efficacy
Per CBER’s request in Pre-BLA meeting, the Applicant conducted analyses to assess
efficacy of the 9vHPV vaccine in the following populations:
• S1P0 (comprised of subjects who were seropositive and PCR-negative to the
relevant HPV type at Day 1).
• S0P1 (comprised of subjects who were seronegative and PCR-positive to the
relevant HPV type at Day 1).
• S1P1 (comprised of subjects who were seropositive and PCR-positive to the
relevant HPV type at Day 1).
Protocol V503-001 did not include a screening visit to exclude HPV-positive subjects.
This study design allowed for an investigation of the therapeutic efficacy of 9vHPV
among subjects who were infected with one or more vaccine types at enrollment.
Overall, there was no evidence that administration of 9vHPV impacted the course of
ongoing genital HPV infections.
Reviewer’s comment: The absence of therapeutic efficacy is not surprising, as only a
small proportion of PCR positive women are likely to have a viral infection that is
productive of L1 viral proteins. Thus, antibody responses induced by the L1 VLP in
9vHPV are unlikely to clear the corresponding viruses or alter progression of genital
epithelial cell dysplasia.
6.1.12 Safety Analyses
6.1.12.1 Methods
Safety analyses were performed on all the subjects who received at least one
vaccination and had safety follow-up. In this study, safety was reported separately for
the dose-ranging substudy (phase 2b) and the efficacy substudy (phase 3):

Page 55

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•

•

Dose-ranging substudy: The dose-ranging substudy comprised all subjects
enrolled in Part A (from Day 1 through Month 7). The safety report for the doseranging substudy documented the respective safety profiles of the three 9vHPV
vaccine dose formulations and qHPV vaccine.
Efficacy substudy: The efficacy substudy comprised all subjects enrolled in Part
A who received qHPV or the mid-dose formulation of 9vHPV as well as all
subjects enrolled in Part B. The safety report for the efficacy substudy cohort
represented the full extent of safety data collected in Protocol V503-001 for
qHPV and the selected dose formulation of 9vHPV, from Day 1 through the visit
cut-off date of April 10, 2013.

This section assesses only the safety data from Part B (phase 3, efficacy substudy)
because Part B includes uniform follow-up for the vast majority of subjects exposed to
the mid-dose formulation of 9vHPV. Safety data from Part A are incorporated in Section
8 of this review (Integrated Summary of Safety).
All subjects were followed for adverse experiences for 15 calendar days, including the
vaccination day, after each injection using a VRC. In addition, all subjects were followed
for SAEs, regardless of causality, occurring from Day 1 through Month 7 in the doseranging substudy, or Day 1 through 180 days post-dose 3 in the efficacy substudy.
Reviewer’s comment: Although both injection site and systemic adverse reactions
were collected for 15 days after each vaccination via VRC, only temperature and
injection-site pain, swelling and erythema observed in the 5 days after each vaccination
were designated as solicited adverse reactions. Injection site reactions observed after 5
days were designated as unsolicited adverse events.
6.1.12.2 Overview of Adverse Events
Table 26 provides a summary of clinical adverse experiences occurring by vaccination
group from Day 1 through the visit cut-off date of April 10, 2013. As shown in Table 26,
12 subjects in the efficacy substudy discontinued study medication due to an adverse
experience, including 8 in the 9vHPV group and 4 in qHPV group. Of these, 8 were
vaccine-related, including 5 in 9vHPV group and 3 in qHPV group. Four hundred sixteen
SAEs were reported during the entire course of this substudy, including 233 in the
9vHPV vaccine group and 183 in qHPV vaccine group (Table 26). Reported SAEs in the
efficacy substudy included four vaccine-related SAEs (two in the 9vHPV group and two
in the qHPV group) and 10 deaths (5 in the 9vHPV group and 5 in the qHPV group).
None of the deaths were deemed vaccine-related by the investigator.

Page 56

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 26: Adverse Event Summary (Vaccination and Follow-up Periods, Day 1 through
Visit Cut-Off Date) (Study V503-001, All Vaccinated Subjects, Efficacy Substudy)
9vHPV (N=7,071) qHPV (N=7,078)
n (%)
n (%)
Subjects with one or more adverse events
6,661 (94.2)
6,444 (91.0)
Injection-site
6,423 (90.8)
6,024 (85.1)
Systemic
4,052 (57.3)
3,957 (55.9)
Subjects with vaccine-related adverse
6,519 (92.2)
6,202 (87.6)
reactions
6,422 (90.8)
6,024 (85.1)
Injection-site
Systemic
2,088 (29.5)
1,930 (27.3)
Subjects with serious adverse events (SAE) 233 (3.3)
183 (2.6)
Subjects with vaccine-related SAE
2 (<0.1)
2 (<0.1)
Subjects who died
5 (0.1)
5 (0.1)
Subjects who discontinued due to an
8 (0.1)
4 (0.1)
adverse event
Subjects who discontinued due to a
5 (0.1)
3 (<0.1)
vaccine-related adverse event
Subjects who discontinued due to an SAE
3 (<0.1)
1 (<0.1)
Subjects who discontinued due to a
1 (<0.1)
0 (0.0)
vaccine-related SAE
Source: Adapted from STN 125508/0, Module 5.3.5.1.p001, CSR_Table 12-4, p750.
N=Subjects with any follow-up; n=subjects with any adverse event.
Summary of Injection-Site Adverse Reactions
The numbers and percentages of subjects with injection-site adverse reactions from Day
1 to 5 following any vaccination are presented in Table 27. The proportion of subjects in
9vHPV group who reported at least one injection-site adverse reaction within 5 days of
any vaccination (90.2%) was higher than the corresponding proportion of subjects in the
qHPV group (84.0%). Across both treatment groups, the most common injection-site
adverse experiences following any vaccination visit were injection-site pain, swelling,
and erythema. Erythema and swelling were reported increasingly frequently with each
dose of vaccination. The frequencies of erythema (9vHPV vs. qHPV) post vaccination 1,
2 and 3 were 10.6% vs. 8.1%, 18.0% vs. 12.9% and 22.6% vs. 15.6%, respectively. The
frequencies of swelling (9vHPV vs. qHPV) post vaccination 1, 2 and 3 were 12.5% vs.
9.3%, 23.3% vs. 14.6% and 28.3% vs. 18.7%, respectively.
Table 27: Injection-Site Adverse Reactions Reported 1 to 5 days Post-Vaccination at a
Frequency of ≥1% (Efficacy Substudy of V503-001, Safety Population)
Adverse Reactions

Intensity

All Injection Site AEs

Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total

Bruising

Erythema

9vHPV (N=7071)
n (%)
6,377 ( 90.2)
3,723 (52.7)
2,339 (33.1)
315 (4.5)
137 (1.9 )
123 (1.7)
12 (0.2 )
2 (0.0)
2,407 (34.0)

qHPV (N=7078)
n (%)
5,948 (84.0 )
4,036 (57.0)
1,722 (24.3)
190 (2.7)
134 (1.9)
116 (1.6)
16 (0.2)
2 (0.0)
1,810 (25.6)

Page 57

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Adverse Reactions

Intensity

9vHPV (N=7071)
qHPV (N=7078)
n (%)
n (%)
Mild
1,921 (27.2)
1,555 (22.0)
Moderate
370 (5.2)
197 (2.8)
Severe
114 (1.6)
57 (0.8)
Hematoma
Total
64 (0.9)
45 (0.6)
Mild
58 ( 0.8)
42 (0.6)
Moderate
6 (0.1)
3 (0.0)
Hemorrhage
Total
69 (1.0)
50 (0.7)
Mild
55 (0.8)
48 (0.7)
Moderate
11 ( 0.2)
2 (0.0)
Severe
3 (0.0)
0(0.0)
Mass
Total
90 (1.3)
46 (0.6)
Mild
58 (0.8)
33 (0.5)
Moderate
29 (0.4)
10 (0.1)
Severe
3 (0.0)
3 (0.0)
Pain
Total
6,356 (89.9)
5,910 (83.5)
Mild
3,754 (53.1)
4,043 (57.1)
Moderate
2,300 (32.5)
1,682 (23.8)
Severe
302 (4.3)
185 (2.6)
Pruritus
Total
388 (5.5)
282 (4.0)
Mild
301 (4.3)
223 (3.2)
Moderate
80 (1.1)
56 (0.8)
Severe
7 (0.1)
3 (0.0)
Swelling
Total
2,830 (40.0)
2,035 (28.8)
Mild
1,958 (27.7)
1,594 (22.5)
Moderate
597 (8.4)
332 (4.7)
Severe
272 (3.8)
109 (1.5)
Source: Summarized from STN 125508/0, Module 5.3.5.1.p001_CSR, Tables 12-14 and 12-15
(p774-9).
N=Number of subjects vaccinated, n=number of subjects with the respective events.

Summary of Systemic Adverse Reactions
Table 28 presents the numbers and percentages of subjects with systemic clinical
adverse reactions (reported by ≥1% of subjects in one or more vaccination groups) by
system organ class from Day 1 to 15 following any vaccination visit. In both vaccination
groups, the most common clinical adverse reactions were headache, nausea, pyrexia
and nasopharyngitis, which occurred at generally similar frequencies between the
vaccination groups. The frequency of systemic clinical adverse reactions numerically
decreased across vaccination visits within each vaccine group. For example, the
percentages of subjects with one or more systemic adverse reactions in the 9vHPV
group post-vaccination 1, 2, and 3 were 17.7%, 11.8% and 10.4%, respectively.
The majority of subjects across the vaccination groups experienced systemic adverse
reactions, most of which were of mild or moderate intensity. Percentages of severe
systemic adverse reactions were similar in the 9vHPV group (11.7%) compared with the
qHPV group (10.8%).

Page 58

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 28: Systemic Adverse Reactions by System Organ Class Reported 1 to 15 Days
Post-Vaccination at a Frequency ≥ 1% (V503-001, Efficacy Substudy, Safety Population)
Adverse Events
9vHPV (N=7,071)
qHPV (N=7,078)
n (%)
n (%)
Subjects with one or more systemic adverse
3,948 (55.8)
3,883 (54.9)
events
Gastrointestinal disorders
1,175 (16.6)
1,148 (16.2)
Abdominal pain
169 (2.4)
170 (2.4)
Abdominal pain upper
178 (2.5)
182 (2.6)
Diarrhea
236 (3.3)
246 (3.5)
Nausea
512 (7.2)
459 (6.5)
Vomiting
141 (2.0)
131 (1.9)
General disorders and administration site
932 (13.2)
893 (12.6)
conditions
Fatigue
237 (3.4)
219 (3.1)
Malaise
92 (1.3)
85 (1.2)
Pyrexia
470 (6.6)
463 (6.5)
Infections and Infestations
1,113 (15.7)
1,135 (16.0)
Influenza
311 (4.4)
295 (4.2)
Nasopharyngitis
376 (5.3)
388 (5.5)
Injury, poisoning and procedural
79 (1.1)
99 (1.4)
complications
Musculoskeletal and connective tissue
543 (7.7)
543 (7.7)
disorders
Back pain
130 (1.8)
121 (1.7)
Myalgia
139 (2.0)
137 (1.9)
Pain in extremity
98 (1.4)
108 (1.5)
Nervous system disorders
2,317 (30.3)
1,999 (28.2)
Dizziness
346 (4.9)
307 (4.3)
Headache
1,876 (26.5)
1,756 (24.8)
Migraine
84 (1.2)
85 (1.2)
Psychiatric disorders
82 (1.2)
76 (1.1)
Reproductive system and breast disorders
440 (6.2)
419 (5.9)
Dysmenorrhea
239 (3.4)
212 (3.0)
Respiratory, thoracic and mediastinal
544 (7.7)
520 (7.3)
disorders
Cough
112 (1.6)
118 (1.7)
Nasal congestion
71 (1.0)
65 (0.9)
Oropharyngeal pain
328 (4.6)
300 (4.2)
Skin and subcutaneous tissue disorders
236 (3.3)
229 (3.2)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p001_CSR, Table 12-18 (p786-7).
N=Number of subjects vaccinated, n=number of subjects with the respective events.

Table 29 presents the numbers and percentages of subjects with vaccine-related
systemic clinical adverse reactions, as judged by the investigators, by preferred term
from Day 1 to 15 following any vaccination visit. The most common (frequency ≥2%)
vaccine-related systemic clinical adverse reactions were headache, pyrexia, nausea,
dizziness, and fatigue. The overall frequency of vaccine-related systemic adverse
reactions was similar between the two treatment groups.
Table 29: Vaccine-Related Systemic Adverse Reactions Reported 1 to 15 Days PostVaccination at a Frequency of ≥1% (V503-001 Efficacy Substudy, Safety Population)
Adverse Reaction

9vHPV (N=7071)
n (%)

qHPV (N=7078)
n (%)

Page 59

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
9vHPV (N=7071)
qHPV (N=7078)
n (%)
n (%)
Headache
1031 (14.6)
969 (13.7)
Pyrexia
357 (5.0)
301 (4.3)
Nausea
311 (4.4)
261 (3.7)
Dizziness
211 (3.0)
197 (2.8)
Fatigue
166 (2.3)
150 (2.1)
Diarrhea
87 (1.2)
71 (1.0)
Myalgia
69 (1.0)
48 (0.7)
Oropharyngeal pain
73 (1.0)
40 (0.6)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p001_CSR, Table 14.5-38 (p1909-1918).
N=number of subjects vaccinated, n=number of subjects with respective events.
Adverse Reaction

6.1.12.3 Deaths
At the time of database closure for the current analyses (April 10, 2013), 10 subjects in
the efficacy substudy (5 in 9vHPV group and 5 in qHPV group) had died (no deaths
occurred in the dose ranging substudy). Subject AN 22093 in 9vHPV group died of
acute promyelocytic leukemia after the visit cut-off date of April 10, 2013. Table 30
summarizes the 11 deaths in this study. None of the deaths were considered by the
investigator to be vaccine related.
Table 30: Summary of Deaths Occurring in Study V503-001
Treatment
Group
9vHPV

Subject
ID
69699

Age
(Years)
20

Death
Causality
Automobile
accident
Sudden
death

Days PostVaccination
226 days
post dose 3
678 days
post dose 3

9vHPV

70563

25

9vHPV

71972

21

Suicide

15 days
post dose 2

9vHPV

72132

17

9vHPV

72831

23

Acute
lymphoblastic
leukemia
Hypovolemic
shock and
septic shock

Approx. 880
days post
dose 3
530 days
post dose 3

9vHPV

22093

29

Acute
promyelocytic
leukemia

1304 days
post dose 3

qHPV

71426

25

qHPV

75127

24

Automobile
accident
Airplane

811 days
post dose 3
7 days post

Comments
Patient died immediately at the
scene of the accident.
Patient died during night. No
history of underlying disease.
No autopsy was performed.
Patient was treated for
depression with selective
serotonin reuptake inhibitor.
Autopsy was performed
(results not available)
Patient was diagnosed with
ALL 25 days post dose 3
Patient was diagnosed with
Ovarian tumor at 59 days post
dose 3, and the tumor was
removed then. The patient died
approximately 15 months after
the surgery due to
hypovolemic and septic shock
per autopsy
Patient was diagnosed with
leukemia at 1291 days post
dose 3, died due to multiple
hemorrhages, tumor lysis
syndrome, and pneumonia.
Died due to cervical spinal cord
injury per autopsy.
Patient sustained multiple

Page 60

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Treatment
Group

Subject
ID

Age
(Years)

Death
Causality
crash
Cerebral
hemorrhage

Days PostComments
Vaccination
dose 3
lesions per hospital record.
qHPV
20453
25
1114 days
Death due to cerebral
post dose 3 hemorrhage per autopsy.
Cause of hemorrhage was not
identified.
qHPV
20497
17
Trauma
141 days
Patient was shot outside her
(gunshot)
post dose 3 home, died at ER.
qHPV
69125
23
Stomach
510 days
Advanced stomach cancer
adenocarcino post dose 3 involved in colon and ovaries
ma
with ascites.
Source: Generated by CBER reviewer from STN 125508/0_Module 5.3.5.1.p001, Section 14.6:
Narratives of SEAs (p2453-2536)

Reviewer’s comments: This reviewer concurs with the Applicant’s assessment of
causality that none of the deaths was related to the study vaccines.
6.1.12.4 Nonfatal Serious Adverse Events (SAE)
The numbers and percentages of subjects in both vaccination groups with any SAE was
provided in the submission (CSR for Study V503-001, Table 12-31, p826-832) by system
organ class (SOC) from Day 1 through visit cut-off date. Approximately 2.9% (n=416) of
subjects reported one or more SAE during the safety follow-up period in the efficacy
substudy, 3.3% (n=233) in the 9vHPV group and 2.6% (n=183) in the qHPV group. The
most frequent SAEs were related to pregnancy (abortion induced and abortion
spontaneous) and appendicitis in both groups.
The proportion of subjects with SAEs occurring between Day 1 and the visit cut-off date
was similar between the 9vHPV group and the qHPV group when examined by either
preferred term or by SOC, except for abortion spontaneous and abortion induced. The
numbers of spontaneous abortion and induced abortion in the 9vHPV group were 36 and
73, respectively, while the corresponding numbers for the qHPV group were 24 and 54.
Reviewer’s comments: The slightly higher proportion of SAEs in 9vHPV group was
largely driven by the higher fetal loss [31 more cases (12 more spontaneous and 19
more elective abortions) in the 9vHPV group than in the qHPV group]. However, the
overall proportions of fetal loss (Day 1 throughout visit cut-off date) in the two groups
were similar (23.9% vs. 24.1%, 9vHPV vs. qHPV) as shown in Table 78 (Section
9.1.1.2). This difference is likely due to the fact that not all abortions were reported as
an SAE (per protocol, a fetal loss was collected as an SAE only for pregnancies with a
last menstrual period between Day 1 and 180 days post-dose 3). Please refer to
Section 9.1.1.1 for a more detailed discussion of the numerical imbalance between
treatment groups in spontaneous abortions.
This reviewer has reviewed the narratives of all the SAEs in this study and concurs with
the Applicant’s assessment of causality.
Table 31 presents non-fatal SAEs occurring within 28 days of any vaccination. There
was one non-fatal SAE (appendicitis in Subject 10882) in the low-dose group and no
SAE in the high-dose group reported within 28 days following any vaccination in the
9vHPV dose-ranging substudy.

Page 61

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer comment: No SAEs that occurred outside the 28 day vaccination window
were judged to be vaccine related by the investigator or this reviewer.
Table 31: SAEs Reported from Day 1 through Day 28 after Each Vaccination by Subject
and Treatment Group (Study V503-001)
Treatment Group
Subject ID
9vHPV Group
10882
10645
73662
10603
18372
71222
75503
20344
67672
19765
69495
19912
18222
18091
69530
70385
69797
18389
73025
74701
72684
74921
22026
72886
72970
73689
19805
75481
22332
68617

68617

67890
75726
72178
qHPV Group
71483
20358
72752
10174

SAE

Dose

Day of
Onset

Related

Outcome

Appendicitis
Malignant Melanoma
Syncope
Endometriosis
Bipolar disorder
Urinary tract infection
Pyelonephritis acute
Cholangitis
Malignant melanoma
Tonsillitis streptococcal
Pyrexia
Chronic tonsillitis
Hemorrhagic fever
Vertigo positional
Cervical dysplasia
Pyelonephritis
Cervical dysplasia
Bipolar disorder
Cholecystitis infective
Major depression
Ligment rupture
Anemia
Anaphylactic reaction
Ovarian cyst
Pharyngitis
Hypersensitivity
Sensory disturbance
Crohn's disease
Allergy to vaccine
Appendicitis
Bladder injury
Femur and humerus
fracture
Hypovolemic shock
Multiple injuries
Pelvic fracture
Humerus fracture
Hyperglycemia
Urinary tract infection
Deep vein thrombosis

1
1
1
1
2
3
2
2
3
1
3
3
2
1
2
3
2
2
1
2
3
3
3
2
1
3
3
3
1
2
2
2

2
6
11
1
2
16
7
7
1
14
2
10
2
12
23
24
1
24
18
16
9
1
6
5
19
4
17
3
1
16
2
2

N
N
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
N
N

Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Continuing
Resolved
Resolved
Resolved
Sequelae

2
1
1
1
3
1
1

2
2
2
21
15
8
17

N
N
N
N
N
N
N

Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved

Anemia
Gastroenteritis
Urinary tract infection
Malignant palate neoplasm

3
3
3
2

27
8
23
19

N
N
N
N

Resolved
Resolved
Resolved
Resolved

Page 62

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Treatment Group
SAE
Dose
Day of Related
Onset
Subject ID
19620
Cystitis hemorrhagic
2
6
N
18065
Conjunctivitis
1
28
N
69410
Appendicitis
1
9
N
69716
Gastritis
2
1
N
21301
Pyelonephritis acute
1
7
N
67318
Cleft lip and palate
2
10
N
70242
Cervical dysplasia
2
25
N
68675
Foreign body in eye
2
26
N
17856
Dysmenorrhoea
2
11
N
21343
Dyspnoea
3
19
N
74925
Hypoaesthesia
3
18
Y
69320
Cervical dysplasia
2
1
N
72039
Abdominal pain lower
1
4
N
70312
Appendicitis
3
2
N
22112
Urinary tract infection
1
12
N
21785
Pyelonephritis
3
18
N
21291
Cholelithiasis
1
7
N
71271
Bipolar disorder
2
12
N
68223
Headache
2
2
Y
71111
Nasal polyps
3
15
N
Source: Generated by CBER clinical reviewer from STN 125508/0_Module
5.3.5.1.p001_Table14.5-42 (p1939-2015)

Outcome
Resolved
Continuing
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved

Four SAEs were considered by the investigators to be vaccine-related (two in the 9vHPV
group and two in the qHPV group) are summarized below:
• Pyrexia: A 26 year-old White female (AN 69495) presented with fever, body pain,
headache and malaise two days after the third dose of 9vHPV. She was referred
to an infectious disease physician. She had a fever of 38.60C. Physical exam was
normal, and no laboratory tests were ordered. The infectious disease physician
prescribed Paracetmol and Nimesulide to her. The symptoms had completely
disappeared within one day. She was not hospitalized and was diagnosed as
fever of unknown etiology. She was followed up by the study site three days
later, and she stated that she was well without symptoms. The event was
considered severe in intensity and was related to 9vHPV by the reporting
investigator.
• Allergy to vaccine: A 20 year-old Asian female (AN 75481) from Denmark with a
medical history of asthma but no medical history of allergic reaction had a severe
allergic reaction three hours after the administration of the first dose of 9vHPV.
Symptoms included swelling of the mouth and throat, rhinorrhea, rash over all
her body, and difficulty breathing. She self-treated with two inhalations of betaadrenergic agonist terbutaline sulfate for breathing problems and one oral dose
of 10 mg cetirizine hydrochloride for urticaria. The reaction duration was 23
hours. She recovered and did not receive any further doses of the vaccine. The
reporting investigator felt that allergic reaction was serious (life-threatening) and
was related to 9vHPV because there was a close temporal association and there
was no clear alternate food or drug identified as the cause.
• Headache: A 23 year old Multi-racial female (AN 68223) from Columbia
developed a headache two days after she received her second dose of qHPV.
The headache was persistent with dizziness and nausea. She experienced
intense occipital headache nearly two months later that was intolerable despite

Page 63

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•

medication. She then went to the emergency room due to the increased intensity,
and was hospitalized overnight and treated with naproxen. The subject reported
the headache as well as associated phonophobia, nausea and chills without
fever. Brain CT was normal. No additional laboratory tests were performed. She
recovered from headache the following day, naproxen was discontinued, and she
was discharged on the same date. The headache lasted for approximately eight
weeks. She received her third dose of qHPV one and a half months later. The
reporting investigator felt that headache was related to qHPV.
Hypoesthesia: A 21 year old white female (AN 74925) from Canada with a history
of migraine headaches experienced bilateral numbness of her extremities and
perioral area 18 days after her third dose of qHPV (on April 14, 2010). The
symptoms were episodic in nature, with fluctuations in frequency and duration.
She was referred by her family doctor to a neurologist on December 29, 2010.
She described symptoms of episodic burning and paresthesias involving the
perioral area, fingers and toes. These symptoms lasted less than 1 minute. She
also described joint pain in multiple areas including wrist, fingers, ankles and
knees; they felt swollen and were tender to palpation. These symptoms also
fluctuated and were episodic in nature. The patient also described multiple areas
of muscle soreness and stiffness, and occasional blurred vision of the right eye.
Other than those symptoms the patient was healthy. Laboratory workup including
blood chemistry, live functions, serology for autoimmune disorders, and MRI for
brain and spine were performed. The results from these tests were
unremarkable. The neurologist and the patient reported symptoms improving in
severity and frequency on a follow up visit on March 11, 2011. No definitive
evidence of underlying neurological cause for symptoms was reported by the
neurologist. On January 1, 2012, she recovered from all her symptoms without
treatment. She was currently well and denied any new symptoms or focal
neurological deficits. The reporting investigator felt that bilateral numbness to
extremities was related to qHPV.

Reviewer’s comments: There was no pattern or any cluster of the same SAE in terms
of SOC or preferred term in either group for SAEs reported within 28 days following any
vaccination. This reviewer concurs with the investigators’ causality assessments. Based
on the information provided, the case of pyrexia (AN 69495) does not appear to be an
SAE as specified in 21 CFR 312.32.
SAEs of hypersensitivity or allergy were rare. Three such events were reported, all in
9vHPV group. One event (AN 75481, narrative of this case is described above) was
deemed related to 9vHPV by the investigator, and the other two events were deemed
unrelated to 9vHPV by the investigator, but were deemed related to the concomitant
medications, Dolol (AN 72970) and parenteral iron (AN 74921).
Deep vein thrombosis (DVT) was reported in the post-marketing experience of Gardasil.
Subject AN 72178, a 26 year-old white female, experienced pain and swelling of the
right leg 17 days after her first dose of 9vHPV and was then hospitalized because of
worsening symptoms. She was diagnosed with DVT and treated with Innohep and
Marevan. Her symptoms improved and she was discharged two days later. She had no
known risk factor other than hormonal contraception, and no prior episodes of DVT. The
contraceptive was interrupted. The reporting investigator considered that DVT was not
related to 9vHPV but was related to hormonal contraceptives. She received her second
and third doses of 9vHPV as scheduled without problems.

Page 64

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comments: This reviewer concurs with the reporting investigator that DVT
was unlikely related to 9vHPV because of the proposed alternate etiology.
6.1.12.5 Adverse Events of Special Interest (AESI)
New Medical Conditions Considered Potentially Indicative of Autoimmune
Disorders
Table 32 displays the numbers and percentages of subjects by vaccination group who
reported new medical conditions potentially indicative of an autoimmune disorder
(reported by at least one subject in one or more vaccination groups), regardless of
relatedness. A total of 104 subjects [57 in 9vHPV group (0.8%) and 47 in qHPV group
(0.7%)] reported such conditions that were considered autoimmune conditions by the
investigators. Two subjects in the 9vHPV group reported 3 conditions considered to be
autoimmune, as well as related to study vaccine, by the investigators including: AN
72316 (Raynaud’s phenomenon) and AN 17613 (goiter and hyperthyroidism).
Table 32: Subject with Adverse Events Potentially Indicative of An Autoimmune
Disorder Considered As Autoimmune Conditions by Reporting Investigators by System
Organ Class (Study V503-001, Day 1 through Visit Cut-off Date, Efficacy Substudy)
Adverse Events
Blood and lymphatic system disorders
Antiphospholipid syndrome
Idiopathic thrombocytopenic purpura
Endocrine disorders
Autoimmune thyroiditis
Basedow's disease
Goiter
Hyperthyroidism
Hypothyroidism
Thyroid dysfunction in pregnancy
Eye disorders
Uveitis
Gastrointestinal disorders
Coeliac disease
Colitis ulcerative
Crohn's disease
Immune system disorders
Sarcoidosis
Metabolism and nutrition disorders
Type 1 diabetes mellitus
Musculoskeletal and connective tissue disorders
Ankylosing spondylitis
Arthralgia
Arthritis
Connective tissue disorder
Juvenile idiopathic arthritis
Polyarthritis
Rheumatoid arthritis
Sjogren's syndrome
Systemic lupus erythematosus

9vHPV (N=7106)
n (%)
1 (<0.1)
1 (<0.1)
0 (0.0)
19 (0.3)
4 (0.1)
1 (<0.1)
2 (<0.1)
3 (<0.1)
10 (0.1)
0 (0.0)
1 (<0.1)
1(<0.1)
12 (0.2)
5 (0.1)
1 (0.1)
3 (<0.1)
1 (<0.1)
1 (<0.1)
3 (<0.1)
3 (<0.1)
9 (0.1)
1 (<0.1)
2 (<0.1)
1 (<0.1)
0 (0.0)
0 (0.0)
1 (<0.1)
2 (<0.1)
1 (<0.1)
2 (<0.1)

qHPV (N=7109)
n (%)
1 (<0.1)
0 (0.0)
1 (<0.1)
22 (0.3)
5 (0.1)
0 (0.0)
1 (<0.1)
7 (0.1)
9 (0.1)
1 (<0.1)
0 (0.0)
0 (0.0)
9 (0.1)
4 (0.1)
3 (<0.1)
2 (<0.1)
0 (0.0)
0 (0.0
0 (0.0)
0 (0.0)
5 (0.1)
0 (0.0)
0 (0.0)
0 (0.0)
1 (<0.1)
1 (<0.1)
0 (0.0)
1 (<0.1)
1 (<0.1)
1 (<0.1)

Page 65

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Adverse Events
Nervous system disorders
Multiple sclerosis
Renal and urinary disorders
IgA nephropathy
Skin and subcutaneous tissue disorders
Alopecia areata
Cutaneous vasculitis
Pigmentation disorder
Psoriasis
Vitiligo
Vascular disorders
Raynaud's phenomenon

9vHPV (N=7106)
n (%)
5 (0.1)
5 (0.1)
0 (0.0)
0 (0.0)
5 (0.1)
0 (0.0)
0 (0.0)
0 (0.0)
4 (0.1)
1 (<0.1)
2 (<0.1)
2 (<0.1)

qHPV (N=7109)
n (%)
2 (<0.1)
2 (<0.1)
1 (<0.1)
1 (<0.1)
9 (0.1)
1 (<0.1)
1 (<0.1)
1 (<0.1)
5 (0.1)
1 (<0.1)
0 (0.0)
0 (0.0)

Source: Adapted from STN 125508/0_Module 5.3.51.p001, Table 12-50 (P896-7).
Reviewer’s comment: One case of multiple sclerosis (MS) in the qHPV group (AN
70545) was not reported in the Table 12-50 of the clinical study report of Study V503001 but was reported in Table 12-49, p893-5. In addition, Subject AN 21474 in the qHPV
group developed spondylitic myelopathy in March 2010 and was also diagnosed with MS
after the visit cut-off date (April 10, 2013) and before database lock date (July 26, 2013).
The table above has been modified to include these two cases.
Table 33 summarizes the cases of MS reported in Study V503-001.

Page 66

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 33: Cases of Multiple Sclerosis (MS) Diagnosed in Study V503-001
Subject ID

Demographics/
Country

Medical History

Vaccination
Dates

Onset Date

Diagnosis
Date

Confounders

Outcome

Sponsor
Assessment

23 Yrs, Multiracial,
Columbia

Inguinal
herniorrhaphy,
hallux valgus and
tonsilectomy

4/1/09
5/29/09

8/16/09
78 days
post dose 2

3/24/10

Took Tamiflu
from 8/158/20/09

unknown

Not related

22 Yrs, White,
Denmark

None reported

6/17/09
8/24/09

A few hours
after the
second
dose

None
reported

Asymptomatic
as of 12/16/09,
but on therapy
with Avonex

Not related

21 Yrs, White,
Canada

Eczema,
gastroesophageal
reflux, headache,
migraine and
psoriasis

10/1/08
11/25/08
3/23/09

4/30/09
37 days
post dose 3

3/16/10

continuing

Not related

AN 73675

25 Yrs, White,
Denmark

Gastric acid reflux

9/9/09
11/9/09
3/17/10

1/6/10
59 days
post dose 2

1/6/10

Enteritis
stating on
4/24/09 and
treatment with
Cipro on
4/28/09
None
reported

Not related

AN 20852

26 Yrs, Multiracial, Mexico

Depression and
pharyngotonsilitis

None
reported

21 Yrs, White,
USA

None

9/1/10

None

Treatment on
Avonex

Not related

AN 70728

25 Yrs, Asian,
Japan

None

10/2010
>14 months
post dose 3
9/1/10
374 days
post dose 3
1/20/11
417 days
post dose 3

4/1/11

AN 21266

3/9/09
4/17/09
8/10/09
3/24/09
5/22/09
8/24/09
6/22/09
8/22/09
11/30/09

Asymptomatic,
Avonex
treatment from
3/1/10 to
12/27/11, and
Fingolimod
hydrochloride
was initiated on
12/17/11.
Treatment on
Avonex

1/20/11

None

Treatment on
pridol and
methycobal

Not related

qHPV
AN 21474

AN 70545

9vHPV
AN 17698

(Spondylitic
myelopathy)

12/1/11
(MS)
11/17/09

Page 67

Not related

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comments: Three cases of MS [one in the qHPV group (AN70545), two in
the 9vHPV group (AN17698 and AN 73675)] had onset of symptoms temporally
associated with vaccination (within two months of vaccination).
Four subjects, three in 9vHPV group (AN20852, AN 21266 and AN 70728) and one in
qHPV (AN 21474), experienced onset of MS related symptoms at more than one year
after last vaccination.
Subject AN 21474 had onset of symptoms on August 18, 2009 (78 days post-dose 2 of
qHPV), was diagnosed as spondylitic myelopathy on March 24, 2010, and was then
diagnosed with MS on December 1, 2011. The case narrative and data submitted for this
patient in Clinical Study Report describe that the patient recovered from the spondylitic
myelopathy on May 25, 2010. However, it is possible that these two diagnoses represent
evolving assessment of the same process. The Applicant was unable to provide
additional information, stating that it was “unable to obtain the neurological consultation
report despite multiple attempts. This patient was uncooperative with the investigator.
Additional information is not expected.”
Narratives of 9vHPV Related Autoimmune Disorders other than MS
Subject AN 72316, a 23-year-old White female, reported numbness, tingling and
coolness in both hands and feet on October 2, 2010 (213 days after dose 3 of 9vHPV)
and was diagnosed as Raynaud’s syndrome based on the clinical symptoms. The
reporting investigator considered the Raynaud’s syndrome to be possibly related to
9vHPV because the subject experienced similar symptoms intermittently during the
winter 2009 (after the second dose of 9vHPV, November 19, 2009). However, the
symptoms were absent in spring and summer 2010 (The third dose of 9vHPV was
administered on March 4, 2010) and became bothersome immediately prior to diagnosis
in October 2010. Although the relatedness of the event to 9vHPV could be not excluded,
the symptoms did not appear to be closely associated with the administration of the
study vaccine.
Subject AN 17613, a 20-year-old female from Thailand, received her first, second and
third doses of 9vHPV on October 2, 2008, November 26, 2008, and April 20, 2009,
respectively. On February 16, 2011 (668 days post-dose 3), the subject reported
palpitation, weight loss, mild tremor, and a large thyroid gland. After laboratory testing
(free T4 >7.77 ng/dl, free T3 >32.55 pg/ml, and TSH <0.005 mlU/L), she was diagnosed
with thyrotoxicosis and diffuse goiter. The reporting investigator felt this could be related
to the vaccine because in 2006 the subject’s average pulse rate was 80 beats per
minute (BPM) and blood pressure (BP) was 115/70 mmHg, but after entering the study
they began to rise (Day 1: pulse rate=71 BPM, BP=116/70 mmHg; Month 2: pulse
rate=123 BPM, BP=112/75 mmHg; Month 6: pulse rate=143 BPM, BP=135/78 mmHg
and before starting treatment of thyrotoxicosis: pulse rate=137 BPM, BP=143/75
mmHg). This reviewer concurs with the investigator that the thyrotoxicosis is possibly
related to the study vaccine.
Reviewer’s comments: The potential autoimmune disorders observed in the two
groups in general are balanced by preferred term except MS, type 1 diabetes mellitus,
and Raynaud’s disease. The incidence rate of MS observed in the 9vHPV group is on
the upper end of the range (<5 to 30 per 100,000 person-years) of incidences of MS
reported in the general population of similar ages (34). The rates observed in V503-001

Page 68

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

for the 9vHPV and qHPV treatment groups, respectively, were 20.7/100,000 and
8.3/100,000 person-years. The five cases observed in the 9vHPV group appeared to be
randomly distributed across the study regions.
Overall the numbers of reported cases are small and the clinical significance of the
imbalances between the treatment groups are unknown. The rates of autoimmune
disorders following 9vHPV as compared with qHPV are discussed in further detail in
Section 8 (Integrated Summary of Safety).
6.1.12.6 Clinical Test Results
No routine laboratory safety tests were conducted in this study.
6.1.12.7 Dropouts and/or Discontinuations
Table 34 presents the adverse events leading to study discontinuation by treatment
group, their relatedness, intensity and outcome. In total, 14 subjects did not complete
the 3-dose regimen due to an adverse event, 10 from the 9vHPV group (two of them
from the low-dose 9vHPV cohort: AN 10849 and AN 10424), and four subjects from the
qHPV group. In general, adverse events that led to discontinuation were related to early
local and systemic reactogenicity and hypersensitivity.
Table 34: Summary of Subjects with Clinical Adverse Events That Led to Discontinuation
(Study V503-001, Day 1 through Visit Cut-Off Date, All Vaccinated Subjects)
Treatment
Group
Subject ID
9vHPV Group
AN 10849
AN 10424
AN 18464

AN 68226
AN 10888

SAE

Dose

Day of
Onset

Intensity

Related

Outcome

Rash
Dysmenorrhoea
Asthenia, Dizziness,
Fatigue, Hyperhidrosis,
Injection site pain,
Nausea and Pyrexia
Injection site pain
Hypoesthesia,
Paresthesia
Headache
Abortion Spontaneous
Injection site swelling
Allergy
Complete suicide

1
2
2

8
9
1

Mild
Severe
1
Severe

Y
N
Y

Resolved
Resolved
Resolved

1
1

1
1

Moderate
Moderate

Y
N

Resolved
Resolved

AN 71291
1
2
Severe
Y
Resolved
2
AN 21275
1
93
SAE
N
NA
AN 20790
2
1
Mild
Y
Resolved
2
AN 75481
1
1
SAE
Y
Resolved
2
AN 71972
1
15
SAE
N
Dead
qHPV Group
2
AN 18065
Tension headache
1
40
SAE
N
Not resolved
AN 20609
Rash papular
2
6
Severe
Y
Resolved
AN 22087
Swollen tongue
2
2
Moderate Y
Resolved
AN 75312
Urticarial
2
5
Moderate Y
Resolved
Source: Generated by CBER reviewer from STN 125508/0.2_Module 1.11.3_Reponses to
CBER’s Information Request#1 (p7-11).
1
All were severe except injection site pain and nausea that were moderate in intensity.
2
SAE was not rated in intensity.
3
Per protocol, abortion was counted as an SAE.

Page 69

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comments: Subject AN 71972, a 21 year old female from Sweden, had
treatment for depression with selective serotonin reuptake inhibitor medication. The
suicide was likely related to her underlying medical condition. Please also refer to
Section 6.1.12.3.
Subject AN 75481 developed a severe allergic reaction three hours after the
administration of her first dose of 9vHPV. Please refer to Section 6.1.12.4 for details.
This reviewer concurs with the Applicant’s assessments of causality of the adverse
events that led to discontinuation except hypoesthesia and paresthesia that occurred in
Subject AN 10888. The subject experienced hypoesthesia and paresthesia on the same
day of administration of her first dose of 9vHPV and events lasted for 3 days. There was
no alternative explanation for the events. Because of the close temporal association
with the treatment, this reviewer concludes that the events are possibly related to
9vHPV. Of note, one subject (AN 74925) in the qHPV group experienced hypoesthesia
and paresthesia 18 days after her third dose, which was assessed by the Applicant as
related to qHPV (Please refer to Section 6.1.12.4 for details)
6.1.13 Study Summary and Conclusions
6.1.13.1 Summary of Efficacy
New HPV Types (HPV 31, 33, 45, 52, 58)
The 9vHPV vaccine significantly reduced the primary efficacy cases of the composite
endpoints of HPV type 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and
vaginal disease, HPV type 31-, 33-, 45-, 52-, and 58-related cytological abnormalities,
and HPV type 31-, 33-, 45-, 52-, and 58-related invasive cervical and external genital
procedures. Efficacy of 9vHPV in the PPE population for all these endpoints was greater
than 90% with the LB of 95% CI greater than 60%. Efficacy was also demonstrated in
the PPE population with respect to high-grade cervical, vulvar, and vaginal disease
related to the individual HPV types 31, 33, or 52, but the study was underpowered to
demonstrate vaccine efficacy against this endpoint for the other two HPV types (45 and
58) individually. However, 9vHPV efficacy in preventing HPV 58-related high-grade
cervical, vulvar, and vaginal lesions was established in the HN-TS population. Moreover,
efficacy of 9vHPV was consistently demonstrated against cervical, vulvar, and vaginal
disease (any grade), as well as persistent infection, caused by each of the new HPV
types. As persistent HPV infection is a requirement for the development of anogenital
malignancies related to HPV, and persistent infection with HPV types 16, 18, 31 or 33 is
associated with progression to high-grade cervical lesions(35, 36), it is reasonable to
conclude that 9vHPV vaccine will prevent high-grade cervical disease caused by each of
the new HPV types.
Most of the cases of HPV type 31-, 33-, 45-, 52-, and 58-related high grade disease
were cervical disease cases. Limited endpoint cases precluded demonstration of
efficacy in preventing HPV 31-, HPV 33-, HPV 45-, HPV 52-, and HPV 58-related highgrade vulvar, vaginal, and anal lesions. Given that pathobiology of HPV-related highgrade vulvar, vaginal, and anal disease is similar to that of high-grade cervical disease,
and that 9vHPV prevents HPV 31-, HPV 33-, HPV 45-, HPV52-, and HPV 58-related
persistent infection and high-grade cervical disease, it can be inferred that 9vHPV also

Page 70

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

prevents HPV 31-, HPV 33-, HPV 45-, HPV52-, and HPV 58-related high-grade vulvar,
vaginal, and anal disease.
Original HPV Types (6, 11, 16, 18)
The qHPV vaccine was shown to prevent HPV 6, 11, 16 and 18-related cervical, vulvar,
vaginal and anal disease. V503-001 results demonstrated that the 9vHPV induced noninferior anti-HPV 6, 11, 16, and 18 antibody GMTs compared with qHPV in females 16
through 26 years of age. The GMT ratios of 9vHPV/qHPV were 1.02, 0.8, 0.99, and
1.19 for HPV types 6, 11, 16, and 18, respectively, with the LB 95% CI for GMT ratio
greater than 0.67 for each HPV type.
Supportive analyses assessed 9vHPV efficacy in preventing disease and persistent
infection caused by the original types compared to the historical placebo group of the
Gardasil Vaccine Program as well as the concurrent qHPV comparator. These analyses
showed 90% efficacy of 9vHPV compared with historical placebo in preventing disease
caused by original types in the PPE population. In addition, the efficacy of 9vHPV in
preventing persistent infection related to HPV types 6, 11, 16 and 18 was similar to that
of concurrent qHPV comparator.
6.1.13.2 Safety: 9vHPV Vaccine Versus qHPV Vaccine
The 9vHPV vaccine had an acceptable safety profile in females 16 through 26 years of
age. The safety profile was generally similar to that of the qHPV vaccine with the
notable exception of higher rates of injection-site reactions following 9vHPV. Please
also refer to Section 6.1.12.5 for discussion of the small numerical imbalance with a
higher rate of MS (5 cases in the 9vHPV group and 2 cases in the qHPV group) and to
Section 9.1 for discussion of the numerical imbalance with a higher rate of spontaneous
abortions in women who became pregnant within 30 days of any vaccination [19.1% in
the 9vHPV group (17 of 89 pregnancies with known outcome) and 8.0% in the qHPV
group (7 of 88 pregnancies with known outcome)].
6.1.13.3 Conclusion
This reviewer concludes that Study V503-001 provides evidence to support the
effectiveness of 9vHPV in females 16 through 26 years of age in preventing persistent
infection and anogenital disease caused by the 9 HPV types included in the vaccine.
The safety profile of 9vHPV was favorable in the study population and was generally
similar to the licensed qHPV vaccine. Further assessment of the observed small
numerical imbalances in rates of multiple sclerosis and spontaneous abortions would
require much larger studies best conducted in a post-marketing setting (see Section 11,
Risk-Benefit Considerations).
6.2 Trial #2: V503-002 (Designated as Study 2 in the Draft Package Insert)
Title: A Phase 3 Clinical Trial to Study the Immunogenicity, Tolerability, and
Manufacturing Consistency of 9vHPV in Preadolescents and Adolescents (9 through 15
year olds) with a Comparison to Young Women (16 through 26 year olds)

Page 71

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.2.1 Objectives
6.2.1.1 Primary Safety Objective
• To evaluate the tolerability of 9vHPV in preadolescent and adolescent boys and
girls 9 through 15 years of age and young women 16 through 26 years of age.
6.2.1.2 Primary Immunogenicity Objectives
Adolescent-Adult Immunobridging Substudy
• To demonstrate that administration of 9vHPV induces non-inferior GMTs for antiHPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies in girls and boys 9 through
15 years of age compared with young women 16 through 26 years of age.
Manufacturing Lot Consistency Substudy
• To demonstrate that the final manufacturing process (FMP) results in 9vHPV that
induced consistent anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibody
responses.
6.2.1.3 Secondary Objectives
• To demonstrate that 9vHPV induces non-inferior immune responses with respect
to seroconversion rates for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in
girls and boys 9 through 15 years of age compared with young women 16
through 26 years of age.
• To demonstrate that the FMP results in 9vHPV that induces consistent
seroconversion percentages to HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58.
6.2.2 Design Overview
This was a multicenter immunogenicity and safety/tolerability phase 3 trial with a target
enrollment of approximately 2800 subjects (1800 preadolescent and adolescent girls,
600 preadolescent and adolescent boys and 400 young women). Two immunogenicity
substudies were conducted: an adult-adolescent immunobridging substudy that included
approximately 600 girls, 600 boys and 400 young women; and a lot consistency
substudy that included all 1800 girls equally randomized to 3 FMP lots. The lot
consistency substudy was double-blinded with respect to FMP lot number. All subjects
were followed for safety for 12 months.
6.2.3 Population
6.2.3.1 Boys and Girls 9 through 15 Years of Age
• Male or female subjects between the ages of 9 years and 0 days and 15 years
and 364 days on the day of enrollment, in good physical health.
• Must not yet have had coitarche and did not plan on becoming sexually active
during the Day 1 through Month 7 period.
6.2.3.2 Women 16 through 26 Years of Age
• Female subjects between the ages of 16 years and 0 days and 26 years and 364
days on the day of enrollment, in good physical health.
• Had never had Pap testing or only had normal Pap test results.

Page 72

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•

Had a lifetime history of 0 to 4 male and/or female sexual partners at the time of
enrollment.

6.2.4 Study Treatments or Agents Mandated by the Protocol
Please refer to Section 6.1.4 for study treatment.
The product formulations used for this study were Lots WL00033284, WL00033286 and
WL00033287 (Data source: Table 2, page 5 of Module 3.2.P.5.4, STN 125508/0)
6.2.5 Directions for Use
Please refer to Section 6.1.5 for directions for use.
6.2.6 Sites and Centers
The study was conducted in 70 centers; 21 centers in the U.S. and 49 centers Ex-U.S.
The median number of subjects enrolled at each center was 40 (ranging 10 – 228).
Reviewer’s comments: The trial was conducted in 72 centers internationally as
reported in the original submission. Two study centers (Study Sites ---------(b)(4)----------)
were excluded from assessment in this review because of GCP non-compliance issue.
As a result, the total study centers included in this review were reduced to 70. Please
refer to Section 3.2 for detailed discussion of the issue.
6.2.7 Surveillance/Monitoring
6.2.7.1 Immunogenicity
Serum samples were collected from all subjects at Day 1 and Month 7. Serum anti-HPV
6, 11, 16, 18, 31, 33, 45, 52, and 58 antibody titers were measured using a competitive
Luminex Immunoassay (HPV-9 cLIA). The following endpoints were collected from each
study subject to assess immunogenicity:
• cLIA titers for each of the vaccine HPV types.
• Serostatus (i.e., above or below assay cutoff) for each of the vaccine HPV types.
All subjects who were part of the defined PPI population were included in the
immunogenicity summary.
6.2.7.2 Safety
The following measures were collected from each study subject to assess safety:
• Temperatures (within 5 days following any vaccination) via VRC.
• All adverse events (within 14 days following any vaccination) via VRC.
• All SAEs that occurred from Days 1 through 180 following the last vaccination
• All SAEs that resulted in death or were determined to be related to the study
vaccine that occurred at any time during the study. All subjects who received at
least one injection of study vaccine and had safety follow-up data were included
in the safety summary.
6.2.8 Endpoints and Criteria for Study Success
Safety
• Adverse reactions from Day 1 through 15 after each vaccination via VRC.
• SAEs from Day 1 through 6 months after the last vaccination.

Page 73

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•

New medical conditions throughout the study.

Immunogenicity
• Anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 antibody responses (GMTs
and seroconversion rates) at Month 7.
Criteria for Study Success
• Demonstration of non-inferior immunogenicity for individual HPV types GMTs of
the 9vHPV vaccine in children 9 through 15 years of age compared with those in
females 16 through 26 years of age.
• Demonstration of lot consistency of the three lots of the 9vHPV vaccine.
Please refer to Section 6.2.9.1 for details.
6.2.9 Statistical Considerations and Statistical Analysis Plan
6.2.9.1 Statistical Criteria for Success
Non-inferiority Comparison of Immunogenicity between Preadolescents/Adolescents and Young Women
The primary analyses of antibody GMTs for each of HPV types 6, 11, 16, 18, 31, 33, 45,
52, and 58 were addressed by one-sided tests of non-inferiority conducted at the
α=0.025 level for each HPV type. Testing was conducted using an analysis of variance
(ANOVA) model with a response of log individual titers and a fixed effect for comparison
group. The statistical criterion for non-inferiority required that the LB of the two-sided
95% CI for the GMT ratio (9- to 15-year-old boys vs. 16- to 26-year-old young women, or
9- to 15-year-old girls vs. 16- to 26-year-old young women) be greater than 0.67 for each
HPV type.
Similarly, the secondary analyses of seroconversion rates for each of HPV types 6, 11,
16, 18, 31, 33, 45, 52, and 58 was conducted at the α=0.025 level using the method of
Miettinen and Nurminen. The statistical criterion for non-inferiority required that the LB of
the two-sided 95% CI for the difference in seroconversion rate (9- to 15-year-old boys
minus 16- to 26-year-old young women, or 9- to 15-year-old girls minus 16- to 26-yearold young women) be greater than -5 percentage points for each HPV type.
Lot Consistency Analyses
The primary analyses of antibody GMTs for lot consistency were addressed by 3
pairwise (Lot 1 vs. Lot 2, Lot 1 vs. Lot 3, and Lot 2 vs. Lot 3) comparisons for each of
HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Each pairwise comparison tested the
equivalence of the 2 lots using 2 one-sided tests at the 0.025 level. Testing was
conducted using an analysis of covariance (ANCOVA) model with a response of the
natural log of individual titers and fixed effects for vaccine lot and age strata. Successful
demonstration of lot consistency required that the 95% CI for the GMT ratio for each
pairwise comparison between lots be contained entirely within the interval (0.5, 2.0).
The secondary analyses of seroconversion rates for lot consistency were addressed
similarly as immunobridging study as described above. Successful demonstration of lot

Page 74

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

consistency required that the 95% CI for the difference in seroconversion rates for each
pairwise comparison between lots be entirely contained within the interval (-5%, 5%).
Safety
Adverse experiences were summarized descriptively as frequencies and percentages by
vaccination group and type of adverse experience, by vaccination visit and across all
vaccination visits. Elevated temperatures (≥100.0°F or ≥37.8°C, oral) within 5 days
following each vaccination were summarized in a similar manner. In addition, risk
differences and associated 95% CIs were computed comparing the groups across all
vaccination visits with respect to injection-site adverse reactions on the VRC, specific
systemic adverse events, severe injection-site adverse reactions, SAEs and elevated
temperatures. P-values were computed only for those adverse experiences that were
solicited on the VRC (pain/tenderness/soreness, swelling, and redness) and elevated
temperatures. The probability of observing at least one SAE in this study depended on
the number of subjects enrolled and the rate of SAEs in the general population. If no
SAEs were observed among all 2800 study subjects, this study would provide 97.5%
probability that the true rate for SAEs was <0.14%.
6.2.9.2 Sample Size Calculation and Power for Immunobridging Substudy
Immunobridging hypotheses were tested by comparing the approximately 600
preadolescent and adolescent girls (or boys) vs. the approximately 400 young women
(16 through 26 years of age) who received the same lot of vaccine. The sample size for
the preadolescent and adolescent group (~600 per group) was primarily driven by the lot
consistency objective and also by consideration of the overall safety database in 9- to
15-year-old subjects. The power and sample size were calculated based on the following
assumptions: 1) the exclusion rates for the PPI population were approximately 20% for
the 9- to 15-year-old girls and boys group and 40% for the 16- to 26-year-old young
women group, 2) a standard deviation (SD) of the natural-log-transformed titers of 1.2,
and 3) non-inferiority margin for GMT ratio was 1.5 fold. The estimates of exclusion rates
and SD were based on data from previous qHPV vaccine studies. Under these
assumptions, the study would provide >90% power to show non-inferiority of 9vHPV to
qHPV at an overall one-sided, 2.5% alpha-level.
6.2.9.3 Sample Size and Power for Manufacturing Lot Consistency Substudy
This study randomized 1800 girls (9 through 15 years of age) into each of the 3
manufacturing lots (600 girls per lot). The sample size was driven by lot consistency
objective and overall safety database consideration in 9- to 15-year-old girls. The power
and sample size calculation for lot-consistency were based on the following
assumptions: 1) each lot had an approximately 20% exclusion rate for the PPI
population, 2) between-lot variance was not above 1.2% of total variance (between-lot
variance + within-lot variance), and 3) equivalence margin for GMT ratio was 2.0 fold.
The power and sample size were calculated to take consideration of both within-lot and
between-lot variability. Under these assumptions, the study would provide >90% power
to show consistency of the 3 lots for all 9 HPV types at an overall one-sided, 2.5% alphalevel
6.2.9.4 Handling of Dropouts or Missing Data
The ANCOVA model used in the primary immunogenicity analyses allowed inclusion of
data from patients who had missing/non-evaluable antibody titers either at pre-

Page 75

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

vaccination or at post-vaccination, but not at both time points. The statistical inference
from this ANCOVA model was valid under the assumption that the missing data
mechanism was ignorable (or more specifically, missing at random). Based on prior
study results, the missing data rate for the titer response was relatively small and was
not related to unobserved response or vaccination group.
For immunogenicity assessments, antibody titers below the lower limit of test were
imputed to half of the detection limit, and titers above the upper limit of test imputed to
the upper limit. There was no other imputation for missing data.
6.2.9.6 Multiple Comparisons/Multiplicity
The immunobridging and manufacturing lot consistency substudies were considered
separately. The success of one substudy was not contingent on the success of the
other. Therefore, either or both of the substudies could be successful for the study in
general to be a success. No multiplicity adjustment was taken relative to the two
substudies.
For immunobridging primary hypotheses, success was required on all 9 vaccine HPV
types. Therefore, no multiplicity adjustment was made to account for the multiple HPV
types. However, for testing the co-primary hypotheses of non-inferiority of GMTs in girls
vs. young women and in boys vs. young women, a closed stepwise testing procedure
was used to control the overall Type I error rate at 0.025 (1-sided).
For lot consistency primary hypotheses, success required that consistency be
established for all 9 vaccine HPV types. Therefore, no multiplicity adjustment was
necessary for the manufacturing lot consistency substudy.
6.2.10 Study Population and Disposition
6.2.10.1 Populations Enrolled/Analyzed
Per Protocol Immunogenicity (PPI) Population: Please refer to Section 6.1.10.1.
All Type-Specific Naïve Subjects with Serology (ANSS) Population
A supportive immunogenicity analysis was carried out on the all type-specific naïve
subjects with serology population. To be included in this population, subjects must:
1. Have received all 3 vaccinations.
2. Have provided post dose 3 serology data.
3. Be seronegative for the relevant HPV type at Day 1 and (for the 16-26 year old
female group only) PCR negative for the relevant HPV type on all swabs and
biopsies from Day 1 through Month 7.
Safety Population: All subjects who received at least one study vaccination and have
follow-up data.
6.2.10.1.1 Demographics
Table 35 summarizes the demographic data for the participants enrolled in the study. In
general, the population for females 16 through 26 years of age was similar to that of
Study V503-001 except that V503-002 had a higher proportion of Asians (26.5% in
V503-002 vs. 14.3% in V503-001), and lower proportions of multi-racial population

Page 76

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

(11.4% in V503-002 vs. 26.8% in V503-001) and Hispanic or Latino population (27.5% in
V503-002 vs. 35.4% in V503-001). The demographics among the three lot groups (Lot
1, Lot 2 and Lot 3) were balanced regarding age, race, ethnicity and geographic region.
Table 35: Subject Characteristics at Baseline (Study V503-002, All Randomized
Subjects)
Characteristics

Subjects in population
Age (Years)
9 to 12
13 to 15
16 to 26
Mean
SD
Median
Race
American Indian Or
Alaska Native
Asian
Black
Multi-Racial
Native Hawaiian or
other Pacific Islander
White
Ethnicity
Hispanic or Latino
Not Hispanic Or
Latino
Region
Africa
Asia-Pacific
Europe
Latin America
North America

9- to 15Year-Old
Females
(Lot 1)
n (%)
632

9- to 15Year-Old
Females
(Lot 2)
n (%)
626

9- to 15Year-Old
Females
(Lot 3)
n (%)
632

9- to 15Year-Old
Males

16- to 26Year-Old
Females

Total

n (%)
644

n (%)
465

n (%)
2999

427 (67.6)
205 (32.4)
0 (0.0)

420 (67.1)
206 (32.9)
0 (0.0)

425 (67.2)
207 (32.8)
0 (0.0)

434 (67.4)
210 (32.6)
0 (0.0)

0 (0.0)
0 (0.0)
465 (100.0)

1706 (56.9)
850 (27.7)
470 (100.0)

11.7
1.8
12

11.6
1.8
11

11.6
1.9
11

11.7
1.8
12

21.3
2.7
21

13.1
4.0
12

1 (0.2)

1 (0.2)

0 (0.0)

0 (0.0)

0 (0.0)

4 (0.1)

134 (21.2)
50 (7.9)
81 (12.8)
0 (0.0)

124 (19.8)
59 (9.4)
91 (14.5)
0 (0.0)

127 (20.1)
52 (8.2)
86 (13.6)
0 (0.0)

161 (25.0)
37 (5.7)
149 (23.1)
3 (0.5)

123 (26.5)
48 (10.3)
53 (11.4)
1 (0.2)

669 (22.3)
246 (8.2)
460 (15.3)
4 (0.1)

366 (57.9)

351 (56.1)

367 (58.1)

292 (45.3)

240 (51.6)

1616 (53.9)

176 (27.8)

191 (30.5)

193 (30.5)

195 (30.3)

128 (27.5)

883 (29.4)

456 (72.2)

435 (69.5)

439 (69.5)

449 (69.7)

337 (72.5)

2116 (70.6)

32 (5.1)
132 (20.9)
206 (3268)
125 (19.8)
137 (21.7)

34 (5.4)
120 (19.2)
182 (29.1)
147 (23.5)
143 (22.8)

29 (4.6)
126 (19.9)
185 (29.3)
136 (21.5)
156 (24.7)

30 (4.7)
160 (24.8)
143 (22.2)
160 (24.8)
151 (23.4)

40 (8.6)
120 (25.8)
183 (39.4)
60 (12.9)
62 (13.3)

165 (5.5)
658 (21.9)
899 (30.0)
628 (20.9)
649 (21.6)

Source: Adapted from STN 125508/0.43, Module 1.11.3_Table 1 (p15-17).

6.2.10.1.2 Medical/Behavioral Characterization of the Enrolled Population
Per enrollment eligibility criteria, girls and boys 9 through 15 years of age had no sexual
history and the girls had no baseline cervicovaginal examination. The sexual history,
gynecological and pregnancy history and contraceptive use at enrollment of the young
women 16 through 26 years of age was similar to the subjects enrolled in V503-001.
6.2.10.2 Subject Disposition
A total of 3036 subjects were screened in this study, 2999 were randomized, and 2991
received at least one vaccination. A summary of subject disposition is presented in Table
36.
Among the 2999 randomized subjects, a total of 101 subjects (3.4%) discontinued during
the entire study period (Day 1 through Month 12). Most subjects who discontinued prior
to Month 12 either were lost to follow-up or withdrew. Only one subject discontinued due
to a clinical adverse experience (Please refer to Section 6.2.12.7).

Page 77

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Eight randomized subjects were discontinued prior to their first vaccination: ANs 28015,
28057, 31900, 30684, 31649, and 31650 withdrew consent; and ANs 32898 and 32964
were discontinued due to protocol violation.
Table 36: Subject Disposition (Study V503-002, All Randomized Subjects)
Population and
Disposition

9- to 15Year-Old
Females
(Lot 1)
n (%)
632

9- to 15Year-Old
Females
(Lot 2)
n (%)
626

9- to 15Year-Old
Females
(Lot 3)
n (%)
632

9- to 15Year-Old
Males

16- to 26Year-Old
Females

Total

n (%)
644

n (%)
465

n (%)
2999

630 (99.7)
621 (98.3)
619 (97.9)

625 (99.8)
616 (98.4)
610 (97.4)

632 (100)
626 (99.1)
625 (98.9)

641 (99.5)
635 (98.6)
630 (97.8)

463 (99.6)
457 (98.3)
450 (96.8)

2991(99.7)
2955 (98.5)
2934 (97.8)

607 (96.0)

604 (96.5)

619 (97.9)

624 (96.9)

440 (94.6)

2894 (96.5)

Discontinued
Adverse Events
Lost to Follow up
Physician Decision
Pregnancy
Protocol Violation
Withdrawal by
Subjects

25 (4.0)
0 (0.0)
12 (1.9)
1 (0.2)
0 (0.0)
0 (0.0)
12 (1.9)

22 (3.5)
0 (0, 0)
8 (1.2)
0 (0.0)
0 (0.0)
1 (0.2)
13 (2.1)

13 (2.1)
0 (0.0)
10 (1.6)
0 (0.0)
1 (0.2)
0 (0.0)
2 (0.3)

20 (3.1)
1 (0.2)
6 (0.9)
0 (0.0)
0 (0.0)
0 (0.0)
13 (2.0)

21 (4.5)
0 (0.0)
10 (2.2)
1 (0.2)
0 (0.0)
2 (0.4)
8 (1.7)

101 (3.4)
1 (0.0)
46 (1.5)
2 (0.1)
1 (0.0)
3 (0.1)
48 (1.6)

Unknown

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

4 (0.9)

4 (0.1)

Subjects in population
Vaccinated at
Vaccination 1
Vaccination 2
Vaccination 3
Subject Disposition
Completed

Source: Adapted from STN 125508/0.43, Module 1.11.3_Table 2 (p18-19).

6.2.11 Efficacy Analyses
6.2.11.1 Analyses of Primary Endpoint(s)
Adolescent-Adult Immunobridging Substudy
Table 37 displays the non-inferiority analysis of Month 7 type-specific anti-HPV antibody
GMTs comparing 9- to 15-year-old boys and girls to 16- to 26-year-old young women in
the PPI population. For each vaccine HPV type, the LB 95% CI for the GMT ratio
exceeded 0.67. Therefore, the success criterion was met, supporting the conclusion that
GMTs in 9- to 15-year-olds were non-inferior to those in 16- to 26-year-old young
women. In fact, antibody GMTs were higher in 9-15 year-olds than in 16-26 year old
young women, with GMT ratios ranging from 1.83 to 3.35 and LB 95% CI exceeding 1.7
for all HPV types. The results from the analysis in the ANSS population were similar to
the results from the PPI analysis population.
Table 37: Non-Inferiority Analyses of Month 7 Anti-HPV Antibody Geometric Mean
Titers (GMT) Comparing Boys and Girls 9 through 15 Years of Age with Young Women
16 through 26 Years of Age (Study V503-002, Per-Protocol Immunogenicity Population)
Antibody
Assay
Anti-HPV 6

Group A (N=630)
n/GMT

Group B (N=641)
n/GMT

Group C (N=463)
n/GMT

503/1703.1

537/2083.4

328/900.8

Anti-HPV 11

503/1291.5

537/1486.3

332/706.6

A/C GMT Ratio
[95% CI]
1.89
[1.68, 2.12]
1.83

B/C GMT Ratio
[95% CI]
2.31
[2.06, 2.60]
2.10

Page 78

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Group A (N=630)
n/GMT

Group B (N=641)
n/GMT

Group C (N=463)
n/GMT

Anti-HPV 16

513/6933.9

546/8683.0

329/3522.6

Anti-HPV 18

516/2148.3

544/2855.4

345/882.7

Anti-HPV 31

506/1894.7

543/2255.3

340/753.9

Anti-HPV 33

518/985.8

544/1207.4

354/466.8

Anti-HPV 45

518/707.7

547/912.1

368/272.2

Anti-HPV 52

517/926.2

545/1055.5

337/419.6

Anti-HPV 58

516/1289.0

544/1593.3

332/590.5

Antibody
Assay

A/C GMT Ratio
[95% CI]
[1.63, 2.05]
1.97
[1.75, 2.21]
2.43
[2.13, 2.80]
2.51
[2.12, 2.79]
2.11
[1.88, 2.37]
2.60
[2.25, 3.00]
2.21
[1.96, 2.49]
2.18
[1.94, 2.46]

B/C GMT Ratio
[95% CI]
[1.88, 2.36]
2.46
[2.20, 2.76]
3.23
[2.83, 3.70]
2.99
[2.63, 3.40]
2.59
[2.31, 2.90]
3.35
[2.90, 3.87]
2.52
[2.22, 2.84]
2.70
[2.40, 3.03]

Source: Adapted from STN 125508/0.43, Module 1.11.3, Tables 3 and 4 (p 20-1)
All subjects in these analyses received the same lot of 9vHPV (Lot 1). Group A: 9-15 year old females;
Group B: 9-15 year old males; Group C: 16-26 year old females.
N=Number of subjects who were randomized to the respective vaccination group and received at least
one injection.
n=Number of subjects contributing to the analysis.

Manufacturing Lot Consistency Substudy
Table 38 displays the analysis of type-specific Month 7 anti-HPV antibody GMT
comparing subjects in the PPI population randomized to the 3 manufacturing lots of
9vHPV vaccine. For each HPV type, the 95% CI of the GMT ratio for all three pairwise
comparisons was contained between the interval (0.5, 2.0), which was the pre-specified
success criterion for lot consistency. Overall, for all HPV vaccine types, the Month 7 antiHPV GMT responses from the 3 manufacturing lots of 9vHPV vaccine were consistent.
Table 38: Lot Consistency Analyses of 9vHPV Anti-HPV Antibody Geometric Mean
Titers (GMT) at Month 7 (Study V503-002, PPI Population)
Antibody Assay
Anti-HPV 6
Anti-HPV 11
Anti-HPV 16
Anti-HPV 18
Anti-HPV 31
Anti-HPV 33
Anti-HPV 45
Anti-HPV 52
Anti-HPV 58

Lot 1 GMT/Lot 2 GMT
Ratio [95% CI]
1594.3/1655.5
0.96 [0.87, 1.07]
1219.6/1233.6
0.99 [0.89, 1.10]
6429.5/6801.5
0.95 [0.85, 1.05]
1975.5/1990.9
0.99 [0.88, 1.12]
1745.8/1759.1
0.99 [0.88, 1.1a]
917.7/886.8
1.03 [0.93, 1.15]
638.4/786.6
0.81 [0.71, 0.93]
857.8/954.8
0.90 [0.84, 1.07]
1198.9/1271.8
0.94 [0.85, 1.05]

Lot 1 GMT/Lot 3 GMT
Ratio [95% CI]
1594.3/1546.5
1.03 [0.92, 1.15]
1219.6/1136.5
1.07 [0.96, 1.20]
6429.5/6411.3
1.00 [0.90, 1.12]
1975.5/1768.2
1.12 [0.98, 1.27]
1745.8/1693.4
1.03 [0.91, 1.16]
917.7/867.2
1.06 [0.95, 1.18]
638.4/615.5
1.04 [0.91, 1.19]
857.8/904.2
0.95 [0.84, 1.07]
119897/1112.5
1.08 [0.96, 1.21]

Lot 2 GMT/Lot 3 GMT
Ratio [95% CI]
1655.5/1546.5
1.07 [0.96, 1.20]
1233.6/1136.5
1.09 [0.97, 1.22]
6801.5/6411.3
1.06 [0.95, 1.19]
1990.9/1768.2
1.13 [0.99, 1.28]
1759.1/1693.4
1.04 [0.92, 1.18]
886.8/867.2
1.02 [0.91, 1.14]
786.8/615.5
1.28 [1.11, 1.47]
954.8/904.2
1.06 [0.94, 1.19]
1271.8/1112.5
1.14 [1.02, 1.28]

Page 79

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Source: Adapted from STN 125508/0.43, Module 1.11.3, Table 5 (p 22-24)

6.2.11.2 Analyses of Secondary Endpoints
Adolescent-Adult Immunobridging Substudy
Table 39 displays the non-inferiority analysis comparing 9- to 15-year-old boys and girls
to 16- to 26-year-old young women with regard to the proportion in the PPI population
who became seropositive for each vaccine HPV type by Month 7. The LB 95% CI
exceeded -5.0 percentage points, the pre-specified success criterion, for all HPV types.
Table 39: Non-Inferiority Comparison of Month 7 HPV Type-Specific Seroconversion
Rates among 9- to 15-Year-Old Boys and Girls and 16- to 26-Year-Old Young Women
(Study V503-002, PPI Population)
Antibody Assay

Group A
SCR (%)

Group B
SCR (%)

Group C
SCR (%)

A-C
% [95% CI]

B-C
% [95% CI]

Anti-HPV 6
99.8%
99.8%
99.7%
0.1 [-0.8, 1.5]
0.1 [-0.8, 1.5]
Anti-HPV 11
100.0%
100.0%
100.0%
0.0 [-0.8, 1.2]
0.0 [-0.7, 1.2]
Anti-HPV 16
100.0%
100.0%
100.0%
0.0 [-0.7, 1.2]
0.3 [-0.7, 1.2]
Anti-HPV 18
99.8%
100.0%
99.7%
0.1 [-0.8, 1.4]
0.3 [-0.4, 1.6]
Anti-HPV 31
100.0%
100.0%
99.7%
0.3 [-0.5, 1.7]
0.3 [-0.4, 1.7]
Anti-HPV 33
100.0%
100.0%
99.7%
0.3 [-0.5, 1.6]
0.3 [-0.4, 1.6]
Anti-HPV 45
99.8%
100.0%
99.5%
0.4 [-0.6, 1.8]
0.5 [-0.2, 2.0]
Anti-HPV 52
100.0%
100.0%
99.7%
0.3 [-0.4, 1.7]
0.3 [-0.4, 1.7]
Anti-HPV 58
100.0%
100.0%
100.0%
0.0 [-0.7, 1.2]
0.0 [-0.7, 1.2]
Source: Adapted from STN 125508/0.43, Module 1.11.3, Tables 6 and 7 (p 25-28).
All subjects in these analyses received the same lot of 9vHPV (Lot 1). Group A: 9-15 year old females;
Group B: 9-15 year old males; Group C: 16-26 year old females.
N=Number of subjects who were randomized to the respective vaccination group and received at least
one injection. The numbers of subjects who contributed to these analyses are the same as those in
Table 37.
SCR=seroconversion rate

Lot Consistency Analyses
Table 40 displays the lot-to-lot comparison of Month 7 HPV type-specific seroconversion
rates in the PPI population. Equivalence was established in all 3 pairwise comparisons
for each vaccine HPV type.
Table 40: Lot Consistency Analysis by Month 7 HPV Type-Specific Seroconversion
Rates (Study V503-002, PPI Population)
Antibody
Assay
Anti-HPV 6
Anti-HPV 11
Anti-HPV 16
Anti-HPV 18
Anti-HPV 31
Anti-HPV 33
Anti-HPV 45
Anti-HPV 52
Anti-HPV 58

Lot 1
SCR (%)
99.8
100
100
99.8
100
100
99.8
100
100

Lot 2
SCR (%)
99.8
100
100
100
100
100
100
100
100

Lot 3
SCR (%)
99.3
99.6
99.6
99.7
99.8
99.6
99.7
99.7
99.7

Lot 1 - Lot 2
% (95%CI)

Lot 1 - Lot 3
% (95%CI)

Lot 2 - Lot 3
% (95%CI)

-0.0 (-1.0, 0.9)
0.0 (-0.8, 0.7)
0.0 (-0.7, 0.7)

0.5 (-0.4, 1.7)
0.4 (-0.4, 1.4)
0.4 (-0.4, 1.3)

-0.2 (-1.1, 0.5)

0.2 (-0.7, 1.1)
0.2 (-0.6, 1.0)

0.5 (-0.4, 1.7)
0.4 (-0.4, 1.4)
0.4 (-0.4, 1.3)
0.4 (-0.4, 1.3)

0.0 (-0.8, 0.7)
0.0 (-0.7, 0.7)
-0.2 (-1.1, 0.5)

0.4 (-0.4, 1.3)
0.2 (-0.7, 1.1)

0.0 (-0.7, 0.7)
0.4 (-0.4, 1.3)
0.4 (-0.4, 1.3)
0.0 (-0.7, 0.7)
Source: Adapted from STN 125508/0.43, Module 1.11.3, Table 8 (p 29-32)

0.2 (-0.5, 1.0)

0.4 (-0.4, 1.3)
0.4 (-0.4, 1.3)
0.4 (-0.4, 1.3)
0.4 (-0.4, 1.33)

Page 80

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
The numbers of subjects who were randomized to the respective groups and received at least one injection, and
the numbers of subjects who contributed to these analyses are the same as those in Table 38.
SCR=seroconversion rate

6.2.11.3 Subpopulation Analyses
In general, antibody responses to each HPV type among ethnic groups and races were
similar. Boys had numerically higher anti-HPV antibody responses than girls, and
females in younger age category generally had higher anti-HPV antibody responses
than older subjects. Subgroup analyses of pooled 9vHPV immunogenicity data from all
studies are discussed in Section 7.1.7.2.
6.2.11.4 Dropouts and/or Discontinuations
The overall dropout rate was 3.4% (range 2.0% to 4.7% among the different groups).
The small percentage of dropouts likely did not significantly affect the immunogenicity
analyses. In addition, the statistical inference from the ANCOVA model is valid under
the assumption that the missing data mechanism is ignorable (or missing at random).
6.2.12 Safety Analyses
6.2.12.1 Methods
Safety analyses were performed on all subjects who received at least one dose of the
vaccine and had at least one follow up visit.
All subjects were followed for adverse reactions for 15 days after each injection via VRC
and for SAEs from Day 1 through 6 Months post-dose 3 regardless of causality.
6.2.12.2 Overview of Adverse Events
Injection-Site Adverse Reactions
Table 41 displays the numbers and percentages of subjects with injection-site adverse
reactions (and severe injection site reactions) from Days 1 to 5 following any vaccination
visit (reported by ≥1% of subjects in one or more vaccination groups).
In general, the overall rates of injection site reactions were similar among the three
groups. Boys 9 through 15 years of age tended to have numerically lower rates of
injection site reactions compared with the other two groups, especially for injection site
pain, erythema and swelling. The percentages of subjects with injection site reactions
following each vaccination were consistent. The percentage of subjects with injection
site erythema and swelling increased in each group following the second and the third
vaccination. Most of the adverse reactions resolved within one week of onset.

Page 81

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 41: Injection-Site Adverse Reactions (Days 1 to 5 Following Any Vaccination)
Reported by ≥1% of Subjects in Any Group (Study V503-002)
Adverse
Intensity
9-15-Year-Old
9-15-Year-Old
16-26-Year-Old
Reactions
Grading
Females (N=1878) Males (N=639)
Females (N=461)
n (%)
n (%)
n (%)
All Reactions Any
1533 (81.6)
460 (72.0)
395 (85.7)
Severe
80 (4.3)
5 (0.8)
12 (2.6)
Anesthesia
Any
2 (0.1)
2 (0.3)
5 (1.1)
Severe
0 (0.0)
0 (0.0)
0 (0.0)
Erythema
Any
567 (29.8)
160 (24.9)
132 (28.6)
Severe
42 (2.2)
12 (1.9)
5 (1.1)
Hematoma
Any
31 (1.6)
8 (1.2)
16 (3.4)
Severe
0 (0.0)
0 (0.0)
0 (0.0)
Hemorrhage Any
19 (1.1)
4 (0.6)
3 (0.6)
Severe
0 (0.0)
0 (0.0)
0 (0.0)
Induration
Any
19 (1.1)
7 (1.1)
2 (0.4)
Severe
1 (0.1)
1 (0.2)
0 (0.0)
Pain
Any
1525 (81.2)
457 (71.5)
391 (84.8)
Severe
78 (4.2)
3 (0.5)
16 (3.4)
Pruritus
Any
62 (3.2)
6 (0.9)
16 (3.4)
Severe
1 (0.1)
1 (0.2)
0 (0.0)
Swelling
Any
666 (35.5)
172 (26.9)
151 (32.8)
Severe
86 (4.6)
33 (5.2)
17 (3.7)
Source: Generated by the clinical review from Table 9 (p33-35) and Table 10 (p36),
SNT 125508/0.43, Module 1.11.3
Systemic Adverse Reactions
Table 42 presents the numbers and percentages by MedDRA SOC of subjects with
systemic clinical adverse reactions from Days 1 to 15 following any vaccination visit
(reported by ≥1% of subjects in one or more vaccination groups). In all vaccination
groups, the most common clinical adverse experiences were headache and pyrexia,
which occurred at similar frequencies among all demographic groups. The frequency of
systemic clinical adverse reactions was similar across vaccination visits among all
demographic groups. However, women 16 through 26 years of age had a numerically
higher proportion of severe AEs (7.9%), as compared to 9 through 15 year-old girls
(5.1%) and boys (4.5%).
Most subjects (>90%) had a maximum temperature below 37.8oC from Days 1 to 5.
There was no difference in percentage of subjects with temperature ≥ 37.8oC between 9to 15-year-old males or females and the 16- to 26-year-old females.
Table 42: Systemic Adverse Events (Days 1 to 15 Following Any Vaccination) by System
Organ Class (Reported by ≥ 1% of Subjects in One or More Groups, Study V503-002)
Adverse Events

No. subjects with follow-up
No. of subjects with one or more AE
Ear and labyrinth disorders

9- to 15-YearOld Females
n ( %)
1878
863 (46.0)
18 (1.0)

9- to 15-YearOld Males
n ( %)
639
277 (43.3)
4 (0.6)

16- to 26-YearOld Females
n ( %)
461
266 (57.7)
6 (1.3)

Page 82

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Adverse Events

9- to 15-YearOld Females
n ( %)
13 (0.7)
220 (11.7)
38 (2.0)
61 (3.2)
34 (1.8)
37 (2.0)
6 (0.3)
41 (2.2)
260 (13.8)

9- to 15-YearOld Males
n ( %)
2 (0.3)
65 (10.2)
11 (1.7)
14 (2.2)
15 (2.3)
12 (1.8)
6 (0.9)
9 (1.4)
106 (16.6)

Eye disorders
Gastrointestinal disorders
Abdominal pain
Abdominal pain upper
Diarrhoea
Nausea
Toothache
Vomiting
General disorders and administration
site conditions
Fatigue
31 (1.7)
8 (1.3)
Feeling hot
5 (0.3)
1 (0.2)
Malaise
8 (0.4)
5 (0.8)
Pyrexia
195 (10.2)
85 (13.3)
Infections and infestations
270 (14.4)
105 (16.4)
Gastroenteritis
28 (1.5)
16 (2.5)
Influenza
22 (1.1)
9 (1.4)
Nasopharyngitis
83 (4.4)
19 (3.0)
Upper respiratory tract infection
55 (2.9)
27 (4.2)
Urinary tract infection
2 (0.1)
0 (0.0)
Injury, poisoning and procedural
39 (2.1)
24 (3.8)
complications
Musculoskeletal and connective tissue
78 (4.2)
17 (2.7)
disorders
Back pain
14 (0.7)
3 (0.5)
Myalgia
16 (0.9)
1 (0.2)
Neck pain
11 (0.6)
3 (0.5)
Pain in extremity
20 (1.1)
4 (0.6)
Nervous system disorders
396 (21.1)
108 (16.9)
Dizziness
52 (2.8)
9 (1.4)
Headache
352 (18.7)
98 (15.3)
Psychiatric disorders
4 (0.2)
3 (0.5)
Reproductive system and breast
31 (1.7)
0 (0.0)
disorders
23 (1.2)
Dysmenorrhoea
0 (0.0)
Respiratory, thoracic and mediastinal
155 (8.3)
34 (5.3)
disorders
Cough
51 (2.7)
17 (2.7)
Oropharyngeal pain
71 (3.8)
12 (1.9)
Rhinorrhea
10 (0.5)
4 (0.6)
Skin and subcutaneous tissue disorders 47 (2.5)
11 (1.7)
Source: Adapted from STN 125508/0.43, Module 1.11.3,Table 11 (p37-38).

16- to 26-YearOld Females
n ( %)
6 (1.3)
69 (15.0)
9 (2.0)
10 (2.2)
17 (3.7)
10 (2.2)
7 (1.5)
8 (1.7)
74 (16.1)
13 (2.8)
7 (1.5)
9 (2.0)
43 (9.3)
79 (17.1)
2 (0.4)
10 (2.2)
23 (5.0)
16 (3.5)
5 (1.1)
8 (1.7)
29 (6.3)
10 (2.2)
5 (1.1)
5 (1.1)
3 (0.7)
119 (25.8)
15 (3.3)
105 (22.8)
5 (1.1)
25 (5.4)
17 (3.3)
31 (6.7)
7 (1.5)
16 (3.5)
5 (1.1)
21 (4.6)

Vaccine-Related Systemic Adverse Reactions
Table 43 presents the numbers and percentages by SOC of subjects with systemic
clinical adverse reactions from Day 1 to 15 following any vaccination visit (reported by
≥1.0% of subjects in one or more vaccination groups) considered by the investigator to
be vaccine-related.
• The most common (≥2.0%) vaccine-related systemic clinical adverse reactions
across treatment groups were headache and pyrexia.

Page 83

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•
•

The overall frequency of vaccine-related systemic adverse reactions was higher
among 16- to 26-year-old females.
The overall profile of vaccine-related systemic clinical adverse reactions was
generally similar across all demographic cohorts.

Table 43: Vaccine-Related Systemic Adverse Reactions (Days 1 to 15 Following Any
Vaccination Visit) by System Organ Class (Reported by ≥ 1% of Subjects in One or More
Vaccination Groups, Study V503-002)
Adverse Events

9- to 15-YearOld Females
n ( %)
1878
400 (21.3)

9- to 15-YearOld Males
n ( %)
639
144 (22.5)

No. subjects with follow-up
No. of subjects with one or more vaccinerelated AE
Gastrointestinal disorders
68 (3.56
25 (3.9)
Nausea
24 (1.3)
8 (1.3)
General disorders and administration
164 (8.7)
64 (10.0)
site conditions
Fatigue
19 (1.0)
3 (0.5)
Feeling hot
4 (0.2)
1 (0.2)
Malaise
6 (0.3)
4 (0.6)
Pyrexia
127 (6.8)
57 (8.9)
Infections and infestations
32 (1.7)
9 (1.4)
Musculoskeletal and connective tissue
23 (1.2)
3 (0.5)
disorders
Nervous system disorders
211 (11.2)
68 (10.6)
Dizziness
32 (1.7)
4 (0.6)
Headache
183 (9.7)
60 (9.4)
Respiratory, thoracic and mediastinal
16 (0.8)
7 (1.1)
disorders
Skin and subcutaneous tissue disorders 10 (0.5)
5 (0.8)
Source: Adapted from STN 125508/0.43, Module 1.11.3, Table 12 (p39).

16- to 26-YearOld Females
n ( %)
461
121 (26.2)
15 (3.3)
6 (1.3)
57 (12.4)
12 (2.6)
6 (1.3)
8 (1.7)
32 (6.9)
8 (1.7)
7 (1.5)
54 (11.7)
8 (1.7))
46 (10.0)
1 (0.2)
8 (1.7)

6.2.12.3 Deaths
No subject died during the entire course of the study.
6.2.12.4 Nonfatal Serious Adverse Events
Thirty-four subjects (15 from the 9- to 15-year-old female cohort, 11 from the 9- to
15-year-old male cohort, and 8 from the 16- to 26-year-old female cohort) experienced a
nonfatal SAE (excluding events of fetal loss) during the entire study period. The rates of
these events varied among the 3 demographic cohorts. The most common SAEs were
appendicitis and asthma among the 9- to 15-year-old male and female cohorts. All SAEs
resolved.
Table 44 presents the SAEs that occurred within 28 days following any vaccination. Two
subjects (1 from the 9- to 15-year-old male cohort, and 1 from the 16- to 26-year-old
female cohort) experienced SAEs that were considered by the investigator to be vaccine
related. Subject 31765 discontinued the study due to asthmatic crisis and did not
complete the 3-dose regimen.

Page 84

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 44: SAEs Reported by Subjects Immunized with 9vHPV from Day 1 to Day 28
after Any Vaccination (Study V503-002)
Subject
SAE
Dose
Day of Relateda
Outcome
Number
Onset
28763b
Acute tonsillitis, Gastritis
3
23
No
Resolved
28668b
Pneumonia
2
9
No
Resolved
b
28195
Asthma
3
3
No
Resolved
28655b
Appendicitis
2
16
No
Resolved
28471b
Concussion, Tongue injury
1
4
No
Resolved
c
31765
Asthmatic crisis
1
2
Yes
Resolved
31824c
Appendicitis
2
11
No
Resolved
32402c
Suicidal ideation
3
8
No
Resolved
31751c
Ankle fracture
1
24
No
Resolved
c
31743
Pharyngotonsillitis
3
2
No
Resolved
31678c
Tibia fracture
2
4
No
Resolved
33221d
Foot fracture
2
12
No
Resolved
d
33179
Headache
3
1
Yes
Resolved
32875d
Biliary colic
3
25
No
Resolved
Source: Generated by the clinical review from information in STN 125508/0, Module 5.3.5.1.p002,
CSR, Table 12-21 (282-296)
a
b
c
d
As judged by the investigators; 9-15 year-old females; 9-15 year-old males; 16-26 year-old
females.

Subject AN 33179, a 21-year-old white female from Belgium, experienced a severe
headache, fever, and photophobia on the same day that she received her third dose of
9vHPV. On July 2, 2010, the subject was bitten by a spider and treated with clindamycin
(July 5 to 9, 2010). She received her third dose of 9vHPV on July 7, 2010. On the same
day (July 7, 2010), she complained of a severe headache, fever and photophobia for
which she took paracetamol at home with no improvement. She also reported that she
had experienced some neck pain for a few days. On July 8, 2010, she was hospitalized
for further observation of neck stiffness, fever (39°C), and headache. She had a normal
neurologic examination and terminal neck stiffness. X-rays of the thorax and cervical
spine, brain CT, lumbar puncture, urine culture and hemoculture were all negative. On
July 9, 2010, both the fever and the infected spider bite were resolved and only a mild
headache remained. The subject was discharged on July 10, 2010 with a diagnosis of
viral infection or adverse event due to study vaccination. No action was taken with study
therapy, and the subject continued in the study. The investigator felt that the headache
was related to study therapy.
Reviewer’s comment: Based on the limited information, it is difficult to determine the
cause of fever, headache and photophobia. Because of the close temporal association,
the events were possibly caused by the vaccination.
Subject AN 31765, a 10 year-old white male with a history of seasonal allergic rhinitis
and bronchial asthma, experienced cough, breathing difficulty and weakness on
December 17, 2009 (one day after his first dose of 9vHPV). On December 18, 2009, he
was hospitalized due to the asthma crisis with wheezing and moderate breathing
difficulty. The asthma crisis was treated with albuterol, prednisone, cephradine,
beclomethasone, ipratriopium, and cetrizine. Cough, breathing difficulty and weakness
stopped on December 19, 2009. On December 22, 2009, he was discharged from

Page 85

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

hospital. The investigator determined that the asthma crisis was possibly related to the
vaccine solely based on temporal association.
Reviewer’s comment: The patient had a history of asthma and the most current
episode of asthma was one year ago (in December 2008). However, no triggering factor
for the asthma crisis was identified. Because of the close temporal association of the
asthma crisis and the administration of the vaccine, this reviewer agrees that the asthma
crisis is possibly related to the vaccine.
Reviewer’s comment: After review of case narratives for all of the SAEs including
those that occurred not in the 28-day window of vaccination in this study, this reviewer
concurs with the Applicant that all of the SAEs other than those discussed in detail
above were not related to the study vaccine.
6.2.12.5 Adverse Events of Special Interest (AESI)
Twenty-two subjects experienced new medical conditions that were potentially indicative
of a systemic autoimmune disorder. Among them, 17 subjects reported mild or
moderate arthralgia, which resolved shortly after onset in a majority of cases. None of
these episodes of arthralgia was considered to be autoimmune disorder or vaccine
related by the investigators.
• Among 9- to 15-year-old females: 13 subjects reported arthralgia, 1 subject
reported a goiter, 1 subject reported ulcerative colitis, and 1 subject reported
vitiligo.
• Among 9- to 15-year-old males: 1 subject reported arthralgia, and 1 subject
reported post-traumatic pain.
• Among 16- to 26-year-old females: 3 subjects reported arthralgia, and 1 subject
reported androgenic alopecia.
Reviewer’s comment: The Applicant provided individual narratives of subjects AN
30613 (goiter), AN 29201 (vitiligo), AN 33111 (androgenic alopecia) and AN 28183
(ulcerative colitis) in Sections 14.5.1 and 14.5.4 of the clinical study report. Subject AN
30613 had a history of hypothyroidism. Subject AN 29201 noted a single white patch of
skin on her face two days post dose 1. Androgenic alopecia and ulcerative colitis
occurred approximately six months after the last vaccination in Subjects AN33111 and
AN 28183, respectively. The reviewer agrees with the reporting investigators that none
of these cases are likely to be related to the vaccine due to either pre-existing medical
condition, or lack of a biological plausibility.
6.2.12.6 Clinical Test Results
No routine laboratory safety tests were conducted within the context of the study.
6.2.12.7 Dropouts and/or Discontinuations
Among the 2999 randomized subjects, a total of 101 subjects (3.4%) discontinued during
the entire study period (Day 1 through Month 12). In the opinion of this clinical reviewer,
the low dropout rate would not significantly impact safety evaluation. Please refer to
Section 6.2.10.2 for reasons for discontinuation.
One subject (AN 31765) discontinued study due to an episode of asthma crisis
(discussed above).

Page 86

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.2.13 Study Summary and Conclusions
6.2.13.1 Summary of Immunogenicity Results
Adult-Adolescent Immunobridging Substudy
Immunogenicity was assessed at 4 weeks after dose 3. The results showed that:
• All three demographic groups responded to vaccination with marked increases in
antibody titers to anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies in
>99% of subjects in the PPI population. Post-dose 3 antibody GMTs were
numerically higher in boys and girls 9 through 15 years of age than in girls and
women 16- to 26-year-olds.
• Non-inferiority was demonstrated with regard to GMTs and seroconversion rates
for Month 7 anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibodies in the 9-15
year-old girls as well as 9-15 year-old boys compared with 16-26 year-old
women.
Manufacturing lot consistency substudy
• The three vaccine lots induced consistent antibody responses, in terms of GMTs
and seroconversion rates, against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and
58.
6.2.13.2 Summary of Safety Data
• The proportion of subjects who reported at least one injection-site adverse
reaction within 5 days of any vaccination was generally similar between the 9- to
15-year-old females (1533/1878 [81.6%]) and the 16- to 26-year-old females
(395/461 [85.7%]). The percentage of subjects with injection-site adverse
experiences was numerically lower among 9- to 15-year-old males (460/639
[72.0%]). The percentages of subjects with injection site reactions following each
vaccination were consistent. However, the percentage of subjects with injection
site erythema and swelling increased in each group following the second and the
third vaccination.
• The proportion of subjects who reported at least one systemic adverse
experience within 15 days of any vaccination was generally lower among 9- to
15-year-old females (863/1878 [46.0%]) and 9- to 15-year-old males (277/639
[43.3%]) as compared with 16- to 26-year-old females (266/461 [57.7%]).
• One subject discontinued the study due to an adverse experience, and two
subjects experienced an SAE (asthmatic crisis and headache, n=1 each) that
was judged to be vaccine-related.
• Four subjects reported adverse events considered to be a systemic autoimmune
disorder: goiter, vitiligo, androgenic alopecia, and ulcerative colitis. However,
none was deemed vaccine-related.
• During the study period, 42 SAEs were reported during the entire course of the
study, including 2 vaccine-related SAEs.
• No subject died during the entire course of the study.
• The overall safety of 9vHPV in this study population was generally similar to the
overall safety profile of qHPV and of 9vHPV in the context of study V503-001.
6.2.13.3 Conclusions

Page 87

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Immunogenicity
• Immune responses to HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 following a
3-dose regimen of 9vHPV were non-inferior in 9-15 year-old boys and girls
compared with those observed in 16-26 year-old women. These results support
the bridging of efficacy findings in 16-26 year-old women to 9-15-year-old boys
and girls.
• Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 antibody GMTs at four weeks postdose 3 were equivalent in 9 through 15 year-old girls randomized to three
separate lots of the Final Manufacturing Process, supporting lot-to-lot
manufacturing consistency.
Safety
• The 9vHPV vaccine had an acceptable safety profile in 9 through 15 year-old
girls and boys and 16 through 26 year-old women.
6.3 Trial #3: V503-009 (Designated as Study 3 in the Draft Package Insert)
Title: A Randomized, Double-Blinded, Controlled with Gardasil (qHPV), Phase 3 Clinical
Trial to Study the Immunogenicity and Tolerability of 9vHPV in 9- to 15-Year-old Girls
6.3.1 Objectives
6.3.1.1 Primary Objective
• To demonstrate that administration of 9vHPV induces non-inferior GMTs for
serum anti-HPV 16 and anti-HPV 18 compared to qHPV in preadolescent and
adolescent girls 9 through 15 years of age.
6.3.1.2 Secondary Objectives
• To evaluate the tolerability of 9vHPV in the girls 9 through 15 years of age.
• To summarize humoral immune responses (including anti-HPV 6, 11, 16, 18,
GMTs and seroconversion rates at four weeks post-dose 3) in girls 9 through 15
years of age who received 9vHPV or qHPV.
6.3.2 Design Overview
The study was a qHPV controlled, randomized, double-blinded, multicenter, phase 3
clinical trial to study the immunogenicity and tolerability of 9vHPV in preadolescent and
adolescent girls 9 through 15 years of age. Enrolment was stratified 1:1 for 9 to 12 yearold and 13 to 15 year-old girls to ensure comparable representation of both age strata.
The planned study duration for each subject was 7 months.
6.3.3 Population
The study population included 9 through 15 year-old healthy girls, who had:
• Not yet experienced coitarche and did not plan on becoming sexually active
during the study period.
• No known allergy to any vaccine component or history of severe allergic reaction
that required medical intervention.
• No history of immunosuppressive condition or treatment or autoimmune condition
• Not previously received a marketed HPV vaccine or participated in an HPV
vaccine clinical trial.

Page 88

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•

No history of a positive HPV test.

6.3.4 Study Treatments or Agents Mandated by the Protocol
6.3.4.1 Treatment
Please refer to Section 6.1.4 for details of study treatment.
6.3.4.2 Batch number used in this Study
The 9vHPV Vaccine: WL00034579 (expiry date: 27 May 2012).
The qHPV Vaccine: WL00029942 (expiry date: 11 June 2011) and WL00040674 (expiry
date: 23 October 2013).
6.3.5 Directions for Use
Refer to Section 6.1.5.
6.3.6 Sites and Centers
Twenty-four centers participated to the study: 3 in Belgium, 4 in Denmark, 4 in Finland, 3
in Italy, 5 in Spain and 5 in Sweden. The number of subjects enrolled in each center
ranged from 4 to 69, with the majority of the centers enrolled around 20 subjects.
6.3.7 Surveillance/Monitoring
All subjects were randomized to a standard 3-dose regimen (Day 1, Month 2, Month 6)
of either 9vHPV or qHPV. Serum samples were collected at Day 1 before vaccination
and Month 7 for anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibody assays. The
primary time point for comparison of immune responses was Month 7, i.e. approximately
4 weeks following the third vaccination.
Safety information was collected Day 1 through approximately 4 weeks following the
third vaccination or for a total of approximately 7 months for each subject as scheduled
in the protocol.
6.3.8 Endpoints
6.3.8.1 Immunogenicity
• Primary immunogenicity endpoints: cLIA GMTs for anti-HPV 16 and 18
antibodies at 4 weeks post-dose 3.
• Secondary immunogenicity endpoints: cLIA GMTs for anti-HPV 6 and 11
antibodies at 4 weeks post-dose 3 and cLIA seroconversion rates for each of
anti-HPV 6, 11, 16 and 18 antibodies by 4 weeks post-dose 3.
6.3.8.2 Safety
Safety assessment focused on the injection site adverse reactions and elevated
temperatures during Day 1 to Day 5 post-vaccination and systemic adverse events
during Day 1 to Day 15 post-vaccination, reported on the VRC. In addition, SAEs were
collected regardless of causality throughout the study.

Page 89

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.3.9 Statistical Considerations and Statistical Analysis Plan
The sample size and power calculations were based on the primary immunogenicity
endpoints. It was expected that there would be an approximately 20% exclusion rate
from the Per Protocol Set (PPS) used for the primary analyses. Thus, with a total sample
size of 600 enrolled subjects, the primary analysis would include 480 girls (240 in each
group)., The true GMT ratio was assumed to be 1, and the standard deviation was
estimated at 1.2 for both the anti-HPV 16 and 18 post-vaccination antibody titers (natural
log scale). The statistical criterion for non-inferiority required that the LB of the two-sided
95% CI for the GMT ratio (9vHPV vs. qHPV) be greater than 0.67 for each of the HPV
types 16 and 18. Based on 240 evaluable subjects per group and the above
assumptions, the study would have over 90% power to demonstrate the non-inferiority of
9vHPV compared to qHPV for anti-HPV 16 and 18 antibody responses.
Descriptive summaries of adverse event rates were provided for each group, and
comparisons were made between subjects receiving the 9vHPV vaccine and those
receiving the qHPV vaccine.
No multiplicity adjustment was conducted and no interim analysis was planned.
For immunogenicity assessments, results below the lower limit of quantification were
imputed to half of the detection limit, and results above the upper limit of quantification
were imputed to the upper limit. There was no other imputation for missing data.
6.3.10 Study Population and Disposition
6.3.10.1 Populations Enrolled/Analyzed
The planned and enrolled numbers of subjects were 600 in total and 300 per arm.
Per Protocol Immunogenicity (PPI) Population
The PPI population served as the primary set of subjects for the analysis of immune
responses to each of the 9 HPV types. To be included in this set of subjects, subjects
must:
1. Have received all three vaccinations with the correct dose of the correct clinical
material, and each vaccination visit must have occurred within acceptable day
ranges as specified in the protocol.
2. Have provided Month 7 serology result within 21 to 49 days post dose 3.
3. Have been seronegative to the relevant HPV type at Day 1.
4. Have had no other protocol violations that could have interfered with the
evaluation of subject's immune response to the study vaccine.
Safety Set
Safety analyses included all subjects who received at least 1 study vaccination and had
safety follow-up data.
6.3.10.1.1 Demographics
Demographic data and other baseline characteristics were similar for subjects receiving
the 9vHPV vaccine and subjects receiving the qHPV vaccine. Table 45 summarizes the
demographic characteristics at baseline for the subjects randomized in the study. All
subjects were recruited from Europe.

Page 90

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 45: Summary of Demographic Characteristics at Baseline (Study V503-009)
Characteristics
9vHPV (n=300)
qHPV (n=300)
Total (n=600)
Age (Years)
9 to 12
150
150
300
13 to 15
150
150
300
Mean ± SD
12.5 ± 1.9
12.6 ± 1.9
12.6 ± 1.9
Race
Black
1 (0.3%)
1 (0.3%)
2 (0.3%)
White
296 (98.7%)
294 (98.0%)
590 (98.3%)
Asian
0 (0.0%)
1 (0.3%)
1 (0.2%)
Multi-Racial
3 (1.0%)
4 (1.3%)
7 (1.2%)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p009, CSR, Table 10-5 (p69)

6.3.10.1.2 Medical/Behavioral Characterization of the Enrolled Population
Overall, 34.1% of the subjects received concomitant medications between Day 1 and
Day 15 following any vaccination (32.4% in the group receiving 9vHPV vaccine and
35.7% in the group receiving qHPV vaccine). The most frequently reported concomitant
medications were analgesics (16.2%), anti-inflammatory and anti-rheumatic products
(15.2%), antibacterial for systemic use (4.0%), cough and cold preparations (2.8%) and
antihistamines for systemic use (2.7%).
6.3.10.1.3 Subject Disposition
A total of 603 subjects were screened, and of those 600 subjects were enrolled in the
study. The disposition of subjects is presented in Table 46.
Table 46: Disposition of Study Subjects (Study V503-009)
9vHPV
qHPV
N (%)
N (%)
Randomized
300
300
Received at least one dose
300 (100%)
300 (100%)
Received only one dose
2 (0.7%)
0 (0.0%)
Received only two doses
2 (0.7%)
4 (1.3%)
Received all three doses
296 (98.7%)
296 (98.7%)
Completed the study
294 (98.0%)
295 (98.3%)
Subject withdrew
6 (2.0%)
5 (1.7%)
Adverse events
1 (0.3%)
1 (0.3%)
Withdrawal of consent
2 (0.7%)
3 (1.0%)
Protocol violation
1 (0.3%)
0 (0.0%)
Lost to follow-up
2 (0.7%)
1 (0.3%)

Total
N (%)
600
600 (100%)
2 (0.3%)
6 (1.0%)
592 (98.7%)
589 (98.2%)
11 (1.8%)
2 (0.3%)
5 (0.8%)
1 (0.2%)
3 (0.5%)

Source: Adapted from STN 125508/0, Module 5.3.5.1.p009, CSR, Table 14.1 (p110)

6.3.11 Efficacy Analyses
6.3.11.1 Analyses of Primary Endpoints
The primary analysis was the non-inferiority comparison of post-dose 3 anti-HPV 16 and
18 antibody GMTs for 9vHPV versus qHPV in the PPS population. As seen from Table
47, non-inferiority of antibody response to 9vHPV compared to qHPV was demonstrated

Page 91

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

for HPV types 16 and 18 since the LB of the two-sided 95% CI of anti-HPV GMT ratio
(9vHPV/qHPV) was greater than 0.67 for both HPV types.
Similar non-inferiority was also demonstrated for HPV types 6 and 11 (Table 47). In
addition, all subjects in the PPS population in both groups seroconverted against HPV
types 6, 11, 16 and 18 (Table 47).
Table 47: Comparison of Immune Responses Between 9vHPV and qHPV for HPV 6,
11, 16 and 18 in PPI Population of 9 through 15 Year-old Girls (Study V503-009, PPI
population)
Antibody
Assay

1

9vHPV
%SC (95% CI)

1

qHPV
%SC (95% CI)

1

1

9vHPV
qHPV
9vHPV/qHPV
GMT mMU/ml GMT mMU/ml
GMT Ratio
(95% CI)
(95% CI)
(95% CI)
Anti-HPV6
100
100
1679
1566
1.07
(98.7, 100)
(98.6, 100)
(1519, 1857)
(1412, 1736)
(0.93, 1.23)
Anti-HPV11 100
100
1316
1417
0.93
(98.7, 100)
(98.6, 100)
(1184, 1462)
(1274, 1577)
(0.80, 1.08)
Anti-HPV16 100
100
6740
6887
0.97
(98.7, 100)
(98.6, 100)
(6135, 7404)
(6221, 7626)
(0.85, 1.11)
Anti-HPV18 100
100
1957
1795
1.08
(98.7, 100)
(98.6, 100)
(1737, 2204)
(1567, 2057)
(0.91, 1.29)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p009, CSR, Tables 11.1, 11.2 and 11.3
(p75-76)
1
The numbers of individuals contributing to the analysis for HPV 6, 11, 16 and 18 were 273, 273,
276 and 276, respectively in 9vHPV group, and 261, 261, 270 and 269, respectively in qHPV
group. The numbers of individuals randomized to each group were 300.
PPI=Per protocol immunogenicity
SC=Seroconversion

6.3.11.2 Analyses of Secondary Endpoints
Please refer to Section 6.3.11.1 for comparisons between 9vHPV and qHPV of anti-HPV
6 and 11 antibody GMTs and of seroconversion rates for HPV types 6, 11, 16 and 18.
6.3.11.3 Subpopulation Analyses
No subpopulation analysis was conducted for this study, as subpopulation analyses
were conducted for the integrated immunogenicity data as described in Section 7.1.7.2.
6.3.11.4 Dropouts and/or Discontinuations
Overall, 11 subjects (1.8%) withdrew from the study: 6 subjects (2.0%) in 9vHPV group
and 5 (1.7%) in qHPV group.
Reviewer’s comment: The low dropout rate in this study would not have significant
impact on the immunogenicity results.
6.3.12 Safety Analyses
6.3.12.1 Methods
Please refer to Section 6.2.12.1.
6.3.12.2 Overview of Adverse Events

Page 92

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

In total, 599 subjects were enrolled and included in the safety database, 299 subjects in
9vHPV group and 300 subjects in qHPV group. Overall 287 subjects (96.0%) in the
9vHPV group and 281 subjects (93.7%) in the qHPV group reported at least one
adverse event during the entire study. Vaccine related adverse events were reported for
93.3% of 9vHPV recipients and 90.3% of qHPV recipients from Day 1 to Month 7.
Injection-Site Adverse Reactions
Table 48 summarizes the numbers and percentages of subjects reporting at least one
injection-site adverse reaction from Day 1 to Day 5 following any dose of vaccine. The
most frequent injection-site reaction was injection-site pain, reported with similar
percentages for both vaccines. Injection-site swelling was more frequently reported with
9vHPV (47.8%) compared with qHPV (36.0%), with a risk difference of 11.8% [95% CI:
(3.9, 19.6)]. Other injection-site reactions were similar between the two groups in terms
of frequencies and severity. No injection site bruising or mass was reported in either
group.
Injection-site reactions were overall reported with the same frequency after each dose.
Consistent with the results observed in Studies V503-001 and V503-002, injection site
swelling and erythema tended to be more frequent after Dose 2 and Dose 3.
Table 48: Injection-Site Adverse Reactions Reported 1 to 5 days Post-Vaccination at a
Frequency of ≥1% (Study V503-009 Safety Population)
Adverse Reactions Intensity
9vHPV (N=299)
qHPV (N=300)
n (%)
n (%)
All Injection Site
Total
267(89.3)
265 (88.3)
Reactions
Mild
139 (46.5)
157 (52.3)
Moderate
111 (37.1)
96 (32.0)
Severe
17 (5.7)
12 (4.0%)
Erythema
Total
102 (34.1)
88 (29.3)
Mild
86 (28.8)
67 (22.3)
Moderate
11 (3.7)
15 (5.0)
Severe
5 (1.6)
6 (2.0)
Hematoma
Total
11 (3.7)*
14 (4.7)
Mild
10 (3.3)
12 (4.0)
Moderate
0 (0.0)
0 (0.0)
Hemorrhage
Total
3 (1.0)
6 (2.0)
Mild
3 (1.0)
5 (1.7)
Moderate
0 (0.0)
1 (0.3)
Induration
Total
6 (2.0)
3 (1.0)
Mild
2 (0.7)
2 (0.7)
Moderate
4 (1.3)
1 (0.3)
Pain
Total
267 (89.3)
265 (88.3)
Mild
142 (47.5)
158 (52.7)
Moderate
108 (36.1)
97 (32.3)
Severe
17 (5.7)
10 (3.3)
Pruritus
Total
12 (4.0)
8 (2.7)
Mild
8 (2.7)
6 (2.0)
Moderate
4 (1.3)
1 (0.3)
Severe
0 (0.0)
1 (0.3)

Page 93

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Adverse Reactions

Intensity

Reaction

Total
Mild
Moderate
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe

Swelling

Warmth

9vHPV (N=299)
n (%)
1 (0.3)
0 (0.0)
1 (0.3)
143 (47.8)
100 (33.4)
25 (8.4)
18 (6.0)
2 (0.7)
2 (0.7)
0 (0.0)
0 (0.0)

qHPV (N=300)
n (%)
3 (1.0)
3 (1.0)
0 (0.0)
108 (36.0)
68 (22.7)
21 (7.0)
19 (6.3)
5 (1.7)
3 (1.0)
1 (0.3)
1 (0.3)

Source: Generated by CBER reviewer from STN 125508/0, Module 5.3.5.1.p009_CSR, Tables
14.48 (p175-6) and 14.49 (p177).
N=Number of subjects vaccinated, n=number of subjects with the respective events.
*Missing intensity data for one subject.

Systemic Adverse Events
Systemic adverse events, regardless of assessed causality, were reported for 47.5% of
the 9vHPV recipients and 52.0% of qHPV recipients. Table 49 summarizes the
proportions of subjects (≥ 1% in either treatment group) with systemic adverse events
from Day 1 to Day 15 following any dose of vaccine that were considered to be vaccinerelated by the reporting investigators. The most frequently reported systemic adverse
reactions were headache, pyrexia, nausea and orpharyngeal pain. There were no
statistically significant differences between 9vHPV and qHPV in vaccine-related
systemic adverse reactions except for fatigue, which was more frequent in the qHPV
group.
Table 49: Summary of Vaccine-Related Systemic Adverse Reactions Reported at A
Frequency of ≥ 1% in at Least One Group from Day 1 to Day 15 Following Any Dose
(Study V503-009 Safety Population)
Adverse Reactions
9vHPV (N=299)
qHPV (N=300)
n (%)
n (%)
Total vaccine-related systemic adverse
62 (20.7)
73 (24.3)
reactions
Abdominal pain upper
5 (1.7)
4 (1.3)
Fatigue
0 (0.0)
8 (2.7)
Headache
34 (11.4)
34 (11.3)
Nausea
9 (3.0)
11 (3.7)
Oropharyngeal pain
8 (2.7)
2 (0.7)
Pyrexia
15 (5.0)
8 (2.7)
Upper respiratory tract infection
1 (0.3)
3 (1.0)
Source: Adapted STN 125508/0, Module 5.3.5.1.p009_CSR, Tables 12.9 (p92-3).
N=Number of subjects vaccinated, n=number of subjects with the respective events.

6.3.12.3 Deaths
No death was reported in this study.

Page 94

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.3.12.4 Nonfatal Serious Adverse Events
Three subjects (two in the qHPV group and one in the 9vHPV group) experienced SAEs
during the study (from Day 1 to Month 7), none assessed by the Investigator as vaccinerelated. The three cases are summarized below.
Subject AN 51204
Subject AN 51204, a 13-year-old white girl from Spain, developed pulmonary vasculitis
and anemia diagnosed approximately 2 months after receiving the second dose of
9vHPV on 23 June 2011. She had received a first dose of 9vHPV on 19 April 2011. The
subject was healthy, with no relevant medical family history. She had menarche in
December 2010, with cycles every 15-20 days, lasting approximately 5 days, with
profuse bleeding. She had been hospitalized in March 2011 for abdominal pain due to
ovarian cyst.
On 1 September 2011, the subject presented to medical attention with tiredness for
approximately four months, dyspnea for two months, tachycardia on slight exertion, and
appetite decrease with weight loss of 5 kg since the symptoms started. She had an
episode of fever (max. 39.5°C). Lab tests showed anemia. Chest X-ray showed baseline
multifocal disease with poorly defined “nodular” images in both the inferior lobes,
indicating edema or hemorrhage, with probable interstitial thickening. The subject was
hospitalized on 8 September 2011. Lab investigations on admission showed hemoglobin
8.4 g/dl, leukocytes 4,130/mm3 (59% neutrophils, 30% lymphocytes, 5.3% monocytes),
platelets 355,000/mm3, ESR 40 mm (the first hour), iron 31 mcg/dL, transferrin saturation
index 13%, and LDH 421 IU/l. Complement testing (C2, C3, C4, CH50) was within
normal range. Antinuclear Antibodies (ANA) were positive at 1/1280 as well as anti-DNA
antibodies; Anti-neutrophils cytoplasmic antibodies (ANCA), anti-proteinase 3,
antimyeloperoxidase, antireticulin, and anti-glomerular basement membrane antibodies
testing were all negative. Anti-transglutaminase and antiendomysial antibodies were
negative. Viral serology were negative (HBV, HCV, HIV, herpes simplex virus, CMV,
Adenovirus and Parvovirus B19). Chest CT scan showed extensive diffuse bilateral
opacities predominantly in the inferior lobes, and small parenchymatous consolidations
in both lung bases, also in the middle lobe. Lung function tests showed lung disorder of
restrictive nature consistent with the suspected diagnosis of vasculitis or hemosiderosis.
Fibrobronchoscopy showed that bronchial trees contained erythematous mucosa and
traces of blood, both old and recent, combined with small areas of inflammation of the
interalveolar septum (focal capillaritis).
The subject received oral ferrous sulphate, cyclophosphamide (planned for 6 courses)
and oral prednisone. During hospitalization, her condition gradually improved. She was
discharged on 5 October 2011. Final diagnosis was isolated pulmonary capillaritis with
positive ANA and multifactorial anemia. Anemia was mainly related to profuse menstrual
bleeding cycles before the current disease but was exacerbated by diffuse alveolar
hemorrhage secondary to main diagnosis. It was considered to be resolved on 5
December 2011 as the last hemoglobin (1 December 2011) was 13.8 g/dL. The latest
information received on March 2012 was that the subject was asymptomatic since 21
December 2011, considered as the date of resolution of the pulmonary vasculitis.
Thoracic CT-scan showed resolution of previous lesions. ANA: 1/1280 with anti-DNA
antibody: 25 (Normal: 0-10) on 12 September 2011; and ANA: 1/320 with anti-DNA

Page 95

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

antibody: 13 on 03 February 2012. The subject had received 5 courses of
cyclophosphamide. Prednisone was stopped on 23 February 2012.
The subject was withdrawn from the study due to adverse event, because the drug used
to treat pulmonary capillaritis was immunosuppressive.
According to the investigator, the diagnosis of diffuse alveolar hemorrhage secondary to
focal pulmonary capillaritis, together with the high level of antinuclear antibodies,
suggested an underlying connective tissue disease. Anemia was mainly related to
profuse menstrual bleeding cycles before the current disease but was exacerbated by
diffuse alveolar hemorrhage. The investigator assessed the relationship of both SAEs as
not vaccine-related.
Reviewer’s comments: This reviewer agrees with the reporting investigator that anemia
was most likely due to profuse menstrual bleeding.
An information request (IR) was sent to the Applicant on September 16, 2014 requesting
a rationale for assessing the pulmonary vasculitis as vaccine unrelated. On October 10,
2014, the Applicant submitted a response to STN 125508 and confirmed its assessment
that the event was unlikely related to the vaccine because the subject was ANA positive
before vaccination. Although the subject was ANA positive (ANA titer: 1/320) at
baseline, the ANA titer at the onset of pulmonary vasculitis increased to 1/1280, and was
reduced to the baseline level (i.e., 1/320) when symptoms resolved after treatment with
cyclophosphamide and prednisone. Based on the provided information, the condition
appears to have been preexisting. However, given that the subject became
symptomatic and her ANA titers increased post vaccination it is impossible to exclude
vaccine-induced exacerbation.
Subject AN 51128
Subject AN 51128, a 14-year-old white girl from Sweden, experienced partial complex
epilepsy 36 days after she had received her first dose of qHPV on 2 April 2011. The
subject had no familial history of neurological disease or epilepsy. On 08 May 2011, she
had a left-sided occipital headache after a run. She went to bed and was woken up by
her father about one hour later. He found that she had ‘aberrant rapport’, but thought
that this was due to the fact that she was half asleep. She slept for another hour and
when she woke up she still had a headache, vomited once and was dysphasic. When
she arrived at the Emergency Unit Care her condition worsened. She could not orientate
herself in time or place. The right pupil was dilated but reacted normally to light. She also
had episodes similar to apnea. She was admitted to the hospital. A CT scan of the skull,
MRI, chest X-ray and lumbar puncture were normal. EEG showed several short
seizures starting in the left temporal lobe but also regional slowing. She was treated with
Oxacarbezin. The subject's condition improved and she was discharged on 16 May
2011. She received her Dose 2 and Dose 3 of qHPV and did not experience any
adverse event. The latest information received on March 2012 was that the subject was
doing fine. She was still treated with Oxacarbezin and had no more seizures.
The Investigator assessed the event was not related to study vaccine or study
procedure.
Reviewer’s comments: This reviewer agrees with the reporting investigator that the
event was unlikely related to the qHPV vaccine based on a negative work-up that did not

Page 96

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

point to an inflammatory or immune mediated event that might implicate the vaccine and
based on the de novo presentation and unknown etiology of most epilepsy diagnoses.
Subject AN 50011
Subject AN 50011, a 12 year-old white girl from Finland, experienced a HenochSchönlein purpura of moderate intensity 46 days following administration of the second
dose of qHPV on 2 May 2011. The subject was healthy and was not taking any
concomitant treatment. On 15 June 2011 the subject had otitis media treated with
Amoxicillin trihydrate and ciproxinhydrocortison eardrops. On 17 June 2011 purpura and
swelling of lower limbs and hands were noticed. Amoxicillin and eardrops were stopped.
Then the subject complained of stomach pain and had diarrhea and arthralgia in elbow,
wrists and calves. She was hospitalized on 24 June 2011. Physical exam was normal
except tender calves. Lab tests showed leukocytosis at 14,000 with mainly neutrophils at
66%, hemoglobin at 145, CRP at 64 and normal thrombocytes value. Urine sample
showed 10 leukocytes and 5 erythrocytes per visual fields. The subject was treated with
cefuroxim with paracetamol for pain. On 26 June 2011 the urine culture did not show any
pathogens, and antibiotics were stopped. Urine albumin/creatinine ratio was (slightly)
increased at 5.42 mg/mmol. The subject was discharged in good general condition on 26
June 2011. Henoch-Schönlein purpura was diagnosed. On 7 July 2011 the subject still
had petechiae without other symptoms. Lab test showed 1 erythrocyte per visual fields.
Urine albumin/creatinine ratio was increased at 13.6 mg/mmol. She had two other site
visits on 18 August 2011 and 01 September 2011. On 10 November 2011 the subject
was considered as recovered, as her physical examination was normal as well as all lab
values. The subject was withdrawn from the study due to the serious adverse event.
The investigator assessed the adverse event as not related to study vaccine or
procedure.
Reviewer’s comments: Considering that about 50% of cases of Henoch-Schönlein
purpura are preceded by an upper respiratory infection, the otitis media preceding the
disorder is a much more likely etiology than qHPV. This reviewer concurs with the
investigator’s assessment of causality.
6.3.12.5 Adverse Events of Special Interest (AESI)
Overall 8 subjects presented with a new condition potentially indicative of an
autoimmune disorder: 3 subjects receiving 9vHPV vaccine and 5 subjects receiving
qHPV vaccine.
Subjects receiving 9vHPV vaccine:
• One subject (AN 51204) experienced an SAE considered of isolated pulmonary
capillaritis with positive ANA, which was diagnosed approximately two months
after the second dose of 9vHPV vaccine. The isolated pulmonary capillaritis was
considered not to be related to 9vHPV by the reporting investigator. As discussed
in Section 6.3.12.4 above, the pulmonary vasculitis was likely a pre-existing
condition. However, exacerbation by the vaccination could not be ruled out.
• Knee pain was reported for one subject (AN 51154) 33 days after Dose 1 and
joint pain in arms for one subject (AN 50113) 3 days after Dose 1. None of these
conditions were assessed as vaccine-related and the investigator did not
consider that they were autoimmune conditions. This reviewer concurs that knee

Page 97

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

pain and joint pain reported in these two subjects are unlikely autoimmune
conditions. Please refer to the Reviewer’s comments below.
Subjects receiving qHPV vaccine:
• One subject (AN 50011) experienced an SAE of Henoch-Schönlein purpura that
started 46 days after Dose 2. The narrative of this subject is presented in Section
6.3.12.4 above.
• Alopecia areata was reported in an 11-year old girl (AN 50205) 3 days after Dose
3 of qHPV vaccine. The event was of mild intensity, considered to be an
autoimmune condition and not related to qHPV by the Investigator. The subject
had not yet recovered at the end of the study. This reviewer concurs with the
investigator that alopecia areata is an autoimmune condition. However, this
reviewer considers the event as possibly related to the qHPV vaccine because of
the temporal association. In addition, alopecia areata was also reported in the
package insert of Gardasil, two cases of alopecia areata in Gardasil group
(N=3093) and none in placebo control group (N=2303).
• Knee pain was reported for subjects AN 51114 and AN 50270 at 14 days after
Dose 1 and 98 days after Dose 2, respectively, and was considered by the
investigator not to be vaccine-related.
• One subject (AN 51039) experienced arthralgia two days after Dose 3 of qHPV.
The event, of mild intensity, lasted 2 days and resolved, was considered by the
investigator to be vaccine related but not to be an autoimmune condition.
Reviewer’s comments: Some cases of knee pain or arthralgia reported in this study
were temporally associated with the vaccines. As described in the package insert of
Gardasil, the proportions of subjects with arthralgia among subjects who received
Gardasil and subjects who received placebo were similar [1.1% in Gardasil (N=10,706),
and 1.0% in placebo (N=9,412)]. Based on these results, this reviewer concurs that
arthralgia observed in this study is unlikely caused by the vaccines.
No allergic reactions were deemed related to the vaccine by the investigator. This
reviewer concurs with the assessment.
Six subjects experienced one episode of syncope or presyncope during the study,
including two episodes after 9vHPV vaccine and four episodes after qHPV vaccine. Of
them, three cases were considered by the investigator to be vaccine related (one in
9vHPV and two in qHPV group). All these events were of mild or moderate intensity, and
none led to discontinuation.
No pregnancies were reported during the course of the study. No syncope with fall
resulting in injury was reported in this study.
6.3.12.6 Clinical Test Results
No clinical laboratory parameters were analyzed for this study.
6.3.12.7 Dropouts and/or Discontinuations
Eleven subjects (1.8%) withdrew from the study, six in 9vHPV and five in qHPV groups.
Two subjects, one subject in each group, withdrew from the study due to AE. Please
refer to Section 6.3.12.4 for details.

Page 98

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

6.3.13 Study Summary and Conclusions
The study was conducted to provide a comparative assessment of the immunogenicity
and safety of 9vHPV versus qHPV in girls of 9 through 15 years of age.
A total of 600 girls were enrolled to receive 3 doses of either 9vHPV or qHPV, at Day 1,
Months 2 and 6. Post-vaccination anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 antibody
titers were evaluated one month after the third dose of study vaccine by cLIA in the per
protocol immunogenicity analysis population.
The primary objective, non-inferiority of anti-HPV 16 and 18 antibodies following 9vHPV
compared with qHPV, was demonstrated since the lower bound of the two-sided 95% CI
of the GMT ratio was greater than 0.67 for both HPV types. In addition, GMTs for antiHPV 6 and 11 antibodies were non-inferior for 9vHPV compared with qHPV.
The overall safety profile of 9vHPV was similar to that of qHPV with the exception of
injection-site swelling (reported by 47.8% of 9vHPV recipients vs. 36.0% of qHPV
recipients, p<0.05). Importantly, most events of injection-site swelling were mild or
moderate in intensity, and the number of subjects reporting severe injection-site swelling
was similar in the two groups. Three subjects reported serious adverse events, two of
which (1 in each treatment group) were auto-immune in nature and possibly vaccine
related.
In conclusion, the immunogenicity data from this study further support the effectiveness
of 9vHPV in girls 9 through 15 years of age with respect to prevention of disease due to
HPV types 6, 11, 16, and 18, while the safety profile of 9vHPV vaccine in this population
is similar qHPV and to the safety profile of 9vHPV observed in the other studies
reviewed in this submission.
7. INTEGRATED OVERVIEW OF EFFICACY
7.1 Indication #1
The 9vHPV vaccine is indicated in girls and women 9 through 26 years of age for the
prevention of the following diseases caused by HPV types included in the vaccine:
• Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16, 18, 31, 33,
45, 52, and 58.
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18,
31, 33, 45, 52, and 58:
• CIN 2/3 and AIS
• CIN 1
• VIN 2/3
• VaIN 2/3
• VIN 1 and VaIN 1
• AIN 1, 2 and 3
The 9vHPV vaccine is indicated in boys 9 through 15 years of age for the prevention of
the following diseases caused by HPV types included in the vaccine:
• Anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11.

Page 99

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16,
18, 31, 33, 45, 52, and 58:
• AIN Grades 1, 2 and 3
Reviewer’s comment: The Applicant did not conduct a study assessing the efficacy of
9vHPV in preventing anal lesions. Effectiveness of GARDASIL 9 against anal lesions
was inferred from the efficacy of GARDASIL against anal lesions caused by HPV types
6, 11, 16 and 18 in men and antibody responses elicited by GARDASIL 9 against the
HPV types covered by the vaccine, which was agreed upon by CBER in pre-submission
discussions. Please refer to Section 2.5.1.4 for Reviewer’s Comments regarding this
issue.
7.1.2 Demographics and Baseline Characteristics
Table 50 presents the basic characteristics of subjects enrolled in the clinical
development program for 9vHPV by age group and gender.
For all three populations, the most common race was White, and subjects were mostly of
non-Hispanic/Latino ethnicity. Furthermore, the most common regions were Europe,
Latin America and North America. Compared with the adult population, the younger
female population on average included a higher percentage of White subjects and less
subjects of Hispanic or Latino ethnicity. The younger female subjects also were less
likely to be from Latin America. Compared with the adult population, the younger male
population on average included less subjects of Hispanic or Latino ethnicity, and the
regional mix was slightly different with somewhat more subjects from Asia-Pacific and
North America and fewer subjects from Europe and Latin America.
Table 50: Subject Characteristics in the Immunogenicity Population of 9vHPV Program
(Studies V503-001, -002, -005, -007, and -009)
Subjects in population
Gender
Male
Female

Age (Years)
Mean ± SD
Median
Range
Race
White
Black
Asian
Other
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
NULL

16-26 y/o Women
N (%)
7264

1

9-15 y/o Girls
N (%)
2764

2

3

9-15 y/o Boys
N (%)
1218
1218 (100.0)

7264 (100.0)

2764 (100.0)

22 ± 2
22
16 to 26

12 ± 2
12
9-15

12 ± 2
12
9-15

4004 (55.1)
281 (3.9)
1108 (15.3)
1871 (25.8)

1749 (63.3)
182 (6.6)
425 (15.4)
408 (14.8)

665 (54.6)
60 (4.9)
199 (16.3)
294 (24.1)

2,526 (34.8)
4,737 (65.2)
1 (<0.1)

750 (27.1)
2014 (72.9)

381 (31.3)
837 (68.7)

Page 100

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
16-26 y/o Women
N (%)

1

9-15 y/o Girls
N (%)

2

3

9-15 y/o Boys
N (%)

Region
Africa
40 (0.6)
95 (3.4)
30 (2.5)
Asia-Pacific
993 (13.7)
413 (14.9)
194 (15.9)
Europe
2531 (34.8)
1102 (39.9)
373 (30.6)
Latin America
2319 (31.9)
545 (19.7)
286 (23.5)
North America
1381 (19.0)
609 (22.0)
335 (27.5)
Source: Adapted from STN 125508/0.43_Module 1.11.3, Table 14-16 (p49-51).
Note: For Protocol 005 and 007, subjects in the concomitant groups were excluded.
1
Data from Protocol 001 and 002
2
Data from Protocol 002, 005, 007 and 009
3
Data from Protocol 002, 005, and 007

7.1.3 Subject Disposition
Table 51 presents subject disposition for subjects enrolled in the clinical development
program for 9vHPV by age group and gender. Overall, over 96% of vaccinated subjects
completed the vaccination phase of the studies (i.e., received all 3 vaccinations) in each
of these three populations. Overall, 353 subjects discontinued from vaccination or from
study participation during the vaccination period, and 8 subjects discontinued from the
studies due to adverse events (please refer to the discussions in the individual studies).
The most common reasons for discontinuation were withdrawal of consent or subjects
being lost to follow-up.
Table 51: Disposition of Subjects in Immunogenicity Population (Protocol 001, 002, 005,
007 and 009)1
Population and Disposition
16-26 y/o Women2 9-15 y/o Girls3
9-15 yo Boys4
N (%)
N (%)
N (%)
Subjects in Population
7264
2764
1218
Vaccinated at
Dose 1
7255 (99.9)
2760 (99.9)
1214 (99.7)
Dose 2
7172 (98.7)
2721 (98.4)
1191 (97.8)
Dose 3
7087 (97.6)
2704 (97.8)
1182 (97.0)
Completed
7,012 (96.5)
2675 (96.8)
1174 (96.4)
Discontinued (Total)
Due to Adverse Event
Lost to Follow up
Physician Decision
Pregnancy
Protocol Violation
Withdrawal by Subject

244 (3.4)
5 (0.1)
124 (1.7)
4 (0.1)
0 (0.0)
6 (0.1)
105 (1.4)

68 (2.5)
1 (0.0)
28 (1.0)
1 (0.0)
1 (0.0)
2 (0.1)
35 (1.3)

41 (3.4)
2 (0.2)
14 (1.1)
0 (0.0)
1 (0.1)
24 (2.0)

Unknown5

8 (0.1)

21 (0.8)

1 (0.1)

Source: Adapted from STN 125508/0.43, Module 1.11.3, Tables 17-19 (p52-54).
Note: For Protocol 005 and 007, subjects in the concomitant groups were excluded.
1
For Protocol 002 the disposition records were collected Day 1 through Month 12, for all other
protocols, the records were collected Day 1 through Month 7.
2
Data from Protocol 001 and 002
3
Data from Protocol 002, 005, 007 and 009
4
Data from Protocol 002, 005, and 007
5
Unknown: A disposition record did not exist at the time of reporting

Page 101

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

7.1.4 Analysis of Primary Endpoint(s)
7.1.4.1 Efficacy Endpoint Analyses
Protocol 001 (V503-001) was the only study that examined histopathologic endpoint
efficacy data, which is reviewed in Section 6.1. Therefore, there is no integrated analysis
of efficacy.
7.1.4.2 Integrated Analyses of 9vHPV Immunogenicity in 16 through 26 Year-old Women
and 9 through 15 Year-old Males and Females
The primary immunogenicity endpoints were antibody GMTs at Month 7 (4 weeks postdose 3) corresponding to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The
secondary immunogenicity endpoints were the Month 7 seroconversion rates for each of
HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. A subject with a cLIA titer at or above
the serostatus cutoff for a given HPV type was defined as seropositive for that HPV type
(or seroconverted if baseline titers were below the cutoff). The seropositivity cutoffs for
HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were 30, 16, 20, 24, 10, 8, 8, 8, and 8
mMU/mL, respectively.
The PPI populations from Studies V503-001, -002,-005, -007, and -009 (except subjects
in the concomitant vaccination groups in Studies 005 and 007) were pooled together as
an integrated PPI population for comparison of immunogenicity between subgroups.
Table 52 summarizes the anti-HPV responses in the integrated PPI population across
protocols at Month 7 in terms of antibody GMTs and seroconversion rates by HPV types,
ages and genders.
The seroconversion rates for each HPV type at Month 7 were generally similar. At least
99.6% of subjects in the integrated PPI population were seropositive for the respective
vaccine HPV type at 4 weeks post-dose 3 in all three demographic cohorts.
Both females and males 9 through 15 years of age had higher GMTs for each vaccine
HPV type compared with females 16 through 26 years of age. Males 9 through 15 years
of age tended to have higher GMTs than females in the same age group.
Reviewer’s comments: The difference in immunogenicity of 9vHPV between children
(boys and girls 9 through 15 years of age) and young women 16 through 26 years of age
is unlikely caused by the difference in demographics between the young male population
and the adult women population. As shown in Section 7.1.7.2 (subgroup analyses), the
anti-HPV antibody responses among race, ethnic group and geographic region are
similar, and antibody responses in the younger population, regardless of gender, are
higher than in the older population.
For all three cohorts, antibody GMTs at Month 7 were generally consistent within the
same cohorts among the different protocols, with variations no greater than 15%.
Table 52: Summary of Month 7 Anti-HPV Antibody Responses in the PPI1 Population
Across Studies (V503-001, -002, -005, -007, and -009)
Population
N2
n3
GMT
% Seroconversion
(95%CI) mMu/ml
(95% CI)

Page 102

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Population

N2

n3

GMT
(95%CI) mMu/ml

% Seroconversion
(95% CI)

Anti-HPV 6
9-15 Year-old Girls
2760 2306
1745.0 (1684.4, 1807.8) 99.7 (99.4, 99.9)
9-15 year-old Boys
1214 1033
2087.4 (1982.0, 2192.6)
99.9 (99.5, 100)
16-26 Year-old
7255 4321
893.7 (873.5, 914.3)
99.8 (99.6, 99.9)
Women
Anti-HPV 11
9-15 Year-old Girls
2760 2307
12905 (1244.6, 1338.0)
99.9 (99.7, 100)
9-15 year-old Boys
1214 1033
1468.4 (1395.9, 1544.7)
100 (99.7, 100)
16-26 Year-old
7255 4327
669.3 (653.6, 685.4)
100 (99.9, 100)
Women
Anti-HPV 16
9-15 Year-old Girls
2760 2362
7154.7 (6912.8, 7405.0) 99.9 (99.7, 100)
9-15 year-old Boys
1214 1053
8468.3 (8071.1, 8885.0)
100 (99.6, 100)
16-26 Year-old
7255 4361
3159.0 (3088.6, 3231.1)
100 (99.9, 100)
Women
Anti-HPV 18
9-15 Year-old Girls
2760 2376
2087.6 (2003.6, 2175.0) 99.9 (99.6, 100)
9-15 year-old Boys
1214 1051
2631.7 (2483.2, 2789.2)
100 (99.6, 100)
16-26 Year-old
7255 4884
809.9 (789.2, 831.1)
99.8 (99.7, 99.9)
Women
Anti-HPV 31
9-15 Year-old Girls
2760 2354
1888.7 (1815.9, 1964.3) 100 (99.6, 100)
9-15 year-old Boys
1214 1048
2189.8 (2070.9, 2315.5)
100 (99.7, 100)
16-26 Year-old
7255 4806
664.8 (647.4, 682.6)
99.8 (99.6, 99.9)
Women
Anti-HPV 33
9-15 Year-old Girls
2760 2373
965.0 (931.6, 999.6)
99.9 (99.7, 100)
9-15 year-old Boys
1214 1053
1182.6 (1124.0, 1244.4) 100 (99.7, 100)
16-26 Year-old
7255 5056
419.2 (409.6, 429.1)
99.7 (99.5, 99.8)
Women
Anti-HPV 45
9-15 Year-old Girls
2760 23851056 729.6 (698.2, 762.5)
99.8 (99.6, 100)
9-15 year-old Boys
1214 5160
842.7 (790.4, 898.5)
100 (99.7, 100)
16-26 Year-old
72
254.1 (247.0, 261.5)
99.6 (99.4, 99.7)
Women
Anti-HPV 52
9-15 Year-old Girls
2760 2381
981.8 (946.0, 1018.9)
99.9 (99.7, 100)
9-15 year-old Boys
1214 1054
1072.0 (1015.9, 1131.3) 100 (99.7, 100)
16-26 Year-old
7255 4792
382.4 (373.0, 392.0)
99.8 (99.6, 99.9)
Women
Anti-HPV 58
9-15 Year-old Girls
2760 2353
1309.2 (1262.5, 1357.6) 99.9 (99.7, 100)
9-15 year-old Boys
1214 1050
1558.3 (1481.7, 1638.9) 100 (99.6, 100)
16-26 Year-old
7255 4818
489.2 (477.5, 501.2)
99.8 (99.6, 99.9)
Women
Source: Generated by the clinical reviewer from STN 125508/0.43, Module 1.11.3_Tables 20-22
(p55-62)
1
PPI population consisted of all individuals who received all 3 doses of 9vHPV, did not have
major protocol deviations, and were naïve (PCR negative and seronegative) to the relevant HPV
types prior to dose 1 and PCR negative from Day 1 through 1 month after dose 3.
2
N=Number of subjects who were randomized to the respective group and received at least one
injection.
3
n=Number of subjects who contributed to the analysis (i.e., PPI).

Page 103

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comment: The number of subjects contributing to each category of the
integrated analyses varies depending on the baseline status of HPV positivity for each
HPV type.
7.1.5 Analysis of Secondary Endpoint(s)
Please refer to Section 7.1.4 for the results of seroconversion rates (the secondary
endpoints).
7.1.6 Other Endpoints
7.1.6.1 Study of 9vHPV Immunogenicity in Prior Gardasil Recipients (Study V503-006,
Designated as Study 4 in the Draft Packaging Insert)
A phase 3 randomized, international, placebo-controlled, double-blind clinical trial was
conducted to assess the tolerability and immunogenicity of 9vHPV in females 12-26
years of age who had previously received qHPV.
The number of subjects enrolled in this study was 924: 618 subjects randomized to
9vHPV and 306 subjects randomized to placebo. The two vaccination groups were well
balanced with respect to the demographic characteristics. The mean age of randomized
subjects was 19 years. All subjects were between 12 and 26 years of age as specified in
the protocol, including 182 subjects 12 to 15 years of age, and 742 subjects 16 through
26 years of age. The geographic locations indicated that 44.2% were from Europe,
32.0% were from North America, 18.5% were from Latin America, and 5.3% of the
subjects were from the Asia-Pacific region. The largest race/ethnicity category was
White (77.3%) followed by Multi-racial (16.1%), Asian (5.8%), Black or African American
(0.6%), and American Indian or Alaska Native (0.1%).
Table 53 presents a summary by vaccination group of anti-HPV 6, 11, 16, 18, 31, 33, 45,
52, and 58 antibody GMTs at Day 1, Month 2, and Month 7, with associated 95% CI’s.
The results show that antibody GMTs for HPV types 6, 11, 16, and 18 increased
substantially following the first vaccination with 9vHPV but did not change much with
further vaccinations. Antibody GMTs for HPV types 31, 33, 45, 52, and 58 increased
substantially following each of the first and third vaccinations in the 9vHPV vaccine
group, while antibody GMTs for subjects in the placebo group remained around or below
the assay limits of detection. The highest antibody GMTs for HPV types 6, 11 and 16
were observed at Month 2 in all vaccine groups. For the rest of the six HPV types, the
highest antibody GMTs were observed at Month 7.
The seroconversion rates for HPV types 31, 33, 45, 52 and 58 were all ≥98.3% with the
LB of the 95% CI ≥96.7% at one month after the third vaccination (data not shown). The
results met the pre-specified statistical criterion for success that the LB of the 95% CI for
seroconversion rate be greater than 90% for the five new HPV types.
Antibody GMTs were numerically higher in 12- to 15-year-old subjects than in 16- to 26year-old subjects at both Month 2 and Month 7 (data not shown), which is consistent
with other studies in this submission and with previous immunogenicity data for qHPV.

Page 104

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 53: Summary of Anti-HPV Antibody GMTs by Vaccination Group (Study V503006, Modified PPI Population)
Antibody
Assay
Anti-HPV 6

Time Point

9vHPV 9vHPV
Placebo Placebo
N
GMT (95% CI)
N
GMT (95% CI)
Day 1
499
348.2 (320.2, 378.8)
248
372.4 (330.6, 419.6)
Month 2
505
2426.7 (2254.2, 2612.3)
245
363.4 (326.9, 404.0)
Month 7
511
2207.4 (2052.7, 2373.9)
251
323.8 (291.9, 359.2)
Anti-HPV 11 Day 1
513
253.0 (232.3, 275.6)
261
263.6 (233.8, 297.1)
Month 2
511
2,077.8 (1,925.9, 2,241.6)
256
253.3 (227.6, 282.0)
Month 7
515
1,824.0 (1,695.5, 1,962.2)
261
225.4 (203.4, 249.7)
Anti-HPV 16 Day 1
513
1,066.1 (973.8, 1,167.1)
261
1,103.7 (972.2, 1,253.1)
Month 2
511
13,877.6 (12,846.3, 14,991.7) 256
1,076.1 (964.9, 1,200.1)
Month 7
515
11,192.8 (10,393.6, 12,053.6) 261
966.9 (871.3, 1,072.9)
Anti-HPV 18 Day 1
513
154.2 (135.4, 175.5)
261
136.1 (113.4, 163.2)
Month 2
511
2,187.9 (1,975.2, 2,423.5)
256
130.1 (112.6, 150.3)
Month 7
515
2,285.8 (2,067.4, 2,527.3)
261
112.8 (98.0, 129.9)
Anti-HPV 31 Day 1
513
4.1(<4, 4.5)
261
4.3 (<4, 5.0)
Month 2
511
201.1 (180.5, 224.0)
256
4.3 (<4, 5.0)
Month 7
515
260.0 (237.6, 284.5)
261
4.7 (4.1, 5.3)
Anti-HPV 33 Day 1
513
< 4 (<4, <4)
261
< 4 (<4, <4)
Month 2
511
70.0 (63.2, 77.4)
256
< 4 (<4, <4)
Month 7
515
175.2 (162.5, 188.9)
261
< 4 (<4, <4)
Anti-HPV 45 Day 1
513
< 3 (<3, <3)
261
< 3 (<3, <3)
Month 2
511
15.1 (13.5, 16.8)
256
< 3 (<3, <3)
Month 7
515
97.4 (89.8, 105.7)
261
< 3 (<3, <3)
Anti-HPV 52 Day 1
513
< 3 (<3, <3)
261
< 3 (<3, <3)
Month 2
511
56.0 (51.2, 61.2)
256
< 3 (<3, <3)
Month 7
515
264.1 (244.6, 285.1)
261
< 3 (<3, <3)
Anti-HPV 58 Day 1
513
< 4 (<4, <4)
261
< 4 (<4, <4)
Month 2
511
83.2 (76.4, 90.5)
256
< 4 (<4, <4)
Month 7
515
269.7 (250.8, 290.0)
261
< 4 (<4, <4)
Source: Adapted from STN 125508/0, Module 5.3.5.1.p006_ CSR, Table 10-11 (p118-120)
The modified PPI population includes all subjects who did not have general protocol violations, received all 3
vaccinations within acceptable day ranges, and had a Month 7 serum sample collected within an acceptable
day range.
The numbers of subjects who were randomized to 9vHPV and the placebo groups and received at least one
injection were 615 and 306, respectively. N = Number of subjects contributing to the analysis.

7.1.6.2 Antibody Responses to the 9vHPV vaccine among Prior qHPV Recipients (Study
V503-006) Compared with Subjects Naïve to HPV Vaccination (Studies V503-001, -002,
-005, -007 and -009)
Table 54 shows summaries of Month 7 anti-HPV antibody responses among 12 to 26
year-old females who had previously completed 3 doses of qHPV and received 9vHPV
in Protocol V503-006, compared with the same age group of HPV vaccine-naïve females
who received 9vHPV in Protocols V503-001, -002, -005 (non-concomitant arm), -007
(non-concomitant arm), and -009. Summaries are provided within two age strata (12- to
15-year-old and 16- to 26-year-old subjects).
• The 9vHPV vaccine was immunogenic, both in prior qHPV recipients and in
subjects naïve to HPV vaccination, as shown by high seroconversion rates
(>99%) for all vaccine HPV types.
• Anti-HPV 6, 11, 16, and 18 antibody GMTs following completion of the 9vHPV
vaccination series were greater in prior qHPV recipients than in subjects naïve to
HPV vaccination.

Page 105

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

•

Anti-HPV 31, 33, 45, 52, and 58 antibody GMTs following completion of the
9vHPV vaccination series were lower in prior qHPV recipients than in subjects
naïve to HPV vaccination

Table 54: Month 7 Anti-HPV Antibody Responses to 9vHPV in 12 to 26 Year Old Females
Comparing Prior qHPV Recipients to HPV Vaccine Naïve Subjects (Studies V503-001, 002, -005, -006, and -007, PPI Population)
Assay
Age
n1
Prior qHPV Recipients n2
Subjects Naïve to HPV
(cLIA)
Group
(N=615)1
Vaccine (N=8,761)2
GMT (95% CI)
GMT (95% CI)
Anti-HPV6
12 to 15 98
3209 (2708, 3802)
1278 1488 (1419, 1559)
16 to 26 413 2020 (1875, 2176)
4321 894 (873, 915)
Anti-HPV11 12 to 15 100 2747 (2319, 3255)
1279 1104 (1053, 1157)
16 to 26 415 1653 (1531, 1784)
4327 669 (654, 685)
Anti-HPV16 12 to 15 100 16122 (13740, 18918) 1305 6046 (5784, 6320)
16 to 26 415 10251 (9526, 11031)
4361 3159 (3088, 3231)
Anti-HPV18 12 to 15 100 3647 (2990, 4447)
1314 1700 (1610, 1796)
16 to 26 415 2043 (1870, 2232)
4884 810 (789, 831)
Anti-HPV31 12 to 15 100 423 (352, 510)
1302 1538 (1461, 1619)
16 to 26 415 231 (211, 253)
4806 665 (647, 683)
Anti-HPV33 12 to 15 100 256 (217, 302)
1319 822 (785, 860)
16 to 26 415 160(147, 174)
5056 419 (410, 429)
Anti-HPV45 12 to 15 100 148 (119, 183)
1321 591 (557, 627)
16 to 26 415 88 (80, 97)
5160 254 (247, 262)
Anti-HPV52 12 to 15 100 395 (331, 472)
1318 823 (784, 864)
16 to 26 415 240 (220, 261)
4792 382 (373, 392)
Anti-HPV58 12 to 15 100 425 (359, 503)
1300 1111 (1060, 1164)
16 to 26 415 242 (223, 262)
4818 489 (478, 501)
Source: Adapted from STN 125508/0_Module 2.7.3_Table 2.7.3-hpvdiseases: 132 & 134 (p398
and p400)
N=Subjects contributing to the analysis.
1
Data from Study V503-006.
2
Data from Studies V503-001, -002, -005, and -007.

Reviewer’s comment: Stronger responses to HPV types 6, 11, 16, and 18 in prior
qHPV vaccine recipients are consistent with an anamnestic response.
The clinical significance of lower responses to HPV 31, 33, 45, 52, and 58 in prior qHPV
recipients is not clear. The Applicant stated that within the range of anti-HPV responses
observed, vaccine efficacy was not correlated with Month 7 anti-HPV 31, 33, 45, 52, or
58 antibody titers. Specifically, 9vHPV prevented HPV 31, 33, 45, 52, and 58-related
persistent infection and disease in HPV vaccine naïve subjects with relatively low antiHPV 31, 33, 45, 52, or 58 levels at Month 7 [Section 2.7.3.2.1.9 of the ISE, p186]. The
Applicant speculated that the lower anti-HPV 31, 33, 45, 52, and 58 antibody responses
in prior qHPV vaccine recipients were not expected to negatively impact the efficacy of
the 9vHPV vaccine in that population. However, clinical efficacy data to confirm this
assertion in prior qHPV recipients are not presently available.

Page 106

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

7.1.7 Subpopulations
7.1.7.1 Subgroup Analyses of Clinical Efficacy
Subpopulation analyses were conducted based on the demographic and baseline
characteristics in PPE and HN-TS populations. The efficacy point estimates for each
subgroup in both PPE and HN-TS populations are relatively consistent (range from 87%
to 100%); the 95% CI vary greatly.
Please refer to Section 6.1.11.3 (subgroup analyses of efficacy) for details.
7.1.7.2 Subgroup Analyses of Immunogenicity
Impact of Race, Ethnicity and Geographic Region on Immunogenicity of 9vHPV in
16 through 26 Year-old Females
Table 55 and Table 56 present the Month 7 antibody GMTs against the original HPV
types and new HPV types, respectively, in 16 through 26 year-old females, by race,
ethnicity, region, and age.
Compared with the other ethnic groups, Asians had slightly lower anti-HPV 6 and 11
antibody responses and slightly higher anti-HPV 58 antibody responses; Blacks had
slightly higher anti-HPV 16, 18, 31, 45, and 52 antibody responses, and Caucasians had
slightly lower anti-HPV 18, 31, and 45 antibody responses. Hispanics or Latinos
generally (except for HPV 58) had slightly higher anti-HPV antibody responses
compared with other ethnicities.
Females in the 16-17 year of age category generally had higher anti-HPV antibody
responses than older subjects.

Page 107

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 55: Month 7 Anti-HPV 6, 11, 16 and 18 Antibody GMTs by Baseline Subject Characteristics Among 16 through 26 Year-old
Females Who Received 9vHPV in Protocols 001 and 002 (PPI Population)
Subgroup
Race
Asian
Black
Caucasian
Other
Ethnicity
Hispanic or
Latino
Not Hispanic or
Latino
Region
Africa
Asia-Pacific
Europe
Latin America
North America
Age (Years)
16 to 17
18 to 26

HPV 6
N

GMT (95% CI)

HPV 11
n

GMT (95% CI)

HPV 16
n

GMT (95% CI)

HPV 18
n

GMT (95% CI)

763
123
2,415
1,020

837 (793, 884)
935 (817, 1,071)
895 (869, 923)
929 (887, 974)

764
122
2,421
1,020

595 (562, 629)
670 (582, 772)
691 (670, 713)
678 (645, 712)

792
152
2,361
1,056

3,071 (2,913, 3,238)
3,984 (3,532, 4,494)
3,078 (2,985, 3,173)
3,308 (3,160, 3,462)

831
170
2,669
1,214

851 (799, 906)
995 (867, 1,142)
756 (730, 782)
886 (842, 933)

1,415

937 (900, 975)

1,415

687 (659, 716)

1,452

3,335 (3,207, 3,468)

1,668

873 (836, 913)

2,906

873 (850, 898)

2,912

661 (642, 680)

2,909

3,075 (2,991, 3,161)

3,216

779 (755, 804)

16
691
1,454
1,292
868

1,030 (709, 1,496)
818 (773, 866)
851 (818, 885)
947 (908, 987)
953 (906, 1,003)

15
692
1,458
1,458
870

764 (511, 1,143)
589 (555, 625)
660 (634, 688)
686 (657, 716)
730 (692, 769)

20
722
1,412
1,336
871

5,218 (3,747, 7,267)
2,943 (2,785, 3,110)
2,929 (2,816, 3,047)
3,355 (3,222, 3,494)
3,413 (3,246, 3,589)

21
758
1,604
1,537
964

1,377 (930, 2,038)
827 (775, 883)
714 (683, 747)
888 (848, 929)
838 (791, 888)

135
4,186

1,106 (973, 1,259)
888 (867, 908)

136
4,191

838 (733, 958)
664 (649, 681)

148
4,213

4,056 (3,590, 4,583)
3,131 (3,061, 3,204)

150
4,734

1,052 (908, 1,219)
803 (782, 825)

Source: Adapted from STN125508/0_Module 2.7.3_Table 2.7.3-hpvdiseases: 81 (p280-281)

Page 108

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 56: Month 7 Anti-HPV 31, 33, 45, 52 and 58 Antibody GMTs by Baseline Subject Characteristics Among 16 through 26 Yearold Females Who Received 9vHPV in Protocols 001 and 002 (PPI Population)
Subgroup
Race
Asian
Black
Caucasian
Other
Ethnicity
Hispanic or Latino
Not Hispanic or
Latino
Region
Africa
Asia-Pacific
Europe
L. America
N. America
Age (Years)
16 to 17
18 to 26

HPV 31
N

GMT (95% CI)

HPV 33
n

GMT (95% CI)

HPV 45
n

GMT (95% CI)

HPV 52
N

GMT (95% CI)

HPV 58
n

GMT (95% CI)

858
169
2631
1141

711 (668, 757)
786 (683, 906)
621 (598, 642)
725 (687, 765)

865
189
2733
1278

420 (397, 445)
415 (368, 468)
417 (404, 431)
424 (405, 444)

885
190
2824
1261

281 (263, 301)
345 (298, 400)
227 (219, 236)
290 (274, 307)

788
166
2690
1148

354 (333, 376)
444 (388, 508)
388 (376, 401)
381 (362, 401)

814
161
2720
1123

520 (491, 552)
493 (432, 563)
484 (468, 499)
481 (457, 506)

1579

718 (685, 752)

1752

428 (412, 446)

1747

285 (271, 299)

1597

390 (373, 407)

1554

482 (462, 503)

3227

640 (620, 661)

3304

415 (403, 427)

3413

240 (232, 248)

3195

379 (367, 391)

3264

493 (478, 507)

23
785
1584
1454
960

986 (674, 1444)
674 (631, 719)
579 (553, 606)
726 (692, 761)
717 (676, 761)

18
782
1635
1616
1005

443 (300, 653)
407 (384, 432)
397 (381, 413)
429 (412, 447)
451 (428, 475)

24
810
1714
1604
1008

518 (343, 782)
268 (249, 287)
208 (198, 218)
291 (277, 306)
272 (255, 290)

20
717
1620
1465
970

553 (377, 812)
341 (319, 363)
365 (350, 381)
391 (374, 409)
432 (409, 457)

15
743
1647
1425
988

707 (458, 1091)
497 (468, 529)
468 (449, 488)
483 (462, 505)
527 (500, 556)

153
4,653

967 (833, 1121)
657 (639, 675)

158
4,898

506 (444, 577)
417 (407, 427)

156
5004

343 (292, 404)
252 (245, 259)

152
4640

487 (424, 560)
379 (370, 389)

150
4668

629 (548, 721)
485 (474, 497)

Source: Adapted from STN125508/0_Module 2.7.3_Table 2.7.3-hpvdiseases: 82 (p282-283)

Page 109

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Compared with other regions, subjects from the Asia-Pacific region had slightly lower
anti-HPV 6 and anti-HPV 11 antibody responses, while subjects from Europe had slightly
lower anti-HPV 18 and anti-HPV 31 antibody responses (and to lesser degree anti-HPV
58 antibody responses). Subjects from Latin America and North America had generally
higher anti-HPV antibody responses compared to other regions (except for Africa).
Subjects from Africa were few, and those available had generally the highest anti-HPV
antibody responses compared with other regions.
Impact of Race, Ethnicity and Geographic Region on Immunogenicity of 9vHPV in
9 through 15 Year-old Females
The subgroup analyses for 9 through 15 year-old females are shown in Table 57 (for
HPV 6, 11, 16 and 18) and Table 58 (for HPV31, 33, 45, 52 and 58)
Females 9 to 12 years of age generally had higher anti-HPV antibody responses than 13
to 15 year-old females.
Compared with the other ethnic groups, Asians had slightly lower anti-HPV 11 and antiHPV 52 antibody responses. Blacks had the highest antibody responses especially for
anti-HPV 18, and anti-HPV 52 antibodies, and Caucasians had slightly lower anti-HPV
45 antibody responses. Hispanics or Latinos generally (except for HPV type 58) had
slightly higher anti-HPV antibody responses compared with other ethnicities.
Compared with subjects from Latin America, North America and Africa, subjects from
Asia-Pacific and Europe tended to have lower antibody responses across HPV types.
For HPV types 18 and 45, subjects from Europe had somewhat lower antibody
responses than other regions. The highest antibody titers tended to be among subjects
from North America.

Page 110

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 57: Month 7 Anti-HPV 6, 11, 16 and 18 Antibody GMTs by Baseline Subject Characteristics in 9 through 15 Year-old Females
Who Received 9vHPV in Protocols 002, 005, 007 and 009 (PPI Population)
Subgroup
Race
Asian
Black
Caucasian
Other
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
Region
Africa
Asia-Pacific
Europe
Latin America
North America
Age (Years)
9 to 12
13 to 15

HPV 6
N

GMT (95% CI)

HPV 11
n

GMT (95% CI)

HPV 16
n

GMT (95% CI)

384
136
1427
360

1544 (1417, 1683)
2128 (1841, 2458)
1698 (1624, 17765)
2055 (1880, 2246)

383
136
1428
360

1078 (987, 1177)
1596 (1376, 1851)
1284 (,227, 1344)
1472 (1344, 1612)

392
142
1463
365

639 (5922, 7001)
9698 (8438, 11147)
6827 (6537, 7130)
8588 (7874, 9368)

392145
1467
372

2056 (1860, 2273)
3042 (2579, 3589)
1926 (1829, 2029)
2516 (2269, 2789)

606
1700

1811 (1690, 1940)
1722 (1652, 1795)

606
1701

1318 (1229, 1415)
1281 (1228, 1336)

623
1739

7497 (7011, 8017)
7036 (6760, 7323)

630
1746

2121 (1958, 2298)
2076 (1979, 2177)

73
373
932
460
468

1785 (1468, 2170)
1527 (1400, 1665)
1541 (1459, 1628)
1944 (1798, 2101)
2227 (2062, 2406)

73
373
933
460
468

1385 (1134, 1693)
1069 (978, 1168)
1173 (1109, 1241)
1407 (1299, 1524)
1647 (1522, 1783)

78
382
955
469
478

8670 (7197, 10445)
6367 (5854, 6925)
6159 (5840, 6495)
8157 (7561, 8801)
9029 (8375, 9735)

79
382
957
474
484

2870 (2298, 3583)
2036 (1841, 2251)
1706 (1601, 1819)
2389 (2182, 2616)
2639 (2413, 2887)

1470
836

2027 (1942, 2116)
1341 (1266, 1420)

1471
836

1492 (1428, 1561)
998 (941, 1058)

1511
851

8424 (8081, 8781)
5354 (5065, 5659)

1521
855

2530 (2407, 2658)
1484 (1389, 1585)

Source: Adapted from STN125508/0.43, Module 1.11.3 _Table 25 (p67-68)

Page 111

HPV 18
n

GMT (95% CI)

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 58: Month 7 Anti-HPV 31, 33, 45, 52 and 58 Antibody GMTs by Baseline Subject Characteristics in 9 through 15 Year-old
Females Who Received 9vHPV in Protocols 002, 005, 007 and 009 (PPI Population)
Subgroup
Race
Asian
Black
Caucasian
Other
Ethnicity
Hispanic or
Latino
Not Hispanic
or Latino
Region
Africa
Asia-Pacific
Europe
L. America
N. America
Age (Years)
9 to 12
13 to 15

HPV 31
n

GMT (95% CI)

HPV 33
n

GMT (95% CI)

HPV 45
n

GMT (95% CI)

HPV 52
n

GMT (95% CI)

HPV 58
n

GMT (95% CI)

385
144
1459
366

1809 (1643, 1992)
2604 (2224, 3049)
1759 (1674, 1848)
23152 (2097, 2556)

392
147
1466
368

877 (804, 956)
1178 (1022, 357)
935 (894, 978)
1118 (1023, 1223)

395
148
1469
373

790 (710, 880)
1099 (923, 1309)
645 (610, 681)
928 (831, 1036)

392
147
1469
373

852 (778, 933)
1292 (1114, 1500)
966 (921, 1012)
1092 (995, 1199)

389
147
1448
369

1241 (1135, 1357)
1519 (1313, 1757)
12818 (1223, 1342)
1423 (1298, 1559)

632

1976 (1831, 2133)

627

1003 (937, 1075)

632

765 (703, 834)

631

979 (911, 1053)

623

1252 (1167, 1344)

1731

1858 (1775, 1945)

1746

952 (913, 992)

1753

717 (681, 755)

1750

983 (941, 1026)

1730

1330 (1275, 1388)

79
375
947
468
485

2546 (2060, 3145)
1783 (1619, 1965)
1580 (1486, 1679)
2150 (1971, 2345)
2352 (2160, 2562)

79
382
955
472
485

1037 (856, 1255)
865 (793, 943)
839 (794, 886)
1075 (994, 1162)
1234 (1143, 1333)

80
385
956
475
489

1044 (824, 1322)
781 (7001, 870)
574 (536, 615)
864 (784, 952)
885 (805, 974)

80
382
957
474
488

1255 (1027, 1533)
840 (767, 920)
879 (830, 932)
1450 (967, 1140)
1239 (1143, 1344)

79
379
938
470
487

1342 (1102, 1634)
1224 (1119, 1338)
1175 (1109, 1243)
1352 (1247, 1466)
1642 (1517, 1778)

1505
849

2252 (2147, 2362)
1383 (1298, 1473)

1514
859

1112 (1065, 1161)
752 (710, 796)

1524
861

880 (834, 928)
524 (488, 563)

1524
857

1153 (1102, 1206)
738 (695, 784)

1506
847

1517 (1452, 1586)
1007 (949, 1068)

Source: Adapted from STN125508/0.43, Module 1.11.3 _Table 26 (p69-70)

Page 112

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Impact of Race, Ethnicity and Geographic Region on Immunogenicity of 9vHPV in
9 through 15 Year-old Males
Table 59 and Table 60 display summaries of the Month 7 antibody GMTs against the
original HPV types and the new HPV types, respectively, in 9 through 15 year-old males
by race, ethnicity, region, and age.
Compared with the other ethnic groups, Asians had the lowest antibody responses
across HPV types, except for HPV type 45. Blacks had slightly higher anti-HPV 16, antiHPV 45 and anti-HPV 52 antibody responses, and Caucasians generally had antibody
responses in-between other ethnic groups. Hispanics or Latinos generally had slightly
higher anti-HPV antibody responses compared to other subjects.
Compared with subjects from Latin America, North America and Africa, subjects from
Asia-Pacific and Europe had lower antibody responses across HPV types. For HPV
types 18 and 45, subjects from Europe had somewhat lower antibody titers than subjects
from other regions.
Males 9-12 years of age category generally had higher anti-HPV antibody responses
than older subjects.

Page 113

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 59: Month 7 Anti-HPV 6, 11, 16 and 18 Antibody GMTs by Baseline Subject Characteristics in 9 through 15 Year-old Males
Who Received 9vHPV in Protocols 002, 005 and 007 (PPI Population)
Subgroup
Race
Asian
Black
Caucasian
Other
Ethnicity
Hispanic or Latino
Not Hispanic or Latino
Region
Africa
Asia-Pacific
Europe
Latin America
North America
Age (Years)
9 to 12
13 to 15

HPV 6
N

GMT (95% CI)

HPV 11
n

GMT (95% CI)

HPV 16
n

GMT (95% CI)

HPV 18
n

GMT (95% CI)

185
39
560
249

1755 (1558, 1975)
2025 (1566, 2619)
2065 (1930, 22109)
2432 (2197, 2692)

185
39
560
249

1184 (1052, 1333)
1438 (1111, 1862)
1517 (1417, 1624)
1607 (1451, 1780)

190
44
567
252

7606 (6800, 8510)
10145 (8042, 12799)
8027 (7524, 8564)
10035 (9107, 11058)

188
44
566
253

2478 (2161, 2841)
2958 (2230, 3924)
2485 (2297,2688)
3067 (2726, 3450)

320
713

2458 (2247, 2688)
1936 (1823, 2056)

320
713

1623 (1483, 1776)
1404 (1321, 1492)

324
729

9668 (8873, 40534)
7984 (7539, 8456)

325
726

3036 (2737, 3368)
2469 (2303, 2647)

20
182
315
248
268

1614 (1132, 2301)
1730 (1537, 1947)
1797 (1643, 1965)
2472 (2235, 2734)
2452 (2226, 2702)

20
182
315
248
268

1225 (855, 1748)
1171 (1040, 1319)
1333 (1219, 1459)
1659 (1499, 1837)
1736 (1575, 1914)

22
186
319
251
275

8853 (6388, 12270)
7573 (6766, 8476)
7178 (6589, 7820)
10090 (9161,11114)
9394 (8566,10303)

22
184
318
252
275

2632 (1773, 3907)
2469 (2154, 2831)
2097 (1889, 2326)
3260 (2901, 3663)
2936 (2626, 3283)

667
366

2249 (2113, 2394)
1815 (1668, 1974)

667
366

1585 (1489, 1687)
1278 (1174, 1390)

676
377

9316 (8781, 9885)
7136 (6592, 7725)

677
374

2959 (2755, 3177)
2129 (1934, 2343)

Source: Adapted from STN125508/0.43, Module 1.11.3_Table 27 (p71-72)

Page 114

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 60: Month 7 Anti-HPV 31, 33, 45, 52 and 58 Antibody GMTs by Baseline Subject Characteristics in 9 through 15 Year-old
Males Who Received 9vHPV in Protocols 002, 005, and 007 (PPI Population)
Subgroup
Race
Asian
Black
Caucasian
Other
Ethnicity
Hispanic or
Latino
Not Hispanic or
Latino
Region
Africa
Asia-Pacific
Europe
L. America
N. America
Age (Years)
9 to 12
13 to 15

HPV 31
n

GMT (95% CI)

HPV 33
N

GMT (95% CI)

HPV 45
n

GMT (95% CI)

HPV 52
n

GMT (95% CI)

HPV 58
n

GMT (95% CI)

189
44
563
252

1790 (1571, 2039)
2573 (1966, 3367)
2132 (1978, 2299)
2629 (2350, 2942)

189
43
567
254

933 (829, 1051)
1201 (936, 1540)
1182 (1103, 1265)
1409 (1272, 1561)

190
44
566
256

794 (681, 923)
1174 (860, 1602)
766 (703, 836)
1027 (902, 1168)

189
43
566
256

823 (729, 938)
1232 (947, 1603)
1151 (1070, 1237)
1085 (974, 1209)

189
44
562
255

1380 (1225, 1553)
1449 (1133, 1852)
1567 (1463, 1379)
1705 (1540, 1888)

324

2560 (2318, 2828)

326

1417 (1295, 1551)

328

1007 (898, 1128)

328

1085 (985, 1194)

328

1724 (1576, 1886)

724

2042 (1910, 2183)

727

1090 (1026, 1159)

728

778 (721, 840)

726

1085 (999, 1138)

722

1488 (1401, 1581)

22
185
316
251
274

2086 (1431, 3042)
1772 (1555, 2019)
1864 (1688, 2059)
2690 (2406, 3008)
2529 (2272, 2814)

21
185
319
253
275

998 (702, 1417)
926 (823, 1042)
1007 (920, 1101)
1436 (1298, 1588)
1425 (1293, 1570)

22
186
319
255
274

937 (605, 1450)
792 (681, 921)
662 (590,743)
1088 (957, 1237)
910 (804, 1030)

22
185
318
255
274

1015 (703, 1467)
830 (731, 943)
1086 (986, 1197)
1082 (972, 1206)
1249 (1126, 1386)

22
185
314
255
274

1162 (823, 1641)
1371 (1217, 1545)
1446 (1320, 1584)
1772 (1601, 1962)
1681 (1525, 1854)

675
373

2421 (2260, 2594)
1826 (1664, 2003)

677
376

1310 (1230, 1394)
984 (904, 1070)

679
377

941 (870, 1019)
690 (621, 768)

678
376

1199 (1123, 1282)
875 (801, 957)

676
374

1735 (1631, 1845)
1283 (1181, 1394)

Source: Adapted from STN125508/0.43, Module 1.11.3_Table 28 (p73-74)

Page 115

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Summary of Subgroup Analyses
Younger subjects, regardless of gender, race, ethnicity or region, generally had
numerically higher antibody GMTs than older subjects. Boys had numerically higher
antibody GMTs than girls among the corresponding age groups. There were some
variations in antibody GMTs against different HPV types across different races,
ethnicities or regions. However, the clinical significance of these variations in antibody
GMTs is unclear, as antibody GMTs for all 9 HPV types were robust across the race,
ethnicity, or region category.
7.1.8 Persistence of Efficacy
7.1.8.1 Persistence of Efficacy
As described in Section 6.1, both 9vHPV and qHPV groups were generally comparable
with respect to the proportions of subjects completing each of the scheduled follow-up
visits. The only primary endpoint case in PPE population was observed at Month 12, and
all the six primary endpoint cases in the HN-TS population were observed at or before
Month 18, in the 9vHPV vaccine group. In contrast, primary endpoint cases were
observed in the PPE and HN-TS populations from Month 12 throughout Month 54 in the
qHPV vaccine group. As shown in the post-marketing follow-up studies, the protective
efficacy of qHPV against HPV 6-, HPV 11-, HPV 16- and HPV 18-related disease lasts
at least 6 years. Taken together, these results suggest that the protective efficacy of
9vHPV against HPV 6-, HPV 11-, HPV 16-, HPV 18-, HPV 31-, HPV 33-, HPV 45-, HPV
52-, and HPV 58-related persistent infection and disease lasts at least 4 years and likely
longer.
7.1.8.2 Persistence of Immunogenicity
Per protocol, approximately 20% of the subjects enrolled in Protocol V503-001 were
tested for persistence of serum anti-HPV responses during the follow-up period. Table
61 and Table 62 present anti-HPV antibody GMTs and seropositivity rates, respectively,
in subjects 16 through 26 years of age at Months 3 (one month after the second dose), 7
(one month after the third dose), 12 and 24.
For both 9vHPV and qHPV recipients, anti-HPV antibody GMTs were highest at Month
7, and at Month 24 anti-HPV antibody GMTs had fallen to 10-20% of Month 7 values
regardless of HPV types. Anti-HPV antibody GMTs against the origi-l types (i.e., HPV 6,
11, 16 and 18) were similar between qHPV and 9vHPV recipients at all time points.
Seropositivity rates for all HPV types except HPV 18 and 45 remained >97% in 9vHPV
recipients at Month 24. Seropositivity rates for HPV types 18 and 45 among 9vHPV
recipients were 86.5% and 87.4%, respectively, at Month 24, meaning that anti-HPV 18
and HPV 45 antibodies were undetectable at Month 24 in >10% of 9vHPV recipients.
Similarly, anti-HPV 18 antibodies were undetectable at Month 24 in >10% of qHPV
recipients.
Table 61: Persistence of Type-Specific Anti-HPV Antibody GMTs in 16 through 26 Yearold Women in Study V503-001 (1PPI Population)
9vHPV
9vHPV (N2=6,792)
qHPV
qHPV (N2=6,795)
Antibody
3
3
n
GMT (95%CI)
n
GMT (95%CI)
Assay

Page 116

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Antibody
Assay

9vHPV
n3

9vHPV (N2=6,792)
GMT (95%CI)

qHPV
n3

qHPV (N2=6,795)
GMT (95%CI)

Anti-HPV 6
Month 03
788
734 (693, 778)
761
720 (679, 763)
Month 07
3,993
893 (872, 915)
3,975
875 (854, 897)
Month 12
800
331 (312, 350)
781
319 (301, 339)
Month 24
715
209 (196, 223)
689
205 (192, 219)
Anti-HPV 11
Month 03
790
529 (492, 560)
762
678 (640, 719)
Month 07
3,995
666 (650, 683)
3,982
830 (809, 851)
Month 12
810
212 (200, 226)
788
265 (249, 281)
Month 24
763
123 (116, 131)
734
148 (139, 158)
Anti-HPV 16
Month 03
794
2,436 (2,304, 2,576)
785
2,475 (2,340, 2,618)
Month 07
4,032
3,131 (3,057, 3,207)
4,062
3,157 (3,082, 3,233)
Month 12
819
1,042 (980, 1,107)
805
1,032 (970, 1,097)
Month 24
778
521 (485, 559)
758
507 (472, 546)
Anti-HPV 18
Month 03
908
471 (443, 501)
877
371 (350, 395)
Month 07
4,539
805 (783, 827)
4,541
679 (660, 680)
Month 12
972
199 (185, 213)
901
160 (149, 172)
Month 24
886
86 (79, 94)
846
68 (62, 74)
Anti-HPV 31
Month 03
881
438 (407, 471)
838
6 (6, 7)
Month 07
4,466
658 (637, 681)
4,377
10 (9, 10)
Month 12
909
197 (184, 210)
858
4 (<4, 4)
Month 24
863
102 (95, 110)
804
<4 (<4, <4)
Anti-HPV 33
Month 03
937
288 (2739, 304)
910
<4 (<4, <4)
Month 07
4,702
416 (406, 426)
4,750
<4 (<4, <4)
Month 12
958
126 (120, 133)
937
<4 (<4, <4)
Month 24
909
65 (62, 69)
881
<4 (<4, <4)
Anti-HPV 45
Month 03
956
160 (152, 170)
910
<3 (<3, <3)
Month 07
4,792
253 (246, 260)
4,750
<3 (<3, <3)
Month 12
976
69 (65, 73)
937
<3 (<3, <3)
Month 24
928
33 (31, 35)
881
<3 (<3, <3)
Anti-HPV 52
Month 03
895
241 (230, 253)
835
<3 (<3, <3)
Month 07
4,455
380 (372, 388)
4,335
<3 (<3, <3)
Month 12
916
119 (113, 125)
857
<3 (<3, <3)
Month 24
867
58 (55, 61)
808
<3 (<3, <3)
Anti-HPV 58
Month 03
884
281 (265, 298)
863
<4 (<4, <4)
Month 07
4,486
483 (470, 495)
4,446
<4 (<4, <4)
Month 12
905
153 (146, 162)
883
<4 (<4, <4)
Month 24
852
80 (76, 85)
834
<4 (<4, <4)
Source: Adapted from STN 125508/0, Module 2.7.3_Table 2.7.3-hpvdiseases:138 (p407-408).
1
PPI population consisted of all individuals who received all 3 doses of 9vHPV, did not have
major protocol deviations, and were naïve (PCR negative and seronegative) to the relevant HPV
types prior to dose 1 and through 1 month after dose 3.
2
N=Number of subjects who received at least 1 injection.
3
n=Number of subjects who contributed to the analysis.

Page 117

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 62: Persistence of HPV Type-Specific Seropositivity Rates in 16 through 26 Yearold Women in Study V503-001 (1PPI Population)
9vHPV
9vHPV (N2=6,792)
qHPV
qHPV (N2=6,795)
Antibody
n3
SPR (95%CI)
n3
SPR (95%CI)
Assay
Anti-HPV 6
Month 03
Month 07
Month 12
Month 24
Anti-HPV 11
Month 03
Month 07
Month 12
Month 24
Anti-HPV 16
Month 03
Month 07
Month 12
Month 24
Anti-HPV 18
Month 03
Month 07
Month 12
Month 24
Anti-HPV 31
Month 03
Month 07
Month 12
Month 24
Anti-HPV 33
Month 03
Month 07
Month 12
Month 24
Anti-HPV 45
Month 03
Month 07
Month 12
Month 24
Anti-HPV 52
Month 03
Month 07
Month 12
Month 24
Anti-HPV 58
Month 03
Month 07
Month 12
Month 24

788
3,993
800
715

99.5% (98.7%, 99.9%)
99.8% (99.6%, 99.9%)
99.3% (98.4%, 99.7%)
98.0% (96.7%, 98.9%)

761
3,975
781
689

99.9% (99.3%, 100%)
99.8% (99.7%, 99.9%)
99.2% (98.3%, 99.7%)
97.4% (95.9%, 98.4%)

790
3,995
810
763

100% (99.5%, 100%)
100% (99.9%, 100%)
99.8% (99.1%, 100%)
98.7% (97.6%, 99.4%)

762
3,982
788
734

100% (99.5%, 100%)
99.9% (99.8%, 100%)
99.9% (99.3%, 100%)
98.6% (97.5%, 99.3%)

794
4,032
819
778

100% (99.5%, 100%)
100% (99.9%, 100%)
99.9% (99.3%, 100%)
99.9% (99.3%, 100%)

785
4,062
805
758

100% (99.5%, 100%)
100% (99.8%, 100%)
100% (99.5%, 100%)
99.2% (98.3%, 99.7%)

908
4,539
972
886

99.7% (99.0%, 99.9%)
99.8% (99.7%, 99.9%)
97.6% (96.4%, 98.5%)
86.5% (84.0%, 88.6%)

877
4,541
901
846

99.1% (98.2%, 99.6%)
99.7% (99.5%, 99.8%)
94.6% (92.9%, 95.9%)
81.0% (78.2%, 83.6%)

881
4,466
909
863

99.8% (99.2%, 100%)
99.8% (99.6%, 99.9%)
99.3% (98.6%, 99.8%)
97.2% (95.9%, 98.2%)

838
4,377
858
804

33.4% (30.2%, 36.7%)
50.1% (48.7%, 51.6%)
20.2% (17.5%, 23.0%)
14.4% (12.1%, 17.0%)

937
4,702
958
909

99.7% (99.1%, 99.9%)
99.7% (99.5%, 99.9%)
99.7% (99.1%, 99.9%)
98.6% (97.6%, 99.2%)

910
4,750
937
881

9.2% (7.4%, 11.3%)
12.7% (11.8%, 13.7%)
6.8% (5.3%, 8.7%)
7.5% (5.8%, 9.5%)

956
4,792
976
928

99.4% (98.6%, 99.8%)
99.6% (99.4%, 99.8%)
96.9% (95.6%, 97.9%)
87.4% (85.1%, 89.5%)

910
4,750
937
881

4.9% (3.6%, 6.6%)
9.2% (8.4%, 10.0%)
3.1% (2.1%, 4.4%)
1.9% (1.1%, 3.1%)

895
4,455
916
867

99.7% (99.0%, 99.9%)
99.8% (99.6%, 99.9%)
99.5% (98.7%, 99.8%)
98.3% (97.2%, 99.0%)

835
4,335
857
808

3.4% (2.2%, 4.8%)
2.6% (2.2%, 3.1%)
1.9% (1.1%, 3.0%)
3.8% (2.6%, 5.4%)

884
4,486
905
852

99.8% (99.2%, 100%)
99.8% (99.6%, 99.9%)
99.6% (98.9%, 99.9%)
98.1% (97.0%, 98.9%)

863
4,446
883
834

15.3% (13.0%, 17.9%)
20.4% (19.2%, 21.6%)
5.7% (4.2%, 7.4%)
8.5% (6.7%, 10.6%)

Source: Adapted from STN 125508/0, Module 2.7.3_Table 2.7.3-hpvdiseases:139 (p409-413).
1
PPI population consisted of all individuals who received all 3 doses of 9vHPV, did not have major protocol
deviations, and were naïve (PCR negative and seronegative) to the relevant HPV types prior to dose 1 and
through 1 month after dose 3.
2
N=Number of subjects received at least 1 injection.
3
n=Number of subjects contributed to the analysis.
SPR=Seropositivity rate

Page 118

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s notes: Data from later visits (Month 36 and Month 42) are not available for
this submission.
Persistence of anti-HPV antibodies against the original HPV types in this submission for
both 9vHPV and qHPV was similar to that observed in the Gardasil program. In the
Gardasil program, anti-HPV 6, 11 and 16 antibodies remained detectable in a high
percentage of subjects at least 9 years after dose 3, while anti-HPV 18 antibodies
became undetectable in approximately one-third of vaccinees several years after
vaccination. The Applicant speculated that this was likely due to the limits of the
immunoassay sensitivity, as clinical protection against disease associated with all four
HPV types persisted despite this loss of detectable antibodies. In long-term follow-up
studies in the Gardasil program there has been no breakthrough case of HPV-related
disease in the PPE population through at least 6 years post-dose 3, even though many
vaccine recipients who originally seroconverted for HPV type 18 no longer had
measurable anti-HPV 18 antibody by cLIA. In addition, HPV 18 antibodies remained
measurable using two other HPV immunological assays, a total IgG assay and a
---------------------(b)(4)-------------------. These results suggest either that anamnestic
responses may be protective in subjects who have become seronegative or that the
protective antibody level is below the cLIA limit of detection.
Longer-term follow-up is required to definitively evaluate the duration of antibody
persistence for each component of 9vHPV and to determine whether loss of detectable
antibodies by cLIA correlates with loss of clinical efficacy or persistence of efficacy (as
has been observed with Gardasil).
7.1.9 Product-Product Interactions
7.1.9.1 Concomitant Administration with Menactra and Adacel (Study V503-005,
Designed as Study 5 in the Draft Package Insert)
Protocol Title: A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and
Tolerability of V503 (A Multivalent Human Papillomavirus L1 Virus-Like Particle Vaccine)
Given Concomitantly with Menactra and Adacel in Preadolescents and Adolescents 11
to 15 Years Old
Study Sites: 41 sites; 34 sites in the U.S. and 7 sites in Latin America (Chile, Colombia,
Mexico, and Peru).
Study Design: This study was an open-label, randomized, multicenter, comparative
study to evaluate the tolerability and immunogenicity of the concomitant administration of
the first dose of 9vHPV with Menactra and Adacel versus the administration of 9vHPV
non-concomitantly with Menactra and Adacel in 1240 healthy boys and girls 11 to 15
years of age. Subjects were stratified by gender (1:1 ratio) and randomly assigned to 1
of 2 vaccination groups in a 1:1 ratio. Subjects in Vaccination Group 1 (referred to as the
Concomitant Group) received the first dose of 9vHPV in the deltoid muscle of the nondominant arm and Menactra and Adacel at separate injection sites at least 2 inches
apart in the deltoid muscle of the dominant arm on Day 1. Subjects in Vaccination Group
2 (referred to as Non-concomitant Group) received the first dose of 9vHPV on Day 1 and

Page 119

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Menactra and Adacel at Month 1. Subjects in both vaccination groups received the
second dose of 9vHPV at Month 2 and the third dose at Month 6.
The primary immunogenicity objectives were to demonstrate that the first dose of 9vHPV
could be administered concomitantly with Menactra and Adacel without impairing the
antibody responses to HPV types in 9vHPV -or to N. meningitidis serogroups A, C, Y,
and W-135, and diphtheria, tetanus, and pertussis. The primary safety objective of the
study was to demonstrated whether concomitant administration of 9vHPV with Menactra
and Adacel would increase reactogenicity,
Summary of Results
The baseline demographics were similar for the concomitant and non-concomitant
groups. The median age in each vaccination group at enrollment was 12.0 years. All
subjects were between 11 and 15 years of age, with 310 boys and 311 girls assigned to
the concomitant group, and 310 boys and 310 girls assigned to the non-concomitant
group. Approximately 56% of subjects were from North America, and approximately 43%
from Latin America. The race distribution of the study subjects was as follows: 47.4%
White; 35.0% Multiracial; 9.6% American Indian or Alaska Native; 6.4% Black; 1.1%
Asian; and 0.6% Native Hawaiian or Other Pacific Islander.
Responses to 9vHPV Vaccine
The results of the immunogenicity analysis demonstrated non-inferior antibody GMTs
and seroconversion rates for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 4 weeks
post-dose 3 when comparing concomitant vs. non-concomitant administration of the first
dose of 9vHPV with Menactra and Adacel (data not shown in this review).
Responses to Menactra and Adacel
Antibody responses to Menactra and Adacel administered concomitantly with each other
and 9vHPV were also non-inferior to those resulting from concomitant administration of
Menactra and Adacel alone (data not shown in this review). Antibody responses to
Menactra and Adacel were measured by:
• The percentage of subjects who achieved a tetanus and diphtheria titer ≥ 0.1
IU/ml at four weeks after vaccination with Adacel
• The anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), anti-pertectin
(PRN), and anti-fimbrial aggrutinogens (FIM) GMTs at four weeks after
vaccination with Adacel
• The percentage of subjects with a 4-fold or greater rise in antibody titers against
N. meningitidis serogroups A, C, Y, and W-135 at four weeks after vaccination
with Menactra
7.1.9.2 Interaction with Hormonal Contraceptive Use
Table 63 presents Month 7 anti-HPV antibody responses among all female subjects 16
through 26 years of age in the pooled PPI population who received 9vHPV with or
without use of hormonal contraceptive from Day 1 through Month 7. In general, type
specific anti-HPV antibody GMTs were statistically significantly higher in subjects with
use of hormonal contraceptives compared with subjects without use of hormonal
contraceptives. The clinical significance is unknown.

Page 120

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 63: Month 7 Anti-HPV Antibody GMTs among 16 through 26 Year Old Female
Recipients of 9vHPV Vaccine by Status of Hormonal Contraceptive Use from Day 1
through Month 7 (PPI, Protocols 001 and 002)
Antibody
Assay

Subjects with GMT (95% CI)
Subjects without GMT (95% CI)
Hormonal
Hormonal
Contraceptive
Contraceptive
Use(N=5,474)
Use(N=1,778)
n
n
Anti-HPV 6
3,251
912 (888, 936)
1,069
841 (803, 880)
Anti-HPV 11 3,253
685 (667, 704)
1,073
623 (594, 654)
Anti-HPV 16 3,247
3,240 (3,157, 3,326)
1,113
2,933 (2,805, 3,067)
Anti-HPV 18 3,674
824 (799, 848)
1,209
770 (731, 811)
Anti-HPV 31 3,610
677 (657, 698)
1,195
628 (596, 663)
Anti-HPV 33 3,819
425 (414, 436)
1,236
402 (384, 422)
Anti-HPV 45 3,901
261 (252, 269)
1,258
235 (222, 249)
Anti-HPV 52 3,631
397 (385, 408)
1,160
342 (325, 359)
Anti-HPV 58 3,657
496 (482, 510)
1,160
468 (446, 492)
Source: Adapted from STN 125508/0.43_Module 1.11.3_Table 29(p75)
N=Number of females who were randomized and belonged to the respective contraceptive use
group and received at least 1 injection of 9vHPV Vaccine and had any contraceptive use data
from Day 1 through Month 7.
n=Number of subjects evaluable.

7.1.9.3 Interaction with Steroids or Other Immunosuppressants
Table 64 summarizes Month 7 anti-HPV antibody GMTs among all 9vHPV recipients in
the pooled PPI population who reported use of steroids or other immunosuppressive
medications from Day 1 through Month 7. Based on the data presented in the table, the
Applicant concluded that there was no evidence of interference with Month 7 antibody
responses associated from the use of steroids or other immunosuppressants from Day 1
through Month 7.
Table 64: Month 7 Anti-HPV Antibody GMTs Among 9vHPV Recipients by Status of
Steroid or Immunosuppressive Use from Day 1 through Month 7 (PPI Population
regardless of Steroid and Immunosuppressive Use from Protocols 001, 002, 005, 007
and 009)
Antibody
Assay

Subjects with
GMT (95% CI)
Subjects without
ImmunoImmunosuppressant
suppressant
(N=13)
(N=11216)
n
n
Anti-HPV 6
7
1806 (939, 3475)
7660
Anti-HPV 11 7
1373 (705, 2673)
7667
Anti-HPV 16 7
5618 (2874, 10983)
7776
Anti-HPV 18 7
1551 (707, 3507)
8311
Anti-HPV 31 7
1051 (469, 2352)
8208
Anti-HPV 33 6
902 (418, 1945)
84582
Anti-HPV 45 7
674 (279, 1626)
8601
Anti-HPV 52 7
692 (326, 1467)
8227
Anti-HPV 58 6
1175 (524, 2631)
8221
Source: Adapted from STN 125508/0.43_Module 1.11.3_Table 30 (p76)

GMT (95% CI)

1225 (1201, 1,250)
906 (889, 925)
4628 (4536, 4722)
1,232 (1204, 1261)
1,044 (1,02, 1,069)
602 (590, 615)
394 (385, 405)
573 (561, 586)
752 (736, 768)

Page 121

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
N=Number of females who were randomized and belonged to the respective contraceptive use
group and received at least 1 injection of 9vHPV Vaccine and had any contraceptive use data
from Day 1 through Month 7.
n=Number of subjects evaluable.
For 005 and 007, only subjects from the non-concomitant groups are included.

Reviewer’s comments: Effects of steroids and immunosuppressants on immune
responses depend on the doses and classes of immunosuppressnants. Based on the
limited information presented in this submission and the very limited number of subjects
who received immnosupressants during the vaccination period, no definitive conclusion
can be reached regarding whether use of an immunosuppressant interferes with antiHPV immune responses induced by 9vHPV.
7.1.11 Efficacy Conclusions
7.1.11.1 Prevention of Cervical, Vulvar, Vaginal Disease Related to HPV 31, 33, 45, 52,
and 58
1. Administration of a 3-dose regimen of 9vHPV vaccine to females, 16 through 26
years of age, is effective in preventing the development of following:
a. HPV 31-, 33-, 45-, 52-, 58-related high-grade cervical, vulvar, vaginal
disease (CIN 2 or worse, VIN 2/3 or worse, VaIN 2/3 or worse, and AIN
2/4 or worse)
b. HPV 31-, 33-, 45-, 52-, and 58-related cervical, vulvar, and vaginal
disease (any grade)
c. HPV 31-, 33-, 45-, 52-, and 58-related persistent infection
d. HPV 31-, 33-, 45-, 52-, and HPV 58-related cytological abnormalities.
Effectiveness against cervical, vulval, and vaginal disease was demonstrated by
efficacy analyses of histopathological endpoints comparing 9vHPV to qHPV,
whereas effectiveness against anal disease is inferred through similar
pathophysiology and preventative efficacy of qHPV against anal disease endpoints in
clinical trials. The protective efficacy induced by the 9vHPV is durable through at
least 4 years post-vaccination with respect to persistent infection and disease related
to the HPV vaccine types. Please refer to Section 6.1 for details.
2. Administration of a 3-dose regimen of 9vHPV vaccine to females 9 through 15
years of age is protective against cervical, vulvar, vaginal, and anal infection and
disease caused by HPV types 31, 33, 45, 52, and 58.
3. Administration of a 3-dose regimen of 9vHPV vaccine to males 9 through 15
years of age is protective against anogenital infection and disease caused by
HPV types 31, 33, 45, 52, and 58.
The conclusions for both males and females 9 through 15 years of age are inferred
from non-inferior anti-HPV 31, 33, 45, 52, and 58 antibody responses induced by
9vHPV in these populations compared with 16 through 26 year-old females, the
population used to establish clinical efficacy. Please refer to Section 6.2 and Section
7.1.5.

Page 122

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

7.1.11.2 Prevention of Cervical, Vulvar, Vaginal, and Anal Disease Related to HPV 6,
11, 16, and 18
1. Administration of a 3-dose regimen of 9vHPV vaccine to females 16 through 26
years of age is protective against cervical, vaginal, vulvar, and anal infection and
disease caused by HPV types 6, 11, 16, and 18.
This conclusion is inferred from non-inferior anti-HPV 6, 11, 16, and 18 antibody
responses induced by 9vHPV compared with qHPV, which supports bridging the
efficacy findings in the Gardasil Program to 9vHPV. The conclusion is further
supported by efficacy of 9vHPV in preventing infection and disease related to HPV
types 6, 11, 16, and 18, as assessed by vaccine efficacy relative to the historical
placebo control in the Gardasil Program.
2. Administration of a 3-dose regimen of 9vHPV vaccine to females 9 through 15
years of age is protective against cervical, vaginal, vulvar, -and anal infection and
disease caused by HPV types 6, 11, 16, and 18.
3. Administration of a 3-dose regimen of 9vHPV vaccine to males 9 through 15
years of age is protective against anogenital infection and disease caused by
HPV types 6, 11, 16, and 18.
The conclusion for 9 through 15 year-old boys and girls is based on numerically
superior and statistically non-inferior anti-HPV 6, 11, 16, and 18 antibody responses
induced by 9vHPV in these populations compared with 16 through 26 year-old
females.
7.1.11.3 Overall Prevention of Cervical, Vulvar, and Vaginal Disease, Pap Test
Abnormalities, and Cervical and External Genital Procedures
Administration of a 3-dose regimen of 9vHPV to 16 through 26 year-old females also
reduced their:
• Overall risk for development of CIN, VIN and VaIN disease;
• Risk of having an abnormal Pap test, particularly a Pap test that is predictive for
CIN 2/3 and, therefore, requires colposcopic follow-up; and
• Risk of undergoing cervical and external genital diagnostic and therapeutic
procedures, especially definitive therapy procedures.
7.1.11.4 Persistence of Immunogenicity, Lot-consistency and Interaction with Other
Vaccines
• The 9vHPV vaccine induced robust anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and
58 antibody responses through at least 1.5 years post-vaccination.
• The final manufacturing process of 9vHPV vaccine produced lots that generated
consistent anti-HPV responses as measured at Month 7
• Concomitant administration of a 3-dose regimen of 9vHPV with Menactra and
Adacel did not adversely affect immune responses to any of the three vaccines.
• Administration of a 3-dose regimen of 9vHPV to 12 to 26 year-old females who
were previously administered a 3-dose regimen of qHPV induced robust antibody
responses to HPV types 6, 11, 16 and 18 as well as high seroconversion rates
for HPV types 31, 33, 45, 52, and 58. The magnitude of anti-HPV 6, 11, 16, and
18 antibody responses was higher in prior qHPV recipients compared to HPV
vaccine naïve subjects, while the magnitude of anti-HPV 31, 33, 45, 52 and 58

Page 123

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

antibody responses in prior qHPV recipients was statistically significantly lower
than in HPV vaccine naïve subjects. However, the clinical significance is
unknown.
8. INTEGRATED OVERVIEW OF SAFETY
8.1 Safety Assessment Methods
In all clinical trials conducted during the clinical development of the 9vHPV vaccine,
safety was evaluated using VRC-aided surveillance during Days 1 through 15 after each
study vaccination to collect injection site and systemic adverse reactions, as well as
SAEs. SAEs and new onset clinical conditions (including potential autoimmune
disorders) were also collected throughout the study periods.
8.2 Safety Database
8.2.1 Studies/Clinical Trials Used to Evaluate Safety
Six studies collectively contributed to the pooled 9vHPV safety database and included
female subjects 9 to 26 years of age and male subjects 9 through 15 years of age at
enrollment. The data presented in this Summary of Clinical Safety were collected from
over 13,000 9vHPV recipients that adequately represent the indicated population. In
total, 5307 children 9 through 15 years of age and 8053 young women 16 through 26
years of age received at least one dose of the 9vHPV vaccine. Over 97% of subjects
received all three doses of the 9vHPV vaccine. A listing of the clinical trials used to
support the safety of 9vHPV is shown in Section 5.3.
The pooled safety population -excludes subjects who received the low-dose or highdose formulation of 9vHPV in Part A of Protocol V503-001 because the dose levels of
9vHPV were different. Safety analyses in these subjects are presented in Section 8.5.1.
Prior qHPV vaccine recipients who received saline placebo in Protocol V503-006 are
also excluded from the pooled safety population.
Some analyses presented in Section 8 cover the “Entire Study Period.” For Protocol
V503-001, the entire study period varies by subject enrollment date and includes Day 1
through the visit cut-off date of April 10, 2013. For Protocol V503-002, the entire study
period includes Day 1 through Month 12. For Protocols V503-005, V503-006, V503-007,
and V503-009/GDS01C, the entire study period includes Day 1 through Month 7.
8.2.2 Overall Exposure, Demographics of Pooled Safety Populations
A total of 20,751 subjects were vaccinated in 6 clinical trials. A total of 13,360 subjects
received at least 1 dose of 9vHPV vaccine, and 7391 subjects received at least 1 dose
of qHPV vaccine.
A summary of the numbers of subjects from the six clinical trials who were vaccinated
with 9vHPV and completed Month 7 follow-up or discontinued prior to Month 7 is shown
in Table 65. Protocols V503-001 and -002 are ongoing (extended follow-up). Protocols
V503-005, -006, -007, and -009 are completed. Among the 13,360 vaccinated subjects,
a total of 328 subjects (2.5%) discontinued study vaccinations. Most subjects who
discontinued were either lost to follow-up or withdrew consent. Fifteen subjects

Page 124

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

discontinued study vaccinations due to an adverse experience, and seven subjects
discontinued study vaccinations due to a protocol violation.
Table 65: Disposition and Demographics of Subjects Who Received 9vHPV Vaccine
(Protocols 001, 002, 005, 006, 007, and 009) (Day 1 through Month 71)
Disposition and Subgroup
Subjects in Population
Vaccinated at
Vaccination 1
Vaccination 2
Vaccination 3
Completed
Discontinued
Adverse Event
Lost To Follow-Up
Physician Decision
Pregnancy
Protocol Violation
Withdrawal By Subject
2
Unknown
Gender
Male
Female
Age (Years)
9 to 15
16 to 17
18 to 26

9vHPV
N (%)
13285
13285 (100.0)
13102 (98.6)
12959 (97.5)
12843 (96.7)
409 (3.1)
12 (0.1)
198 (1.5)
4 (< 0.1)
1 (<0.1)
5 (<0.1)
189 (1.4)
33 (0.2)
1784 (13.4)
11501 (86.6)
5237 (39.4)
301 (2.3)
7747 (58.3)

Mean
17.9
SD
5.3
Median
19.0
Range
9 to 26
Race
Asian
1889 (14.2)
Black
575 (4.3)
Other
3046 (22.9)
White
7775 (58.5)
Ethnicity
Hispanic Or Latino
4290 (32.3)
Not Hispanic Or Latino
8994 (67.7)
Null
1 (<0.1)
Region
Africa
165 (1.2)
Asia-Pacific
1738 (13.1)
Europe
4773 (35.9)
Latin America
3642 (27.4)
North America
2967 (22.3)
Source: Adapted from STN125508/0.43_Module 1.11.3., Table 31 and 32 (p77-78)
1
For Protocol 002 the disposition records were collected at Month 12. For 005 and 007, only
subjects from the non-concomitant groups are included and the study medication disposition is
based on both the 9vHPV vaccine and other study vaccine.
2
A disposition record did not exit at the time of reporting.

Page 125

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

The race distribution of the integrated safety population for 9vHPV was similar when
stratified by age to 16 through 26 year-old women (56.2% White; 25.4% Other Races or
Multiracial; 14.7% Asian; 3.7% Black) and 9 through 15 year-old girls and boys (61.2%
White; 18.9% Other Races or Multiracial; 14.6% Asian; 5.3% Black) [Data source:
STN125508/0_Module 2.7.4_Appendix 2.7.4: 3 and 4, p162-165].
The race distribution of the safety population for qHPV was similar to the integrated
safety population for 9vHPV. Please refer to Section 6.1.10.1.1 for details.
The race distribution of the safety population for Study V503-009 was different from the
race distribution of 9 through 15 year-olds in the integrated safety population since
V503-009 was conducted only in Europe. However, the race distributions for 9vHPV
and qHPV in this study were similar. Please refer to Section 6.3.10.1.1 for details.
8.2.3 Categorization of Adverse Events
All verbatim terms for reported AE were coded using the Medical Dictionary for
Regulatory Activities version 16 (MedDRA v16), and the resulting system organ class
(SOC) and preferred terms (PTs) were used for tabulation of rates.
8.3 Caveats Introduced by Pooling of Data across Studies/Clinical Trials
The only study to include a placebo-controlled arm was V503-006, a small study to
investigate the safety and immunogenicity of 9vHPV in prior qHPV recipients. The
pivotal study, V503-001, had an active comparator control, qHPV. Therefore, the
category and frequency of the adverse events observed in the historical AAHS placebo
controls in the previous Gardasil vaccine program were used as a reference for safety
assessment. However, the safety surveillance of the Gardasil vaccine program was
different from that of the 9vHPV vaccine program. For the Gardasil vaccine program,
SAEs were collected from Day 1 to 15 following any vaccination and fetal loss was not
collected as an SAE. For the 9vHPV vaccine program, SAEs were collected for much
longer period for Studies V503-001 and V503-002 (at least for 6 months after last
vaccination), and fetal loss was collected as an SAE. In addition, in the 9vHPV program,
all subjects were evaluated for safety using VRC-aided surveillance. In contrast, in the
Gardasil vaccine program, only a subset of subjects was evaluated using VRC-aided
surveillance. All of these factors limit comparison of safety data for 9vHPV to historical
safety data for AAHS placebo control collected in the Gardasil vaccine program.
In addition, the majority of 9 through 15 year-old subjects were enrolled in open label
studies (V503-002, -005, and -007). Consequently, there was potential for observation
bias for safety assessments (see also Reviewer’s comments in Section 8.4.7).
Reviewer’s comments: Safety analyses of the only one qHPV controlled study, V503001, are presented in Section 6.1.12. The population of the placebo controlled study,
V503-006, was subjects who were previously vaccinated with qHPV and were different
from that of other five clinical trials. In addition, the remaining four clinical trials were
open label studies. Therefore, this section only presents the integrated safety analyses
of the database for 9vHPV recipients.

Page 126

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

8.4 Safety Results
8.4.1 Deaths
A total of 5 subjects who received 9vHPV died during the entire study period; all of them
occurred in Study V503-001. Of the 5 deaths, one each was due to trauma (road traffic
accident); completed suicide; cancer (acute lymphocytic leukemia); hypovolemic and
septic shock; and sudden death. None of the deaths were considered related to the
9vHPV by the investigators or this clinical reviewer. Please refer to Section 6.1.12.3 for
details.
8.4.2 Nonfatal Serious Adverse Events
Among the 13,309 subjects who received 9vHPV, 305 (2.3%) experienced non-fatal
SAEs during the entire study period. Per protocol, fetal loss was also considered to be a
‘non-fatal SAE’ if a fetal loss occurred during Day 1 through six months post dose 3.
Overall, the most frequent SAEs were elective abortion (79 cases, or 0.6% of the study
population) and other fetal loss (64 cases, of which, 37 were spontaneous abortion).
Rates of spontaneous abortions are discussed separately in Section 9.1.1.1. Infections
and infestations were the most frequent SAEs not related to fetal loss (61 cases, of
which 21 were appendicitis).
Of the 162 SAEs not related to fetal loss, 66 occurred within 28 days after any vacci-tion.
Table 66 lists the SAEs within 28 days following any 9vHPV vaccination in Studies
V503-005, 006, 007 and 009. For Studies V503-001 and -002, please refer to Section
6.1.12.4 and Section 6.2.12.4 for the subjects who experienced SAEs within 28 days
following any vaccination with 9vHPV or qHPV.
Table 66: Non-fatal SAEs (Excluding Events of Fetal Loss) Reported from Day 1 through
Day 28 after Any Vaccination with 9vHPV (Protocols 005, 006, 007 and 009)
Protocol
Subject
SAE
Dose Day of Related Outcome
Number
Onset
V503-005
34107
34090
34475
35254
34260

Appendicitis
Seroma
Affective disorder
Gastroenteritis
Testicular torsion

2
1
2
1
3

27
9
1
6
8
14
2

N
N
N
N
N
N
N
Y

Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved
Resolved

37083
37801

Syncope
Tonsillitis

2
1

39147

Non-cardiac chest
pain
Thermal burn
Appendiceal
abscess
Forearm fracture
Appendicitis
Appendicitis
Pyelonephritis
Eating disorder

1

8

N

Resolved

1
3

24
9

N
N

Resolved
Resolved

1
1
3
1
1

7
20
9
22
23

N
N
N
N
N

Resolved
Resolved
Resolved
Resolved
Resolved

V503-006

V503-007

40212
40105
39203
39318
40567
40424
40515

Page 127

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Protocol

Subject
Number

SAE

Dose

Day of
Onset

Related

Outcome
Resolved
Resolved
Resolved
Resolved

40230

Viral pharyngitis

3

1

N

51204
51204

Anemia
Pulmonary vasculitis

2
2

9
9

N
N

V503-009

Source: Generated by the clinical review from information in STN 125508/0_Module 2.7.4_Appendix
2.7.4:41 (p402-475) and Appendix 2.7.4:42 (p476-517)

Reviewer’s comment: This reviewer reviewed the narratives of all the SAEs including
those that occurred outside the 28-day window of vaccination in this submission and
concurs with the investigator’s assessment of causality.
8.4.3 Study Dropouts/Discontinuations
A total of 15 9vHPV recipients (0.1%) discontinued study vaccinations due to a clinical
adverse experience. Among them, 12 subjects (0.1%: 6 subjects in V503-001, 1 in
V503-002, 2 in V503-005 and 3 in V503-006) discontinued due to a vaccine related
adverse experience. The vaccine-related adverse events that led to discontinuation in
Study V503-001 were allergy, headache, fatigue, injection-site pain, injection-site
swelling, and rash; in V503-002 asthma crisis; in V503-005 pyrexia and pain in
extremity; and in V503-006 abdominal pain, injection-site swelling and swelling tongue.
Please refer to the individual studies for additional details.
8.4.4 Common Adverse Events
•
•
•

The most common (≥10%) local and systemic adverse reactions in females 16
through 26 years of age were injection-site pain (89.7%), injection-site swelling
(40.2%), injection-site erythema (34.3%) and headache (14.7%).
The most common (≥10%) local and systemic reactions in girls 9 through 15
years of age were injection-site pain (82.5%), injection-site swelling (37.3%),
injection-site erythema (30.3%) and headache (12.9%).
The most common (≥10%) local and systemic reactions in boys 9 through 15
years of age were injection-site pain (72.4%), injection-site swelling (28.2%),
injection-site erythema (24.2%) and headache (12.5%).

.
Please refer to Sections 8.4.6 and 8.4.7 for details.
8.4.5 Clinical Test Results
No routine clinical laboratory evaluations were conducted in any of the studies.
8.4.6 Systemic Adverse Events
8.4.6.1 Summary of Common Systemic Adverse Events
The numbers and percentages of 9vHPV recipients with systemic adverse experiences
within 15 days following any vaccination visit (reported by ≥1% of subjects) are listed in
Table 67 by system organ class. The most common (≥ 10%) vaccine-related systemic
adverse event was headache.

Page 128

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 67: Systemic Adverse Events within 15 Days Following Any 9vHPV Vaccination
(Rate ≥ 1%) by System Organ Class and Relationship to Vaccination (Protocols 001,
002, 005, 006, 007, and 009)
Population and Adverse Event Classification

Overall
N (%)
13234
7136 (53.9)
6098 (46.1)
133 (1.0)
2019 (15.3)
291 (2.2)
383 (2.9)
372 (2.8)
750 (5.7)
292 (2.2)
1968 (14.8)

Subjects in population with follow-up
with one or more systemic adverse events
with no systemic adverse events
Ear and labyrinth disorders
Gastrointestinal disorders
Abdominal pain
Abdominal pain upper
Diarrhea
Nausea
Vomiting
General disorders and administration site
conditions
Fatigue
376 (2.8)
Malaise
159 (1.2)
Pyrexia
1198 (9.1)
Infections and infestations
2090 (15.8)
Influenza
396 (3.0)
Nasopharyngitis
659 (5.0)
Upper respiratory tract infection
256 (1.9)
Injury, poisoning and procedural
249 (1.9)
complications
Musculoskeletal and connective tissue
868 (6.6)
Disorders
Back pain
186 (1.4)
Myalgia
207 (1.6)
Pain in extremity
189 (1.4)
Nervous system disorders
3637 (27.5)
Dizziness
522 (3.9)
Headache
3,230 (24.4)
Migraine
129 (1.0)
Reproductive system and breast disorders
572 (4.3)
Dysmenorrhoea
343 (2.6)
Respiratory, thoracic and mediastinal
1,063 (8.0)
Disorders
Cough
269 (2.0)
Nasal congestion
127 (1.0)
Oropharyngeal pain
594 (4.5)
Skin and subcutaneous tissue disorders
426 (3.2)
Source: Adapted from STN 125508/0.43_Module 1.11.3_Table 33 (p80-81)

Vaccine-Related
N (%)
13234
3735 (28.2)
9499 (71.8)
34 (0.3)
809 (6.1)
92 (0.7)
123 (0.9)
122 (0.9)
457 (3.5)
104 (0.8)
1,353 (10.2)
258 (1.9)
113 (0.9)
882 (6.7)
284 (2.1)
86 (0.6)
96 (0.7)
23 (0.2)
4 (0.0)
295 (2.2)
41 (0.3)
103 (0.8)
49 (0.4)
2099 (15.9)
321 (2.4)
1,845 (13.9)
38 (0.3)
55 (0.4)
22 (0.2)
195 (1.5)
34 (0.3)
21 (0.2)
117 (0.9)
146 (1.1)

8.4.6.2 Summary of Vaccine-Related Systemic Adverse Events
Table 68 presents by age and gender the numbers and proportions of vaccine-related
systemic adverse reactions observed Day 1 through Day 15 following any 9vHPV
vaccination.

Page 129

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 68: Vaccine-Related Systemic Adverse Reactions within 5 Days Following Any
9vHPV Vaccination (Rate ≥ 1% in One or More Vaccination Groups) by Age and Gender
across All Studies1
Adverse
Experiences
Headache
Pyrexia
Nausea
Dizziness
Fatigue
Diarrhea
Oropharyngeal
Pain

16 to 26 Year-old
Women
2
(N =8022)
3
n (%)
1,177 (14.7)
413 (5.1)
340 (4.2)
234 (2.9)
188 (2.3)
94 (1.2)
77 (1.0)

9 to 15 Year-old
Girls and Boys
2
(N =5212)
3
n (%)
668 (12.8)
470 (8.9)
117 (2.2)
87 (1.6)
70 (1.3)
28 (0.5)
40 (0.8)

9 to 15 Year-old
Girls
2
(N =3436)
3
n (%)
444 (12.9)
281 (8.1)
79 (2.3)
65 (1.9)
44 (1.3)
17 (0.5)
29 (0.8)

9 to 15 Year-old
Boys
2
(N =1776)
3
n (%)
224 (12.5)
189 (10.5)
38 (2.1)
22 (1.2)
26 (1.4)
11 (0.6)
11 (0.6)

Abdominal
57 (0.7)
66 (1.3)
46 (1.3)
20 (1.1)
Pain Upper
Source: Adapted from STN125508/0.43_Module 1.11.3_Table 34(p82-83) and Table 35 (p84-88)
1
Data for 16 through 26 year-old women were from Protocols 001, 002 and 006. Data for 9
through 15 year-olds were from Protocols 002, 005, 006, 007 and 009.
2
N=Subjects in population with follow-up.
3
n=Subjects with one or more corresponding adverse reactions.

8.4.6.3 Solicited Systemic Adverse Reactions
Temperature was solicited using VRC-aided surveillance for 5 days after each
vaccination. Table 69 shows by severity grade percentages of subjects with an
increased temperature within 5 days following each dose of 9vHPV.
Table 69: Distribution of Maximum Temperatures within 5 Days Following
Each and Any Vaccination among 9vHPV Recipients across All Studies (Protocols 001,
002, 005, 006, 007 and 009)
Temperatures

Dose 1
N (%)
13285
184
13101

Dose 2
N (%)
13102
262
12840

Dose 3
N (%)
12959
290
12669

Any Dose
N (%)
13285
134
13151

Subjects in population
Without temperature data
With temperature data
Temperature (Oral or Oral
Equivalent)
< 37.8°C
12691(96.9)
12498 (97.3)
12251(96.7)
12101 (92.0)
≥ 37.8°C < 38.9°C
350 (2.7)
292 (2.3)
338 (2.7)
866 (6.6)
≥ 38.9°C < 39.9°C
50 (0.4)
41 (0.3)
70 (0.6)
156 (1.2)
≥ 39.9°C < 40.9°C
8 (0.1)
8 (0.1)
8 (0.1)
23 (0.2)
≥ 40.9 °C
2 (0.0)
1 (0.0)
2 (0.0)
5 (0.0)
Source: STN125508/0.43_Module 1.11.3_Tables 36-39(p89-92).
Note: Percentages are calculated based on the number of subjects with temperature data.

8.4.7 Local Reactogenicity
8.4.7.1 Summary of Injection Site Reactogenicity
Table 70 presents the numbers and percentages of subjects with injection-site adverse
reactions (rate ≥1% in one or more vaccination groups) reported across the studies
within 5 days following any 9vHPV vaccination. The proportions of subjects reporting an

Page 130

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

injection site adverse reaction were approximately equal post-dose 1 (67.6%), post-dose
2 (67.7%), and post-dose 3 (68.0%). Among subjects who received 9vHPV vaccine, the
rates of injection-site pain was approximately equal (65.6%, 65.4% and 65.5%) across
the 3 reporting time periods. However, the rates of injection-site swelling (12.3%, 20.9%
and 26.2% post dose 1, 2 and 3 respectively) and injection-site erythema (9.8%, 16.5%
and 20.5% post dose 1, 2 and 3 respectively) increased following each successive dose
of 9vHPV.
The majority of injection site adverse reactions were mild and moderate in intensity.
Most of the severe adverse reactions were injection site pain. Among the severe
injection site adverse reactions, the proportion accounted for by pain was 96.2% (332
out of 345) for 16 through 26 year-old women, 98.2% (162 out of 165) for 9 through 15
year-old females and 93.8% (30 out of 32) for 9 through 15 year-old males.
Table 70: Injection Site Adverse Reactions within 5 Days Following Any 9vHPV
Vaccination (Rate ≥ 1% in One or More Vaccination Groups) by Age and Gender across
All Studies1
9 to 15 Year-old
9 to 15 Year-old 9 to 15 Year-old
Girls and Boys
Girls
Boys
2
2
2
(N =3436)
(N =1776)
(N =5212)
3
3
3
n (%)
n (%)
n (%)
Total AEs
4153 (79.7)
2850 (82.9)
1303 (73.4)
Mild
2512 (48.2)
1617 (47.1)
895 (50.4)
Moderate
1444 (27.7)
1068 (31.1)
376 (21.2)
Severe
197 (3.8)
165 (4.8)
32 (1.8)
Pain
4131 (79.3)
2836 (82.5)
1295 (72.9)
Swelling
1783 (34.2)
1282 (37.3)
501 (28.2)
Erythema
1470(28.2)
1041 (30.3)
429 (24.2)
Pruritus
138 (2.6)
109 (3.1)
29 (1.6)
Bruising
2 (0.0)
2 (0.1)
0 (0.0)
Hematoma
103 (2.0)
75 (2.2)
28 (1.6)
Mass
13 (0.2)
10 (0.3)
3 (0.2)
Hemorrhage
51 (1.0)
35 (1.0)
16 (0.9)
Induration
57 (1.1)
37 (1.1)
20 (1.1)
Source: Adapted from STN125508/0.43_Module 1.11.3_Tables 40-41(p93-96) and Tables
Adverse
Reactions

16 to 26 Year-old
Women
2
(N =8022)
3
n (%)
7219 (90.0)
4222 (52.6)
2652 (33.1)
345 (4.3)
7193 (89.7)
3225 (40.2)
2750 (34.3)
447 (5.6)
137 (1.7)
106 (1.3)
97 (1.2)
76 (0.9)
58 (0.7)

42-43 (p97-01)
Data for 16 through 26 year-old women were from Protocols 001, 002 and 006. Data for
9 through 15 year-olds were from Protocols 002, 005, 006, 007 and 009.
2
N=Subjects in population with follow-up.
3
n=Subjects with one or more corresponding adverse reactions.
1

Reviewer’s comments: Injection site adverse reactions were collected for 15 days after
each vaccination, but only the adverse reactions with onset in the first 5 days after each
vaccination are reported in the draft package insert. The same approach was used for
the approved Gardasil package insert. In addition, there was no significant difference in
the frequencies of injection site adverse reactions between the first 5 days and the first
15 days-. In the six studies, the frequencies of injection site adverse reactions within the
first 15 days post dose 1, 2 and 3 were 72.3%, 67.7% and 68.1%, respectively, while the
those within the first 5 days post dose 1, 2 and 3 were 67.6%, 67.5% and 68.0%,
respectively [Data source: STN125508/0_Module 2.7.4_Appendixes 2.7.4: 22-27 (p359364)].

Page 131

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

The frequencies of both injection site reactions and systemic adverse experiences in 9
through 15 year-olds in general were numerically lower than those in 16 through 26
year-olds. Since the study design for 9 through 15 year-olds clinical trials (V503-002,
005, 007 and 009) was open label, and the study design for 16 through 26 year-old
females (V503-001) was randomized and double-blind, it is possible that this difference
was caused in part by observation bias. However, there were similar observations in the
placebo controlled studies in the Gardasil program, with numerically lower rates of
adverse reactions among younger subjects compared with older subjects. For example,
the rates of injection-site reactions in 10 to 15 year-old males, 10 to 15 year-old females
and 16 to 23 year-old females were 74.0%, 80.4% and 87.5%, respectively..
8.4.7.2 Severity of Solicited Injection Site Reactions
Table 71 presents the numbers and percentages by severity grade of subjects in all
studies with solicited injection-site reactions within 5 days following any vaccination.
Table 71: Solicited Injection Site Adverse Reactions within 5 Days Following Each and
Any 9vHPV Vaccination by Intensity across the Studies (Protocols 001, 002, 005, 006,
007 and 009)
Dose 1
N (%)
13231

Dose 2
N (%)
13069

Dose 3
N (%)
12933

Any Dose
N (%)
13234

Subjects in population
Adverse Reactions
Pain
Mild
7093 (53.6)
6249 (47.8)
5892 (45.6)
6778 (51.2)
Moderate
1526 (11.5)
2131 (16.3)
2319 (17.9)
4032 (30.4)
Severe
89 (0.7)
205 (1.6)
303 (2.3)
524 (4.0)
Swelling
Mild
1280 (9.6)
2,010 (15.4)
2408 (18.6)
3,384 (25.6)
Moderate
242 (1.8)
506 (3.9)
639 (4.9)
1,042 (7.8)
Severe
110 (0.8)
229 (1.7)
346 (2.7)
574 (4.3)
Erythema
Mild
1141 (8.6)
1832 (14.0)
2159 (16.7)
3358 (25.4)
Moderate
125 (0.9)
262 (2.0)
347 (2.7)
617 (4.7)
Severe
30 (0.2)
65 (0.5)
152 (1.2)
232 (1.7)
Source: STN125508/0.43_Module 1.11.3_Table 44-51(p102-110).
Note: Percentages are calculated based on the number of subjects with temperature data.

8.4.8 Adverse Events of Special Interest
The potential autoimmune disorders observed in the 9vHPV and the qHPV groups in
general are balanced by preferred term except MS, type 1 diabetes mellitus, and
Raynaud’s disease. The overall the number of reported cases of type 1 diabetes mellitus
(3 cases in 9vHPV vs. no case in qHPV), Raynaud’s phenomenon (2 cases in 9vHPV
vs. no case in qHPV) and MS (5 cases in 9vHPVvs. 2 cases in qHPV) were small, and
the clinical relevance of the imbalance between treatment groups is unclear.
8.5 Additional Safety Evaluations
8.5.1 Dose Dependency for Adverse Events
The safety profile of the 3 dose formulations (termed low, mid and high dose formulation)
was assessed in Part A of Protocol V503-001. Approximately 1240 female subjects 16
through 26 years of age were equally randomized to one of the 3 dose formulations of

Page 132

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

9vHPV vaccine or qHPV vaccine (approximately 310 subjects per group). The 3 dose
formulations had essentially the same safety profile.
8.5.2 Product-Demographic Interactions
The adverse experience profile of 9vHPV was assessed by age, gender and
racial/ethnic grouping. The following racial categories were evaluated: White, Black,
Asian, and Other. The ethnic categories included only Hispanic/non-Hispanic. Subjects
were included in specific categories based on the subjects’ own identification of their
racial/ethnic group. Analysis of adverse experiences by race/ethnicity also indirectly
assessed the impact of region of origin: most subjects of Asian descent were enrolled in
Asia, most Hispanic-Americans were enrolled in Latin America, most subjects of African
descent were enrolled in the Americas and Africa, and subjects of "Other Races" were
generally enrolled in Latin America (i.e., mixed Black, White, and/or Native American
descent). Please also refer to Section 8.4.6 and Section 8.4.7 for subgroup analyses by
age and gender.
8.5.3.1 Injection Site Reaction Subgroup Analyses by Race and Ethnicity
For each race or ethnic group, the rates of solicited injection-site reactions (erythema,
pain and swelling) in boys and girls 9 through 15 years of age were numerically lower
compared with those among the young women 16 through 26 years of age in the
corresponding race and ethnic group. In general, the rates of injection-site reactions
were comparable among race and ethnic groups. The rates of injection-site reactions in
Blacks for both age groups were numerically lower compared with those among other
race and ethnic groups in the corresponding age group. Table 72 presents the rates of
solicited injection site reactions among 16 through 26 year-old female subjects and 9
through 15 year-old boys and girls by race and ethnicity groups.
Table 72: Solicited Injection Site Reactions within 5 Days Following Any 9vHPV
Vaccination by Race and Ethnicity across Studies (Protocols 001, 002, and 006)
Adverse Events

White
n (%)

Black
n (%)

Asian
n (%)

Other Race
n (%)

Hispanic
n (%)

NonHispanic
n (%)

16-26 Year-olds
Subjects with
4,514
291
1,180
2,037
2,736
5,285
Follow-up
Subjects with
4,190 (92.8)
239 (82.1)
1,019 (86.4)
1,816 (89.2)
2,447 (89.4)
4,816 (91.0)
one or more AE
Erythema
1,785 (39.5)
63 (21.6)
364 (30.8)
538 (26.4)
727 (26.6)
2,023 (38.3)
Pain
4,155 (92.0)
237 (81.4)
999 (84.7)
1,802 (88.5)
2,430 (88.8)
4,762 (90.1)
Swelling
1,923 (42.6)
117 (40.2)
470 (39.8)
715 (35.1)
994 (36.3)
2,231 (42.2)
9-15 Year-olds
Subjects with
3,230
280
701
1,001
1,541
3,671
Follow-up
Subjects with
2,768 (85.7)
187 (66.8)
548 (78.2)
736 (73.5)
1,173 (76.1)
3,066 (83.5)
one or more AE
Erythema
1,055 (32.7)
50 (17.9)
136 (19.4)
229 (22.9)
400 (26.0)
1,070 (29.1)
Pain
2,696 (83.5)
180 (64.3)
530 (75.6)
725 (72.4)
1,155 (75.0)
2,976 (81.1)
Swelling
1,199 (37.1)
91 (32.5)
195 (27.8)
298 (29.8)
488 (31.7)
1,295 (35.3)
Source: Generated by CBER reviewer from STN125508/0.43_Module 1.11.3_Tables 52-63: 81 (p111-124).

8.5.3.2 Systemic Adverse Reactions: Subgroup Analyses by Race and Ethnicity
The rates of subjects with one or more systemic adverse reactions among each race
and ethnic group were comparable in women 16 through 26 years of age. Table 73

Page 133

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

presents for 16 through 26 year-old females the rates across all studies of systemic
adverse reactions within 15 days following any 9vHPV vaccination (Rate ≥ 1%),
regardless of causality and by system organ class and preferred term.
Table 73: Systemic Adverse Events within 15 Days Following Any 9vHPV Vaccination Regardless of
Causality and by System Organ Class and Preferred Term (Rate ≥ 1%) among 16 through 26 Year-Old
Females (Protocols 001, 002, and 006)
Adverse Events

Subjects in population
with follow-up
with one or more
systemic adverse events
Ear and labyrinth
disorders
Gastrointestinal
disorders
Abdominal pain
Abdominal pain upper
Diarrhea
Nausea
Vomiting
General disorders and
administration site
conditions
Fatigue or Malaise
Pyrexia
Infections and
infestations
Influenza
Nasopharyngitis
Upper respiratory tract
infection
Injury, poisoning and
procedural
complications
Musculoskeletal and
connective tissue
Disorders
Arthralgia
Back pain
Myalgia
Neck pain
Pain in extremity
Nervous system
disorders
Dizziness
Headache
Migraine
Psychiatric disorders
Reproductive system
and breast disorders
Dysmenorrhoea
Respiratory, thoracic
and mediastinal
Disorders
Cough
Nasal congestion
Oropharyngeal pain

White
n (%)

Black
n (%)

Asian
n (%)

Other Races
n (%)

Hispanic
n (%)

NonHispanic
n (%)
5285

4514

291

1180

2037

2736

2552 (56.5)

177 (60.8)

549 (46.3)

1233 (60.5)

1679 (61.4)

2832 (53.6)

47 (1.0)

3 (1.0)

--*

--*

--*

--*

802 (17.8)

41 (14.1)

144 (12.2)

348 (17.1)

467 (17.1)

868 (16.4)

87 (1.9)
125 (2.8)
146 (3.2)
409 (9.1)
101 (2.2)
551 (12.2)

10 (3.4)
7 (2.4)
9 (3.1)
10 (3.4)
--*
59 (20.3)

15 (1.3)
28 (2.4)
37 (3.1)
48 (4.1)
--*
161 ( 1 3.6)

74 (3.6)
44 (2.2)
68 (3.3)
104 (5.1)
47 (2.3)
297 (14.6)

99 (3.6)
56 (2.0)
95 (3.5)
146 (5.3)
60 (2.2)
404 (1 4.8)

87 (1.6)
148 (2.8)
165 (3.1)
425 (8.0)
99 (1.9)
664 (12.6)

206 (4.6)
240 (5.3)
688 (15.2)

10 (3.4)
39 (13.4)
37 (12.7)

37 (3.1)
99 (8.4)
141 (11.9)

71 (3.5)
167 (8.2)
405 (19.9)

84 (3.1)
238 (8.7)
535 (19.6)

245 (4.6)
307 (5.8)
736 (13.9)

134 (3.0)
285 (6.3)
--*

14 (4.8)
8 (2.7)
3 (1.0)

--*
57 ( 4 . 8 )
38 ( 3 . 2 )

172 (8.4)
110 (5.4)
--*

217 (7.9)
131 (5.2)
--*

114 (2.2)
325 (6.1)
61 (1.2)

60 (1.3)

3 (1.0)

18 (1.5)

--*

--*

75 (1.4)

378 (8.4)

19 (6.5)

67 (5.7)

154 (7.6)

206 (7.5)

412 (7.8)

52 (1.2)
92 (2.0)
90 (2.0)
55 (1.2)
49 (1.1)
1371 (30.4)

--*
6 (2.1)
4 (1.4)
--*
4 (1.4)
109 (37.5)

--*
13 (1.1)
25 (2.1)
--*
--*
211 (17.9)

--*
38 (1.9)
37 (1.8)
--*
45 (2.2)
740 (36.3)

--*
55 (2.0)
54 (2.0)
--*
56 (2.0)
1003 ( 36.7)

--*
94 (1.8)
102 (1.9)
57 (1.1)
--*
1428 (27.0)

213 (4.7)
1202 (26.6)
61 (1.4)
55 (1.2)
251 (5.6)

11 (3.8)
100 (34.4)
4 (1.4)
--*
30 (10.3)

40 (3.4)
172 (14.6)
--*
12 (1.0)
58 (4 .9)

123 (6.0)
667 (32.7)
32 (1.6)
24 (1.2)
156 (7.7)

152 (5.6)
902 (33.0)
47 (1.7)
27 (1.0)
199 (7.3)

235 (4.4)
1239 (23.4)
57 (1.1)
64 (1.2)
296 (5.6)

136 (3.0)
399 ( 8.8)

21 (7.2)
21 (7.2)

32 (2.7)
74 (6.3)

90 (4.4)
127 (6.2)

117 (4.3)
164 (6.0)

162 (3.1)
457 (8.6)

72 (1.6)
54 (1.2)
267 (5.9)

3(1.0)
--*
8 (2.7)

19 (1.6)
--*
41 (3.5)

34 (1.7)
--*
62 (3.0)

41 (1.5)
--*
73 (2.7)

87 (1.6)
65 (1.2
305 (5.8)

Page 134

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Adverse Events

White
n (%)

Black
n (%)

Asian
n (%)

Other Races
n (%)

Hispanic
n (%)

NonHispanic
n (%)
193 ( 3.7)

Skin and subcutaneous
168 (3.7)
5 (1.7)
38 (3.2)
71 (3.5)
89 ( 3.3)
tissue disorders
Source: Generated by CBER reviewer from STN125508/0.43_Module 1.11.3_Tables 64-69(p125-136).
*--: no data or the percentage was <1%.

The rates of subjects with one or more systemic adverse reactions among Blacks and
Asian were numerically lower (around 30%) compared with those (around 50%) among
Whites, Hispanic, Non-Hispanic and other Races in boys and girls 9 through 15 years of
age. Table 74 present for 9 through 15 year-old males and females the rates across all
studies of systemic adverse events within 15 days following any 9vHPV vaccination
(Rate ≥ 1%), regardless of causality and by system organ class and preferred term.
Table 74: Systemic Adverse Events within 15 Days Following Any 9vHPV Vaccination
Regardless of Causality and by System Organ Class and Preferred Term (Rate ≥ 1%) among
9 through 15 Year-old Males and Females (Protocols 002, 005, 006, 007 and 009)
Adverse Events

White
n (%)

Black
n (%)

Asian
n (%)

Hispanic
n (%)

701

Other
Races
n (%)
1001

1541

NonHispanic
n (%)
3671

Subjects in population
with follow-up
with one or more
systemic adverse
events
Ear and labyrinth
disorders
Ear pain
Eye disorders
Gastrointestinal
disorders
Abdominal pain
Abdominal pain upper
Diarrhea
Nausea
Vomiting
General disorders
and administration
site conditions
Fatigue or Malaise
Pyrexia
Infections and
infestations
Gastroenteritis
Influenza
Nasopharyngitis
Rhinitis
Upper respiratory tract
infection
Injury, poisoning and
procedural
complications
Musculoskeletal and
connective tissue
Disorders
Back pain
Myalgia
Pain in extremity

3230

280

1769 (54.8)

96 (34.3)

236 (33.7)

524 (52.3)

775 (50.3)

1850 (50.4)

51 (1.6)

1 (0.4)

--*

11 (1.1)

20 (1.3)

45 (1.2)

31(1.0)
35 (1.1)
514 (15.9)

1 (0.4)
--*
20 (7.1)

--*
40 (5.7)

10 (1.0)
9 (0.9)
110 (11.0)

17 (1.1)
170 (11.0)

26 (0.7)
38 (1.0)
514 (14.0)

67 (2.1)
157 (4.9)
73 (2.3)
157 (4.9)
93 (2.9)
552 (17.1)

9 (3.2)
6 (2.1)
3 (1.1)
--*
40 (14.3)

7 (1.0)
--*
10 (1.4)
--*
10 (1.4)
92 (13.1)

31 (3.1)
12 (1.2)
23 (2.3)
17 (1.7)
27 (2.7)
211 (21.1)

39 (2.5)
21 (1.4)
35 (2.3)
37 (2.4)
40 (2.6)
290 (18.8)

66 (1.8)
158 (4.3)
77 (2.1)
142 (3.9)
93 (2.5)
605 (16.5)

94 (2.9)
364 (11.3)
532 (16.5)

--*
35 (12.5)
14 (5.0)

--*
83 (11.8)
71 (10.1)

39 (3.9 )
171 (17.1)
202 (20.2)

46 (3.0)
230 (14.9)
272 (17.7)

116 (3.1)
423 (11.5)
547 (14.9)

50 (1.5)
41 (1.3)
147 (4.6)
39 (1.2)
109 (3.4)

1 (0.4)
4 (1.4)
3 (1.1)
--*
4 (1.4)

--*
--*
28 (4.0)
--*
17 (2.4)

29 (2.9)
20 (2.0)
45 (4.5)
--*
56 (5.6)

30 (1.9)
35 (2.3)
75 (4.9)
--*
53 (3.4)

51 (1.4)
30 (0.8)
148 (4.0)
39 (1.1)
133 (3.6)

116 (3.6)

--*

13 (1.9)

21 (2.1)

36 (2.3)

115 (3.1)

187 (5.8)

9 (3.2)

18 (2.6)

36 (3.6)

64 (4.2)

186 (5.1)

32 (1.0)
31 (1.0)
63 (2.0)

--*
2 (0.7)
2 (0. 7)

--*
6 (0.9)
6 (0.9)

--*
12 (1.2)
12 (1.2)

--*
23 (1.5)
20 (1.3)

--*
--*
63 (1.7)

Page 135

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0
Adverse Events

White
n (%)

Black
n (%)

Asian
n (%)

Other
Races
n (%)
208 (20.8)

Hispanic
n (%)

NonHispanic
n (%)
861 (23.5)

Nervous system
880 (27.2)
47 (16.8)
71 (10.1)
345 (22.4)
disorders
Dizziness
10 (1.4)
90 (2.8)
10 (3.6)
25 (2.5)
45 (2.9)
90 (2.5)
Headache
799 (24.7)
43 (15.4)
60 (8.6)
187 (18.7)
307 (19.9)
782 (21.3)
Reproductive system
61 (1.9)
--*
--*
12 (1.2)
23 (1.5)
54 (1.5)
and breast disorders
Dysmenorrhoea
52 (1.6)
--*
--*
9 (0.9)
17 (1.1)
47 (1.3)
Respiratory, thoracic
365 (11.3)
10 (3.6)
20 (2.9)
47 (4.7)
97 (6.3)
345 (9.4)
and mediastinal
Disorders
Cough
9 (0.9)
118 (3.7)
4 (1.4)
10 (1.4)
32 (2.1)
109 (3.0)
Nasal congestion
--*
48 (1.5)
1 (0.4)
--*
--*
41 (1.1)
Oropharyngeal pain
190 (5.9)
3 (1.1)
--*
19 (1.9)
34 (2.2)
182 (5.0)
Skin and
99 (3.1)
5 (1.8)
13 (1.9)
27 (2.7)
34 (2.2)
110 (3.0)
subcutaneous tissue
disorders
Source: Generated by CBER reviewer from STN125508/0.43_Module 1.11.3_Tables 70-75(p137-167).
*--sign means no data available or the percentage was <1%.

8.5.5 Product-Product Interactions
8.5.5.1 Concomitant Administration with Menactra and Adacel (Study V503-005)
Overall Adverse Event Summary
The primary safety objective of this open-label, randomized study was to evaluate the
tolerability of the concomitant administration of a first dose of 9vHPV with Menactra and
Adacel in boys and girls 11 to 15 years of age. Please refer to Section 7.1.9.1 for details
of the study design.
The frequency of AEs was generally similar between the concomitant and conconcomitant groups. One subject (0.2%) in each group (1/613 in the concomitant group
and, 1/611 in the non-concomitant group) was discontinued due to an AE. Five subjects
in each group (5/613 in the concomitant group and 5/611 in the non-concomitant group)
(0.8%), reported SAEs over the duration of the study. All the reported SAES were not
related to study treatment.
In the concomitant group, one discontinuation (AN 34232) of the study vaccination
occurred due to a vaccine-related severe pyrexia that resolved spontaneously after two
days on Day 2 following Vaccination 2. This patient continued in the study follow-up. In
the non-concomitant group, one discontinuation (AN 34258) of the study vaccination
followed by discontinuation from the study occurred due to vaccine-related severe pain
in the extremity following dose 1 of 9vHPV, which resolved spontaneously after 4 days.
Comparison of Injection-Site Adverse Reactions
Injection-site reactions were assessed in the concomitant and non-concomitant groups
with respect to the numbers and percentages of subjects who reported solicited
injection-site reactions at the 9vHPV injection-site (following the first dose) and at the
Menactra/Adacel injection-site. Generally, the solicited injection-site reactions at both

Page 136

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

9vHPV and Menactra/Adacel injection-sites were similar between concomitant and nonconcomitant groups in terms of the frequency and intensity of the reactions.
Summary of Systemic Adverse Experiences
The numbers and percentages of subjects who reported specific systemic clinical AEs
within 15 days following Vaccination 1 are compared by system organ class between the
concomitant and non-concomitant groups. The proportions of systemic adverse
experiences were similar between the two groups. Most of the AEs were mild or
moderate. The proportions of severe systemic adverse experiences in the concomitant
and non-concomitant groups were 4.7% and 3.8%, respectively.
The solicited systemic adverse reactions and maximum oral temperatures in Days 1 to 5
following Vaccination 1 were also similar between the concomitant and non-concomitant
groups (approximately 8% of subjects with temperature ≥ 37.8°C in each group).
Summary of Serious Adverse Events
There were 11 SAEs in 10 subjects reported during this study, all of which were nonfatal.
The number of subjects with SAEs in the study was comparable in the two groups, with
six in the concomitant group and 5 in the non-concomitant group, all of which resolved.
In the concomitant group, two subjects had appendicitis, and one subject each had
abdominal wall seroma, mood disorder, and left testicular torsion. In the nonconcomitant group, one subject had gastroenteritis and orthostatic hypotension, and one
subject each had appendicitis, bronchitis, classic dengue and depression disorder. None
was vaccine-related as judged by the investigators. None of the SAEs resulted in
discontinuation. No subject died in this study.
SAEs occurring within 28 days following any vaccination are listed in Section 8.4.2.
Reviewer’s comments: This reviewer concurs with the investigators that none of the
SAEs were vaccine related.
Conclusion
The safety profile was generally favorable and similar between the concomitant and nonconcomitant groups.
8.5.5.2 Study of 9vHPV in Prior Gardasil Recipients (Study V503-006)
Summary of Overall Clinical Adverse Experiences
The safety profile of 9vHPV was evaluated in a placebo controlled, double-blind trial with
females 12 to 26 years of age who previously received a 3-dose regimen of qHPV. A
summary of clinical adverse experiences by vaccination group from Day 1 through the
end of the study is provided in Table 75.

Page 137

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 75: Adverse Event Summary (Day 1 to End of Study) (Study V503-006, All
Vaccinated Subjects)
9vHPV Vaccine
n (%)
608
583 (95.9)
554 (91.1)
374 (61.5)
566 (93.1)
554 (91.1)

Placebo
n (%)
305
229 (75.1)
135 (44.3)
177 (58.0)
175 (57.4)
135 (44.3)

Subjects in population with follow-up
Subjection with one or more adverse events
Subjects with injection-site reactions
Subjects with non-injection-site reactions
Subjects with vaccine-related adverse events
Subjects with vaccine-related injection-site
reactions
Subjects with vaccine-related non-injection-site
186 (30.6)
79 (25.9)
reactions
Subjects with SAE
3 (0.5)
3 (1.0)
Subjects with vaccine-related SAE
1 (0.2)
1 (0.3)
Subjects who died
0 (0.0)
0 (0.0)
Subjects who discontinued due to an AE
3 (0.5)
0 (0.0)
Subjects who discontinued due to a vaccine3 (0.5)
0 (0.0)
related AE
Subjects who discontinued due to an SAE
0 (0.0)
0 (0.0)
Source: Replicated from STN125508/0_Module 5.3.5.1.p006_CSR_Table 12-2 (p140)

Three subjects in the 9vHPV group (3/608 [0.5%]) discontinued study vacci-tion due to
an adverse experience. Subject AN37058 experienced abdominal pain and diarrhea 14
days after her second dose. Subject AN37035 experienced a swollen tongue 1 day after
her first dose. The third subject (AN 37080) experienced injection-site swelling and
erythema 1 day after her first dose of 9vHPV. This subject was the only one with AEs of
erythema and swelling with a maximum size >6 and ≤7 inches. All of these adverse
experiences resolved after a few days and were judged by the investigators to be
vaccine related and non-serious.
A total of 20 subjects (13 in 9vHPV, 7 in qHPV) reported from post-Day 1 through Month
7 an incident condition that was potentially indicative of a systemic autoimmune disorder.
In the 9vHPV vaccine group, 13 subjects reported arthralgia. In the placebo group, 4
subjects reported arthralgia, 2 subjects reported goiter, and 1 subject reported
hypothyroidism. None of these events was considered to be an autoimmune condition by
the reporting investigator.
Reviewer’s comments: This reviewer concurs with the reporting investigators that the
arthralgia observed in the 13 subjects vaccinated with 9vHPV was not a systemic
autoimmune disorder.
This was the only placebo controlled study to evaluate the safety profile of the 9vHPV
vaccine. However, the study population included subjects who were vaccinated
previously with qHPV. Thus, the safety profiled obtained from this population may not be
applicable to HPV vaccine naïve population.
Summary of Injection Site Reactions
Table 76 presents the numbers and proportions of subjects who reported at least one
injection-site adverse reaction within 5 days of any vaccination. Across both vaccination

Page 138

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

groups, the most common injection-site adverse reactions following any vaccination visit
were pain, swelling, and erythema.
Table 76: Injection Site Reactions of 9vHPV in 12 to 26 Year-old Females Who were
Previously Vaccinated with qHPV (Rate ≥ 1% in Days 1 to 5 Post-vaccination, Study
V503-006)
Adverse
Intensity Grading 9vHPV
Saline Placebo
Events
N (%)
N (%)
Population
608
305
Pain
Total
549 (90.3)
116 (38.0)
Mild
316 (52.0)
105 (34.4)
Moderate
209 (34.4)
10 (3.3)
Severe
24 (3.9)
1 (0.3)
Swelling
Total
298 (49.0)
18 (5.9)
Mild
182 (29.9)
13 (4.3)
Moderate
65 (10.7)
3 (1.0)
Severe
46 (7.6)
1 (0.3)
Erythema
Total
257 (42.3)
26 (8.5)
Mild
190 (31.3)
22 (7.2)
Moderate
39 (6.4)
0 (0.0)
Severe
20 (3.3)
1 (0.3)
Pruritus
Total
47 (7.7)
4 (1.3)
Mild
31 (5.1)
4 (1.3)
Moderate
14 (2.3)
0 (0.0)
Severe
2 (0.3)
0 (0.0)
Hematoma
Total
29 (4.8)
7 (2.3)
Mild
24 (3.9)
6 (2.0)
Moderate
5 (0.8)
1 (0.3)
Reaction
Total
8 (1.3)
1 (0.3)
Mild
6 (1.0)
0 (0.0)
Moderate
2 (0.3)
1 (0.3)
Mass
Total
7 (1.2)
2 (0.7)
Mild
6 (1.0)
2 (0.7)
Moderate
1 (0.2)
0 (0.0)
Source: Adapted from STN125508/0_Module 5.3.5.1.p006_CSR_Table 12-6 (p148-9) and Table
12-7 (p150).

Reviewer’s comments: Although the proportions of subjects with overall injection site
reactions were similar to those in HPV vaccine naïve females in the other studies, the
proportions of injection site swelling and erythema and the corresponding intensities
were numerically higher among subjects who were previously vaccinated with qHPV
(Please refer to Tables 30, 44 and 73).
Summary of Systemic Adverse Experiences
Systemic clinical adverse experiences from Day 1 to 15 following any vaccination were
analyzed by system organ class. In both vaccination groups, the most common clinical
adverse experiences were headache (9vHPV 30.9% vs. placebo 26.6%), fatigue (9vHPV
3.5% vs. placebo 3.6%), and pyrexia (9vHPV 6.7% vs. placebo 3.3%).

Page 139

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

The numbers and percentages of subjects who reported specific systemic clinical
adverse experiences from Day 1 to 15 following any vaccination were similar between
9vHPV and placebo groups, except for higher frequencies of the following events:
• Abdominal Discomfort: 1.3% (8/608) in the 9vHPV group vs. no case in the
placebo group.
• Dizziness: 4.9% (30/608) in the 9vHPV group vs. 2.0% (6/305) in the placebo
group.
• Nausea: 8.6% (52/608) in the 9vHPV group vs. 3.9% (12/305) in the placebo
group.
• Pyrexia: 6.7% (41/608) in the 9vHPV group vs. 3.3% (10/305) in the placebo
group.
Most of the systemic adverse experiences reported by subjects across the two groups
were of mild or moderate intensity. The proportion of subjects in the 9vHPV group with
severe systemic adverse experiences was 10.4% (63/608), while that for the placebo
group was 11.1% (34/305).
Table 77 presents by system organ class the numbers and percentages of subjects with
vaccine-related systemic adverse experiences from Day 1 to 15 following any
vaccination (rate ≥1% in one or more vaccination groups).
Table 77: Vaccine-Related Systemic Adverse Events within 15 Days Post-Vaccination
(Rate ≥1% in One or More Vaccination Groups) Among Females 12 to 26 Years of Age
Previously Vaccinated with qHPV (Study V503-006)
Adverse Events
9vHPV
Saline placebo
N (%)
N (%)
Subjects in population with follow-up
608
305
with one or more systemic adverse events
186 (30.6)
79 (25.9)
Gastrointestinal disorders
44 (7.2)
12 (3.9)
Abdominal pain upper
9 (1.5)
2 (0.7)
Diarrhea
4 (0.7)
3 (1.0)
Nausea
24 (3.9)
6 (2.0)
Vomiting
6 (1.0)
3 (1.0)
General disorders and administration site
50 (8.2)
16 (5.2)
conditions
11 (1.8)
7 (2.3)
Fatigue
5 (0.8)
3 (1.0)
Malaise
Pyrexia
31 (5.1)
5 (1.6)
Infections and infestations
15 (2.5)
7 (2.3)
Influenza
7 (1.2)
3 (1.0)
Musculoskeletal and connective tissue
11 (1.8)
4 (1.3)
Disorders
Nervous system disorders
129 (21.2)
61 (20.0)
Dizziness
18 (3.0)
5 (1.6)
Headache
119 (19.6)
55 (18.0)
Psychiatric disorders
7 (1.2)
5 (1.6)
Skin and subcutaneous tissue disorders
11 (1.8)
2 (0.7)
Source: Adapted from STN125508/0_Module 5.3.5.1.p006_CSR_Table 12-14 (p162).

Summary of Serious Adverse Events

Page 140

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Five subjects reported six non-fatal SAEs (three in the 9vHPV group and three in the
placebo group). The three SAEs reported by two subjects in the placebo group were
thoracic and lumbar vertebral fraction (both in Subject AN 37897, snowboarding
accident) and migraine (resulting in hospitalization, Subject AN 37974). The three SAEs
in 9vHPV group are summarized below.
Narrative Summary of SAEs in the 9vHPV Group
Subject AN37083, a 15 year-old white female, was previously vaccinated with Gardasil
vaccine in 2007/2008. On December 5, 2010 (13 days post dose 2 of 9vHPV), she had
an episode of syncope for about 30 minutes. She was hospitalized for clinical
evaluation. Following extensive evaluation, she was diagnosed with dysautonomia. She
recovered from the syncope and was discharged. The investigator assessed the
syncope as not related to vaccine. She received her third dose of 9vHPV on February 9,
2011, as scheduled without subsequent syncope.
Subject AN 37571, an 18 year old white female, developed appendicitis 75 days after
her second dose of 9vHPV. She was hospitalized and underwent laparoscopic
appendectomy the same day. She recovered and received her third dose of 9vHPV as
scheduled. The SAE was considered by the investigator not to be related to the vaccine.
Subject AN 37801, an 18 year old white female, experienced tonsillitis and fever of
38.2oC on the second day after she received her first dose of 9vHPV.
Lymphadenopathy on both sides of the neck was noted. She was hospitalized and
treated with drainage of swollen tonsils, IV Penicillin and a 10-day course of
Metronidazole and Vepicombin. Tonsil incision or puncture in the following 3 consecutive
days produced 1-1.5 ml of purulent fluid. No bacteriological testing was performed. She
recovered from tonsillitis 3 days later and was discharged from the hospital with a
diagnosis of left peritonsillar abscess. She received her second and third doses of
9vHPV as scheduled. The reporting investigator concluded that tonsillitis was related to
9vHPV.
Reviewer’s comments: The symptoms of dysautonomia in Subjects AN 37083
appeared to be consistent with those of postural tachycardia syndrome (POTS). A link
between POTS and Gardasil vaccination has been postulated in a recent report
(Blitshteyn S. Eur J Neurol, 2014; 21: 135-139), though the mechanism for such an
association remains unclear. In this report, six subjects developed symptoms of POTS
within 6 days to 2 months after immunization with Gardasil vaccine. Two patients
experienced significant symptomatic exacerbation following a subsequent Gardasil
injection, suggesting a positive re-challenge result. Since Subject AN 37083 received
Gardasil vaccination approximately two years ago, and her symptoms of dysautonomia
only occurred after the second dose of 9vHPV, it is difficult to determine if the
dysautonomia or syncope is related to 9vHPV.
Conclusion
The overall safety and tolerability profile of 9vHPV was favorable when administered to
12- to 26-year-old females who were previously vaccinated with qHPV. Safety and
tolerability findings in that population were generally consistent with those previously
reported in HPV-vaccine naïve 9- to 26-year-old -females following administration of a 3-

Page 141

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

dose regimen of the qHPV vaccine and in HPV vaccine naïve 9 through 15 year-old
males and females and 16 through 26 year-old females following administration of
9vHPV in other studies included in this submission.
8.5.5.3 Concomitant Administration with Repevax (Study V503-007)
The safety and immunogenicity of the 9vHPV vaccine when concomitantly administered
with Repevax was investigated, and the study design and clinical evaluation were similar
to those of Study V503-005. This reviewer assessed all the immunogenicity and safety
data of this trial. Concomitant administration of the 9vHPV with Repevax did not
negatively impact on immunogenicity of 9vHPV vaccine and Repevax, as well as the
safety profile. Since Repevax is not licensed in the U.S., the evaluation of this trial is not
documented in this review. However, the safety data is included in the pooled integrated
safety analyses.
8.6 Safety Conclusions
Based on the integrated safety data for 9vHPV, this reviewer concludes that:
• The safety profile of 9vHPV is favorable in female subjects 16 through 26 years
of age, as well as in female and male subjects 9 through 15 years of age. The
safety profile of 9vHPV is generally similar to that of qHPV among subjects 9 to
26 years of age.
• Use of 9vHPV among subjects 9 to 26 years of age is associated with an
increase in injection-site adverse reactions compared with qHPV. However,
most of the injection-site adverse reactions in subjects administered 9vHPV are
mild or moderate in intensity.
• In general, frequencies and intensities of injection-site adverse reactions are
similar following administration of a first, second, and third dose of 9vHPV;
however, the frequencies of injection-site erythema and swelling were increased
at each consecutive vaccine administration.
• The safety profiles of 9vHPV in males 9 through 15 years of age and females, 9
through 15 years of age are generally similar.
• The safety profile of 9vHPV does not appear to be impacted by racial
background, ethnicity, or continent of origin.
• The safety profile of 9vHPV is favorable in females 12 to 26 years of age who
previously received a 3-dose regimen of qHPV. However, administration of
9vHPV in prior qHPV recipients is associated with higher proportions of subject
with injection-site swelling and erythema than in subjects who are naïve to HPV
vaccination. Most of these injection-site adverse reactions are mild in intensity.
• The safety profile of 9vHPV is not impacted by concomitant vaccination with
Menactra and Adacel.
• Overall rates of new onset autoimmune disorders were similar between 9vHPV
recipients and qHPV recipients and were generally within rates observed in the
general population. However, there was an imbalance between 9vHPV and
qHPV in small numbers of cases of multiple sclerosis, type 1 diabetes mellitus,
and Raynaud’s phenomenon with higher rates of each among 9vHPV recipients.
The incidence rates for these medical conditions in the 9vHPV group are within
the ranges reported in the general population of similar ages.

Page 142

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

9. ADDITIONAL CLINICAL ISSUES
9.1 Special Populations
9.1.1 Human Reproduction and Pregnancy Data
9.1.1.1 Pregnancy Outcomes in Clinical Studies
Table 78 presents the pregnancy outcome summary from all studies submitted to the
application. Overall, 1213 subjects who received 9vHPV in Protocols V503-001, -002
and 006 experienced 1373 pregnancies. The vast majority of these pregnancies (~98%)
occurred in subjects enrolled in Protocol V503-001. An adverse pregnancy outcome
was defined as spontaneous abortion (SAB), late fetal death ectopic pregnancy or
congenital anomaly. The overall proportion of pregnancies with a known outcome that
ended in a fetal loss (excluding elective abortion) was 12.4% (146/1178) for 9vHPV
recipients and 14.3% (158/1108) for qHPV recipients
Table 78: Summary of Outcomes for Pregnancies that Occurred from Study Day 1
through Visit Cut-Off Date (All Vaccinated Subjects, Protocols V503-001, -002 and -006)
Population and Pregnancy
9vHPV (N=10,105)
qHPV ((N=7,093)
Outcomes
n (%)
n (%)
Number of Subjects
10,055
7,093
Subjects with pregnancies
1,213 (12.1)
1,129 (15.9)
Number of pregnancies
1,373
1,300
Number of pregnancies
1,178
1,108
with known outcome
Live Births1
897 (76.1)
841 (75.9)
Infant Outcome
Normal
868 (96.8)
811 (96.4)
Congenital Anomaly
14 (1.6)
18 (2.1)
Other Abnormality
7 (0.8)
11 (1.3)
Unknown
9 (1.0)
5 (0.6)
1
Fetal Loss
281 (23.9)
267 (24.1)
Type of Loss
Ectopic Pregnancy
13 (1.1)
7 (0.6)
Spontaneous Abortion
122 (10.4)
143 (12.9)
Late Fetal Death
3 (0.3)
4 (0.4)
Elective Abortion
143 (12.1)
113 (10.2)
Fetal outcome
Normal
54 (19.2)
43 (16.1)
Congenital Anomaly
6 (2.1)
3 (1.1)
Other Abnormality
2 (0.7)
1 (0.4)
Unknown
215 (76.5)
216 (80.9)
Source: Adapted from STN 125508/0.43_Module 1.11.3_Tables 76-77(p168-171).
1
Percentages of “Live Births”, “Fetal Loss” and “Type of Loss-” are calculated based on the
number of fetuses/infants with known outcome. Percentages under “Infant Outcome” are
calculated based on “Live Births”. Percentages under “Fetal Outcome” are calculated based on
“Fetal Loss”.
N=Number of vaccinated subjects in each vaccination group. n=Number of cases with the
respective category. The “Unknown” category reports the number of congenital anomaly
outcomes that were reported by the study site as “Unknown”.

Page 143

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Reviewer’s comments: The proportions of pregnancies ending in spontaneous
abortion, congenital anomaly and late fetal mortality observed in both the 9vHPV and
qHPV groups were within the ranges reported in the literature for the general population
of women of child-bearing age(37-39). However, the results should be interpreted with
caution when compared to literature reports because pregnancy outcomes vary with
age, ethnicity and race, and no populations reported in literature exactly match the
populations in this study,
The Applicant provided analyses to evaluate differences in pregnancy outcomes among
subjects whose estimated date of conception (EDCn) occurred within 30 days of any
9vHPV vaccination compared with subjects whose EDCn occurred more than 30 days
after any 9vHPV vaccination. Table 79 presents the summary of pregnancy outcomes in
9vHPV recipients by EDCn.
Table 79: Summary of Pregnancy Outcomes among 9vHPV Recipients--Comparing
Estimated Date of Conception (EDCn) within 30 Days of Any Vaccination vs. Not within
30 Days of Any Vaccination (Protocols 001, 002, and 006, Entire Study Period)
Population and Pregnancy
EDCn within 30 Days
EDCn not within 30 Days
Outcomes
n (%)
n (%)
Number of Subjects with
91
1,140
pregnancies
Number of pregnancies
92
1,281
Number of pregnancies
with known outcome
89
1,089
Live Births1
44 (49.4)
853 (78.3)
Infant Outcome
Normal
41 (93.2)
827 (97.0)
Congenital Anomaly
0 (0.0)
14 (1.6)
Other Abnormality
1 (2.3)
6 (0.7)
Unknown
2 (4.5)
7 (0.8)
1
Fetal Loss
45 (50.6)
236 (21.7)
Type of Loss
Ectopic Pregnancy
0 (0.0)
13 (1.2)
Spontaneous Abortion
17 (19.1)
105 (9.6)
Late Fetal Death
1 (1.1)
2 (0.2)
Elective Abortion
27 (30.3)
116 (10.7)
Fetal outcome
Normal
11 (24.4)
43 (18.2)
Congenital Anomaly
0 (0.0)
6 (2.5)
Other Abnormality
0 (0.0)
2 (0.8)
Unknown
34 (75.6)
181 (76.7)
Source: Adapted from STN 125508/0.43_Module 1.11.3 Tables 78 &79(p172-175)).
1
Percentages of “Live Births”, “Fetal Loss” and “Type of Loss-” are calculated based on the
number of fetuses/infants with known outcome. Percentages under “Infant Outcome” are
calculated based on “Live Births”. Percentages under “Fetal Outcome” are calculated based on
“Fetal Loss”.
N=Number of vaccinated subjects in each vaccination group.
n=Number of cases with the respective category.
The “Unknown” category reports the number of congenital anomaly outcomes that were reported
by the study site as “Unknown”.

Page 144

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Because of the protocol requirement for the use of effective contraception from Day 1
through Month 7 and the pregnancy testing prior to each vaccination, only approximately
1% of study subjects who received 9vHPV became pregnant within 30 days of a
vaccination. Pregnancies within this timeframe represented only 6.7% (89/1373) of all
pregnancies reported in subjects who received 9vHPV. Based on the cut-off date for the
current analyses, outcomes were available for 1178 pregnancies. The great majority of
pregnancies whose outcomes were not available at the time of the visit cut-off date were
ongoing (i.e., subjects had not completed their pregnancies). There were no congenital
anomalies reported in pregnancies with an EDCn within 30 days of a study vaccination.
Twenty congenital anomalies were reported among pregnancies with an EDCn not
within 30 days of a study vaccination, including:
• Fourteen congenital anomalies in live infants (including 3 cases that had an
intra-uterine diagnosis and 11 cases diagnosed beyond the neonatal period)
• Six congenital anomalies associated with fetal loss (all 6 cases reported were
elective abortions based on intra-uterine diagnosis)
The SAB rate among the 9vHPV recipients who became pregnant within 30 days of any
vaccination was higher than those who became pregnant not-within 30 days of
vaccination (19.1% vs. 9.6%).
Reviewer’s comment: On April 23, 2014, this reviewer requested that the Applicant
provide the SAB rate among qHPV recipients who became pregnant within 30 days of
any vaccination. The data provided by the Applicant showed that the SAB rate in
subjects who received qHPV and became pregnant within 30 days of any vaccination
was 8.0% (7 spontaneous abortions out of 88 pregnancies with known outcome). The
SAB rate in subjects who received qHPV and had a pregnancy not-within 30 days of any
vaccination was 13.3% (136 out of 1020).
CBER reviewers conducted extensive analyses to explore potential confounding factors
that may contribute to the increased SAB rate for pregnancies beginning within 30 days
of vaccination with 9vHPV. These factors included age, race, geographic regions,
smoking history, previous history of SABs, concomitant medications, history of sexually
transmitted diseases, and baseline serostatus of HPV types. Even after adjusting for
these potentially confounding factors the imbalance in SAB rates remained.
A similar imbalance in elective abortions was also observed between subjects who
became pregnant within 30 days vs. not-within 30 days of vaccination in the 9vHPV
group (30.3% vs. 10.7%, Table 79), and in the qHPV group [36% (38/88) within 30 days
vs. 7.9% (81/1020) not-within 30 days, data submitted to STN 125508/0.13]. The cause
of these imbalances in elective abortions is unknown.
On June 13, 2014, the review team requested that the Applicant provide further
assessments and interpretations for the imbalance in SAB rates. Table 80 presents the
summary of the Applicant’s assessment identifying Latin American region as a potential
confounding variable, based on the large proportion of SABs reported from Latin
American countries and known social and legal barriers to elective abortion in those
countries.

Page 145

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Table 80: Comparison of Spontaneous Abortion Rates between 9vHPV Recipients and
qHPV Recipients Based on Proximity of Estimated Date of Conception (EDCn) Relative
to Vaccination Dates (Protocols 001, All Study Population and Non-Latin American
Population)
Population and
EDCn within 30
EDCn not-within
All SAB
Treatment Group
Days of
30 Days of
n/N (%)
Vaccination
vaccination
n/N (%)
n/N (%)
Entire Population
9vHPV Group
17/60 (28.3%)
105/960 (10.9%)
121/1012 (12.0%)
qHPV Group
7/55 (12.7%)
136/933 (14.6%)
143/988 (14.5%)
Non-Latin Americans
9vHPV Group
5/25 (20.0%)
54/591 (9.1%)
58/610 (9.5%)
qHPV Group
1/31 (3.2%)
70/570 (12.3%)
71/601 (11.8%)
Source: The Table is created by the reviewer based on the data submitted to STN 125508/0.13
(Module 1.11.3) and STN 125508/0.25 (Module 1.11.3) per CBER request.
n=number of spontaneous abortions; N=number of subjects with natural pregnancy outcomes
(i.e., live births, spontaneous abortions, or late fetal death and excluding those terminating in
elective abortion).

As seen in Table 80, even for the Non-Latin American population, the SAB rate among
subjects who received the 9vHPV vaccine and became pregnant within 30 days of any
vaccination was still higher (20%) compared with the SAB rates among subjects who
received the 9vHPV or qHPV vaccine and became pregnant not-within 30 days of
vaccination (9.1% and 12.3% respectively). Because of small numbers of SABs in these
post hoc analyses, it is difficult to determine whether the observed imbalance in SAB
represents a real risk. Consequently, the review team recommended a post-marketing
assessment of SAB, to be conducted collaboratively by FDA and the Centers for
Disease Control and Prevention (CDC) using Vaccine Safety Datalink (VSD).
Reviewer’s comments: Elective abortions are not included in the denominators in
Table 80. As a result, the spontaneous rates in Table 80 are different from the
corresponding rates in Table 79.
9.1.2 Use during Lactation
Breastfeeding was not a contraindication to enrollment or vaccination. Administration of
9vHPV or qHPV to nursing mothers in the phase 3 studies was reported and followed for
outcome of both the mother and her infant until the infant was weaned.
A total of 86 lactating subjects received 9vHPV in Protocols V503-001 and V503-002
(including 85 subjects in Protocol V503-001 and 1 subject in Protocol V503-002). By
comparison, in Protocol V503-001, a total of 87 subjects administered qHPV were
lactating during the vaccination period. No subjects who were lactating during the
vaccination period were enrolled in Protocols V503-005, -006, -007 and -009.
The adverse experience profile of 9vHPV (injection-site reactions and fever in Day 1 to 5
and systemic adverse events in Day 1 to 15 after each vaccination) in lactating women
was generally similar to the adverse experience profile in the overall Safety Population.

Page 146

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

A total of 10 SAEs were reported by 10 lactating 9vHPV recipients. Seven SAEs were
related to pregnancy (e.g., spontaneous abortion, premature labor), and the remaining
three were elective abortion, hemorrhagic fever and ependymoma.
There were no SAEs reported in breastfed infants -9vHPV or qHPV recipients. No safety
signals of clinical concern were identified among these infants.
9.1.3 Pediatric Use and PREA Considerations
The investigational vaccine has been adequately studied in children 9 years of age and
older.
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), this application is
required to contain an assessment of the safety and effectiveness of the product for the
claimed indication in all pediatric age groups. The Applicant requested a partial waiver
from the requirements of PREA for children 0-8 years of age. CBER agreed to grant the
waiver request because initiating vaccination prior to age 8 does not represent a
meaningful therapeutic benefit over initiating vaccination at 9 years of age and older, and
Gardasil 9 is not likely to be used in a substantial number of children in this age group
because the objective of immunization with this vaccine is to prevent diseases that occur
following exposure to HPV.
9.1.4 Immunocompromised Patients
The safety and effectiveness of 9vHPV have not been formally evaluated in
immunocompromised patient populations. Small numbers of subjects were vaccinated
concomitantly with immunosuppressive therapies, and the immunogenicity of 9vHPV in
these subjects compared to the general study population is discussed in detail in Section
7.1.9.4.
9.1.5 Geriatric Use
The safety and effectiveness of 9vHPV have not been evaluated in a geriatric
population, defined as individuals aged 65 years and over.
9.2 Safety Update Reports
9.2.1 Safety Update Report Four Months after the Submission of the BLA
The Applicant submitted a Safety Update Report to STN 125508/0.9 on April 10, 2014.
The safety update included data from three completed clinical trials (V503-005, V503007, and V503-009) and three extension studies of completed clinical trials (V503-001,
V503-002, and V503-006).
In this report, the same investigator from Denmark reported three SAEs assessed as
vaccine-related: one subject (AN 19756) experienced hypersomnia at more than four
years after the third dose of 9vHPV, and two subjects (AN 71508 and AN 71686)
experienced postural tachycardia syndrome (POTS) at more than three years after the
third dose of 9vHPV and qHPV, respectively.
The safety update also reported rates of spontaneous abortions that occurred during the
extended reporting period: 9.4% (128 spontaneous abortions out of 1364 pregnancies

Page 147

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

with known outcomes) in 9vHPV recipients, and 11.7% (156 out of 1334) in qHPV
recipients.
Reviewer’s comments: A recent study (Blitshteyn S. Postural tachycardia syndrome
following human papillomavirus vaccination, Eur J Neurol, 2014; 21: 135-9) reported that
six patients developed new onset POTS 6 days to 2 months following Gardasil
vaccination, suggesting a causal association between POTS and HPV vaccines. Given
the lack of temporal association with vaccination of the events reported in the safety
update, these events were unlikely related to vaccination.
Based on the safety update provided, the conclusions regarding the safety of 9vHPV is
unchanged.
10. CONCLUSIONS
10.1 Efficacy and Immunogenicity
•

•

•

•
•
•
•

Administration of a 3-dose regimen of 9vHPV vaccine to females 16 through 26
years of age induced statistically non-inferior anti-HPV 6, 11, 16, and 18 antibody
responses compared with qHPV vaccine, supporting the bridging of the
protective efficacy of the qHPV vaccine in preventing cervical, vaginal, vulvar,
external genital and anal infection and disease caused by HPV types 6, 11, 16,
and 18 to the 9vHPV vaccine.
Administration of a 3-dose regimen of 9vHPV vaccine to female 16 through 26
years of age was effective in preventing the primary endpoint of HPV
31/33/45/52/58-related, high-grade cervical, vulvar, and vaginal disease (CIN 2
or worse, VIN 2/3 or worse, VaIN 2/3 or worse), the secondary endpoint of the
five new HPV type related persistent infection, and the exploratory endpoint of
invasive procedures (genital biopsy and definitive therapy). Effectiveness in
preventing anal disease caused by these five new HPV types is inferred by
similar disease pathophysiology and immunogenicity of 9vHPV with respect to
these HPV types.
Administration of a 3-dose regimen of 9vHPV vaccine to pre-adolescents and
adolescents 9 through 15 years of age induced statistically non-inferior anti-HPV
6, 11, 16, 18, 31, 33, 45, 52 and 58 antibody responses compared with anti-HPV
responses induced in females 16 through 26 years of age, supporting inference
in the pediatric population of 9vHPV protective efficacy in preventing ano-gential
diseases due to the vaccine HPV types.
The 9vHPV vaccine induced robust anti-HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58
antibody responses through at least 1.5 years post-vaccination.
The final manufacturing process of the 9vHPV vaccine produced materials that
generated consistent Month 7 anti-HPV cLIA responses.
Concomitant administration of a 3-dose regimen of 9vHPV vaccine with Menactra
and Adacel did not interfere with antibody responses to any of the three
vaccines.
Administration of a 3-dose regimen of 9vHPV vaccine in females 12 to 26 years
of age who were previously administered a 3-dose regimen of qHPV vaccine
induced higher anti-HPV 6, 11, 16 and 18, and lower anti-HPV 31, 33, 45, 52 and
58 responses compared with females 12 to 26 years of age who were naïve to

Page 148

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

HPV vaccines. The clinical significance of the reduced responses to the five new
HPV types is unclear.
10.2 Safety conclusion:
•

•

•
•
•

•

•

The safety profile of the 9vHPV vaccine was favorable and generally similar to
that of the qHPV vaccine among subjects 9 to 26 years of age. Use of 9vHPV
vaccine among subjects 9 to 26 years of age was associated with an increased
frequency of injection-site adverse reactions compared with qHPV vaccine.
However, most of the injection-site adverse reactions in subjects administered
9vHPV vaccine were mild or moderate in intensity.
In general, across the 3-dose series of vaccine administration, injection-site
adverse experiences were reported in similar frequencies following
administration of a first, second, and third dose of 9vHPV vaccine; however, the
frequencies of the adverse reactions of injection-site erythema and injection site
swelling were increased at each consecutive vaccine administration.
The adverse experience profiles of 9vHPV vaccine in males and females 9
through 15 years of age were similar to each other and to the adverse
experience profile in females 16 through 26 years of age.
The adverse experience profile of 9vHPV vaccine was not impacted by racial
background, ethnicity, or continent of origin.
The 9vHPV vaccine was generally tolerated in prior qHPV vaccine recipients.
No safety issues were identified following administration of 9vHPV to nursing
mothers, and vaccination did not appear to impact the health of breastfeeding
infants of mothers who received 9vHPV vaccine.
The rates of new onset of medical conditions of potential autoimmune disorders
were similar between the 9vHPV and qHPV treatment groups except for small
numerical imbalances in cases of multiple sclerosis. Women 16 through 26
years of age who received the 9vHPV vaccine reported more cases than women
who received the qHPV vaccine. However, the rate of multiple sclerosis in the
9vHPV group was within the range reported in the general population of similar
ages.
The spontaneous abortion rate among women who received the 9vHPV vaccine
was similar to rate among women who received qHPV. However in a post-hoc
subanalysis the spontaneous abortion rate among women who received the
9vHPV vaccine and became pregnant within 30 days of any vaccination was also
numerically higher than the corresponding rate in women who were immunized
with the qHPV vaccine. The clinical significance of this imbalance is unknown.

Page 149

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

11. RISK-BENEFIT CONSIDERATIONS AND RECOMMENDATIONS
11.1 Risk-Benefit Considerations
A comparison of the risks and benefits of licensure of the 9vHPV vaccine for use in the indicated populations is presented in Table
81.
Table 81: Risk-Benefit Assessment of the 9vHPV Vaccine
Decision Factor
•
•
Analysis of
Condition

•
•
•
•

Unmet Medical
Need
•
•

Clinical Benefit
•

•

Evidence and Uncertainties
HPV infection is nearly universal in sexually active populations.
In a subset of females infected with oncogenic strains, persistence of
infection can lead to anogenital dysplasias, and eventually to anogenital
cancers.
Treatment for anogenital dysplasia can result in serious iatrogenic morbidity,
such as cervical stenosis, infertility, and preterm birth.
Infection with certain non-oncogenic strains can lead to genital warts.
Genital warts are associated with substantial pain and discomfort,
particularly related to treatment. The psychosocial impact can also be
debilitating.
Gardasil and Cervarix prevent approximately 70% of cervical cancer caused
by HPV 16 and 18 and are marketed worldwide. Nearly 100% of cervical
and a-l cancers are caused by oncogenic HPV types. Neither vaccine
provides protection against anogenital cancers caused by HPV types other
than HPV 16 and 18.
Aside from the HPV vaccines, no other drug or biologic is approved for
prevention of HPV infection. Prevention is otherwise limited to condom
use, which is minimally effective.
The Applicant submitted results from one well-controlled clinical efficacy trial
in women 16 through 26 years of age that demonstrated protection against
high-grade and low-grade genital lesions, genital warts, persistent
infections, Pap abnormalities, and invasive procedures associated with the
five new HPV types in 9vHPV and also demonstrated non-inferiority of
antibody responses to the four original HPV types compared to qHPV. An
immunogenicity bridging trial demonstrated non-inferior antibody responses
to 9vHPV among males and females 9 through 15 years of age compared to
females 16 through 26 years of age.
Compared to historical data from placebo recipients in the qHPV program,
the efficacy study demonstrated 9vHPV protective efficacy against HPVassociated genital disease endpoints regardless of HPV type -among
females naïve to HPV infection.
The point estimates of 9vHPV prophylactic efficacy against high-grade

•
•
•

•
•

•

•
•
•

Conclusions and Reasons
Anogenital cancers are progressive, life-threatening diseases.
Anogenital dysplasias are serious conditions, based on the chronic
morbidity many patients experience.
Genital warts is a serious condition, based on the debilitating impact
on physical and psychosocial well-being.

There is a need for effective prevention of HPV infection or anogenital cancers caused by other oncogenic HPV types such as HPV
31, 33, 45, 52 and 58, which are included in the 9vHPV vaccine.
The 9vHPV vaccine has a potential to prevent approximately 90%
of cervical cancer caused by oncogenic HPV types.

Based on direct evidence of efficacy and inference from
immunogenicity endpoints, the 9vHPV vaccine is effective in
preventing pre-cancerous genital lesions and genital warts
associated with the nine vaccine HPV types among males 9
through 15 years of age and females 9 to 26 years of age.
Effectiveness against genital cancers is inferred from the efficacy
demonstrated against pre-cancerous lesions and pathophysiology
of HPV-associated cancers.
Compared with qHPV, 9vHPV offers approximately additional 20%
coverage of cervical, vulvar and vaginal high grade intraepithelial
neoplasia and cancers caused by the oncogenic HPV types.
Although efficacy of 9vHPV against a-l lesions was not assessed,
it is inferred through highly similar pathophysiology to HPVassociated genital disease, prevention of HPV 16 and 18-related

Page 150

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

Decision Factor
•
•

•
•
Risk
•

•
•
Risk
Management

•

Evidence and Uncertainties
genital disease related to the five new HPV types are consistent across the
subgroups investigated.
Efficacy of 9vHPV against anal lesions associated with the five new HPV
types was not assessed in this submission because of infeasibility.
The most common adverse reactions from 9vHPV vaccination are the
injection site reactions such as erythema, swelling, and pain. However,
most injection site reactions are mild or moderate in severity, and they
resolve relatively quickly without sequelae.
Severe allergic reactions that led to study discontinuation were observed in
two subjects
Syncope or fainting occurred in some subjects following injection, although
no syncope with fall resulted in injury.
There was a numerically higher rate of spontaneous abortions among
subjects who became pregnant within 30 days of any vaccination with
9vHPV, compared with subjects who became pregnant within 30 days of
any vaccination with qHPV and subjects who became pregnant not-within
30 days of any study vaccination.
There was a numerically higher case rate of multiple sclerosis in the 9vHPV
t group compared to qHPV control.
It is uncertain whether numerically higher rates of spontaneous abortion and
multiple sclerosis are related to 9vHPV.
Any risk associated with 9vHPV vaccination within 30 days of conception
would be applicable to a very small percentage of 9vHPV recipients.

Conclusions and Reasons
anal lesions by qHPV, prevention of HPV 31, 33, 45, 52 and 58related persistent infection by 9vHPV.
•
•
•

•
•
•

All the evidence indicates that the population-based benefit of
vaccination with 9vHPV outweighs the risk associated with vaccinerelated adverse outcomes.
Although 9vHPV may cause an anaphylaxis and syncope, these
adverse reactions are rare and manageable.
Numerically higher rates of spontaneous abortion and multiple
sclerosis associated with the 9vHPV vaccination are of uncertain
clinical significance and warrant further evaluation in in postmarketing assessments.

The Applicant has proposed a pregnancy registry for post-marketing
assessment of pregnancy outcomes.
Post-market assessment for multiple sclerosis and autoimmune
disorders in general may be conducted via Mini-Sentinel.
Post-marketing assessment of spontaneous abortion may be
conducted via Vaccine Safety Datalink

Page 151

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

11.2 Risk-Benefit Summary and Assessment
As detailed in the table above, the benefit/risk balance for 9vHPV vaccine is favorable
among females 9 to 26 years of age and males 9 through 15 years of age. On the basis
of the data from this submission, 9vHPV is effective in preventing (1) HPV 16, 18, 31,
33, 45, 52, and 58-related cervical, vulvar, vaginal, and anal cancers, and the high-grade
pre-cancers that immediately precede them; and (2) HPV 6, 11, 16, 18, 31, 33, 45, 52,
and 58-related CIN, VIN, VaIN, AIN, and genital warts, and persistent infection. The
proposed indication for 9vHPV is supported by the data presented in this application.
The most common adverse reactions observed with 9vHPV in the proposed population
are injection site reactions (pain, swelling and erythema), headache, pyrexia, nausea,
dizziness and fatigue. These adverse reactions are typically mild to moderate, and
resolve within several days. Allergic reactions are rare and manageable.
Although numerically higher rates of spontaneous abortions and multiple sclerosis were
associated with the 9vHPV vaccination, the relatedness and clinical significance are
uncertain. These safety concerns could be addressed by post-marketing assessments.
Currently there is no available vaccine licensed for prevention of anogenital cancers
caused by HPV types other than HPV 16 and 18. The new HPV types in the 9vHPV
vaccine have a potential to prevent approximately 20% cervical cancer. Consequently,
licensure of the 9vHPV vaccine would fill an unmet medical need. In the opinion of this
reviewer, the substantial benefit offered by the 9vHPV outweighs its risks.
11.3 Discussion of Regulatory Options
In the opinion of this reviewer, the clinical data support traditional approval of this BLA.
11.4 Recommendations on Regulatory Actions
In the opinion of this reviewer, the clinical efficacy, immunogenicity and safety data
submitted in this application support approval of this BLA to license Gardasil 9 for use in
females 9 to 26 years of age and males 9 through 15 years of age.
11.5 Labeling Review and Recommendations
At the time this review was finalizing, labeling negotiations with the Applicant were
ongoing. The initial comments and suggestions for package insert revision were sent to
the Applicant on November 10, 2014. We proposed the following labeling revisions:
• Including a statement that the efficacy of Gardasil 9 against anal disease was not
assessed in this submission.
• Including a statement that safety and effectiveness of Gardasil 9 has not been
assessed in women older than 26 years of age.
• Revising Section 8.1 of the proposed PI to include information regarding
spontaneous abortions.
• Deleting the post hoc analysis results comparing efficacy of 9vHPV with historical
placebo control in the Gardasil program.
• Including a statement about the lower immune responses for the five new HPV
types observed among subjects who were previously immunized with qHPV.

Page 152

Clinical Reviewer: Sixun Yang, MD, PhD
STN: 125508/0

The Applicant submitted its initial responses on November 17, 2014 and accepted
CBER’s proposed labeling revisions.
11.6 Recommendations on Postmarketing Actions
This reviewer recommends that post-marketing assessments be conducted to further
evaluate the rates of spontaneous abortions and new onset of selected auto-immune
conditions following vaccination with 9vHPV. The assessment of new onset autoimmune conditions will be conducted by the FDA using Mini-Sentinel, while the
assessment of spontaneous abortions will involve a collaboration between FDA and
CDC using Vaccine Safety Datalink
In addition, the Applicant also committed to conduct the following post-marketing
assessments:
• Long-term immunogenicity, efficacy, and safety of Gardasil 9 through an
extension of Protocol V503-002: The proposed observational study will extend
the base study up to Month 126 for girls and boys between the ages of 9 through
15 years at randomization.
• Long-term efficacy and safety study in collaboration with the Nordic Region
countries of Denmark, Norway and Sweden through the extension of Protocol
V503-001: The observational study will include up to 4453 women 16 through
26 years of age enrolled and vaccinated in these countries during the original
clinical trial who with follow up for up to 12 years
• Pregnancy registry in the U.S. to collect data on spontaneously-reported
exposures to HPV9 during pregnancy: Data in this registry will be used to
assess risks relevant to pregnancy, including pregnancy outcomes of live births,
congenital anomalies, spontaneous abortions, and late fetal deaths.
• Immunogenicity bridging study (V503-003) to support use Gardasil 9 in males 16
through 26 years of age: This study is designed to evaluate the immunogenicity
and safety of V503 in young men in comparison to young women 16 through 26
years of age.

Page 153

